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Preface 
The main task of the Nordic Expert Group for Criteria Documentation of Health 
Risks from Chemicals (NEG) is to produce criteria documents to be used by the 
regulatory authorities as the scientific basis for setting occupational exposure 
limits for chemical substances. For each document, NEG appoints one or several 
authors. An evaluation is made of all relevant published, peer-reviewed original 
literature found. The document aims at establishing dose-response/dose-effect 
relationships and defining a critical effect. No numerical values for occupational 
exposure limits are proposed. Whereas NEG adopts the document by consensus 
procedures, thereby granting the quality and conclusions, the authors are re-
sponsible for the factual content of the document. 
The evaluation of the literature and the drafting of this document on Phosphate 
triesters with flame retardant properties were done by Dr. Bengt Sjögren, 
Karolinska Institutet, Sweden, Dr. Anders Iregren and Dr. Jill Järnberg, Swedish 
Work Environment Authority, Sweden. The draft versions were discussed within 
NEG and the final version was accepted by the present NEG experts on September 
28, 2009. Editorial work and technical editing were performed by the NEG secre-
tariat. The following present and former experts participated in the elaboration of 
the document: 
 
Present NEG experts  
Gunnar Johanson   Institute of Environmental Medicine, Karolinska Institutet, Sweden 
Kristina Kjærheim  Cancer Registry of Norway 
Anne Thoustrup Saber  National Research Centre for the Working Environment, Denmark 
Tiina Santonen   Finnish Institute of Occupational Health, Finland 
Vidar Skaug    National Institute of Occupational Health, Norway  
Mattias Öberg  Institute of Environmental Medicine, Karolinska Institutet, Sweden 
Former NEG experts  
Maria Albin   Department of Occupational and Environmental Medicine,  
Lund University Hospital, Sweden 
Vidir Kristjansson  Administration of Occupational Safety and Health, Iceland 
Kai Savolainen  Finnish Institute of Occupational Health, Finland 
Karin Sørig Hougaard   National Research Centre for the Working Environment, Denmark 
NEG secretariat  
Jill Järnberg and  
Anna-Karin Alexandrie  
Swedish Work Environment Authority, Sweden 
 
This work was financially supported by the Swedish Work Environment 
Authority, the former Swedish National Institute for Working Life, and the 
Norwegian Ministry of Labour. 
All criteria documents produced by the Nordic Expert Group may be down- 
loaded from www.nordicexpertgroup.org. 
 
 
Gunnar Johanson, Chairman of NEG 
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Abbreviations and acronyms 
Phosphate triesters  
TBEP tris(2-butoxyethyl) phosphate 
TBP tri-n-butyl phosphate 
TCEP tris(2-chloroethyl) phosphate 
TCP tricresyl phosphate 
TDCPP tris(1,3-dichloro-2-propyl) phosphate 
TEHP tris(2-ethylhexyl) phosphate 
TEP triethyl phosphate 
TIPP isopropylated triphenyl phosphate including triisopropylated phenyl 
phosphate 
TMCP tri-meta-cresyl phosphate, tri-m-cresyl phosphate 
TMCPP tris(monochloropropyl) phosphate, all isomers 
TOCP tri-ortho-cresyl phosphate, tri-o-cresyl phosphate 
TPCP tri-para-cresyl phosphate, tri-p-cresyl phosphate 
TPP triphenyl phosphate 
 
Other 
ACGIH American Conference of Governmental Industrial Hygienists 
AChE acetylcholinesterase 
BDCPP bis(1,3-dichloro-2-propyl) phosphate 
bw body weight 
CAR constitutively active receptor 
CAS Chemical Abstracts Service 
ChE cholinesterase 
CHO Chinese hamster ovary  
CNS central nervous system 
CYP cytochrome P450 
ECETOC European Centre for Ecotoxicology and Toxicology of Chemicals 
ED50  effective dose for 50 % of the population exposed 
EPA Environmental Protection Agency  
EU European Union 
GC gas chromatography 
HPRT hypoxanthine-guanine phosphoribosyl transferase 
IPCS International Programme on Chemical Safety 
LC50 lethal concentration for 50 % of the exposed animals at single 
administration 
LD50 lethal dose for 50 % of the exposed animals at single administration 
LOAEL lowest observed adverse effect level  
MAK  Maximale Arbeitsplatzkonzentration (maximum concentration at the 
  workplace) 
MN-PCE micronucleus containing polychromatic erythrocyte  
NADPH nicotinamide adenine dinucleotide phosphate  
  
NOAEL no observed adverse effect level 
NTE neurotoxic or neuropathy target esterase 
NTP National Toxicology Program (United States) 
OECD Organisation for Economic Co-operation and Development 
OEL occupational exposure limit 
OPIDN organophosphorus-induced delayed neuropathy  
PNS peripheral nervous system 
PVC polyvinyl chloride 
RACB reproductive assessment by continuous breeding protocol  
SCE sister chromatid exchange  
SP(M)E solid-phase (micro)extraction 
TLV threshold limit value 
TWA time-weighted average 
US United States 
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1. Introduction 
Phosphate esters are frequently utilised as flame retardants and plasticisers but 
also as stabilisers and additives in products such as floor polishes, lubricants and 
hydraulic fluids. Both phosphorous and chlorine provide the flame retardant pro-
perties. The organic parts of the molecule make it possible for the substance to  
be incorporated in organic materials. These parts can also interpose themselves 
between the polymer chains in a plastic and in that way plasticise it. The global 
consumption of organophosphorus compounds used as flame retardants was 
estimated to about 207 000 tonnes in 2004 and the consumption is expected to 
increase (52).  
In Western Europe, the consumption, evenly distributed between chlorinated 
phosphate and non-chlorinated organophosphorus flame retardants, increased  
from 58 000 to 83 000 tons between the years 1998 and 2001 (145). In 2006, the 
estimated annual consumption of chlorinated phosphate and non-chlorinated 
organophosphorus flame retardants within the European Union (EU) was 51 000 
and 40 000 tons, respectively (52). 
This document reviews some phosphate triesters with flame retardant properties, 
as particularly requested by the Swedish Work Environment Authority. The 
phosphorylated mono- and diesters are thus excluded. The following phosphate 
triesters are included:  
Tricresyl phosphate (TCP) Tris(2-ethylhexyl) phosphate (TEHP) 
Tris(2-butoxyethyl) phosphate (TBEP) Triethyl phosphate (TEP) 
Tri-n-butyl phosphate (TBP) Triisopropylated phenyl phosphate (TIPP) 1 
Tris(2-chloroethyl) phosphate (TCEP) Tris(monochloropropyl) phosphate (TMCPP)  
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) Triphenyl phosphate (TPP) 
Thus, emphasis is on compounds having three identical esters although mixed 
phosphate esters are briefly mentioned as they occur in commercial mixtures. This 
document does not include organophosphate pesticides, a highly diverse group of 
chemicals characterised by their strong ability to inhibit the enzyme acetylcholin-
esterase, which deactivates the neurotransmitter acetylcholine (213).  
2. Substance identification  
Substance identification data for the phosphate triesters covered in this document 
are presented in Tables 1-2. In Table 1, the substances are ordered according to 
chemical structure beginning with triaryl followed by trialkyl, and chlorosub-
stituted compounds. Figure 1 reveals the complete structural formulas. From Table 
2 and onwards, substances are listed in alphabetical order with regard to the ab-
breviations used in this document, except for tricresyl phosphate, which is covered 
first due to the early toxicological interest for this particular compound. 
                                                 
1
 More specifically, the abbreviation TIPP in this document covers isopropylated triphenyl 
phosphates with an unspecified number of isopropyl groups. 
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Table 1. Substance identification data for the phosphate triesters. 
Common name Abbreviation Molecular 
formula 
Molecular 
weight 
Structural formula/ 
Side chain R 
General phosphate triesters   R3O4P     – 
 
Triaryl phosphate esters 
 
Triphenyl phosphate  
 
TPP 
 
C18H15O4P 
 
326.3 
 
 
Tri-o-cresyl phosphate  
 
TOCP 
 
C21H21O4P 
 
368.4 
CH3
 
 
Tri-m-cresyl phosphate  
 
TMCP 
 
C21H21O4P 
 
368.4 
CH3
 
 
Tri-p-cresyl phosphate  
 
TPCP 
 
C21H21O4P 
 
368.4 CH3
 
Triisopropylated phenyl 
phosphate/isopropylated 
triphenyl phosphate 
TIPP Unspecific   –     Unspecified structure 
Trialkyl phosphate esters 
Triethyl phosphate TEP C6H15O4P 182.2 CH2 CH3
 
Tri-n-butyl phosphate TBP C12H27O4P 266.3 (CH2)3 CH3
 
 
Tris(2-ethylhexyl) phosphate TEHP C24H51O4P 434.6 CH2
CH2 CH3
(CH2)3CH CH3
 
 
Tris(2-butoxyethyl) phosphate TBEP C18H39O7P 398.5 (CH2)2 (CH2)3O CH3
 
Tris(chloroalkyl) phosphate esters 
Tris(2-chloroethyl) phosphate TCEP C6H12Cl3O4P 285.5 (CH2)2 Cl
 
Tris(1-chloro-2-propyl) 
phosphate 
TMCPP C9H18Cl3O4P 327.6 
CH3
CH2CH Cl
 
 
Tris(2-chloropropyl) 
phosphate 
TMCPP C9H18Cl3O4P 327.6 CH2
CH3
ClCH
 
 
Tris(3-chloropropyl) 
phosphate  
TMCPP C9H18Cl3O4P 327.6 (CH2)3 Cl
 
 
Tris(1,3-dichloro-2-propyl) 
phosphate  
TDCPP C9H15Cl6O4P 430.9 
ClCH2
CH2CH Cl
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Figure 1. Structural formulas of the phosphate triesters.  
            
 
a
 One example of isopropylated triphenyl phosphate. 
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TCP Commercial tricresyl phosphate is a complex mixture containing tri-meta-
cresyl phosphate (TMCP), tri-para-cresyl phosphate (TPCP) as well as mixed 
tricresyl and dicresyl phosphate esters. Theoretically, the total number of tri-cresyl 
phosphate isomers (symmetrical and mixed) is ten. The synthesis and composition 
of commercial TCP have changed over time (Chapter 4). Tri-ortho-cresyl phosphate 
(TOCP) occurs nowadays only as a contaminant in commercial mixtures and usual-
ly in concentrations below 0.1 % (215).  
In its classification systems for hazardous substances, the EU has introduced 
modifications of two of the CAS descriptions for tricresyl phosphate chemicals, 
namely: 
- CAS No. 78-30-8 tricresyl phosphate (containing o-o-o, o-o-m, o-o-p, o-m-m, 
o-m-p and o-p-p isomers). In the present document, this CAS No. is used for 
the o-o-o isomer only (TOCP). 
- CAS No. 78-32-0 tricresyl phosphate (containing m-m-m, m-m-p, m-p-p and  
p-p-p isomers). In the present document, this CAS No. is used for the p-p-p 
isomer only (TPCP).  
The reason for this change was to discourage use of the general TCP mixture 
CAS No. 1330-78-5 (which is proposed to be deleted) and encourage better dis-
closure of ortho-cresyl-containing mixtures. The new CAS numbers will assist in 
identifying those products that contain the toxic ortho-cresyl ingredients. Both the 
mono-ortho and the di-ortho cresyl isomers are more neurotoxic than TOCP (257). 
The analysis of a commercial TCP mixture used in the studies performed by  
the National Toxicology Program (NTP) indicated 28 components, nine of which 
had peak areas greater than 2 % of the total chromatographic peak area. The con-
centrations of TMCP and TPCP were estimated to 21 % and 4 %, respectively, and 
that of TOCP to below 0.1 %. Two peaks representing 24 % and 30 % of the total 
chromatographic peak area were identified by mass spectrometry as tricresyl 
phosphate esters whose isomeric compositions could not be confirmed. The re-
maining five major peaks (2 %, 3 %, 3 %, 4 % and 5 %) were identified as dicresyl 
phosphate esters, but the isomeric composition could not be confirmed. Thus, the 
commercial TCP used in the NTP studies referred to in this document is a complex 
mixture consisting of 18 % dicresyl phosphate esters and 79 % tricresyl phosphate 
esters with 21 % TMCP, 4 % TPCP and no detectable TOCP (< 0.1 %) (174). 
Analysis of TCP used in aircraft engine oils revealed a predominance of meta- 
(non-ortho-) cresyl isomers with ortho-cresyl phosphate isomers present almost 
exclusively as mono-ortho-tricresyl isomers (o-m-m and o-m-p) (42).  
 
TBEP Tris(2-butoxyethyl) phosphate is a technical product that may contain about 
3 % TBP with traces of 2-butoxyethanol and phosphoric acid as impurities (103). 
 
TBP Tri-n-butyl phosphate is one of the trialkyl phosphate esters. 
 
TCEP Tris(2-chloroethyl) phosphate belongs to the group of chlorinated alkyl 
phosphate esters. 
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TDCPP The commercial product tris(dichloropropyl phosphate) has predominant-
ly branched substituent propyl groups in the “iso” orientation joined via the centre 
carbon, tris(1,3-dichloro-2-propyl) phosphate (CAS No. 13674-87-8). The alternate 
isomer, tris(2,3-dichloro-1-propyl) phosphate (CAS No. 78-43-3) exists only as a 
trace in commercial TDCPP because of steric hindrance from chlorine substitution 
on adjacent carbon atoms (102).  
 
TEHP Tris(2-ethylhexyl) phosphate is one of the trialkyl phosphate esters. 
 
TEP Triethyl phosphate belongs to the trialkyl phosphate esters. 
 
TIPP Triisopropylated phenyl phosphate (with an unspecific molecular structure) 
has the CAS No. 68937-41-7. This CAS No. has also been used for a compound 
with three para-positioned isopropyl groups (tris(4-isopropylphenyl) phosphate). 
Tris(isopropylphenyl) phosphate has the CAS No. 26967-76-0, which has also 
been used for tris(2-isopropylphenyl) phosphate . The symmetrical meta-isomer 
tris(3-isopropyl phenyl) phosphate has the CAS No. 72668-27-0. The designation 
TIPP in this document refers rather to isopropylated triphenyl phosphates (with an 
unspecified number of isopropyl groups) and will if possible be specified in each 
study in this document. Isopropylated triphenyl phosphates are substituted with 
isopropyl groups at ortho, meta and/or para positions on one, two or three of the 
phenyl rings. Thus, the number of potential isomers is large. Commercial TIPP 
contains also other compounds such as TPP (27, 55, 251). The percentage of TPP 
varies with the grade of product and ranges from about 5 % to 50 %, with the most 
viscous products having the least amount of TPP. There are several commercial 
products of isopropylated triaryl phosphates. The most substituted product is 
Kronitex® 300 (CAS No. 67426-58-8) when compared to Kronitex® 50 (CAS No. 
67426-57-7), Kronitex® 100 (CAS No. 66797-44-2) and Kronitex® 200 (CAS No. 
96300-97-9) (251). An analysis of Kronitex® 50 and Kronitex® 100 showed TPP 
concentrations of 33 % and 18 %, respectively (167). A later analysis of one com-
mercial isopropylated triphenyl phosphate (208) did not reveal any substantial 
proportion of triisopropylated phenyl phosphate (Table 3). 
 
 
Table 3. Content of one commercial isopropylated triphenyl phosphate (208). 
Component  % 
TPP  24 
Ortho-isopropylphenyl diphenyl phosphate   24 
Ortho-para diisopropylphenyl diphenyl phosphate  18 
Di(ortho-isopropylphenyl) phenyl phosphate  10 
Di(isopropylphenyl) phenyl phosphate  10 
Para-isopropylphenyl diphenyl phosphate  6 
Isopropylphenyl diisopropylphenyl phenyl phosphate  7 
Di(diisopropylphenyl) phenyl phosphate  < 1 
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TMCPP Tris(monochloropropyl) phosphates theoretically comprise four different 
symmetrical isomers, of which the three most common are presented in Table 1. 
Although tris(1-chloro-2-propyl) phosphate (CAS No. 13674-84-5) is the most 
abundant isomer in commercial products, companies have tended to refer to their 
product by the name tris(2-chloropropyl) phosphate (TCPP), though that name 
refers to CAS No. 6145-73-9. This has led to a considerable degree of uncertainty 
in the literature and toxicity databases as to the identity of the substance that has 
undergone toxicity testing. TMCPP toxicity testing has usually been carried out on 
commercial mixtures containing variable amounts of TMCPP isomers, which also 
include e.g. the asymmetrical isomers bis(1-chloro-2-isopropyl) (2-chloropropyl) 
phosphate (CAS No. 76025-08-6) and bis(2-chloropropyl) (1-chloro-2-isopropyl) 
phosphate (CAS No. 76649-15-5) (216). Therefore, the designation TMCPPs  
in this document refers to single isomers or to commercial mixtures containing 
variable amounts of TMCPP isomers. When possible, TMCPP isomers will be 
specified. 
 
TPP Triphenyl phosphate is one of the triaryl phosphate esters. TPP may be a 
substantial part of commercial TIPP (Table 3) (55, 208). 
3. Physical and chemical properties  
The phosphate esters covered in the present document are mainly used as flame 
retardants and plasticisers. All of them except TPP, TMCP and TPCP are liquids 
at room temperature. Most have rather low vapour pressures and for some of them 
(TCP, TBEP and TEHP), the concentration in saturated atmosphere is below 1 
ppm. Data on physical and chemical properties are presented in Table 4.  
 
TCP (commercial) is an almost colourless liquid with a slightly aromatic odour. 
Based on vapour pressure, a saturated atmosphere contains around 0.1 ppm TCP. 
TOCP, TMCP and TPCP are all colourless. Pure TMCP is half-solid and TPCP a 
crystalline solid (99). 
The pyrolytic degradation at 525 oC of two jet engine oils (Castrol 5000 and 
Exxon 2380) containing TCP resulted in the release of carbon dioxide and carbon 
monoxide, as well as a large number of volatiles. Although TCPs were found in 
both bulk oils as well as in the air, the presence of the very potent neurotoxin tri-
methyl propane phosphate could not be demonstrated. Trimethyl propane phosphate 
may be formed from TCP and trimethylolpropane esters, which are both common 
constituents in jet engine oils (246).  
 
TBEP is a light-coloured, high-boiling, viscous liquid with a butyl-like odour 
under normal conditions. It is more soluble in non-polar than polar solvents (103). 
 
TBP is a colourless and odourless liquid. It is thermally unstable and begins to 
decompose at temperatures below its boiling point. At 370 oC, TBP was ex-
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tensively thermally degraded in air and the major generated component was butene 
(180). The weak bond of the molecule is the C-O bond and its splitting leads to 
butene and phosphoric acid. At about 700 oC with an excess of oxygen, complete 
combustion occurs with the formation of carbon dioxide and water (101).  
 
TCEP is a clear, colourless to pale yellow liquid with a slight odour. It is stable to 
short-term exposure at 150 oC, but rapid decomposition occurs above 220 oC. The 
products of thermal decomposition are carbon monoxide, hydrogen chloride, 2-
chloroethane and dichloroethane (102). At 370 oC, also vinyl chloride is formed 
(180).  
 
TDCPP is a clear, viscous liquid, which is soluble in most organic solvents (102). 
Based on vapour pressure, a saturated atmosphere contains less than 13 ppm 
TDCPP. At 370 oC, the halogenated phosphate triester undergoes extensive 
thermal oxidative degradation. The major products formed are 1,3-dichloroprene, 
1,2,3-trichloropropane, hydrogen chloride and acrolein (180). 
 
TEHP is a viscous, colourless to light yellow liquid, which is almost odourless 
(103).  
 
TEP is a colourless liquid (90). Based on vapour pressure, a saturated atmosphere 
contains about 400-500 ppm TEP.  
 
TIPP In commercial products of isopropylated triphenyl phosphates, the percentage 
of TPP varies with the grade of product and ranges from about 5 % to 50 % with 
the most viscous products having the least amount of TPP (251).  
 
TMCPP Variations in manufacturing methods result in commercial formulations 
that contain different proportions of the TMCPP isomers. Mixtures in which the 
linear forms are above trace levels tend to be pale yellow, whereas other mixtures 
are colourless (216). Thus, the most abundant isomer tris(1-chloro-2-propyl) 
phosphate is a colourless liquid (102). Based on vapour pressure, a saturated 
atmosphere contains less than 2 700 ppm. 
 
TPP is a colourless, crystalline substance with a faint, aromatic odour. It begins  
to decompose at about 600 oC but is not completely degraded even at 1 000 oC in 
inert gas. Under these conditions, TPP yields aromatic hydrocarbons, oxygenated 
aromatic compounds and phosphoric oxides including phosphoric acids. With a 
large excess of air, complete combustion to carbon dioxide is accomplished within 
the temperature range 800-900 oC (100).
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4. Occurrence, production and use  
The phosphate triesters included in this document do not occur naturally in the 
environment. They are used as flame retardants in polyvinyl chloride (PVC), 
flexible and rigid polyurethane foams, thermoset resins, thermoplastic materials, 
textile finishes, cellulosics, polyesters, and phenolic and hydraulic fluids. They are 
also used as plasticisers in polymers like PVC, cellulose acetate, polyester, acrylo-
nitrile-butadiene-styrene, polystyrene, synthetic rubber and polyphenylene oxide 
resins. Phosphate triesters are also applied as plasticisers and flame retardants in 
products like paints, lacquers and varnishes. The chlorinated triesters (TCEP, 
TDCPP and TMCPP) are used in flexible and rigid polyurethane foams, rubber 
and textile coatings. They have been found in mattresses, wood preservation 
coatings, sound- and shock-absorbing materials, and foam fillers. Apart from 
being used as flame retardants, some phosphate triesters (e.g. TCP, TBP and TPP) 
are utilised as extreme pressure additives and antiwear agents in hydraulic fluids, 
lubricants, transmission oils and motor oils to prevent surface damage (145).  
Commonly used trade names for the phosphate triesters are shown in Table 2. 
Table 5 presents the annual use of the chemicals as registered in the SPIN database 
(207), which provides data on the use of chemical substances in Norway, Sweden, 
Denmark and Finland. The project is financed by the Nordic Council of Ministers 
Chemical Group and the data are supplied by the Product Registries of the con-
tributing countries. The most commonly used phosphate triester in the Nordic 
countries is tris(1-chloro-2-propyl) phosphate (TMCPP) with an annual use of 
approximately 2 000 tonnes, followed by TCEP, TEHP, TEP and TIPP with yearly 
uses of about 300 tonnes.  
Some common uses of phosphate triesters in the Nordic countries are presented  
in Table 6.  
 
TCP is usually produced by the reaction of synthetically prepared cresols (with 
known isomeric composition) with phosphorus oxychloride (99) to limit the 
formation of unwanted isomers (e.g. TOCP) and contaminants. Early manu-
facturing practices used petroleum or coal tar derived cresols. Commercial TCP  
is a complex mixture containing TMCP and TPCP but also mixed tricresyl and 
dicresyl phosphates. Nowadays, TOCP occurs only as a contaminant in com-
mercial mixtures, usually at very low concentrations (< 0.1 %) (215).  
TCP is used as a plasticiser in vinyl plastic manufacture, as a flame-retardant, a 
solvent for nitrocellulose, in cellulosic moulding compositions, as an additive to 
extreme pressure lubricants and as a non-flammable fluid in hydraulic systems 
(99). It is used in jet turbine engine oils in the formulation of lubricants as anti-
wear additive to enhance load-carrying capacity and tolerance to increasing speed 
of rotating or sliding motion (141). TOCP has also been used as a lead scavenger 
in gasoline (18). 
The synthesis and composition of commercial TCP have changed over time, 
towards a reduction of the TOCP content. So-called Class 1 TCP was manufactured 
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Table 5. Registered annual use of the phosphate triesters in the Nordic countries in 
tonnes (207). Data are presented when available from at least three of the countries 
Denmark, Finland, Norway and Sweden.  
Compound CAS No. 2002 2003 2004 2005 2006 2007 
TCP  1330-78-5 13 8 16 17 14 16 
TOCP a  78-30-8 - - - - - - 
TMCP b  563-04-2 - - - - - - 
TPCP   78-32-0 0.5 0.7 0.8 0.4 3.6 1.5 
TBEP  78-51-3 122 84 60 76 88 73 
TBP  126-73-8 71 86 92 112 103 118 
TCEP  115-96-8 1 315 1 298 2 424 1 110 454 342 
TDCPP c  13674-87-8 - - - - - - 
TEHP  78-42-2 166 133 36 143 130 379 
TEP  78-40-0 81 32 30 39 273 310 
TIPP  68937-41-7 96 72 92 207 236 313 
TMCPP  13674-84-5 1 841 2 037 1 949 1 727 3 225 1 857 
TMCPP d  6145-73-9 - - - - - - 
TMCPP e  26248-87-3 - - - - - - 
TPP  115-86-6 107 96 116 69 115 149 
-: Data are not available for reasons of confidentiality. Generally, data are kept confidential if the 
  substance is a component in less than 4 preparations from less than 3 producers. 
a
 Used in Denmark (amount < 0.1 tonnes/year), Norway and until 2003 in Sweden. 
b Used in Sweden.  
c
 Used in Denmark, Finland and until 2003 in Sweden.  
d Used in Denmark (ca. 260 tonnes/year until 2002, and then ca. 10 tonnes/year) and in Sweden  
  and until 2002 in Norway.  
e
 Used in Denmark and until 2002 in Norway. 
 
from a crude cresol mixture containing about 30 % ortho-cresol. This was the 
“torpedo oil” type responsible for numerous poisonings in Germany during World 
War II and shortly thereafter. It was about 8-10 times more toxic than TOCP itself. 
Class 2 TCPs were detected in two jet engine oils that were intentionally mixed 
into cooking oil and sold for food use in Morocco in 1958. The toxicity of the 
TCPs in the Moroccan oils (named B and C) was 50 and 25 %, respectively, of the 
“torpedo oil”. The Class 3 TCPs were described by Henschler in 1958 as modern 
commercial preparations of greatly reduced ortho-cresol content (~3 %) (82). The 
Class 4 “conventional” TCPs are those commonly available from 1992 and the 
Class 5 “low-toxicity” TCPs are those commercially available from 1997 (141). 
There was an at least 400-fold decrease in the neurotoxicity of TCP from World 
War II to the low-toxicity materials available today. The reduction in activity from 
Class 1 to Class 5 is associated with changes in the phenolic mixture used for syn-
thesising TCP, the introduction of processing alternatives and improved methods 
of purification. Effort has focused on reducing the ortho-cresol content in the re-
action mixture and in the final TCP product. The first commercial TCP was syn-
thesised from a mixture containing approximately 25 % ortho-cresol (82), the TCP 
of Moroccan oils from a mixture containing approximately 12 % ortho-cresol, and 
the “modern” low-ortho commercial preparation from a mixture of approximately 
3 % ortho-cresol. The reductions in ortho-cresol content correlate with a sub-
stantial lowering in the neurotoxicity of the synthesised TCPs. Hydrolysates of 
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currently (1990s) manufactured “low-toxicity” TCPs have extremely low levels  
of all ortho substituted phenols and xylenols and are composed almost entirely  
of meta- and para-cresols (141). 
Mobil Jet Oil II is a synthetic oil product. The product is used worldwide and  
is manufactured by one facility in the United States (US). This oil has been essen-
tially unchanged since its development in the early 1960s. The oil contains 3 % 
TCP, which is a blend of ten TCP isomers including TOCP plus other structurally 
similar compounds (257).  
It is difficult to obtain data on the amount of TOCP in commercially available 
materials containing TCP marketed worldwide. However, conservative estimates 
of 0.1-1 % seem realistic (the concentration is usually below 0.1 %, see Chapter 2). 
This suggests that a product containing 3 % TCP would contain about 0.003-0.03 % 
TOCP. The ‘‘new generation’’ materials are claimed to have an even lower TOCP 
content, although data are sparse. Importantly, however, the focus of attention on 
the toxicity of TOCP has masked the study of the toxic potential of other ortho-
cresyl isomers. It is known that the mono-ortho and the di-ortho isomers are more 
toxic than TOCP. The introduction by the EU of two new CAS numbers (Chapter 
2) will assist in identifying products containing ortho-cresyl ingredients (257).  
In a recent study, analysis of TCP in aircraft turbine engine oil revealed that the 
ortho isomers of TCP were present almost exclusively as mono-ortho tricresyl iso-
mers in concentrations of 13-150 mg/kg oil (42). 
  
TBEP is produced by reacting phosphorus oxychloride and butoxyethanol, and 
stripping hydrochloric acid and excess of butoxyethanol. Another production 
method uses the sodium salt of butoxyethanol (103).  
TBEP is used mainly as a component in floor polishes, a solvent in some resins, 
a viscosity modifier in plastisols, an antifoam, and also as a plasticiser in synthetic 
rubber, plastics and lacquers. TBEP is widely used as a plasticiser in rubber stop-
per for Vacutainer tubes and plastic ware (103).  
 
TBP is prepared by the reaction of phosphorus oxychloride with n-butanol (101). 
TBP is used as a solvent for cellulose esters, lacquers and natural gums, as a 
herbicide and as a defoaming agent for concrete and oil well drilling. It is used  
as a plasticiser in the manufacture of plastics and vinyl resins, an antifoaming 
agent mainly in paper manufacturing plants, in printing inks, and as an extractant 
in the dissolution process in nuclear fuel processing. Its major use is as a base 
stock in the formulation of the fire-resistant aircraft hydraulic fluids (79, 101). 
Some hydraulic fluids contain 70-80 % TBP (63). TBP is also used as a wetting 
agent in casein glue and as a pasting agent in pigment paste (145).  
A novel non-ionic surfactant nanoemulsion designated 8N8 has been tested and 
shown to have bactericidal, virucidal and fungistatic activities. This emulsion is 
composed of an oil phase of TBP, soybean oil and Triton X-100, which is mixed 
with water (75). TBP has also been used for viral inactivation in immune serum 
globulins (10). 
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TCEP was historically used in polyurethane foams and systems, mainly for rigid 
foam but with minor use in flexible polyurethane (102). Among the Nordic 
countries, Norway had the highest registered use in 2001 and 2002 with 1 100 
tonnes/year and Sweden the lowest with less than 20 tonnes/year (207).  
TCEP is not recommended by producers for use as a flame retardant additive for 
use in textiles nor for use in block polyurethane foams because of the probability 
of its decomposition (102).  
In a study measuring TCEP in indoor environments, the highest content was 
reported in an acoustic ceiling (68 g/kg). Lower concentrations were reported in 
polyurethane foam fillers (32 g/kg), polyurethane soft foam (20 g/kg) and wood 
preservation coatings (10 g/kg) (98). 
TCEP has been used in Australia as flame retardant in acrylate and polyurethane 
preparations for sealing rock faces in underground coal mines (166).  
 
TDCPP is produced by the reaction of phosphorus oxychloride and epichloro-
hydrin (102) and was first synthesised by chemists of the Stauffer Chemical 
Company in the 1950s. It was introduced as a flame retardant in the 1950s and  
was later given the commercial trade name Fyrol® FR-2. TDCPP was used as a 
flame retardant in children’s and infants’ sleepwear until May 1977, when it was 
withdrawn in the US from sales to the apparel market after published reports that 
it was mutagenic in bacteria (217). 
Nowadays, TDCPP is used as a flame retardant mainly in polyurethane foams 
and other materials (102). In 2002, about 130 tonnes was used in Denmark (207). 
Mattresses for hospitals and prisons are commonly treated with TDCPP (145). 
 
TEHP is prepared by the reaction of phosphorus oxychloride and 2-ethylhexanol 
(103). TEHP is used in PVC plastisols, as a flame retardant in cellulose acetate 
and as a solvent for certain chemical reactions (103).  
 
TEP is used in ketene synthesis and as flame retardant and plasticiser in plastics 
industry. About three fourth of the annual production of TEP is used as a catalyst 
in the manufacture of ketene. In Finland, TEP is also registered as a component of 
a car paint repair product (237). 
TEP released from polyurethane hard foam for building and indoor use was 
detected in an emission experiment. Emission rates decreased rapidly and after 
168 hours, only traces of TEP could be determined (192). 
 
TIPP often occurs together with TPP in commercial products. In commercial 
flame retardant products, the proportion of TPP may be in the range 4-40 % (243). 
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TMCPP is produced by the reaction of phosphorus oxychloride and propylene 
oxide (102). The most abundant isomer in commercial products is the branched 
isomer, tris(1-chloro-2-propyl) phosphate (216).  
TMCPP was commercialised in the mid-1960s and production increased by 
about 4 % per year the next 30 years (102). In 2002, Finland had the highest use 
(among the Nordic countries) with 1 000 tonnes/year and Sweden the lowest with 
100 tonnes/year (207). The major use of TMCPP is as a flame retardant, mainly in 
polyurethane foams (102). The highest TMCPP level was reported from a poly-
urethane foam filler (180 g/kg). Lower concentrations were reported from poly-
urethane-containing carpet backing (13 g/kg), mattresses (1.5 g/kg) and wallpaper 
of glass fibre (1 g/kg) (98). TMCPP has been found to be emitted from upholstery 
at rates of up to 77 µg/m2/hour (116).  
 
TPP is produced from phosphorus oxychloride and phenol (100). TPP is used as a 
flame-retardant in phenolics and phenylene-oxide-based resins for the manufacture 
of electrical and automobile components, and as a non-flammable plasticiser in 
cellulose acetate for photographic films. Other uses of TPP are as a non-combust-
ible substitute for camphor in celluloid, for impregnating roofing paper, and as  
a plasticiser in lacquers and varnishes. TPP is further found as a component of 
hydraulic fluids and lubricant oils (100). It is also used in artificial leather, thermo-
plastics and synthetic rubber (144). 
5. Measurement and analysis of workplace exposure  
Air sampling of the phosphate triesters requires a method capable of sampling 
both vapours and aerosols. The combination of an adsorbent (Chromosorb 106) 
and a 37 mm filter cassette with glass fibre filter was the best combination for 
mixed phase air sampling of some phosphate triesters originating from hydraulic 
fluids. The triaryl phosphates were recovered solely from the filter, while the 
trialkyl phosphates were recovered from both the filter and the adsorbent (204). 
Air samples may also be collected on solid-phase extraction (SPE) columns 
containing aminopropyl silica, which have been shown to be suitable adsorbents 
for organophosphorus compounds. The SPE sampling has been compared with 
sampling on borosilicate glass fibre filter. For TBP, TCEP, TDCPP and TPP, 
results were comparable. However, the concentration of TEP was almost 5-fold 
higher using the SPE adsorbent as compared to glass fibre filter. A probable 
explanation is that TEP has a higher vapour pressure and might evaporate from  
the filter during sampling (29, 211). Solid-phase microextraction (SPME) with  
e.g. polydimethylsiloxane sorbent has been employed for extraction and pre-
concentration of alkyl and aryl phosphates (104, 197). A molecularly imprinted 
SPE method for extracting the TPP metabolite diphenyl phosphate from aqueous 
solutions has been developed. Recoveries from urine extraction were higher than 
70 % (164). 
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Analysis of phosphate esters is performed by gas chromatography (GC) with 
either nitrogen phosphorus detection (GC-NPD) (211), mass-spectrometry de-
tection (GC-MS) (29, 232), atomic emission detection (GC-AED) (29) or electron 
capture detection (GC-ECD) (202). Following extraction and pre-concentration of 
alkyl and aryl phosphates by SPME, analysis by GC coupled to inductively coupled 
plasma mass spectrometry (GC-ICP-MS) was performed for phosphorus-specific 
determination of these compounds in human plasma. The detection limits for blood 
plasma were 17 ng/l for TBP, 240 ng/l for TCEP and 24 ng/l for TPP (197). Real-
time aerosol mass spectrometry is capable of monitoring submonolayer coverage 
of TBP on the surface of micron-sized particles (133). 
Organophosphate esters may occur in laboratory air and laboratory equipment 
can be contaminated (211). Application of the SPME-GC method presented above 
on plasma samples previously stored in PVC plasma bags revealed the presence of 
TBP and TPP (197). Some batches of sampling tubes containing coconut shell char-
coal sorbent have been found to be contaminated with TMCPP and TDCPP (245).  
6. Occupational exposure data  
This chapter is divided in occupational exposure to phosphate triesters via air-
borne and via dermal exposure, respectively.  
6.1 Airborne exposure 
Air concentrations of phosphate triesters from European indoor environments 
(including homes) are presented in Table 7. The data are from Finland, Germany, 
Sweden and Switzerland. Levels exceeding 1 µg/m3 were found in recycling of 
electronics (TCEP and TPP), in furniture workshops (TBP) and in vehicles and 
garages (TMCPP) (29, 30, 78, 98, 143-145, 163, 202, 212). 
Additional studies are presented below. 
Industry 
TCP was collected close to the breathing zone of a bench worker using a synthetic 
oil containing 1-5 % TCP. The concentrations of TCP were 24 and 280 µg/m3. No 
TOCP was detected (204).  
In an unpublished report from a flexible polyurethane foam plant using TDCPP, 
nine static air samplers were used and the detection limit was 5 µg/m3. In only 2 
out of 9 samples were concentrations above the detection limit, one being 5 µg/m3 
and the other, near the removal of paper in a polyester line, 14 µg/m3 (166). 
The emission rate of TEP from polyurethane hard foam products was > 100 µg/m2 
hour at 24-hour testing. TEP decreased rapidly and after 168 hours only traces 
could be determined (192).  
Sutton et al investigated the TPP concentration in the air of a TPP-manufacturing 
plant and found levels up to 30 000 µg/m3 and a time-weighted average (TWA) of 
3 500 µg/m3. Most air samples were taken by drawing air through two gas washing  
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Table 7. Air concentrations (ng/m3) of some phosphate triesters in indoor environments 
in Europe. The number of samples per site varies. 
TCP TBEP TBP TCEP TDCPP TEHP TMCPP TPP Reference 
Electronics recycling 
nd-810 nd-212 nd-100 nd-1 100 nd-450 nd-90 nd-510 nd-10 300 (163, 202) 
Furniture workshop 
nd nd nd-1 200 nd -69 nd-38 nd nd-131 nd-530 (163) 
Industries 
nd-3 1-36 nd-29 nd-38 0.4-23 nd-2 1-32 nd-180 (145, 202, 212) 
Offices 
nd-0.4 nd-15 nd-870 nd-730 nd-35 nd-14 nd-160 nd-82 (29, 30, 78, 144, 212) 
Schools and other public buildings 
< 2.2 nd-3.3 < 0.2-64 2.0-590 nd-1.7 < 0.2-3.4 19-440 < 0.1-18 (29, 78, 143) 
Hospitals, day care centres, etc. 
nd 1-55 3.7-350 nd-320 nd-150 nd-10 28-750 nd-1.1 (29, 144, 212) 
Shops 
nd-0.2 nd-172 1.7-68 nd-29 nd-19 nd-2.8 nd-96 nd-13 (78, 144, 212) 
In vehicles and garages 
nd nd-15 nd-320 nd-9.4 nd-220 nd-18 nd-2 300 nd-3 (78, 212) 
Homes 
nd < 0.4-80 1-120 nd-600 nd-21 nd-2 7-210 nd-0.9 (98, 144, 212) 
nd: not detected. 
 
bottles arranged in series. TPP was estimated by ultraviolet spectrometry (218). 
These air levels are the highest reported of an organophosphate flame retardant.  
Offices and homes 
The average indoor concentrations of TBEP in Wichita, Kansas, US, and Lubbock, 
Texas, US, were 0.004 and 0.025 µg/m3, mainly in fine aerosol particles. TBEP 
was not found in outdoor aerosol particles (253). In another US study, the mean 
concentration of TBEP in representative samples from seven offices was reported 
to be 0.015 µg/m3 (103). The significance of floor polish, which may contain 1 % 
TBEP (165), as a source of these particles was suggested by the finding that the 
highest concentration (0.025 µg/m3) was observed immediately following floor 
polishing work. The floor dust in a new office building in Austria contained 4.3-
7.8 g TBEP/kg dust. After removal of the floor coating and wet cleaning, the floor 
dust contained 410 mg/kg and, after further 3 months, 90 mg/kg (95). 
TCEP was detected in indoor air in German homes and schools. The 50th per-
centile was 0.010 and the 98th percentile 0.6 µg/m3 (Table 7). The highest level 
was 6 µg/m3 found in a school building with an acoustic ceiling containing 68 g 
TCEP/kg. The geometric means of TCEP and tris(1-chloro-2-propyl) phosphate 
(TMCPP) in domestic dust were 0.7 and 0.5 mg/kg, respectively. Since TCEP and 
tris(1-chloro-2-propyl) phosphate residues in domestic dust were assumed to be 
condensates arising from primary sources, spot check analysis of various indoor 
materials was performed. The results showed that soft foams, paints and wallpapers 
contained mainly TCEP. High levels of tris(1-chloro-2-propyl) phosphate were 
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found in polyurethane-containing carpet backing and foam fillers, 13 and 180 g/kg, 
respectively (98).  
Airborne concentrations of TEHP were collected on filters simultaneously out-
doors and indoors in Wichita, Kansas, US, during the autumn and early winter of 
1981-1982. The average TEHP indoor concentration was 0.006 µg/m3, whereas it 
was not detected in outdoor air (253). The mean concentration in representative 
samples of dust from seven office buildings in the US was 0.005 µg/m3 (Weschler 
and Shields 1986, cited in (103)).  
An indoor TEP air concentration of 0.2 µg/m3 was measured in a newly built 
Japanese house (188). 
Several phosphate triesters were analysed in settled house dust from indoor en-
vironments and in wipe test samples from computer screens and covers. Computer 
covers may contain 0.3-10 % (w/w) of TPP and may thus act as a source of TPP in 
indoor air (144). Samples taken above new running computer monitors contained 
on average 0.56 µg/m3 (193).  
Indoor air samples of phosphate triesters were taken from apartments and family 
houses in the Tokyo Metropolitan area. The means of both TBP and TPP were 
0.010 µg/m3 (179).  
Personal air measurements were performed for 18 subjects representing different 
occupations: aircraft technicians, prison wardens, librarians, day care centre per-
sonnel and taxi drivers (see below). The highest exposures among prison wardens, 
librarians and day care centre workers were to TBEP, TCEP and TMCPP (Figure 
2) (143). 
Figure 2. Occupational exposure levels of phosphate triesters as measured by personal 
air sampling and duplicate samples (with permission from Marklund) (143). TCPP cor-
responds to TMCPP (commercial mixture) in this document. Note the different scales in 
the two figures.  
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Transport 
Among the occupations mentioned above, the aircraft technicians were exposed to 
much higher levels than all the other groups (Figure 2). They were predominately 
exposed to TBP at levels ranging from 0.27 to 2.1 µg/m3, followed by TPP at an 
average level of 0.20 µg/m3. The high exposure to TBP may be explained by a 
high proportion of TBP (19 %) in some hydraulic oils (Skydrol 500B4) (Table 8) 
(146). The taxidrivers were exposed mainly to TMCPP, i.e. tris-(1-chloro-2-
propyl) phosphate (143).  
In another study, the TBP concentrations in the breathing zone of aviation 
mechanics were 61 and 72 µg/m3 (204). 
A survey of cockpit air contamination in three aircraft types revealed TCP con-
centrations below 4 µg/m3 with two exceptions (22 and 49 µg/m3). Ground engine 
starts at high power gave rise to the highest concentrations. Other phosphate tri-
esters (mainly TPP, triisobutyl phosphate and TEHP) were found at total levels 
below 6 µg/m3 (76).  
Two jet engine oils (Castrol 5000 and Exxon 2380) containing TCP were in-
vestigated regarding pyrolytic degradation at 525 oC. The heating resulted in the 
release of carbon dioxide and carbon monoxide as well as a large number of vola-
tiles. Although TCP isomers were found in both bulk oils as well as in the air, the 
presence of the neurotoxic trimethyl propane phosphate that may be formed from 
TCP could not be demonstrated (246).  
Some TCP isomers were measured in engine oils from motor bikes and cars  
and the two main isomers were TOCP and TMCP. Engine oils for motor bikes 
contained 1.7-7.3 µg TOCP/g oil and 1.5-6.8 µg TMCP/g oil. These isomers were 
  
 
Table 8. Contents (µg/g) of some phosphate triesters measured in product samples (146).  
Product  TCP a TBP TEHP TPP 
Waste oil from cars < 0.3 < 0.5 4.2 1.0 
Waste oil from lorries  < 0.3 < 0.5 < 0.3 0.8 
Waste oil from road-construction machines  < 0.3 < 0.5 < 0.3 1.9 
Waste oil from tractors < 0.3 < 0.5 < 0.3 < 0.3 
TurboSuper 10W-30 (engine oil) < 0.3 < 0.5 < 0.3 < 0.3 
Agrol Mendo 46 Bio (hydraulic oil)  < 0.3 < 0.5 < 0.3 < 0.3 
BP Turbo oil 2380 (airport) 12 000 < 0.5 < 0.3 6.1 
BP Turbo oil 2197 engine and accessory oil (airport) 6 300 < 0.5 < 0.3 8.9 
Mobil Jet Oil II Synthetic jet engine oil (airport) 6 500 < 0.5 < 0.3 1.9 
Kilfrost DF PLUS (80) (de-icing fluid, airport) < 0.3 < 0.5 < 0.3 < 0.3 
Skydrol 500B4 (hydraulic fluid, airport) < 0.3 190 000 < 0.3 < 0.3 
Kilfrost ABC-2000 (de-icing fluid, airport) < 0.3 < 0.5 < 0.3 < 0.3 
Binol Vegecool (hydroelectric power station) < 0.3 < 0.5 < 0.3 < 0.3 
Mobil DTE Heavy medium oil (hydroelectric power 
station) 
160 < 0.5 < 0.3 < 0.3 
a
 TCP was semi-quantified using TPP. 
 
  
 22 
also found in exhaust gases from these vehicles. The concentrations were approxi-
mately the same for both isomers in exhaust from motor bikes (0.15-0.30 µg/m3) 
and the proportion (TOCP/TMCP) was the same before and after combustion. The 
levels were somewhat lower in exhaust from cars (0.14 µg/m3) (226).  
Snow samples collected in northern Sweden at a road intersection and an airport 
indicated that traffic is a source of phosphate esters in the outdoor environment. 
TPP was identified in lubricants and in waste oil from vehicles, and thus, leakage 
of transmission and motor oils was a probable source of TPP found at the sampled 
sites. In the three samples from the airport, ten phosphate triesters were detected. 
TBP was the most abundant, at levels three orders of magnitude higher than in the 
reference sample (taken 3 km from the nearest road to ensure minimal influence 
from the local traffic), i.e. 25 compared to 0.019 µg/kg. The main source of TBP 
at the airport was aircraft hydraulic fluid. Analysis of background air and de-
position samples indicated that some phosphate triesters are subject to long-range 
air transportation (146). 
Summary 
The air concentrations of individual phosphate triesters in homes, offices, hospitals, 
day care centres, schools and other public buildings have generally been below 1 
µg/m3. An exception was the higher level of TCEP (6 µg/m3) in a school building 
equipped with an acoustic ceiling. The concentrations of TMCPP (in vehicles and 
garages) and of TBP (furniture workshop) have occasionally exceeded 1 µg/m3. 
Higher levels of phosphate triesters have been reported for TCP for a bench 
worker (280 µg/m3), for TBP among aviation mechanics (72 µg/m3), for TDCPP 
in a polyester line (14 µg/m3) and for TPP in electronics recycling (10 µg/m3).  
6.2 Dermal exposure 
Dermal exposure is likely to contribute significantly to the systemic dose of 
phosphate triesters. Dermal exposure has, however, only been assessed from hand 
wash samples taken from two workers in a circuit board factory and in a furniture 
workshop. The highest mean concentrations were measured for TPP, which 
amounted to 3.3 and 24 µg/hands in the circuit board factory and in the furniture 
workshop, respectively. Lower concentrations were measured for TBP, TCP, 
TEHP and TDCPP (163). However, these results do not give any information 
regarding absorption.  
Dermal exposure and uptake may be important when workers are exposed  
to different oils and fluids containing phosphate esters. The content of some 
phosphate triesters in different oils and fluids are presented in Table 8. 
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7. Toxicokinetics 
7.1 Uptake 
Since all phosphate triesters for which there are data are readily absorbed via the 
oral (TCP, TBP, TCEP, TDCPP, TMCPP) as well as the dermal route (TOCP, 
TBP, TDCPP), a high uptake is likely also if inhaled. However, inhalation uptake 
has not been studied to a great extent. The most important route of exposure is 
unidentified and may vary between phosphate triesters and work procedures. 
 
TCP All three symmetrical isomers of TCP (TMCP, TPCP and TOCP) administered 
by gavage to rats at doses of 2, 20 and 200 mg/kg bw in corn oil were reported by 
the NTP to be well absorbed (174).  
The absorption of a single dermal dose of 50 mg/kg bw of 14C-labelled TOCP 
was studied in male cats. TOCP was applied to an unprotected, preclipped area on 
the back of the neck (approximately 10 cm2). Three cats were sacrificed at 0.5, 1, 
2, 5 and 10 days, respectively, after treatment. The skin at the dosing site was ex-
tracted with acetone. Within the first 12 hours, 73 % of the applied dose disappeared 
from the dosing site. A second phase had a slower rate with a half-time of 2 days.  
TOCP was absorbed from the skin and subsequently distributed throughout the 
body. Within the 10-day experimental period, approximately 28 % and 20 % of the 
applied dose were recovered in the urine and faeces, respectively (169). 
Adult male European ferrets (Mustela putorius furo) were exposed to a single 
oral or dermal dose of 250, 500 or 1 000 mg TOCP/kg bw (214). The neurological 
effects observed (see Chapter 10.4) indicated a high dermal absorption.  
Marzulli et al reported a dermal absorption rate of TOCP of 0.18 µg/cm2/hour, 
using human skin in vitro (148). Applying the ECETOC procedure for evaluating 
skin notation (51), i.e. exposure of 2 000 cm2 of skin (approximately corresponding 
to the skin of the hands and forearms) for 1 hour (equivalent to exposure of 250 
cm2 skin or 70 % of one hand for 8 hours) and using the above human in vitro data, 
a dermally absorbed dose of 0.36 mg of TOCP is obtained. This corresponds to 
72 % of the amount absorbed by inhalation (0.5 mg) during 8-hour exposure at 0.1 
mg/m3 (the present 8-hour threshold limit value (TLV) adopted by the American 
Conference of Governmental Industrial Hygienists (ACGIH) (4)), assuming 10 m3 
inhaled air during 8 hours and a pulmonary retention of 50 %. In conclusion, 
dermal exposure to TOCP may result in significant systemic exposure. 
At least 41 % of a single oral dose of 7.8 mg/kg bw 14C-TPCP in rats was ex-
creted in the urine over 7 days following administration, indicating absorption  
of at least that part of the administered dose. At a higher dose (89.6 mg/kg bw), 
12 % was found in urine after 7 days. As TPCP is also excreted through the bile,  
a higher absorption is possible (120).  
In 1955, Treon et al studied the effects in rabbits of a 24-hour dermal exposure 
to seven commercial TCP mixtures. The minimum lethal dose varied between 0.4-
0.6 ml/kg bw (500-750 mg/kg) and 1.6-3.2 ml/kg bw (2 000-4 000 mg/kg) for the 
different compounds (Treon et al 1955, cited in (215)). It should be remembered 
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that the TCPs from the 1950s were much more toxic than the TCPs from the 
1990s. 
 
TBEP No data were located. 
 
TBP Male Wistar rats were given a single oral or intraperitoneal dose (14 mg/kg 
bw) of 14C-labelled TBP. Within 24 hours after the oral administration, 50 % of 
the radioactivity was recovered in urine, 10 % in exhaled air and 6 % in faeces. 
Following the intraperitoneal injection, 70 % of the radioactivity was found in 
urine, 7 % in exhaled air and 4 % in faeces within 24 hours (220). The low faecal 
excretion rate indicates a very high uptake from the gastrointestinal tract. 
In vitro investigation on isolated human skin has showed a good penetrating 
capacity. The average maximum steady-state rate of penetration through human 
skin in vitro was 10.8 µg/cm2/hour (148). Applying the ECETOC procedure for 
skin notation (51) and using the above human data, a dermally absorbed dose of 
21.6 mg of TBP is obtained. This corresponds to nearly 200 % of the amount 
absorbed (11 mg) during 8-hour inhalation exposure at the present TLV of 0.2 
ppm (3) assuming 10 m3 inhaled air during 8 hours and a pulmonary retention of 
50 %. In conclusion, dermal exposure to TBP may result in significant systemic 
exposure. 
 
TCEP Radiolabelled 14C-TCEP was administered in a single oral dose of 50 
µmol/ kg bw in olive oil to groups of 3-5 male Wistar rats. Absorption was cal-
culated from the radioisotopic measurements of cumulative urinary excretion and 
cumulative exhalation performed for 7 days post-exposure, and of the amount in 
blood and tissues of rats sacrificed at 3, 6, 12, 24, 72 or 168 hours following ad-
ministration. Absorption of radiolabelled TCEP was rapid and radiolabel was 
detected throughout the body as early as 3 hours post-administration. At 168 
hours, 96 % of the administered oral dose had been excreted in the urine (94 %) 
and expired air (1.7 %) (154). 
 
TDCPP Radioactive TDCPP was administered to rats orally at doses of 0.2, 2 and 
20 µmol/kg bw. More than 90 % of given doses were absorbed from the gastro-
intestinal tract within 24 hours. TDCPP was also readily absorbed from the skin  
of rats. Administration of 2 µmol/kg bw applied in 60 µl methanol to a 4-cm2 area 
of the shaved back of rats resulted in a blood concentration of 0.75 nmol/g after  
4 hours. This concentration was one fourth of the concentration (3.05 nmol/g) 
measured in blood two hours after an equal intravenous dose (170). 
Skin from the adult hairless female mouse was removed and mounted in flow-
through diffusion cells. TDCPP penetrated the skin and 39-57 % of the applied 
dose was detected in the receptor fluid by 24 hours (92).  
 
TEHP Nine male rats received a single aerosol exposure during 20 minutes of 720 
or 910 mg/m3 of 32P-TEHP. The animals were killed post-exposure after 5 or 30 
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minutes, 1, 4, 17, 18, 24, 48 or 70 hours. Carcass radioactivity increased to a peak 
corresponding to 81 % retention at 48 hours post-exposure, followed by a decrease 
(140).   
 
TEP and TIPP No data were located. 
 
TMCPP Radiolabelled 14C-tris(1-chloro-2-propyl) phosphate (99 % pure by GC) 
was administered in a single oral dose of 16.4 mg/kg bw (0.05 mmol/kg) in olive 
oil to groups of 3-5 male Wistar rats. Absorption was calculated from the radio-
isotopic measurements of cumulative urinary excretion and cumulative exhalation 
7 days post-exposure, and of the amount in blood and tissues of rats sacrificed at 
3, 6, 12 hours as well as 1, 3 or 7 days following administration. Absorption of 
radiolabelled TMCPP was rapid. Radiolabel was detected throughout the body as 
early as 3 hours post-administration. At 7 days, 76 % of the administered oral dose 
had been excreted in the urine and in expired air or remained in the carcass. An-
other 22 % was excreted in the faeces. TMCPP, however, undergoes enterohepatic 
circulation and it is not clear if this proportion includes unabsorbed TMCPP, 
TMCPP excreted in the bile, or both. Therefore, at least 76 % was absorbed 
following oral administration to rats (154, 216). 
 
TPP No data were located. 
7.2 Distribution  
Adipose tissue act as an important storage compartment for the phosphate tri-
esters, as indicated by their lipophilic properties manifested by e.g. high octanol: 
water partition coefficients (Table 4). Some of the phosphate triesters have been 
detected in human adipose tissue (TBEP, TBP and TDCPP) and several also in 
human milk (TCP, TBEP, TBP, TCEP, TDCPP, TMCPP and TPP). 
 
TCP The distribution of a single dermal dose of 50 mg/kg bw of 14C-TOCP was 
studied in male cats. TOCP was applied to an unprotected, preclipped area on the 
back of the neck. TOCP was absorbed from the skin and subsequently distributed 
throughout the body. No radioactivity was detected in expired air. Generally, the 
highest concentrations of radioactivity were associated with bile, gall bladder, 
urinary bladder, kidneys and liver, and the lowest were found in the neural tissues, 
muscle and spleen. Furthermore, low levels of radioactivity were found in the 
spinal cord and brain. Chemical analyses showed that the parent compound was 
found primarily in the brain, spinal cord and sciatic nerve, while metabolites were 
primarily found in the liver, kidney and lung (169).  
Twenty-four hours after oral administration of 89.6 mg/kg bw of 14C-TPCP to 
rats, the highest concentrations of radioactivity were found in the intestine (in-
cluding contents), followed by the stomach, adipose tissue, liver and kidneys  
(4-13-fold higher than blood concentrations). The lowest concentrations were 
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found in heart, muscle and brain. These levels were lower than those found in 
blood (120).  
After a single oral dose of 50 mg radiolabelled TOCP to hens, the highest plasma 
concentration was found a half to one day after administration. The disappearance 
of TOCP followed monoexponential kinetics with a half-time of 2.2 days (219).  
Male F344 rats were treated orally for 10 days with TOCP (50 mg/kg bw/day) 
and DNA was isolated from liver, kidney, lung, heart, brain and testes 1, 4, 7 and 
28 days after giving the last dose. Analysis by 32P-postlabelling revealed two 
adducts present in the DNA isolated from liver, kidney, lung and heart one day 
after giving the last dose. DNA adducts were not detected in the brain and testes. 
The adduct pattern after in vivo treatment with TOCP was identical with that 
found in bacteria and hepatoma cells treated with the metabolite 2-phenoxy-4H-
1,3,2-benzo-dioxaphosphorin 2-oxide, the major adduct being a cytidine adduct 
and the minor an uridine adduct. Both DNA adducts persisted in the lungs for the 
entire observation period, whereas in the kidney only the cytidine adduct could be 
detected 28 days after the last dose of TOCP. In liver and heart, the adducts were 
detectable only on the first day after completion of the treatment. The results in-
dicate that the compound may pose a genotoxic potential (151). 
The highest TCP level found in pooled human milk samples collected 1997-
2006 from Swedish primiparous women was 3.7 ng/g lipid. TOCP levels were 
below the detection limits, which was in the range 0.2-0.5 ng/g lipid (147).  
 
TBEP was detected in 21 out of 68 male human adipose tissue samples and in 20 
out of 47 female samples, obtained from autopsies from two Canadian cities (135). 
In a later study, TBEP was detected in human adipose tissue autopsy samples from 
three out of six Ontario (Canada) municipalities, based on a detection limit of 20 
ng/g. Mean concentrations were 396 ng/g (range 320-483 ng/g) in Toronto and 
173 ng/g (range, not detected-202 ng/g) in Cornwall (136). 
TBEP was detected in breast milk samples from primiparous women. Levels of 
pooled samples collected between 1997 and 2006 varied between not detected to 
63 ng/g lipid (147). 
 
TBP In a Canadian study, 16 human adipose tissue samples were analysed post 
mortem. TBP was detected in one sample (9 ng/g adipose tissue, with a detection 
limit of 2 ng/g) (134).  
The levels of TBP in pooled breast milk samples from Swedish primiparous 
women collected 1997-2006 were 11-57 ng/g lipid (147). 
 
TCEP After intravenous TCEP administration (20 mg/kg bw), plasma clearance 
was investigated in F344 rats. The clearance of free TCEP from plasma was 30 
ml/min/kg among anaesthetised males, 74 ml/min/kg among awaken males and 53 
ml/min/kg among awaken females. The difference between anaesthetised and 
awaken male rats is presumably due to physiological effects of anaesthesia. There 
was no significant difference between awaken male and female rats (50).  
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14C-labelled TCEP was administered in a single oral dose of 0.05 mmol/kg bw 
in olive oil to male Wistar rats. After 3 hours, the highest concentration of 14C was 
found in the kidney (47 nmol/g tissue) followed by the liver (26 nmol/g tissue) and 
the lung (12 nmol/g tissue). The level in the brain was 6 nmol/g tissue (154).  
Administration of TCEP by gavage (175, 350 or 750 mg/kg bw) to F344 rats 
showed that TCEP was readily distributed to all brain regions of males and females 
(83).  
After a single oral dose of 14C-labelled TCEP in rats, the biological half-times 
in blood were 14 hours (the first phase) and 54 hours (the second phase) (154). 
TCEP levels of 2.1-8.2 ng/g lipid were reported in milk samples collected 1997-
2006 from Swedish primiparous women (147). 
 
TDCPP 14C-labelled TDCPP was administered in a single oral dose of 50 µmol/ 
kg bw in olive oil to male Wistar rats. After 3 hours, the highest concentration of 
14C was found in the liver (50 nmol/g tissue) followed by lung (26 nmol/g tissue) 
and kidney (24 nmol/g tissue) (154). 
After intravenous administration of TDCPP to rats, the compound disappeared 
rapidly from plasma with a half-time of less than 5 minutes (139). 
After a single oral dose of 14C-labelled TDCPP in rats, the biological half-times 
in blood were 13 hours (the first phase) and 42 hours (the second phase) (154).  
14C-TDCPP was bound to DNA present in the liver of male CD-1 mice that 
were given a single intravenous dose of TDCPP at 94.4 µmol/kg bw and sacrificed 
6 hours later. The level of TDCPP in liver DNA was estimated to 8.3 nmol/g. 
Traces of radioactivity were detected in kidney DNA but not in muscle. Larger 
amounts were detected in protein and low-molecular-weight RNA isolated from 
liver and kidney (157). 
TDCPP was present in human adipose tissue autopsy samples from two out of 
six Ontario (Canada) municipalities, based on a detection limit of 1 ng/g. The 
mean concentration was 17 ng/g in Welland, the city with the highest level (136).  
TDCPP was reported to range from 5 to 50 ppb in human seminal plasma 
analysed by negative-chemical-ionisation mass spectrometry (91). 
In human milk, TDCPP levels from 1.6 to 5.3 ng/g lipid were detected (147). 
 
TEHP Nine male rats received a single aerosol exposure during 20 minutes of  
720 or 910 mg/m3 of 32P-TEHP. The animals were killed post-exposure after 5 
minutes, 30 minutes, 1, 4, 17, 18, 24, 48 or 70 hours. TEHP or its metabolites 
were distributed into the lungs (peak of 13 % of total radioactivity after 5 minutes), 
brain and liver (9 and 16 %, respectively, after 30 minutes) and stomach content 
(64 % after 1 hour) (140).  
 
TEP Weanling and adult female rats were administered 500 mg/kg bw of TEP 
intraperitoneally. The concentrations declined in the brain, with half-times of 8 
hours for weanlings and 30 hours for adults, respectively (22).  
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TIPP No data were located. 
 
TMCPP 14C-labelled TMCPP was administered in a single oral dose of 50 µmol/ 
kg bw in olive oil to male Wistar rats. After 3 hours, the highest concentration of 
14C was found in the liver (29 nmol/g tissue) and the kidney (27 nmol/g tissue) 
followed by the lung (9 nmol/g tissue). The concentrations in blood, heart, spleen, 
brain, testis, adipose tissue and muscle were all below 4 nmol/g tissue (154). 
After a single oral dose of 14C-labelled TMCPP in rats, the biological half-times 
in blood were 12 hours (first phase) and 59 hours (second phase), respectively 
(154). 
In human pooled milk collected from Swedish women after delivery of their 
first babies in 1997-2006, levels of tris(1-chloro-2-propyl) phosphate were 22-82 
ng/g lipid (147). 
 
TPP has been analysed in plasma from 3 occupationally non-exposed individuals 
with duplicate samples. The concentrations varied between 120 and 150 ng/g 
plasma (111). 
Analysis of pooled human milk samples showed TPP levels of 3.2-11 ng/g lipid 
(147). 
7.3 Biotransformation  
All investigated phosphate triesters are metabolised and several lose one of the 
ester moieties to form phosphate diesters.  
 
TCP Many studies on the metabolism of TOCP are available. TOCP is metabolised 
to highly neurotoxic derivatives such as saligenin cyclic o-cresyl phosphate 
(Figure 3).There are no data to suggest that TMCP or TPCP is metabolised to 
neurotoxic metabolites. However, exposure to TCP mixtures containing isomers 
with one or two ortho-cresol groups could result in the formation of neurotoxic 
metabolites (109, 174). It has been shown that after a given dose of TOCP, the 
concentrations in plasma of both TOCP and its active metabolite saligenin-o-
cresyl phosphate were much lower in the rat than in the hen. The plasma half-time 
of TOCP was also shorter in the rat compared to the hen. These facts might be one 
explanation for the differences between these two species in the susceptibility to 
TOCP induced organophosphorus-induced delayed neuropathy (OPIDN) (see 
Chapters 9-10) (219).  
In rats, metabolism of 14C-TPCP following oral administration of 7.8 or 89.6 
mg/kg bw was found to involve successive oxidations and hydrolysis resulting in 
the production of p-hydroxybenzoic acid. The major urinary metabolites identified 
were p-hydroxybenzoic acid, di-p-cresyl phosphate and p-cresyl p-carboxyphenyl 
phosphate. The main biliary metabolites were di-p-cresyl phosphate, p-cresyl p-
carboxyphenyl phosphate, and the oxidised triesters di-p-cresyl p-carboxyphenyl 
phosphate and p-cresyl di-p-carboxyphenyl phosphate. Faecal metabolites were 
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Figure 3. Proposed pathway for hydroxylation and cyclisation reactions in the 
metabolism of TOCP. M1 is saligenin-o-cresyl phosphate. M2 and M3 are also possible 
metabolites. Adapted from IPCS, 1990 (99).  
similar to the biliary metabolites. 14CO2 was found in expired air following ad-
ministration and appeared to be formed through decarboxylation of p-hydroxy-
benzoic acid by intestinal microbes (120). 
 
TBEP No data were located. 
 
TBP The metabolic transformation of TBP was studied in male rats following oral 
and intraperitoneal administration of 14C-labelled TBP. The first stage in the meta-
bolic process was oxidation catalysed by cytochrome P450 (CYP) dependent mono-
oxygenase. The generated hydroxyl groups were further oxidised to carboxylic 
acids and ketones. In urine, the major phosphorus-containing metabolites were di-
butyl hydrogen phosphate, butyl dihydrogen phosphate and butyl bis(3-hydroxy-
butyl) phosphates (220). 
 
TCEP In mice, several urinary metabolites of TCEP were identified such as bis(2-
chloroethyl) carboxymethyl phosphate, bis(2-chloroethyl) hydrogen phosphate, 
and bis(2-chloroethyl)-2-hydroxyethyl phosphate glucuronide. The metabolism in 
rats was not induced or inhibited by nine daily doses of 175 mg/kg bw (24). 
TCEP was metabolised by male and female human liver microsomes at a rate  
of 0.027 and 0.031 nmol/min/mg protein, respectively, and by male and female 
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human liver slices at a rate of 1.37 and 1.82 nmol/min/g liver slice, respectively. 
2-Chloroethanol and bis(2-chloroethyl) hydrogen phosphate were found after ex-
posing human liver slices to TCEP. The formation of 2-chloroethanol was lower 
in men than in women, 614 versus 2 118 pmol/min/g liver. In contrast, the for-
mation of bis(2-chloroethyl) hydrogen phosphate was higher in men than in 
women, 404 versus 198 pmol/min/g liver. 2-Chloroethanol and bis(2-chloroethyl) 
hydrogen phosphate were the major metabolites formed, except in two human 
male subjects in which an unidentified metabolite constituted 29-38 % of the total 
TCEP metabolism. TCEP was not metabolised by plasma or whole blood from 
male or female human subjects (38). 
 
TDCPP Following intravenous administration of 0.8 µmol 14C-TDCPP to male 
Sprague Dawley rats, urine collected over 24-hour periods for 5 days contained  
a major metabolite, bis(1,3-dichloro-2-propyl) phosphate (BDCPP) (138, 139). 
TDCPP was rapidly metabolised in vitro (by a NADPH-dependent microsomal 
mixed-function oxidase system and glutathione S-transferase from rat liver) to 
BDCPP; 1,3-dichloro-2-propanol, 3-chloro-1,2-propanediol; and one metabolite 
which was probably a glutathione conjugate (170, 194).  
Gold and coworkers proposed an oxidative dealkylation of TDCPP to 1,3-
dichloro-2-propanone analogous with the known metabolism of other related 
phosphate triesters (73), but this has not been shown. 
 
TEHP No data were located. 
 
TEP Pre-treatment with phenobarbital markedly increased the rate of disappearance 
of TEP from both plasma and brain in rats given 500 mg TEP/kg bw intraperi-
toneally (22).  
Rats and mice were administered 32P-labelled TEP orally or intraperitoneally. 
The de-ethylated compound 32P-diethyl phosphate was found in urine (90 % of the 
radioactive material within 16 hours and nearly all over 96 hours) (110).  
 
TIPP A single dose of 1 000 mg/kg bw of tri-ortho-isopropylphenyl phosphate 
was given by gavage to rabbits. In addition, a commercial product Reolube Hyd  
46 (containing 35 % mono-ortho-isopropylphenyl diphenyl phosphate, 25 %  
di-ortho-isopropylphenyl phenyl phosphate, 10 % tri-ortho-isopropylphenyl 
phosphate and 7 % TPP) was gavaged to rabbits in a dose of 2 000 mg/kg bw. 
Cyclic metabolites of the three ortho-isopropylated phenyl phosphates were 
detected in rabbit bile (261). 
 
TMCPP No data were located. 
 
TPP was metabolised by a NADPH-independent mechanism by microsomes from 
rat liver homogenate, unlike many other phosphates. Diphenyl hydrogen phosphate 
was the only major metabolite of TPP in this in vitro study (194).  
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7.4 Excretion  
Urinary excretion is generally the main pathway for excretion of phosphate tri-
esters.  
In rats given radiolabelled chloro-substituted phosphate triesters, the expired  
air contained higher proportions of radioactivity after exposure to the dichloro-
substituted TDCPP (16 %) compared to the monochloro-substituted compounds 
tris(1-chloro-2-propyl) phosphate (8 %) and TCEP (2 %) (154).  
 
TCP The excretion of a single, dermal dose of 50 mg/kg bw of 14C-TOCP was 
studied in male cats. TOCP was applied to an unprotected, preclipped area at the 
back of the neck. No radioactivity was detected in the expired air. Within the 10-
day experimental period, approximately 28 % and 20 % of the applied dose were 
recovered in the urine and the faeces, respectively (169). 
Excretion of radioactivity following oral administration of 14C labelled TMCP, 
TPCP or TOCP in rats at doses of 0.5, 2, 20 and 200 mg/kg bw was investigated 
by NTP. Radioactivity from TMCP was excreted primarily in the faeces at all dose 
levels. Radioactivity from TPCP was excreted primarily in the urine at 0.5 and 2 
mg/kg and primarily in the faeces at 20 and 200 mg/kg. Radioactivity from TOCP 
was excreted primarily (70 %) in the urine at all doses tested (174). 
Rats receiving 14C-TPCP as a single oral dose of 7.8 mg/kg bw excreted 41 % of 
the dose of radioactivity in the urine, 44 % in the faeces, and 18 % in the expired 
air within 7 days. A majority of the excretion occurred within 24 hours. Rats with 
cannulated bile ducts excreted 28 % of the administered radioactivity in the bile 
during the first 24 hours. Rats treated in a similar manner with 89.6 mg/kg bw of 
14C-TPCP excreted 12 % of the administered radioactivity in the urine, 77 % in the 
faeces and 6 % in the expired air (120).  
 
TBEP No data were located. 
 
TBP Male Wistar rats were given a single oral or intraperitoneal dose (14 mg/kg 
bw) of 14C-labelled TBP. Within 24 hours after the oral administration, 50 % of 
the radioactivity was recovered in urine, 10 % in exhaled air and 6 % in faeces. 
The total excretion after 5 days was 82 %. Following the intraperitoneal injection, 
70 % of the radioactivity was found in urine, 7 % in exhaled air and 4 % in faeces 
within 24 hours. The total excretion after 5 days was 90 % (220).  
 
TCEP Wistar rats were given an oral dose of 50 µmol TCEP/kg bw. Most of the 
14C-labelled TCEP was excreted by 24 hours, and by 7 days, less than 1 % re-
mained in the tissues. Urinary excretion accounted for 96 %, faecal excretion for  
6 % and expired air for 2 % of the label (154). The rapid urinary excretion was 
confirmed by Burka et al, who found 40 % of the label in urine within 8 hours 
after an oral dose of 175 mg 14C-TCEP/kg bw in male and female rats. However 
the excretion rate was even higher among mice, which excreted > 70 % after the 
same dose (24). 
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TDCPP Following intraperitoneal administration of 0.8 µmol 14C-TDCPP to male 
Sprague Dawley rats, urine collected over 24 hours contained a major metabolite, 
BDCPP. In rats receiving intravenous injection, approximately 96 % of the ad-
ministered radiolabelled material was recovered in urine, faeces and exhaled air 
after completion of 5 days’ collection. The urinary proportion was 54 %. More 
than half (62 %) of the urine proportion was BDCPP (138, 139).  
In Wistar rats given 50 µmol TDCPP/kg bw, most of the 14C-labelled TDCPP 
was excreted, and by 7 days less than 3 % remained in the tissues. Urine excretion 
accounted for 43 %, faecal excretion for 39 % and expired air for 16 % of the label 
(154). 
Radiolabelled TDCPP (Fyrol FR-2) was distributed rapidly throughout the body 
in the rat following either oral or dermal administration or intravenous injection. 
About 80 % of the dose was eliminated within 24 hours. About 20 % of a total 
intravenous dose (2 µmol/kg bw) was exhaled as carbon dioxide during the first 
24 hours in rats (170).  
Minegishi et al measured biliary excretion of 14C-TDCPP in cannulated rats for 
48 hours following an oral dose of 50 µmol TDCPP/kg bw. Biliary radioactivity 
peaked at 4-6 hours after administration, and after 48 hours, biliary excretion 
accounted for approximately 40 % of the administered dose (154). 
 
TEHP Rats were exposed to an aerosol of radioactive TEHP 720-910 mg/m3 for 
20 minutes. The faecal excretion was higher than the urinary excretion and at 17 
hours after inhalation, the total excretion was 7 % (140).  
 
TEP and TIPP No data were located. 
 
TMCPP Wistar rats were given 50 µmol TMCPP/kg bw orally. Most of the 14C-
labelled TMCPP was excreted within 24 hours and by 7 days, less than 1 % re-
mained in the tissues. Urinary excretion accounted for 67 %, faecal excretion for 
22 %, and expired air for 8 % of the label (154). 
Also biliary excretion of 14C-TMCPP was measured in cannulated rats for 48 
hours following the same oral dose. Biliary radioactivity peaked within 2 hours of 
administration and after 48 hour, biliary excretion accounted for approximately 
45 % of the administered dose (154). 
 
TPP The TPP metabolite diphenyl phosphate was measured in urine at a level of 
80 µg/l in one aircraft technician (143). 
7.5 Summary 
All phosphate triesters investigated are readily absorbed via the oral as well as the 
dermal route and a high uptake via inhalation is likely.  
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The phosphate triesters are distributed throughout the body. Adipose tissue act 
as an important storage compartment for phosphate triesters as indicated by their 
lipophilic properties.  
All phosphate triesters, for which there are data, are metabolised. Several 
phosphate triesters lose one of the ester groups to form phosphate diesters. Urinary 
excretion is generally the main pathway for excretion.  
8. Biological monitoring 
Biological monitoring is performed by measuring the parent chemical or its meta-
bolites in blood, urine or exhaled air, or by measuring effects of the exposure. No 
studies correlating external exposure to biomarker levels were located. 
8.1 Markers of exposure 
Some of the phosphate triesters or their metabolites have been measured in blood, 
urine and exhaled air. Biological exposure monitoring would be valuable since 
skin absorption may be a major route of exposure. 
However, contamination from rubber and plastic storage materials has to be 
considered. TBEP has been found in blood stored in Vacutainers with rubber 
stoppers (49, 65). Both TBP and TPP have been identified in plasma stored in 
PVC bags (197). 
TPP was found in plasma from three, presumably occupationally non-exposed, 
individuals. The concentrations varied between 120 and 150 ng/g (approximately 
100 µg/l) (111). 
Diphenyl phosphate, a metabolite from TPP, was measured in urine at a level  
of 80 µg/l in one aircraft technician (143). 
Diethyl phosphate was measured in urine among 1 133 children from the US 
National Health and Nutrition Survey (2000-2004). Almost half of the values  
were below the detection limit (47 %). The geometric mean was 4.7 nmol/l and  
the range was 0.4-5 902 nmol/l (19). Diethyl phosphate, however, is not only a 
metabolite of TEP but also of at least one organophosphorus pesticide, namely 
diazinon (15). The origin of the compound is therefore unknown.  
8.2 Markers of effect 
Some of the phosphate triesters inhibit the activity of cholinesterases, which are 
divided in two subgroups, acetylcholinesterase and unspecific cholinesterase.  
Acetylcholinesterase is bound to cell structures in the regions of the cholinergic 
synapses, the grey substance of the central nervous system, the autonomic gang-
lions, the pre- and postganglionic sympathetic synapses, the motor endplates in 
muscles, as well as the parasympathetic postganglionic synapses, and in erythro-
cytes. This enzyme has the physiological function of rapid splitting of the trans-
mitter acetylcholine into choline and acetic acid and thus to inactivate it. 
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The enzymes of the second subgroup, cholinesterases, are less specific and 
ubiquitously present in the organism. These unspecific cholinesterases, also called 
pseudocholinesterases or butyryl cholinesterases, are often measured in plasma or 
serum but occasionally also in other organs. Their concentration in plasma is 7-9 
mg/l (46).  
Determination of acetylcholinesterase inhibition provides a direct measure of a 
biological parameter for the damage, independent of the chemistry of the inhibitor. 
In particular, the determination of the inhibition of erythrocyte acetylcholinesterase 
has proved suitable for quantitative biological monitoring (46).  
In contrast, the use of cholinesterase activity as evidence of exposure to organic 
phosphates is limited by the considerable range of normal plasma and serum 
cholinesterase activity (46).  
The Food and Agriculture Organization of the United Nations and the World 
Health Organization considered a statistically significant inhibition of 20 % or 
more of brain or erythrocyte acetylcholinesterase to be of clear toxicological 
significance (67). 
If the erythrocyte acetylcholinesterase activity decreases after exposure to the 
inhibitor to below 30 % of the individual reference value, clinical manifestations 
of an internal acetylcholine intoxication are to be expected. In Germany, the 
biological exposure limit for acetylcholinesterase inhibitors is a reduction of the 
acetylcholinesterase activity in the isolated erythrocytes to 70 % of the individual 
reference value (48).  
Erythrocyte acetylcholinesterase activity mirrors the activity of neuronal cholin-
esterase. Erythrocyte acetylcholinesterase activity is recommended by ACGIH as  
a biological exposure index for both TOCP and TBP. Pre-exposure baseline de-
termination (on two occasions at least three days apart) at the individual level is 
necessary because of the wide interindividual variation in acetylcholinesterase 
activity. Plasma cholinesterase is not recommended as an index of exposure (2). 
More than half of a group of workers manufacturing TCP and other alkyl phenyl 
phosphates exhibited a decreased level of plasma cholinesterase (lower than 70 % 
of normal activity) but the erythrocyte cholinesterase level was normal (223). 
No decreases in erythrocyte acetylcholinesterase and plasma cholinesterase 
levels were observed in more than 100 workers producing phosphate triester 
plasticisers, the final products being TOCP, tri-xylenyl phosphate and TPP (158). 
In 1960, an outbreak of TOCP intoxications was reported in Bombay, India 
after the consumption of contaminated mustard oil. Erythrocyte acetylcholin-
esterase activity was considerably lower (50 %) early after the onset of clinical 
symptoms among 9 patients admitted to hospital. Consecutive determinations 
showed that the activity returned to normal after 3 months (260).  
A statistically significant correlation between erythrocyte acetylcholinesterase 
activity and monocyte esterase activity was observed among 38 resin-processing 
operators exposed to some aryl phosphate esters (55). In a small group of TBP 
exposed workers, the monocyte esterase activity was not significantly decreased 
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(142). The monocyte esterase has not been further examined as a possible 
indicator of exposure. 
9. Mechanisms of toxicity  
The phosphate triesters in this document have different toxicological effects 
mediated by a variety of mechanisms.  
9.1 Neurotoxicity 
General 
The clinical picture associated with inhibition of acetylcholinesterase leads to an 
accumulation of the transmitter substance in the tissues. Depending on the severity 
of the inhibition, the sequelae vary from the characteristic symptoms of parasym-
pathetic stimulation to motor and central nervous cholinergic crisis. The parasym-
pathetic symptoms comprise increased secretion from tear, sweat and salivary 
glands, as well as from mucous glands in the tracheobronchial tract, and stimulation 
of the smooth muscles of the bronchial tract (dyspnoea, bronchospasm), of the 
gastrointestinal tract (vomiting, diarrhoea, colic) and of the urogenital system 
(urinary incontinence) (46).  
Nasal and oral discharge observed in animals exposed to high aerosol con-
centrations of TCP and Skydrol (TBP) may be a cholinergic effect as decreased 
levels of plasma cholinesterase were observed in these animals (81).  
Organophosphorus-induced delayed neuropathy (OPIDN) 
It has been known since the early 1930s that TOCP in man and hen induce a de-
layed neurotoxic effect characterised by ataxia and weakness of the limbs, 10-14 
days after exposure (107). This delayed response is called organophosphorus-
induced delayed neuropathy (OPIDN) and is characterised by a distal axonopathy 
in susceptible regions of the central and peripheral nervous systems. The primary 
lesion in OPIDN resides in distal regions of long axons where axonopathic events 
lead to distal degeneration of the neurite and secondarily of its myelin sheath (251). 
Aldridge and others studied the relation between exposure to several organo-
phosphorus compounds and OPIDN without finding a clear correlation between 
chemical structure and neurotoxicity (6-8). Later, Johnson presented structural 
characteristics of the aryl phosphates contributing to OPIDN (Section 10.4) and 
also proposed neurotoxic (or neuropathy) target esterase (NTE) to be a critical 
enzyme for inhibition by organophosphorus compounds capable of inducing 
OPIDN (108, 109).  
Despite numerous studies, the NTE hypothesis has not advanced our under-
standing of the mechanism of OPIDN according to Abou-Donia (1). There are 
some arguments against this hypothesis: a) evidence for the involvement of NTE 
is only correlative, b) it has not been shown how inhibition and ageing of NTE 
leads to axonal degeneration, c) NTE, which is present in neuronal and non-
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neuronal tissues and in sensitive and non-sensitive species, has no known bio-
chemical or physiological function, d) some organophosphorus pesticides that 
produce OPIDN in humans do not inhibit or age NTE, e) NTE-knockout mice  
are sensitive to the development of OPIDN, indicating that this enzyme is not 
involved in the mechanisms of OPIDN (1).  
Anomalous hyperphosphorylation of cytoskeletal elements is associated with 
OPIDN and has been proposed as a possible mechanism (1). An increase of cyclin-
dependent kinase 5 and its activator has been observed in the spinal cord of hens 
treated with TOCP (248) and a decrease of some neurofilaments in the spinal cord 
(264) and in the sciatic nerve (265). Delayed polyneuropathy induced by TOCP 
could not be prevented completely by calcium, however, polyneuropathy and the 
dysfunction of nerves and muscles suffering from polyneuropathy can be alleviated, 
as long as calcium tonic is administered before the clinical signs develop (184). 
In a study on chickens, there was no evidence for autoimmunity to have a 
causative role in the development of neurotoxic effects (250). 
9.2 Carcinogenicity 
TBP, TCEP, TDCPP and TEHP are carcinogenic in animal studies. Genotoxicity 
data for TCEP and TDCPP are inconclusive and it is thus unclear if genotoxicity 
is linked to the development of cancer. TBP and TEHP are not genotoxic. For 
TBP, inflammatory and proliferative mechanisms secondary to regeneration 
following ulceration and necrosis have been suggested (11). The presence of DNA 
adducts in several organs of rats exposed orally to TOCP indicates that this com-
pound may pose a genotoxic potential (151).  
9.3 Hormonal and reproductive effects  
The constitutively active receptor (CAR) is a crucial regulator of genes encoding 
for enzymes active in drug and steroid oxidation, conjugation and transport. 
Chemical substances isolated from livers of untreated mice inhibited CAR-
regulated transcriptional activity. The inhibitory substances were identified as di- 
and tri-isopropylated phenyl phosphates. However, when these compounds were 
tested for influence on responses regulated by human CAR, it was found that most 
of them did not inhibit but activated CAR (3-6-fold). Among steroid hormone 
receptors, the human androgen receptor was inhibited by TPP, mono-para-, and 
mono- and di-ortho-isopropyl phenyl phosphate (ca 40-50 %) and activated by di- 
and tri-para-isopropyl phenyl phosphate (2-fold). These results suggest steroid-
dependent biological pathways that may contribute to hormonal and reproductive 
disturbances of some triaryl phosphates (88). In a competitive binding assay, the 
affinity of TPP to the androgen receptor was considered moderate (64).  
An effect on sperms was observed after treatment of rats with TOCP. This 
effect was associated with a decrease of non-specific esterase activity in the testis 
and also with decreased NTE activity (206). 
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Activities of neutral cholesteryl ester hydrolase (an enzyme that converts 
cholesteryl esters to cholesterol in the uptake and storage pathways) and acyl 
coenzyme A:cholesterol acyl transferase (an enzyme that esterifies cholesterol  
to cholesteryl ester) were depressed in TCP treated rats. The inhibition of these 
enzymes most likely resulted in the striking accumulation of cholesteryl ester in 
cytoplasmic lipid droplets of adrenocortical and ovarian interstitial cells observed 
and in elevated intracellular cholesterol levels in adrenocortical cells (130).  
10. Effects in animals and in vitro studies  
The main effects observed in animal and in vitro studies are summarised in Table 
15. A more extensive tabular presentation of the data is given in Appendix 1.  
10.1 Irritation and sensitisation 
After a single dermal exposure, the irritating effect of the phosphate triesters 
varied from no to moderate irritation. After instillations in the eyes, the effect 
varied from no irritation to moderate conjunctivitis (Table 15). Data on airway 
irritation are generally lacking.  
 
TCP The skin of rabbits exposed for 24 hours to commercial mixtures of TCP at 
both lethal and sublethal doses showed mild inflammation and, in a few instances, 
focal acanthosis and slight hyperkeratosis. Repeated dermal exposure produced 
local skin inflammation. Inflammation was more severe in animals that died from 
treatment than among survivors (Treon et al 1955, cited in (215)).  
Rabbits exposed to TCP aerosols at concentrations of 5 900 to 42 200 mg/m3 
for periods of 3 hours to 18 days had considerably increased nasal and oral dis-
charge during and immediately following exposure, and respiratory difficulties 
were noted. Histopathological evaluation of the respiratory tract revealed mucosal 
irritation, including bronchitis, inflammation of the larynx and pulmonary oedema. 
Mortality was very high. The study is also described in Sections 10.2 and 10.4 
(Broadhurst et al 1951, cited in (215)). 
 
TBEP In three studies, TBEP was non-irritating to intact and abraded skin when 
applied topically to albino rabbits (Gabriel 1980c, Monsanto 1984b and Freeman 
1991b, cited in (103)).  
In a 21-day dermal toxicity study on New Zealand White rabbits, groups of 6 
male and 6 female animals were treated with TBEP applications of 0, 10, 100  
or 1 000 mg/kg bw/day, 5 days/week for 3 weeks. The unabraded dorsal clipped 
skin was used. The test sites were occluded for 6 hours after each exposure. The 
highest dose did not result in any adverse systemic effect. Local irritation, oedema 
and desquamation occurred at all dose levels. The skin irritation was dose-related 
and the severity progressed over time. Microscopic observations of the skin (1 000 
mg/kg bw/day) showed squamous cell hyperplasia, hyperkeratosis, hair follicles 
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distended with keratin and surface accumulation of keratin, cellular debris, ulcers, 
inflammation, congestion and haemorrhages (Monsanto 1985e, cited in (103)). 
The results indicate that skin irritation arose when exposure reached several days 
or weeks. 
In four studies, TBEP was non-irritating to the eyes of albino rabbits (Gabriel 
1980b, Monsanto 1984b, Freeman 1991a and Hoechst 1988, cited in (103)). The 
doses were not reported. 
 
TBP A single dermal application of 500 mg TBP to the intact or abraded skin of 6 
rabbits produced severe irritation, inducing erythema and oedema in all the animals. 
Instillation of 100 mg TBP in the conjunctival sac of rabbits gave rise to mild 
irritation, which was noted 1-7 days following the application (FMC 1985a, cited 
in (101)). 
When tested according to OECD guidelines, TBP was slightly irritating to the 
eyes of rabbits (Bayer 1986, cited by (79)). 
 
TCEP In a study conducted according to modern protocol standards, 0.5 ml  
of TCEP was applied to the skin of 3 New Zealand White rabbits under semi-
occlusive dressing for 4 hours. Slight erythema (grade 1) was observed in each 
animal on day 1 only (Liggett and McRae 1991c, cited in (102)).  
In another study, 0.1 ml (140 mg) of TCEP was instilled into the eye of 3 New 
Zealand White rabbits. Slight conjunctival redness (grade 1) was observed in each 
animal on day 1 and in one animal on day 2 (Liggett and McRae 1991a, cited in 
(102)).  
 
TDCPP The acute dermal irritation potential of TDCPP was investigated in 3 
New Zealand White rabbits. Well-defined (score 2) erythema was observed in 2 
animals 1 hour after patch removal, whereas the 3rd animal only showed very 
slight erythema. By 48 hours, the treated sites were normal. TDCPP was classified 
as irritant to rabbit skin (Cuthbert 1989b, cited in (102)).  
Slight conjunctival redness and slight discharge were noted 1 hour after instilla-
tion in the eyes of New Zealand White rabbits. After 24 hours, all treated eyes 
were normal. It was concluded that TDCPP was slightly irritative to the rabbit eye 
(Cuthbert and Jackson 1990, cited in (102)).  
 
TEHP was tested in 3 albino rabbits according to the OECD 404 test guideline. 
Well-defined erythema, slight to moderate oedema, crust formation and des-
quamation were observed. TEHP was classified as a moderate irritant to rabbit 
skin (Guest 1993a, cited in (103)).  
A single dose of 250 mg undiluted TEHP applied to the clipped skin of rabbits 
produced moderate erythema, which persisted for a week. Repeated applications 
of 0.1 ml (90 mg), 5 days/week (10 or 20 applications) produced moderate ery-
thema after the first application. Following the 5th application, all the animals 
exhibited moderate desquamation and a coriaceous condition. The fissures 
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generally cleared within three days, whereas other signs persisted. At the end  
of the observation period, thickening and severe hyperkeratosis of the skin were 
apparent (140).  
TEHP was non-irritating when tested in the eyes of 3 albino rabbits according  
to the OECD 405 test guideline (Guest 1993b, cited in (103)). 
TEHP was instilled into the conjunctival sac of one eye of each of 2 rabbits  
at dose levels from 0.01 to 0.5 ml (9-460 mg). Doses up to 0.05 ml (46 mg) pro-
duced slight conjunctivitis, while doses of 0.1 and 0.5 ml produced moderate 
conjunctivitis, which cleared up in 24 hours (140).  
 
TEP No data were located.  
 
TIPP Three male and 3 female Sprague Dawley rats were exposed to isopropylated 
triphenyl phosphate by dermal application (2 000 mg/kg bw). The test material 
was maintained in contact with the intact skin for 24 hours using an occlusive 
wrap. The skin was observed upon unwrapping and then again daily for 14 days. 
No irritation was observed (FMC 1990a, cited in (74)).  
Isopropylated triphenyl phosphate (0.1 ml or 110 mg) was applicated on the 
shaved backs of 3 New Zealand rabbits. The test site was wrapped with gauze, 
which was covered with cheesecloth. The test material was in contact with the 
skin for 4 hours. The sites were scored at 4.5, 24, 48 and 72 hours after they were 
unwrapped using the method of Draize. No irritation was observed and the test 
substance was classified as non-irritating. The Primary Irritation Score was 0 
(FMC 1990b, cited in (74)).  
Eye irritation from isopropylated triphenyl phosphate was investigated in  
9 rabbits. The treated eyes of 6 rabbits were unwashed through the 7-day ob-
servation period whereas the eyes of 3 rabbits were washed about 4 seconds  
after treatment. The treated eyes were examined at 24, 48, 72 hours and 7 days 
after treatment. There was no irritation in any of the treated eyes at any of the 
observation times (Food and Drug Research Laboratories 1975, cited in (74)).  
Three New Zealand White rabbits were treated with 0.1 ml (110 mg) iso-
propylated triphenyl phosphate in their conjunctival sac of the right eye. Each 
treated eye was held closed for about one second after administration. The eyes 
were evaluated for irritation using the Draize method at 1, 24, 48 and 72 hours 
after dosing. Slight conjunctival redness was observed in two treated eyes 24 
hours after dosing. The irritation had disappeared by the 48-hour observation.  
The Primary Eye Irritation Index was 1.3 at 24 hours and 0 at 48 and 72 hours. 
Thus, isopropylated triphenyl phosphate caused very slight irritation (FMC 1990c, 
cited in (74)). 
 
TMCPP 0.5 ml (650 mg) of tris(1-chloro-2-propyl) phosphate was applied to the 
skin of 3 New Zealand White rabbits under semi-occlusive dressing for 4 hours. 
Slight erythema (grade 1) was noted in one animal on day 1 only. Thereafter, there 
were no signs of skin irritation (Liggett and McRae 1991d, cited in (102)).  
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In two different studies, 0.5 ml (approximately 650 mg each of Antiblaze 80 and 
tris(2-chloropropyl) phosphate, i.e. presumably tris(1-chloro-2-propyl) phosphate) 
was applied to two test sites, one abraded and one intact skin of the back of 6 New 
Zealand White rabbits under an occlusive binder for 24 hours. Sites were scored 
for irritancy at 24 and 72 hours after application. In both cases, the test material 
was classified as not irritative (Smithey 1980b, 1981b, cited in (102, 238)). 
In another study, 0.1 ml (130 mg) of tris(1-chloro-2-propyl) phosphate was in-
stilled into the eye of each of 3 New Zealand White rabbits. Slight conjunctival 
redness (grade 1) was seen in each animal on day 1 only. Thereafter, there were  
no signs of eye irritation (Liggett and McRae 1991b, cited in (102)). 
In older studies, 0.1 ml (130 mg) of tris(2-chloropropyl) phosphate (presumably 
tris(1-chloro-2-propyl)) and of Antiblaze 80, respectively, was instilled into the 
eye of each of 6 New Zealand White rabbits. The test eyes remained unwashed 
and were evaluated for eye irritation 1, 24, 48 and 72 hours post-administration. 
The materials were considered as not irritant (Smithey 1980a, 1981a, cited in 
(102, 238)). 
Unspecified TMCPP was examined using the Magnusson and Kligman method 
for possible contact sensitisation potential in guinea pigs. TMCPP produced no 
skin sensitisation (SafePharm 1979, cited in (102)). 
 
TPP No significant skin irritation was observed when a gauze pad soaked with 
approximately 0.5 ml (600 mg) of a 70 % solution of TPP in alcohol was applied 
to the skin of mice for 72 hours (218). 
The irritation potential of TPP on mucous membranes of the rabbit eye was 
determined according to the OECD guideline 405. The treated eyes were rinsed  
24 hours after instillation. No sign of irritation was detected (Bayer 1990, cited  
in (240)). 
Similar findings were recorded in a study employing 4 hours of treatment with-
out rinse in 6 rabbits (group 1) and rinsing after 4 seconds in 3 additional rabbits 
(group 2). In group 1, conjunctival effects were observed in all 6 animals. These 
effects cleared during the 72-hour observation period. In group 2, no ocular effects 
were observed in any of the 3 animals. The material was found mildly and transient-
ly irritating when not washed out (FMC 1975, cited in (240)). 
A minimal irritating potential of TPP in 6 New Zealand White rabbits was also 
found when 100 mg was instilled into the conjunctival sac of the left eye. The 
eyelids were then held closed for 1 second. After 30 seconds, the compound was 
flushed out of the eyes of 3 of the rabbits. Very slight reactions were seen in 2/3 
washed and 3/3 unwashed eyes 1 hour after compound application. The reactions 
were less severe at 24 hours although all washed and unwashed eyes were affected. 
All (3/3) washed eyes and 1/3 unwashed eyes were normal at 48 hours, 1 unwashed 
eye at 27 hours and the remaining unwashed eye at day 6. Slight opacity and 
damage to the surface epithelium was seen in 1 unwashed eye at 24 hours. This 
was no longer present at 48 hours. Minimal irritating potential of TPP in New 
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Zealand White rabbits was found (highest score 7, score 0-10 minimally irritant) 
(Ciba-Geigy 1983, cited in (240)). 
10.2 Effects of single exposure  
The oral lethal doses for 50 % of the exposed animals at single administration 
(LD50s) of the phosphate triesters included in this presentation are generally above 
1 000 mg/kg bw in the rat (Table 9) indicating a slight acute toxicity. The phos-
phate triesters are thus generally less acutely toxic than many organophosphorus 
pesticides, e.g. demeton, dichlorvos, mevinphos, parathion and terbufos for which 
the rat oral LD50 varies between 2 and 80 mg/kg (213).  
The lethal concentrations for 50 % of the exposed animals at single inhalation 
exposure (LC50) was investigated in rats for some phosphate triesters (TBEP, 
TDCPP, TEP and TMCPP) and was around 5 000 mg/m3 or higher after 4-hour 
exposures.  
In an in vitro study, several of the phosphate triesters (TCP, TBP, TDCPP and 
TPP) were shown to exert strong haemolytic activity in rabbit blood (195). 
 
TCP Commercial TCP products were chemically not the same in the 1950s and 
1990s (141) and the content of TOCP has decreased considerably over time.  
In 1955, Treon et al studied the effects in rabbits of 24-hour dermal exposures 
to seven commercial TCP mixtures. The minimum lethal dose varied between 
0.4-0.6 ml/kg bw (500-750 mg/kg) and 1.6-3.2 ml/kg bw (2 000-4 000 mg/kg) for 
the different mixtures. Lethal doses resulted in diffuse degenerative changes in 
 
Table 9. Acute oral and dermal toxicity of phosphate triesters, LD50s (g/kg bw).  
Compound  Rat, oral Hen, oral  Rabbit, dermal Reference 
TCP > 15.8 > 10.0 > 7.9 (106) 
TOCP 8.4  3.7 (106) 
TBEP 4.7 > 5.0 > 5.0- > 10.0 (32, 33, 103) 
TBP 1.4-3.2 1.5  > 3.1 (32, 33, 101, 106) 
TCEP 0.4-3.6   (102, 235) 
TDCPP > 2.0    (102) 
TEHP > 10-37.1   (103) 
TEP 1.1-1.6   (237) 
TIPP a > 15.8 > 1.0 > 7.9 (106) 
TMCPP b 0.9-4.2 males 
0.7-2.5 females 
 1.2- > 5.0 (102, 238) 
TPP 3.5-10.8 > 5.0 > 7.9 (100, 106) 
a
 Tri-ortho-isopropylphenyl phosphate. Data for some other isomers are given in Appendix IX. 
b
 Presumably tris(1-chloro-2-propyl) phosphate or tris(2-chloro-1-propyl) phosphate.  
LD50: lethal dose for 50 % of the exposed animals at single administration. 
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the brain, liver and kidney, and oedema in the other viscera. Pathological changes 
were not observed in survivors (Treon et al 1955, cited in (215)). 
Mortality was very high in rabbits exposed to TCP aerosols at concentrations  
of 5 900- 42 200 mg/m3 for periods of 3 hours to 18 days. Rabbits had considerably 
increased nasal and oral discharge during and immediately following exposure and 
respiratory difficulties were noted. Diarrhoea was also seen (Broadhurst et al 
1951, cited in (215)). 
Rats were administered 10, 25, 50 or 100 mg TOCP/kg bw intraperitoneally in 
corn oil. After 18 hours, all animals were euthanised. No apparent morphological 
or histopathological changes were found in any tissues. A dose-dependent in-
hibition of fatty acid ethyl ester synthesising activity in the liver was observed 
starting already at 10 mg/kg bw. Similar results were also found for the plasma 
activity (153). 
Adult Long Evans male rats were exposed to single oral doses of TOCP ranging 
from 145 to 3 480 mg/kg bw. Decreased body weight (transient at 145-1 160 mg/kg 
bw) was reported (181). The study aimed at studying OPIDN and is described in 
more detail in Section 10.4. 
In an in vitro experiment investigating the haemolytic activity of various 
phosphate triesters, TCP was found to exhibit strong haemolytic toxicity. The 
concentration of TCP in rabbit blood necessary to lyse 50 % of the erythrocytes 
was 15 µM as compared to 350 µM for sodium n-dodecyl sulphate, which is a 
strong haemolytic substance (195). 
In vitro, apoptosis was induced with 0.1 or 1 mM TOCP in SH-SY5Y human 
neuroblastoma cell cultures (28).  
 
TBEP Groups of 5 male and 5 female Wistar rats were exposed for 4 hours to air 
TBEP concentrations of 3 300, 3 400 or 6 400 mg/m3. No animal died but at all 
concentrations the animals exhibited depressed and irregular respiration, increased 
salivation, sneezing, unsteadiness and tremor. No dose-response information was 
presented. Symptoms cleared in most animals 9 days later. Body weights did not 
change and gross necropsy revealed no abnormalities. The 4-hour LC50 was above 
6 400 mg/m3 (Hoechst 1989, cited in (103)).  
In another study in rats, LC50 was reported to be greater than 4 430 mg/m3 
(Mount 1991, cited in (103)).  
In an in vitro experiment, the concentration of TBEP in rabbit blood necessary 
to lyse 50 % of the erythrocytes was higher (1 100 µM) as compared to that of the 
strongly haemolytic substance sodium n-dodecyl sulphate (350 µM) (195). 
 
TBP Hens were given gelatin capsules of TBP with varying doses (from 500 to 
5 000 mg) to determine LD50, which was 1 500 mg/kg bw. Animals surviving the 
period of acute toxicity appeared normal thereafter (32, 33).  
Male and female adult Sprague Dawley rats received 100, 325 and 1 000 mg/ 
kg bw of TBP in corn oil by gavage. Mean body weight of male rats decreased 
significantly compared to controls at the high-dose level. Transient changes 
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attributable to the general toxicity were noted in forelimb grip strength and mean 
activity level only during the first 24 hours after the highest dose. On day 7 and 
14, there were no differences between the groups. No treatment-related gross 
pathological findings in the animals were observed at necropsy (80).   
Single intraperitoneal injections of 0.062-1 mmol/kg (16-270 mg/kg) of TBP  
in female rats caused a dose-related increase of β-glucuronidase activity in serum 
after 3 hours (221). 
Intratracheal administration of 5 µl (5 mg) TBP (20 % in n-dodecane) in rats 
(body weight 280-300 g, estimated dose 17 mg/kg bw) resulted in an increase of 
the total cell number in bronchoalveolar fluid the first day compared to a control 
group. A mild inhibition of serum cholinesterase (20 %) was also observed on the 
first day only. The activities of superoxide dismutase and catalase were decreased 
to day 7 and those of glutathione peroxidase and glutathione reductase only on 
day 1. The malondialdehyde content was elevated to day 14. TBP caused moderate 
toxic injury of the lung parenchyma with depression of antioxidant enzymes and 
elevated lipid peroxidation (191).  
In an in vitro experiment investigating the haemolytic activity of various phos-
phate triesters, the concentration of TBP in rabbit blood necessary to lyse 50 %  
of the erythrocytes was 250 µM as compared to 350 µM for sodium n-dodecyl 
sulphate, which is a strong haemolytic substance (195). 
 
TCEP Reported LD50s in rats were in the range 400-3 600 mg/kg bw (102, 235).  
Cultured rabbit renal proximal tubule cells were exposed to TCEP. A con-
centration of 10 mg/l decreased cell viability (84 % of the control) but increased 
lactate dehydrogenase (150 % of the control). TCEP at 10 µg/l significantly 
increased cell cycle regulatory protein expression but slightly decreased DNA 
synthesis in primary cultured rabbit renal cells (186). 
In an in vitro experiment, TCEP did not exhibit strong haemolytic toxicity. The 
concentration in rabbit blood necessary to lyse 50 % of the erythrocytes was 3 800 
µM as compared to 350 µM for the strongly haemolytic sodium n-dodecyl sulphate 
(195). 
 
TDCPP Slc/ddY mice were given a single oral intubation of TDCPP in olive oil 
and were observed for 14 days. Clinical signs included ataxia, hyperactivity and 
convulsion. LD50s for male and female mice were 2 670 and 2 250 mg/kg bw, 
respectively (102, 114).  
TDCPP was administered as an aerosol for 4 hours to groups of 5 male and 5 
female rats. LC50 was greater than 5 220 mg/m3 (Anderson 1990b, cited in (102)).  
Strong haemolytic toxicity of TDCPP was reported in an in vitro study. The 
concentration in rabbit blood necessary to lyse 50 % of the erythrocytes was 71 
µM as compared to 350 µM for the strongly haemolytic substance sodium n-
dodecyl sulphate (195). 
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TEHP Wistar rats and Hartley guinea pigs were exposed to aerosols of TEHP. 
Rats were exposed to air concentrations of 283-460 mg/m3 for 30-210 minutes 
without any mortality in any group of 10 animals. Guinea pigs were exposed to the 
same air concentrations for 30-180 minutes, with some mortality in each group. 
The mortality varied from 30 % (at 450 mg/m3 for 30 minutes, 298 mg/m3 for 60 
minutes and 460 mg/m3 for 60 minutes) to 80 % (at 287 mg/m3 for 120 minutes) 
(140).  
 
TEP The LC50 was greater than 8 817 mg/m3 in rats exposed for 4 hours (237). A 
single intraperitoneal injection of TEP (1 mmol/kg, 180 mg/kg bw) in female rats 
(150-200 g) caused an increase of β-glucuronidase activity in serum after 3 hours, 
whereas the metabolite diethyl phosphate did not. The increase caused by TEP 
was less prominent compared to that caused by TBP (221).  
In an in vitro experiment investigating the haemolytic activity of various 
phosphate triesters, TEP did not exhibit strong haemolytic toxicity in rabbit blood 
(195). 
 
TIPP Five male and 5 female Wistar rats received a single oral dose of 20 000 
mg/kg bw of isopropylated triphenyl phosphates. The animals were observed for 
14 days, after which they were sacrificed, necropsied and their organs examined 
for gross lesions. No male rats died but 4 of the 5 females. No clinical signs were 
reported (Food and Drug Research Laboratories 1975, cited in (74)).  
Three male and 3 female Sprague Dawley rats were exposed by dermal app-
lication to 2 000 mg/kg bw of isopropylated triphenyl phosphates. The test material 
was maintained in contact with the intact skin for 24 hours using an occlusive 
wrap. The skin was observed upon unwrapping and then again daily for 14 days. 
There was no mortality, no apparent effect on body weights, no observed irritation 
and no gross lesions at necropsy in any of the animals (FMC 1990a, cited in (74)).  
 
TMCPP Acute oral LD50s for TMCPP in rat have been reported in a series of 
studies and range between 931 and 4 200 mg/kg bw for males and between 707 
and 2 500 mg/kg bw for females (102).  
Inhalation studies with aerosols of TMCPP have been performed. The LC50 was 
reported to be above 4 600 mg/m3 with an exposure duration of 4 hours (Mehlman 
and Singer 1981, Stauffer 1979, Anderson 1990a, cited in (102)). 
Dermal LD50s for rats were above 2 000 mg/kg bw (102). For rabbits, reported 
dermal LD50s were approximately 1 200 to above 5 000 mg/kg bw (102, 238). 
In an in vitro experiment, the concentration of tris(2-chloro-1-propyl) phosphate 
in rabbit blood necessary to lyse 50 % of the erythrocytes was 840 µM as com-
pared to 350 µM for sodium n-dodecyl sulphate, which is a strong haemolytic 
substance (195). 
 
TPP A commercial cresyl diphenyl phosphate preparation was analysed to contain 
approximately 35 % of TPP, 45 % of cresyl diphenyl phosphates, 18 % of dicresyl 
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phenyl phosphates and 2 % of TCP. The product was almost free of the o-cresyl 
isomers as revealed by the analysis of its alkaline hydrolysis products. Twenty-
four hours after a single intraperitoneal injection (75, 150 or 300 mg/kg bw), an 
induction of microsomal CYPs in the liver of Wistar rats with a concomitant in-
crease in the activities of mixed function monooxygenases was observed at the 
two highest doses and possibly also at 75 mg/kg bw. Morphology of hepatocytes 
investigated (for the 300 mg/kg-group only) by light and electron microscopy 
showed proliferation of smooth endoplasmic reticulum, enlargement of the nuclei 
and mitochondria with increased cristae. Hepatic morphology returned to normal 2 
weeks after the treatment. The concentration of the phosphate esters in blood and 
liver decreased rapidly with only traces detected in blood after 24 hours (244). 
Other components than TPP may have contributed to the effects of this mixture. 
The study is also described in Section 10.4. 
In a limited study, cats (n = 1-2) were given subcutaneous doses of 400, 700 or 
1 000 mg/kg bw of TPP (99.99 % pure). At the lowest dose, one of two cats lost 
weight. Higher doses caused prostration. Complete necropsy (performed only at 
700 mg/kg) revealed generalised vascular damage with perivascular oedema in 
many tissues. The liver displayed fatty change (256).  
TPP exhibited strong haemolytic activity in an in vitro experiment. The con-
centration in rabbit blood necessary to lyse 50 % of the erythrocytes was 45 µM  
as compared to 350 µM for sodium n-dodecyl sulphate (a strong haemolytic 
substance) (195).  
In another in vitro study, an inhibition of monocyte antigen presentation was 
observed at 1 µM in the test medium (58).   
10.3 Effects of short-term exposure (up to 90 days)  
Organ toxicity such as liver effects was observed after short-term exposure to 
some of the phosphate triesters (TBP, TCEP, TEP, TIPP, TMCPP and TPP).  
 
TCP In an early study, groups of 3-4 female rabbits were exposed dermally to 
0.25, 0.5, 1, 2 or 5 ml (300, 600, 1 200, 2 400 or 6 000 mg) of commercial TCP, 2 
hours/day, 5 days/week for several weeks. Death was produced by doses as low as 
0.25 ml (300 mg). Degenerative changes were seen in the brain, liver and kidneys 
of rabbits that died. Mild changes were also seen in the liver and kidneys of sur-
vivors (Treon et al 1955, cited in (215)). The study is also described in Section 
10.4.  
Groups of male and female F344 rats received daily oral doses of 400 mg/kg  
bw commercial TCP in sesame oil for 20, 40 or 60 days. The TCP was composed 
of mostly p- and m-isomers of TCP and other substances including substantial 
amounts of cresyl-xylyl, cresyl-ethylphenyl and ethylphenyl-xylyl phosphates.  
No TOCP was detected. Light microscopy revealed hypertrophy and lipidosis  
of adrenocortical (both sexes) and ovarian interstitial cells that progressed with 
duration of exposure (131).  
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Female rats received daily oral doses of 0 or 400 mg/kg bw of the same TCP 
mixture for 40 days. Adrenal glands and ovaries from TCP-treated rats were 
heavier than controls. Microscopic and biochemical studies revealed cholesteryl 
lipidosis composed of cholesteryl ester in the adrenal glands and ovaries in treated 
rats. The activity of neutral cholesteryl ester hydrolase (an enzyme that converts 
cholesteryl esters to cholesterol in the uptake and storage pathways) was inhibited  
by 97 % compared to that of controls, which most likely resulted in the striking 
accumulation of cholesteryl ester in cytoplasmic lipid droplets of adrenocortical 
and ovarian interstitial cells. The activity of acyl coenzyme A:cholesterol acyl 
transferase (an enzyme that esterifies cholesterol to cholesteryl esters) was de- 
pressed by 27 % compared to that of control adrenal glands, resulting in elevated 
intracellular cholesterol levels in adrenocortical cells (130).  
Groups of 10 male Wistar rats were fed diets containing 0, 0.02, 0.05 or 0.1 
g/kg of TCP (90 % o-, m- and p-isomers) for 6 weeks. Doses were estimated (215) 
to be 0, 2.4, 6 and 12 mg/kg bw/day, respectively. After 25 days of exposure, rats 
were immunised with tetanus toxoid. No clinical signs of toxicity were observed, 
and food and water intake, body weight and relative organ weights in treated rats 
were similar to controls. Serum antibody titres to tetanus toxoid were significantly 
reduced at 0.05 and 0.1 g/kg diet. Serum immunoglobulins (IgM and IgG) were 
significantly reduced at 0.1 g/kg while leukocyte and macrophage migration was 
inhibited at 0.05 and 0.1 g/kg. Thus, the results suggest that the immune system 
may be a sensitive target for TCP (14).  
Adult male Long Evans rats were exposed to TOCP at 75, 150 or 300 mg/kg  
bw given 7 times orally in a 2-week period. Corticosterone was added to drinking 
water (400 µg/ml) for a total of 28 days in order to study the interaction of stress 
and exposure to TOCP. At the end of the 28-day testing period, the rats were 
sacrificed. The body weight was reduced at all TOCP doses and significantly so  
at 75 and 300 mg/kg bw. The thymus and spleen weights and cell counts were 
significantly reduced by corticosterone but not affected by TOCP (data only pre-
sented for the 300-mg/kg dose). The percentage of cells from thymus and spleen 
with specific markers (e.g. CD4+8-, CD4+8+, CD4-8-, CD4-8+) were not affected  
by TOCP, nor by corticosterone (53). The study is also described in Section 10.4.  
 
TBEP In a 4-week study, diets containing 0, 0.5, 2, 7.5 or 15 g TBEP/kg were fed 
to male and female Sprague Dawley rats (corresponding to 0, 50, 200, 750, 1 500 
mg/kg bw (44)). In males, no signs of toxicity were found in any group but there 
was a slight decrease in body weight and food consumption in females receiving 
diets containing 7.5 and 15 g/kg. No compound-related changes were observed at 
necropsy (Monsanto 1985b, cited in (103)).  
 
TBP was administered by gavage to male and female Sprague Dawley rats for 14 
consecutive days (0.14 and 0.42 ml/kg bw, i.e. 140 and 410 mg/kg bw). Effects 
were investigated at the end of the feeding period. Relative liver weights were 
increased in low-dose animals. Increased absolute liver weights and serum amylase 
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activity were found in high-dose animals. Histopathological examination (only 
performed in the high-dose group) revealed microscopic degenerative changes  
in 50 % of the seminiferous tubules of the testis in 1/4 rats. No other abnormal 
microscopic changes were observed (123). 
Wistar male rats were fed pellet diets containing 0 or 5 g/kg of TBP for 9 weeks. 
The dietary levels correspond to approximately 500 mg/kg bw/day (44). Both ab-
solute and relative liver weights increased after exposure as did relative weights  
of kidney and testes. Haematological parameters were not different from controls. 
Enzyme activities and all serum components were unaffected except urea nitrogen, 
which was increased (178). 
In a 10-week toxicity study, male Wistar rats (n = 10-11/group) were given TBP 
(> 97 % purity) via the diet at doses of 5 and 10 g/kg (equivalent to approximately 
0, 500 or 1 000 mg/kg bw/day (44)). The body weights and food consumption of 
the treated groups were significantly lower than those of the controls. In both treat-
ment groups, increased relative brain, liver and kidney weights and decreased ab-
solute brain and kidney weights were found compared to the control group. Clinical 
chemistry analysis showed significantly decreased serum glucose and increased 
urea concentrations at both dose levels, and increased total protein and cholesterol 
concentrations at the high dose. The activities of serum alanine and aspartate 
aminotransferase enzymes (ALAT and ASAT) and of alkaline phosphatase (ALP) 
were significantly decreased at both dose levels. The cholinesterase activity in  
the brain was significantly increased in both treatment groups, but no significant 
changes were observed in the serum or liver cholinesterase activities compared  
to the control group. The blood coagulation time of the treated groups was 
significantly prolonged at both dose levels (177). The study is also described in 
Section 10.4. 
The dose-response of TBP for effects on urine and urothelium was evaluated in 
male Sprague Dawley rats (10/group) administered 0, 0.2, 0.7 and 3 g/kg in the 
diet (corresponding to approximately 0, 20, 70 and 300 mg/kg bw (44)) for 10 
weeks. Urothelial effects were seen at the two highest doses but were most severe 
at 3 g/kg diet with ulceration and haemorrhage into the bladder lumen and, as a 
consequence, diffuse papillary and nodular hyperplasia. The bladder epithelial 
changes were reversible, but the ulcer repair process was accompanied by sub-
mucosal fibrosis (11). As the majority of TBP is metabolised, the cytotoxicity may 
be due to one or more of the metabolites. Supporting this hypothesis is the ob-
servation that dibutyl phosphate produces toxic and regenerative changes of the  
rat bladder similar to TBP (Chemicals Investigation Promoting Committee 1995, 
cited in (11)). 
 
TCEP Groups of five F344/N rats of each sex received 22, 44, 88, 175 or 350 mg/ 
kg bw of TCEP in corn oil by gavage 5 days/week with 12 doses over 16 days. No 
clinical signs of toxicity were observed. There was no significant differences in 
body weight between dosed and control animals. Mean absolute and relative kidney 
weights for males receiving 175 or 350 mg/kg bw were significantly greater than 
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those of controls, as were absolute and relative liver weights for high-dose females. 
Absolute and relative lung weights of females receiving 88-350 mg/kg bw were 
significantly decreased. No gross or histopathological lesions attributable to TCEP 
exposure were observed (173).  
Groups of five mice of each sex received 44, 88, 175, 350 or 700 mg/kg bw of 
TCEP in corn oil by gavage 5 days/week with 12 doses over 16 days. Group mean 
body weights were similar to control values at the end of the study. Further, there 
were no chemical-related changes in absolute or relative organ weights. Gross or 
microscopic lesions were not observed (173).  
 
TDCPP The effects of Fyrol FR-2 on immunological function and host sus-
ceptibility to infectious agents were examined following subcutaneous injections 
of 0.25, 2.5 or 25 mg/kg bw/day for 4 days. The treatment induced minimal 
changes regarding these endpoints only at the highest dose as indicated by de-
creased lymphoproliferative responses to mitogens and an increased incidence  
of tumours after tumour cell challenge. Histological examination revealed no 
significant lesions in the brain, vagina, uterus, liver, kidney, adrenals, spleen, bone 
marrow, lung or salivary gland (137). As pointed out by the US Environmental 
Protection Agency (EPA), there is some uncertainty as the test material, reported 
as Fyrol FR-2, was mis-identified by the authors as tris(2,3-dichloropropyl) phos-
phate (243).  
No histological effects were observed in the liver, kidneys or gonads of rats 
given daily doses of 250 mg/kg bw for 10 days by gavage (review by Ulsamer et 
al (235)).  
 
TEHP Rats were given oral doses of 110-1 550 mg TEHP/kg bw/day for 30 days. 
No effect on body weight was seen at 430 mg/kg. At the highest dose, weight loss 
was observed (Smyth 1948, cited in (103)).  
Five rats (F344/N) and 5 mice (B6C3F1) of each sex were administered 0, 375, 
750, 1 500, 3 000 or 6 000 mg TEHP/kg bw in corn oil for 14 consecutive days. 
No animals died. The final mean body weights were lower among male rats that 
received 1 500 mg/kg bw or above and among female rats that received 3 000 
mg/kg bw or above than among vehicle controls. There was no effect of body 
weight gain in mice (172). 
 
TEP Male Wistar rats were fed pellet diets containing 0 or 5 g/kg for 9 weeks. 
The dietary concentrations correspond to approximately 500 mg/kg bw/day (44). 
Both absolute and relative liver and spleen weights as well as absolute weights of 
kidneys and testes increased after exposure. Leukocyte, erythrocyte counts, haemo-
globin and serum component levels such as cholesterol, triglyceride, sodium and 
potassium were not different from controls. Further, the serum cholinesterase 
activity was also normal. Slight morphological changes were found in the liver. 
These included cytoplasmic vacuolisation, increases in the number of binucleated 
cells and enlargement of cell size (178). 
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TIPP Forty male and 40 female Sprague Dawley rats were treated with Kronitex® 
K-100 at doses of 1, 5 and 10 g/kg diet/day for 28 days (corresponding to app-
roximately 100, 500 and 1 000 mg/kg bw/day (44)). Twelve rats died during the 
study but the mortality was not dose-related since 4 deaths occurred in the low-,  
4 in the mid-, and 3 in the high-dose group. There was one death in the control 
group. Body weights were depressed only in the high-dose female rats. Routine 
haematological and clinical chemistry measurements were performed. Abnormal 
haematological values (not specified) were obtained from the high-dose animals 
and abnormal clinical chemistry measurements (not specified) from the mid- and 
high-dose animals. Urinalysis was normal for all animals. At necropsy, no gross 
lesions were observed. Realtive liver weights were increased in all dose groups. 
Kidneys and livers were examined microscopically and appeared normal (74).  
 
TMCPP Groups of 5 female Wistar rats were given 0, 8, 40, 200 and 1 000 mg/kg 
bw of unspecified TMCPP in olive oil by gavage for 7 days. No abnormalities or 
mortality were observed except for one rat that died in the 1 000-mg/kg group. The 
only treatment-related effects were significant increases in the relative weights of 
the liver at 1 000 mg/kg and of the kidneys at or above 40 mg/kg (Kawasaki et al 
1982, cited in (216)).  
In a range-finding study, groups of 5 male Wistar rats received tris(1-chloro-2-
propyl) phosphate (98 %) at doses of 0, 1, 10, 100 or 1 000 mg/kg bw by gavage  
in peanut oil for 7 days. There were no effects on mortality, clinical signs, body 
weight or food intake, and no effect on gross pathology (Bayer 1993, cited in 
(216)).  
Groups of rats fed ad libitum for 14 days at levels of 4.2, 6.6, 10.6 and 16.6 g 
Fyrol PCF/kg diet presented minimal evidence of toxicity. The product contained 
ca 70 % tris(1-chloro-2-propyl) phosphate and ca 22 % tris(2-chloro-1-propyl) 
phosphate. The dietary levels correspond to 420, 660, 1 060, 1 660 mg/kg bw (44). 
No treatment-related changes were seen in haematology, clinical chemistry or 
cholinesterases activity. At the highest dose, increased relative and absolute liver 
weights in males were reported without concomitant histopathological changes 
(Stauffer 1980a, cited in (102, 238)).  
 
TPP In a 35-day study, rats were exposed to dietary levels of 1 and 5 g/kg feed. 
High-dose animals exhibited increased relative liver weights and a slight de-
pression of growth rate. Relative kidney weights were unaffected. No haemato-
logical effects (haemoglobin content, cell volume, erythrocyte and leukocyte 
counts and differential) were found (218). Doses were estimated to be approxi-
mately 100 and 500 mg/kg bw. 
10.4 Neurotoxicity  
Organophosphorus-induced delayed neuropathy (OPIDN) is a neurodegenerative 
disorder characterised by a delayed onset of prolonged ataxia and upper motor 
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neuron spasticity as a result of single or repeated exposures to organophosphorus 
esters. The neurological lesion is a central-peripheral distal axonopathy caused by 
chemical transection of the axon (known as Wallerian-type degeneration), followed 
by myelin degeneration of the distal portions of the long and large-diameter tracts 
of the central and peripheral nervous systems (1).  
It is difficult to produce delayed neurotoxic effects in rodents even at repeated 
dosing (109). Thus, when studying OPIDN, the hen is the experimental animal of 
choice and is consequently used for testing in regulatory protocols (176, 242). This 
is due to the susceptibility of the hens, ease of handling, presence of clearly detect-
able clinical signs and lesions and the temporal similarity of its neuropathy to that 
of man. TOCP is used as a positive control as hens develop weakness and ataxia 
in 7-10 days, which progresses for 2-3 weeks. The severity and progression of 
these effects are scored and used for quantification of the clinical neuropathy 
associated with OPIDN (251). Different chicken strains seem to be more or less 
sensitive to TOCP regarding OPIDN (43).  
In concluding that a chemical induces OPIDN, the US EPA states that at least 
two of the following three factors should be present: 1) evidence of the clinical 
disease, 2) typical nervous system lesions, and 3) appropriate degree of NTE 
inhibition (251). Despite numerous studies, however, the NTE hypothesis (Section 
9.1) has not advanced our understanding of the mechanism of OPIDN according to 
Abou-Donia (1).  
The structural features contributing to OPIDN have been studied and discussed 
(108, 109, 251). Among triaryl phosphates, the following structural characteristics 
are related to OPIDN: 
• Esters having one or more rings substituted in the ortho position are 
neurotoxic provided that the ortho-alkyl group has at least one hydrogen 
atom on the α-carbon (the carbon attached to the phenyl ring). 
• Further substitution in the phenyl ring containing the ortho-substituent 
greatly reduces the neurotoxicity by providing alternative degrading path-
ways. Thus, methyl groups in the meta or para positions, in addition to  
the ortho position, reduce neurotoxicity by opening a route to inactive ex-
cretable products. Further substitution in the other two rings of an ortho-
substituted phosphate ester reduces neurotoxicity only slightly.  
• The delayed neurotoxicity is greater in isomers having only one ortho-
substituent, compared to the symmetrical tri-ortho-ester.   
• The delayed neurotoxicity decreases as the substituent in the ortho position 
becomes larger and more branched. The tert-butyl group is unable to under-
go the activation to the neurotoxic metabolite.  
• Triaryl phosphate esters having no substituents are not neurotoxic.  
• A substituent in the para position requires two hydrogen atoms on the α-
carbon to produce neurotoxicity. Substituents in the meta position do not 
generally produce neurotoxicity. Mixed esters with some substituents in 
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both meta and para positions are less active than the symmetrical tri-para-
esters.  
 
TOCP is the most neurotoxic phosphate triester in this review and known to 
cause OPIDN. TCP (or derivates in its mixture) and the mono-ortho-derivate of 
isopropylated triphenyl phosphate (i.e. ortho-isopropyl phenyl diphenyl phosphate) 
can also cause OPIDN but are less potent. Pure TPP is not neurotoxic but com-
mercial products may contain derivates generating OPIDN. Some other phosphate 
triesters in this document induce neurotoxic effects (TBEP, TCEP and TEP) al-
though they do not produce OPIDN. TEP has a narcotic effect. In addition, TBP 
produced reduction of conduction velocity of the caudal nerve and morphological 
changes of the sciatic nerve in one study but other studies did not discover neuro-
toxic effects. Neurotoxicity at high doses has been reported after exposure to 
TDCPP and TMCPP. Inhalation exposure to TEHP was associated with a slight 
effect on performance in two dogs.   
 
TCP Chemically, the commercial TCP mixtures have changed over time. The 
mixtures of the 1950s were more toxic and their content of TOCP was higher than 
those of later times (see Chapter 4) (141).  
The effects of TOCP on brain NTE, spinal cord NTE, severity of clinical ataxia 
and neuropathology scores were investigated after single oral doses of 50, 90 or 
500 mg/kg bw in hens. There was a clear dose-response on NTE inhibition, clinical 
ataxia and severity of nervous system lesions for the dose-range tested with effects 
starting already at the lowest dose (54). 
Hens were treated with TOCP by gavage at single dosages of 375 and 750 mg/kg 
bw. Twenty-one days after treatment, the levels of neurofilament units in sciatic 
nerves were decreased at both dose levels (265).  
In another experiment by the same research team, hens were given 750 mg/kg 
bw by gavage. Downregulation of neurofilament mRNA in the cerebral cortex was 
observed after 21 days (264). 
 Three strains of chicken were treated with TOCP by gavage. Babcock chickens 
were given a single dose of 800 mg/kg bw whereas Hy-line w36 and isobrown 
chickens were treated with 1 600 mg/kg bw. All groups exhibited decreased brain 
NTE (by 72-86 %) and plasma cholinesterase (by 40-60 %) activities after 24 
hours. Brain cholinesterase activities were unaffected. Clinical signs of OPIDN 
were observed only among the isobrown chickens (43). 
Adult male Long Evans rats were exposed to TOCP over a 63-day period in a 
setting of chronic stress. TOCP was administered in 14 gavage doses of 75, 150  
or 300 mg/kg bw. To model aspects of chronic stress, corticosterone was added  
to the drinking water at 400 µg/ml. The major neuropathological change was the 
presence of axonal degeneration progressing to myelinated fibre degeneration, 
mainly in distal regions of selected fibre tracts and peripheral nerve, seen in 
animals sacrificed on experimental day 63. The cervical spinal cord and medullary 
levels of the sensory gracile fasciculus were most prominently affected. This axono-
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pathy/fibre degeneration was dose-related at the 150- and 300-mg/kg bw levels 
(no effect at 75 mg/kg bw) and was associated with inhibition of the enzyme NTE 
in hippocampal tissue. Corticosterone did not appear to contribute to the neuro-
pathic events or the enzyme inhibition. A cohort of high-dose rats was maintained 
on the corticosterone schedule (corticosterone or vehicle) without further exposure 
to TOCP for an additional 27 days. When these rats were examined on day 90, the 
nerve fibre degeneration had progressed in both groups administered the 300 mg/ 
kg bw dose of TOCP, although hippocampal NTE had returned to control values 
(112). 
Adult male Long Evans rats were exposed to TOCP at 75, 150 or 300 mg/kg bw 
given 7 times orally in a 2-week period. Corticosterone was added to drinking 
water (400 µg/ml) for a total of 28 days in order to study the interaction of stress 
and exposure to TOCP. At the end of the 28-day testing period, the rats were 
sacrificed. Decreased body weight and grip strength were elicited by TOCP and 
corticosterone. The body weight was reduced at all TOCP doses and significantly 
so at 75 and 300 mg/kg bw. A reduction of grip strength was observed only at the 
highest TOCP dose in combination with corticosterone. TOCP alone decreased 
acetylcholinesterase levels in erythrocytes and in several areas of the brain, e.g. 
cortex, hippocampus, basal forebrain and caudate putamen, at all dose levels. The 
NTE and carboxylesterase activities were also significantly reduced in the same 
areas of the brain at all doses. The glial fibrillary acidic protein in the cerebral 
cortex was significantly increased by both TOCP and corticosterone at all doses 
(53).  
A rodent model of OPIDN was developed using adult Long Evans male rats 
exposed to TOCP. The rats were exposed to single doses of TOCP ranging from 
145 to 3 480 mg/kg bw. Decreased body weight (transient at 145-1 160 mg/kg bw) 
was reported. The degree of NTE inhibition, measured at 20 and 44 hours and at 
14 days post-exposure, correlated with the appearance of spinal cord pathology  
14 days post-exposure in a separate group of similarly exposed rats. Dosages that 
inhibited mean NTE activity in spinal cord more than 72 % and in brain more than 
66 % of control values produced marked spinal cord pathology 14 days post-
exposure in more than 90 % of similarly dosed animals. In contrast, dosages of 
TOCP which inhibited mean NTE activity in the spinal cord less than 65 % and in 
the brain less than 57 % produced spinal cord pathology in less than 15 % of the 
animals. The NTE inhibition was non-significant at 145 and 290 mg/kg bw and 
became manifest at 580 mg/kg bw (181). 
Adult male European ferrets (Mustela putorius furo) were exposed to a single 
oral or dermal dose of 250, 500 or 1 000 mg TOCP/kg bw. Corn oil served as the 
vehicle in the oral test and 95 % ethanol was the vehicle in the dermal test. In the 
dermal test, TOCP was applied to a 6 × 6 cm shaved area on the back of the neck. 
At 48 hours post-treatment, half of the animals in each group were killed by 
cervical dislocation for assessment of whole-brain NTE activity. The remaining  
5 animals per group were observed and examined neurologically on a daily basis 
for 54 days. Of the animals dosed orally, only those in the 1 000 mg/kg bw group 
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showed clinical signs indicative of OPIDN. Ferrets dermally administered 250 and 
500 mg/kg bw displayed variable degrees of hind limb weakness and ataxia. All 
ferrets dosed dermally with 1 000 mg/kg bw developed clinical signs characteristic 
of OPIDN ranging from ataxia to partial paresis. Small amounts of axonal de-
generation were also noted in the dorsolateral part of the lateral funiculus and in 
the fasciculus gracilis of spinal cords in high-dose ferrets. The decrease of whole-
brain NTE activity was dose-dependent (18, 25 and 46 %) after dermal dosing 
(214).  
Socialised and non-socialised, stressed and unstressed male and female chickens 
were administered a single peroral TOCP dose of 360 mg/kg bw. TOCP induced  
a delayed neuropathy that caused ataxia in all the chickens. The ataxia was sig-
nificantly more pronounced earlier in males than in females, although the sex 
difference became insignificant 18 days after dosing. Socialised chickens were 
ultimately more affected, with the most notable effects again seen in socialised 
males. This indicated that response to an organophosphate neurotoxicant was also 
dependent on sex and socialisation (175). 
Hens received both TOCP (single dose of 0.5 ml equivalent to 600 mg/kg bw  
by gavage) and different nicotinic acid derivates. TOCP caused complete motor 
paralysis by day 15. A significant alleviation of ataxia was observed when these 
nicotinic acid compounds were administered daily for 10 days starting 2 days 
before treatment with TOCP. The onset of paralysis was delayed for several days 
by these agents, but complete prevention of the neurotoxic symptoms was not 
achieved. However, the mode of action of this alleviation is unknown (34).  
White Leghorn cockerels given 25-800 mg/kg bw of TOCP orally exhibited 
paralysis (1/4 at the lowest dose, 4/4 at the highest doses). After administration of 
1 000 mg/kg bw, a 67 % decrease of plasma cholinesterase activity was observed. 
Brain and spinal cord acetyl cholinesterase activity decreased with 14 and 32 %, 
respectively. No neurotoxic effects were observed in cockerels given TMCP or 
TPCP orally as single doses of 1 000 and 5 000 mg/kg bw or 1 000 mg/kg 5 times 
on alternate days (84). 
In a review paper, Johnson summarised data showing that TOCP at single oral 
doses of 100-250 and 25-400 mg/kg bw was neurotoxic to the hen. In contrast, 
TMCP at single oral doses of 1 200 and 2 000-2 500 mg/kg bw was not. Repeated 
oral dosing of 1 000 mg/kg bw of TMCP (every 2nd day for 5 days) and 210 mg/ 
kg bw for 20 days did not induce a neurotoxic response, whereas a higher total 
dose of 12 500 mg/kg bw did (presumably 500 mg/kg bw for 25 days) (94, 109). 
Hens administered TPCP exhibited no neurotoxic response after single doses 
(1 200 or 2 500 mg/kg) or after repeated dosages up to a total dose of 25 000 
mg/kg bw (94, 109). 
In a study evaluating neurotoxicological responses of a series of phosphate 
ester, a behavioural neurotoxic response was observed in 4/4 hens administered 
300 mg/kg bw of TOCP for 5 days. Histology was not performed. TCP given to 
hens in oral doses of 10 000 mg/kg bw twice a day for 3 days resulted in both 
behavioural (6/6) and histological (6/6) neurotoxic responses (106) (Table 12). 
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In a review, Weiner and Jortner summarised the research (including non-peer 
reviewed industrial reports) on OPIDN of triarylphosphates. In one acute study, 
commercial undiluted TCP (Kronitex® TCP) was marginally neurotoxic to hens at 
levels of 150-300 mg/kg bw and higher. Another commercial TCP (Durad® 125L) 
also caused neurotoxic effects (251). 
The neuropathic effects of TCP (mixed isomers), TOCP and TPCP were in-
vestigated on differentiating mouse N2a neuroblastoma cells. TCP inhibited the 
outgrowth of axon-like processes following exposures of 24 or 48 hours. Dose-
response experiments indicated that TCP and TOCP exhibited similar sustained 
levels of toxicity after both 24 and 48 hours of exposure. The 50 % inhibitory 
concentration in the medium was 0.7 mg/l. By contrast, TPCP demonstrated a 
transient effect on the outgrowth of axon-like processes, which was detectable 
after 24 but not after 48 hours of exposure. The inhibitory effect on axon out-
growth of TOCP, but not TPCP, was enhanced in the presence of a microsomal 
activation system (68).  
The NTP has performed 13-week and 2-year gavage and feed studies in rats and 
mice (described below and in Section 10.6). The TCP mixture comprised 18 % 
dicresyl phosphate esters and 79 % TCPs with 21 % TMCP and 4 % TPCP and no 
detectable TOCP (< 0.1 %) (174). 
 Groups of 10 male and 10 female F344/N rats and B6C3F1 mice received TCP 
in corn oil by gavage at doses of 0, 50, 100, 200, 400 or 800 mg/kg bw for 13 
weeks. All rats and mice survived at all dose levels. In mice, forelimb and hind-
limb grip strength of 400- and 800-mg/kg males and females was significantly 
lower than for controls. Forelimb and hindlimb grip strength of 200-mg/kg fe-
males and hindlimb grip strength of 200-mg/kg males were also significantly 
lower than that of controls. There were significant dose-related decreases in serum 
cholinesterase activities in all dosed groups. The principal lesions occurred in the 
ovary, adrenal gland, spinal cord and sciatic nerve. Multifocal axonal degeneration 
of the spinal cord and sciatic nerve was observed in mice receiving 100 mg/kg bw 
or greater. The number of affected axons generally increased with dose. In rats, the 
only neurobehavioural measure affected by the exposure was a slight but significant 
reduction of hindlimb grip strength in female rats receiving 400 and 800 mg/kg 
bw (174).  
Groups of 95 male and female F344/N rats and 95 male and 95 female B6C3F1 
mice were fed diets containing TCP for 105 weeks. Rats were fed diets containing 
0, 0.075, 0.15 or 0.3 g/kg of the TCP mixture (estimated doses for males were 3,  
6 or 13 mg/kg bw/day and for females 4, 7 or 15 mg/kg bw/day). An additional 
group of animals were given 0.6 g/kg in their diet for 22 weeks and then received 
only control feed. Hindlimb grip strength was significantly reduced in 0.3-g/kg 
males and in both sexes at 0.6 g/kg at the 3-month evaluation but not at the 9- and 
15-month evaluations. At 9 months, serum cholinesterase activities of 0.15-g/kg 
males and 0.3-g/kg females were significantly lower than those of controls. At 15 
months, serum cholinesterase in all exposed groups of females and in high-dose 
males were significantly lower than those in the controls (174).  
  
 55 
Mice were fed diets containing 0, 0.06, 0.125 or 0.25 g/kg of the TCP mixture 
(estimated doses for males were 7, 13, 27 mg/kg bw/day and for females 8, 18 or 
37 mg/kg bw/day). There were no effects on survival, feed consumption, body 
weight or clinical findings. Hindlimb grip strength was significantly reduced in  
the 0.25-g/kg females in the 3-month evaluation but not in the 9- and 15-month 
evaluations. Serum cholinesterase activities were significantly reduced in a dose-
related manner in both sexes at and above 0.06 g/kg at all time points (174).  
Hens were exposed to generic aviation engine oil containing 0.5, 1 or 3 % TCP 
(10, 20 or 60 mg/kg bw/day) by oral gavage 5 days/week for 10 weeks. One group 
of hens received 0.5 % TOCP (10 mg/kg bw/day) during the same time period. 
Higher incidences of clinical ataxia and ataxia of greater severity were observed  
in hens that received 3 % TCP (60 mg/kg bw/day TCP containing 0.24 mg/kg/day 
TOCP) than in hens that received 10 mg/kg bw/day TOCP in corn oil. A similar 
pattern was observed regarding inhibition of plasma cholinesterase, brain NTE, 
and spinal cord NTE activities (Table 10). Thus, the clinical findings and the 
enzyme inhibitor effects could not be explained by the content of TOCP in TCP. 
At 10 mg/kg bw of TCP, 1/30 died. None had ataxia or neuropathological lesions. 
Among animals exposed to 10 mg/kg bw of TOCP, there was no mortality or 
ataxia. Neuropathological lesions (moderate or severe) were present in 3/10 (70).  
Synthetic polyol-based lubricating oils containing 3 % of commercial TCP 
additive were evaluated for neurotoxicity in hens. Groups of 17-20 hens were 
administered the oils by oral gavage at a dose of 1 000 mg/kg, 5 days/week for 13 
weeks. NTE activity in brain and spinal cord of hens dosed with the lubricating 
oils was not significantly different from saline controls after 6 weeks of treatment. 
After 13 weeks of dosing, brain NTE was inhibited 32-34 % in lubricant-treated 
hens. Clinical assessments of walking ability did not indicate any differences be-
tween the control group and lubricant-treated hens. Neuropathological examination 
revealed no alterations indicative of OPIDN. The authors concluded that the results 
indicated that synthetic polyol-based lubricating oil containing up to 3 % TCP had 
low neurotoxic potential and should not pose a hazard under realistic conditions  
of exposure (41). 
 
Table 10. Percentage inhibition of plasma ChE, brain NTE and spinal cord NTE 
activities in hens given TCP or TOCP in engine or corn oil by oral gavage. Adapted  
from Freudenthal, 1993 (70).  
Exposure  
(5 days/week, 10 weeks) 
Daily dose 
(mg/kg bw/day) 
Plasma ChE 
(%) 
Brain NTE 
(%) 
Spinal cord 
NTE (%) 
Engine oil, 3 % TCP 60 49 77 62 
Engine oil, 1 % TCP 20 27 55 34 
Engine oil, 0.5 % TCP 10  23a 47 24 
Engine oil, 0.5 % TOCP 10 41 68 52 
Corn oil, 0.5 % TOCP 10 44 71 55 
Engine oil, no TCP (control) 0 0  0 0 
a
 Non-significant. All other values were significantly different from controls. 
ChE: cholinesterase, NTE: neurotoxic or neuropathy target esterase. 
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In an early study, groups of 3-4 female rabbits were exposed dermally to 0.25, 
0.5, 1, 2 or 5 ml (300, 600, 1 200, 2 400 or 6 000 mg) of a commercial TCP mix-
ture for 2 hours/day, 5 day/week for several weeks. Death, which was produced  
by doses as low as 0.25 ml (300 mg), was preceded by ataxia and tremors. De-
generative changes were seen in the brain of rabbits that died (Treon et al 1955, 
cited in (215)). The study is also described in Section 10.3. 
In another study from the 1950s, mortality was very high in rabbits exposed to 
TCP aerosols at concentrations of 5 900 - 42 200 mg/m3 for periods of 3 hours to 
18 days. The rabbits had considerably increased nasal and oral discharge during 
and immediately following exposure and respiratory difficulties. Diarrhoea was 
also seen. Delayed neuropathy was evident, progressing from hyperexcitability to 
tremors, gait impairment, and in several animals, paralysis of the hind legs. Serum 
cholinesterase was depressed (Broadhurst et al 1951, cited in (215)). 
In continuous inhalation studies (36-163 days) conducted with a mist of a triaryl 
phosphate hydraulic oil (containing TCPs, trixylenyl phosphates and other trialkyl-
phenyl phosphates and with an ortho-cresyl content less than 1.5 %) at concentra-
tions of 1.8-110 mg/m3, 23/27 White Vantress hens exhibited neurotoxic signs at 
23-110 mg/m3, whereas 13/14 birds exposed at 1.8-4.4 mg/m3 appeared normal. 
At repeated exposures (8 hours/day, 5 days/week, 6 weeks), neurotoxic signs were 
noted at 50 mg/m3 but not at 25 mg/m3. Demyelination was not demonstrable in 
nerve tissue of hens exhibiting marked neurotoxicity. Inhalation data for dogs, 
rabbits, rats and monkeys are presented in Appendix I. Oral data in hens indicated 
that the minimally effective neurotoxic dosage was 4-5 times that of TOCP (201).  
 
TBEP Groups of randomised female and male Sprague Dawley rats (in total 10 
rats/sex, i.e. 1-4 animals/group) were administered a single oral dose of undiluted 
TBEP (1 000-3 200 mg/kg bw for females, 1 000-9 000 mg/kg bw for males). 
Physiological parameters were measured in surviving rats 3 weeks following 
TBEP administration. A significant reduction in caudal nerve conduction velocity 
was observed in females (1 750-3 200 mg/kg bw) and males (3 200-9 000 mg/kg 
bw). Light and electron microscopic examination of sciatic nerve sections showed 
degenerative changes in both myelinated and unmyelinated fibres of female (2 000 
mg/kg) and male (6 800 mg/kg) groups. Advanced degeneration was observed 
only at the highest dose levels of both genders (3 200 mg/kg for females, 8 000 
and 9 000 mg/kg for males). Although similar morphological changes were ob-
served in both sexes, females were more susceptible than males to the toxic effects 
of this compound (127). 
In a 14-day repeated dose study, female Sprague Dawley rats were given 0.8 or 
1.12 ml/kg bw (800 or 1 140 mg/kg) and male rats 0.8 or 2.14 ml/kg bw (800 or 
2 280 mg/kg) of TBEP. Electrophysiological measurements were made on days 15 
and 28. A significantly decrease in body weight among low-dose females was 
observed at day 7 but not at day 14. The conduction velocity in the caudal nerve 
was significantly lower in high-dose females than in controls after 14 days. The 
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relative refractory period was longer in low- and high-dose males after 14 days. 
No morphological changes were found using light or electron microscopy (126).  
In another study, male and female Sprague Dawley rats were given 0, 0.25 and 
0.5 ml/kg bw (250 and 500 mg/kg) of TBEP, 5 days/week for 18 weeks. Ob-
servations were made after 6, 12 and 18 weeks. A few females (2/12) from the high-
dose group showed transient muscular weakness and ataxia at the beginning of the 
experiment, which disappeared 4 weeks later. At the latter half of the study, almost 
all treated animals seemed affected by TBEP. Tremor, piloerection, lacrimation 
and increased urination were observed in the high-dose group. Electrophysiological 
changes were observed at 18 weeks in all dosed animals and included a significant 
reduction in nerve conduction velocity as well as increased refractory periods. Most 
of the treated animals exhibited some degeneration of myelin sheaths accompanied 
by axonal swelling and an advanced stage of degeneration in sciatic nerve, as 
examined by light and electron microscopy. There was no morphological sex 
difference. According to the authors, unmyelinated nerve fibres of rats fed TBEP 
were more affected than those of animals treated with TOCP (124).  
In another study performed by the same research team, Sprague Dawley rats 
were dosed by gavage 0.25 or 0.5 ml TBEP/kg bw/day (250 or 500 mg/kg bw  
per day). At 18 weeks, there was a 5-7 % lower erythrocyte acetylcholinesterase 
activity in both dose groups compared to controls in males but not in females. 
Breathing difficulties and ataxia were observed in both dose groups though the 
low-dose group was less affected. Tremor, piloerection, lacrimation and increased 
urination were observed in the high-dose group (122). 
Wistar rats (15/dose group) were given a diet containing 0, 0.3, 3 or 30 g/kg of 
TBEP for 14 weeks. The 0.3 mg/kg diet dose corresponded to 20 and 22 mg/kg 
bw for males and females, respectively. Suppression of body weight gain was ob-
served in both sexes at 30 g/kg diet. Serum cholinesterase was significantly de-
creased in both sexes at 3 and 30 g/kg diet (189).  
Sprague Dawley rats (20/sex/dose group) were fed diets containing 0.3, 3 and 
10 g/kg of TBEP corresponding to 15, 150 and 500 mg/kg bw for 18 weeks. No 
clinical signs of neurotoxicity were observed. The only neurophysiological 
alteration observed was reduced caudal nerve conduction velocity in high-dose 
females. There were no treatment-related changes in peripheral nerve or spinal 
cord histopathology. In the groups exposed to 150 and 500 mg/kg bw, there was  
a decrease of plasma cholinesterase activity (Monsanto 1987a, b, cited in (103)). 
Hens were killed 24 hours after a single dose of TBEP, TOCP or TBP, equal  
to the greater of either the LD50 or 5 000 mg/kg bw. TOCP resulted in heavy in-
hibition of the NTE activity but TBEP and TBP did not inhibit the NTE activity  
to an extent (> 70 %) which earlier was expected to result in OPIDN. TOCP and 
TBEP decreased plasma cholinesterase activities (Table 11) (32). 
In an acute delayed neurotoxicity study in hens, two doses of 5 000 mg TBEP/ 
kg bw were given 21 days apart. Another group of hens were given two dermal 
doses of 5 000 mg/kg bw. All animals survived. Each dose was followed by an 
atropine antidote treatment for 5 days. Two hens dosed orally had equivocal 
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Table 11. Effect of single doses of TOCP, TBEP and TBP on the activity of hen brain 
NTE, brain AChE and plasma ChE. Adapted from Carrington 1989 (32).  
Compound Single dose 
(mg/kg bw) 
Brain NTE  
(%) 
Brain AChE  
(%) 
Plasma ChE  
(%) 
Control  100 100 100 
TOCP  750  8 88 28 
TBEP  5 000  102 55 13 
TBP  1 500  88 97 269 
AChE: acetylcholinesterase, ChE: plasma cholinesterase, NTE: neurotoxic or neuropathy target 
esterase.  
 
focal swollen axons in the spinal cord. No lesions were observed in the hens dosed 
dermally. The lesions seen in the control animals and those exposed to TBEP were 
of minimal severity and representative of spontaneously occurring nervous system 
lesions in hens of this age (32).  
Groups of 5 male and 5 female Wistar rats were exposed for 4 hours to air 
TBEP concentrations of 3 300, 3 400 or 6 400 mg/m3. No animal died but at all 
concentrations the animals exhibited depressed and irregular respiration, increased 
salivation, sneezing, unsteadiness and tremor. No dose-response information was 
presented. Symptoms cleared in most animals 9 days later. Body weights did not 
change and gross necropsy revealed no abnormalities (Hoechst 1989, cited in (103)).  
In summary, TBEP was neurotoxic in rats but did not produce OPIDN in hens. 
Female animals seem to be more susceptible to the neurotoxic effects of TBEP but 
the results are not consistent.  
 
TBP Male and female adult Sprague Dawley rats received TBP in corn oil by 
gavage as a single dose (100, 325 and 1 000 mg/kg bw) and repeatedly for 3 months 
(32.5, 100 and 325 mg/kg bw/day). Behavioural evaluations were performed in 
both studies and neuropathological evaluations in the 3-month study only. In the 
acute study, mean body weight gain decreased significantly compared to controls 
in males at 1 000 mg/kg bw. At the same dose level, transient changes attributable 
to the general toxicity were noted in forelimb grip strength and mean activity level 
during the first 24 hours after dosing. In the subchronic study, high-dose (325 mg/ 
kg bw) males and females had significant body weight decreases. Some mortality 
also occurred at this dosage level. Postdosing salivation was observed rarely at 
32.5 mg/kg bw, frequently in the mid-dose group and on almost all occasions at 
the highest dose. Motor activity levels and qualitative and quantitative functional 
observational battery measurements were comparable between treatment and con-
trol groups, and there were no gross or neurohistopathological findings indicative 
of treatment-related effects. Based on these study results, TBP was considered not 
neurotoxic to rats following either acute or subchronic exposures (80).  
TBP was administered orally to male and female Sprague Dawley rats for 14 
consecutive days at doses of 0.28 and 0.42 ml/kg bw (270 and 410 mg/kg bw).  
A significant reduction in conduction velocity of caudal nerve was observed in 
high-dose males. Electron microscopic examination of sciatic nerve showed 
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morphological changes such as retraction of Schwann cell processes surrounding 
unmyelinated fibres in both sexes of high-dose groups (125).  
In a 10-week toxicity study, male Wistar rats (n=10-11/group) were given TBP 
(> 97 % purity) via the diet at doses of 5 and 10 g/kg (equivalent to approximately 
0, 500 or 1 000 mg/kg bw/day (44)). The cholinesterase activity in the brain was 
significantly increased in both treatment groups, but no significant changes were 
observed in serum and liver cholinesterases activities compared to the control 
group (177).  
Carrington and co-workers assessed the delayed neurotoxicity of some phos-
phate esters including TBP. To determine the dosage to be used, hens were given 
gelatin capsules of TBP of varying doses (from 500 to 5 000 mg) to determine 
LD50, which was 1 500 mg/kg bw. The animals exhibited signs of cholinergic 
toxicity, including salivation, diarrhoea, and impaired respiration, which lasted for 
2-4 days. Animals surviving the period of acute toxicity appeared normal there-
after and no clinical signs of OPIDN were observed. Enzyme activities were 
investigated in 5 hens 24 hours after a single oral dose of 1 500 mg/kg bw. The 
activity of brain NTE or of brain acetylcholinesterase in the treated group was  
not significantly different from the controls. Contrary to other phosphate triesters 
(TOCP and TBEP), TBP caused a significant increase of plasma cholinesterase 
activity (Table 11). In addition, 20 hens were given 2 oral doses of TBP gelatine 
capsules (98 % purity), equivalent to the LD50 (1 500 mg/kg bw), 21 days apart. 
Hens were treated with atropine sulphate (15 mg/kg bw) 3 times daily for 5 days 
following dosing to protect against cholinergic effects. The animals were killed  
21 days after the second dose. The lesions seen in the control animals and those 
exposed to TBP were of minimal severity and representative of spontaneously 
occurring nervous system lesions in hens of this age. None of the hens exhibited 
treatment-related clinical signs or peripheral nerve, spinal cord or brain injury. The 
conclusion was that TBP do not produce OPIDN (32, 33).  
Groups of approximately 10 hens were exposed orally to some phosphate esters. 
Undiluted corn oil solutions with 1 840 mg TBP were administered for two con-
secutive days. The birds (n = 9) were observed daily for possible neurotoxic re-
actions throughout the total 42-day test period. The hens were sacrificed on test 
day 42 and subjected to a gross pathologic and microscopic examination of the 
brain, sciatic nerve and spinal cord. No signs of neurotoxicity were observed 
regarding behaviour or histology (Table 12) (106). 
Intratracheal administration of 5 µl (5 mg) TBP in rats (body weight 280-300 g, 
estimated dose 17 mg/kg bw) resulted in a mild inhibition of serum cholinesterase 
(20 %) on the first day only (191). The study is also described in Section 10.2.  
Rats and rabbits were exposed to TBP concentrations in air up to 4.8 mg/m3,  
5 hours/day, 5 days/week for 4 months. The cholinesterase activity in erythrocytes 
or serum was unaffected. Exposure to 13.6 mg/m3 caused a 33 % inhibition after  
3 months (Kalinina 1971, cited in (47)). According to DFG, the study was in-
sufficiently documented as there were no data for control animals, number or type 
of animals used or analytical monitoring of the exposure level (47).  
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Skydrol 500B-4 is a fire resistant hydraulic fluid composed of 80-90 % phos-
phate esters including dibutyl phenyl phosphate and TBP. Rats inhaled an aerosol 
of 0, 5, 100 and 300 mg/m3, 6 hours/day, 5 days/week for 6 and 13 weeks. Nasal 
discharge was noted among 47/50 mid-exposure rats and 50/50 high-exposure rats 
during the first week of exposure. The incidence of the nasal discharge decreased 
over the course of the study. Plasma cholinesterase levels decreased significantly 
among high-exposure females but not among male rats (81).  
In summary, TBP produced neurotoxic effects in one study in rats but has not 
produced OPIDN in hens.  
 
TCEP The NTP has performed 16-day, 16- or 18-week and 2-year-studies in rats 
and mice administered TCEP by gavage (described also in Sections 10.3 or 10.6). 
In the 16-day study, groups of five F344/N rats and B6C3F1 mice of each sex 
received TCEP in corn oil by gavage 5 days/week with 12 doses over 16 days. 
Rats were given 0, 22, 44, 88, 175 or 350 mg/kg bw. No clinical signs of toxicity 
were observed. Serum cholinesterase activity was significantly reduced in female 
rats administered 175 mg/kg and 350 mg/kg. The activity was approximately 80 % 
of that of controls. No gross or histopathological lesions attributable to TCEP ex-
posure were observed. Mice received 0, 44, 88, 175, 350 or 700 mg/kg bw. Mice 
given 350 or 700 mg/kg bw exhibited ataxia and convulsive movements during 
the first 3 days of dosing. The serum cholinesterase activities were not considered 
chemical-related. No effects on body or organ weights were observed and no histo-
pathological lesions attributable to TCEP (173).  
In the subchronic study, groups of ten F344/N rats of each sex received 0, 22, 
44, 88, 175 or 350 mg/kg bw of TCEP in corn oil by gavage 5 days/week for 16 
weeks (female) and 18 weeks (male). Female rats receiving 175 or 350 mg/kg bw 
experienced occasional periods of hyperactivity after dosing. Periodic convulsions 
were noted in high-dose females during week 12. Female rats receiving 175 or 350 
mg/kg bw had serum cholinesterase activity levels that were 75 % or 59 % of the 
control value, respectively (p < 0.01). The serum cholinesterase activity was not 
reduced in male rats. Necropsy examination showed no gross lesions attributable 
to chemical exposure. However, necrosis of neurons of the hippocampus was 
observed histologically in the brains of 10/10 females and 2/10 males receiving 
350 mg/kg TCEP and in 8/10 females receiving 175 mg/kg. In the more severe 
lesions, mineral deposits were present in the affected areas of the brain. In the 
high-dose females, neuronal necrosis was also observed in the thalamus (149, 173).  
In the corresponding study on mice, groups of ten B6C3F1 mice of each sex 
received 0, 44, 88, 175, 350 or 700 mg/kg bw of TCEP in corn oil by gavage 5 
days/week for 16 weeks. Serum cholinesterase activities were not different from 
controls. Necropsy examination showed no gross lesions attributable to chemical 
exposure (173). 
In the chronic study, groups of 60 male and 60 female F344 rats received 0,  
44 or 88 mg TCEP/kg bw, 5 days/week by gavage for 103 weeks. At 103 weeks, 
there were no adverse effects on the body weight gain and no clinical signs of 
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toxicity. A marked increase in the incidence of degenerative lesions of the brain 
stem and cerebrum (thalamus, hypothalamus and basal ganglia) such as gliosis, 
haemorrhage, necrosis and mineralisation was noted at 88 mg/kg in approximately 
40 % of females compared to 2 % of controls. Similar lesions occurred in a few 
male rats, but these lesions were not clearly related to exposure (150, 173).  
TCEP was given to male ICR mice in order to study spontaneous ambulatory 
activity and to examine the neurochemical mechanism of this effect. The am-
bulatory activity was measured for 2 hours after exposure in 10-minute intervals. 
Single intraperitoneal injection of 200 mg/kg bw of TCEP increased ambulatory 
activity. No effect was seen at 50 mg/kg bw, whereas the activity was higher  
for the first 10 minutes after administration of the 100 mg/kg bw dose. Neither 
mecamylamine (nicotinic cholinergic antagonist) nor scopolamine (muscarinic 
cholinergic antagonist) affected the activity response to TCEP. On the other hand, 
diazepam (benzodiazepine agonist), muscimol (γ-aminobutyric acid (GABA)A 
agonist) and baclofen ((GABA)B agonist) all attenuated the effect of TCEP. Dia-
zepam and muscimol blocked the increase of activity within the first 10 minutes 
after administration of TCEP. These drugs did not attenuate the activity increasing 
effect of scopolamine, suggesting that the mechanism of TCEP action is distinct 
from that of scopolamine. Muscimol and baclofen, but not diazepam, inhibited the 
activity increasing effect of the dopaminergic agonist apomorphine, suggesting 
that dopamine is involved in the control of activity and that GABA can affect 
activity through interaction with dopaminergic neurons. These results suggest that 
TCEP acts as a GABA antagonist and not as a cholinergic agonist, and that TCEP 
increases activity in ICR mice through a GABAergic mechanism (236).  
Female F344 rats gavaged with a single dose of 275 mg TCEP/kg bw convulsed 
within 60-90 minutes and had extensive loss of CA1 hippocampal pyramidal cells 
when examined after 7 days. The seizure-related and neurohistological effects of 
TCEP were significantly attenuated by pre-treatment with atropine or chlordiaz-
epoxide, suggesting that the hippocampal damage was related to the seizures pro-
duced by TCEP. In a second experiment, female rats were exposed to 275 mg/kg 
bw. Three weeks after dosing, the animals were trained on a spatial memory task 
in a water maze. The exposed rats were consistently impaired in performing a re-
peated acquisition task in the water maze. These data support the conclusion that 
the hippocampus is intimately involved in spatial memory in rats (230).  
Single administration of TCEP (175, 350 or 700 mg/kg bw) induced seizures in 
rats. All animals receiving 700 mg/kg by gavage exhibited seizures within 1 hour 
after dosing. Most animals receiving 350 mg/kg also had seizures within 1 hour 
but not as severe as the high-exposed group. Seizures in females progressed over 
12 hours and were occasionally noted 24 hours after dosing. Males experienced 
seizure activity within 1 hour after receiving 350 mg/kg but showed no signs of 
seizure activity 4 hours following dosing. Only mild occasional seizures were pre-
sent at 175 mg/kg. In an experiment with repeated doses, all female rats dosed 
with 350 mg/kg/day showed seizures and died within 7 days. The authors con-
cluded that the low levels of TCEP found in brain tissue at the time of seizures 
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indicated that TCEP is a potent neurotoxicant. There was no sex difference in the 
brain TCEP concentration (83).  
White Leghorn hens (12 months old) were orally exposed to 420 mg TCEP/kg 
bw/day for 5 consecutive days. After 21 days of observation, there were no signs 
of neurotoxicity as compared to TOCP (positive control), which induced inability 
to walk, hypertension, ataxia and prostration (Bullock and Kamienski 1972, cited 
in (102)).  
The neurotoxic effects of TCEP were evaluated in adult (12-14 months old) 
White Leghorn hens given 14 200 mg/kg bw of the chemical in corn oil followed 
3 weeks later by a second dose. Four out of 18 treated hens died within 6 weeks of 
the first dose. No microscopic changes in brain, spinal cord or sciatic nerve were 
found. In a separate group of hens, the activities of brain NTE and plasma cholin-
esterase were determined 24 hours after the first dose of TCEP. Plasma cholin-
esterase activity was inhibited by 87 % and brain NTE activity by 30 %. No de-
layed neurotoxicity was observed (209). 
In summary, TCEP was neurotoxic in rodents but did not produce OPIDN in 
hens. Female rats appear to be more sensitive regarding effects on the nervous 
system than males.  
 
TDCPP Chicken (sex not given) exposed orally to TDCPP at doses of 600, 1 200, 
2 400 or 4 800 mg/kg bw for 5 days exhibited leg and wing weakness at doses of 
1 200 mg/kg or more and 100 % mortality at 4 800 mg/kg. TDCPP was estimated 
to have 5 % of the activity of TOCP in producing paralysis. No further details 
were given (102, 235). 
White Leghorn hens, 12 months old, were orally exposed to 420 mg/kg bw of 
TDCPP for 5 consecutive days. After 21 days of observation, there were no signs 
of neurotoxicity, whereas TOCP, used as a positive control, induced inability to 
walk, ataxia and prostration (Bullock and Kamienski 1972, cited in (102)).  
Groups of 50 male and 50 female Sprague Dawley rats received approximately 
0, 5, 20 and 80 mg TDCPP/kg/day by dietary administration for 2 years. There 
was a slight decrease in plasma cholinesterase activity in females at 80 mg/kg, 
although erythrocyte acetylcholinesterase was unaffected. No further sex 
differences were reported (Aulette and Hogan 1981, cited in (102)). The study  
is also described in Section 10.6. 
 
TEHP Hens were administered a single dose of 250, 500 or 1 000 mg TEHP/kg 
bw by gavage. The animals were observed for 2 months and examined for neuro-
toxicity twice weekly. No abnormalities in behaviour were detected. A single 
intramuscular injection of the same doses did not induce any signs of intoxication 
(Kimmerle 1958, cited in (103)).  
TEHP was studied for its neurotoxic effects in four groups of female chickens 
who received a single dose into the crops as follows: 0, 500 or 2 500 mg TEHP/ 
kg bw or 500 mg TOCP/kg bw as a positive control. The animals were observed 
for 4 weeks. The positive controls (TOCP) had apparent weight loss by the end  
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of the first week and muscular weakness and ataxia were evident by the 12th  
day. The chickens in the TEHP exposed group and unexposed controls appeared 
normal and maintained or gained weight throughout the study. There were no 
macroscopic or microscopic signs of neurotoxicity (140). 
Two cats were administered 1.0 ml (926 mg) TEHP/kg bw by gavage, 5 days/ 
week for 4 weeks. Measurements of erythrocyte acetylcholinesterase activity 
during the test period revealed no inhibitory effects (Bayer 1958, cited in (103)).  
In a 3-month inhalation study, groups of 20 male guinea pigs each were exposed 
to TEHP aerosol for 6 hours/day, 5 days/week for a total of 60 exposures. The 
mean concentrations were 0, 1.6 and 9.6 mg/m3. The mean particle size was 3.8 
µm, respectively. Plasma and erythrocyte cholinesterase activities were unaffected 
in terminal blood samples. Histopathological examination of the spinal cord and 
sciatic nerve showed no pathologic changes (140).  
In a similarly designed study, groups consisting of equal numbers of males and 
females and comprising 2 dogs and 2 rhesus monkeys were exposed to TEHP 
aerosols. Mean exposure levels during the 12-week period were 10.8, 26.4 and 
85.0 mg/m3, respectively. The median particle size was 4.4 µm. Plasma and 
erythrocyte cholinesterase activities were unaffected. No effects were detected in 
the performance of monkeys in a visual discrimination test. The performance of 
dogs trained in conditioned avoidance deteriorated as the exposure concentration 
increased. The percent missed avoidance was 18 % in the high-dose group, 10 % 
in the mid-dose group, 0 % in the low-dose group and 5.8 % in controls (140). The 
study is also described in Section 10.3.  
In a 2-year NTP study, TEHP was administered 5 days/week for 103 weeks to 
groups of 50 male and 50 female F344/N rats and B6C3F1 mice. Male rats received 
2 000 or 4 000 mg/kg bw, female rats received 1 000 or 2 000 mg/kg bw and male 
and female mice received 500 or 1 000 mg/kg bw. No nervous system lesions were 
observed at histopathological examination (172). The study is described in more 
detail in Section 10.6. 
 
TEP The narcotic effect of TEP was tested in rats and mice by intraperitoneal 
injections. The righting reflex was considered as “lost” when an animal remained 
on its back for 30 seconds or longer. The doses effective for 50 % of the exposed 
populations (ED50s) for loss of righting reflex determined with rats were 333 
mg/kg bw for females and 412 mg/kg bw for males. The durations of the loss  
of righting reflex were about equal in males and females. Brain cholinesterase 
activity was 85 % of normal one hour after administration of 500 mg/kg bw. The 
ED50 doses for loss of righting reflex was significantly higher for weanling rats 
compared to adult rats. Male mice were less sensitive than rats to narcosis pro-
duced by TEP. The ED50 for male mice was 600 mg/kg bw. Female mice were not 
tested (21). Weanling and adult rats regained their righting reflex when the plasma 
concentration of TEP was 0.8 µmol/0.2 µl after intraperitoneal administration of 
500 mg/kg bw of TEP. The narcosis was shorter in weanlings as they regained 
their righting reflex after 11 minutes as compared to 36 minutes in adults (22). 
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TEP was given intravenously to female rats. 500 mg/kg bw resulted in deep 
anaesthesia for 4 minutes and weakness and incoordination for 2-3 hours. A 
doubled dose (1 000 mg/kg bw) resulted in deep anaesthesia with superficial re-
spiration for about 1 hour and very pronounced weakness and dyspnoea for more 
than 12 hours. There were no cholinergic symptoms at any of the doses (247). 
The serum cholinesterase activity was normal in Wistar male rats fed pellet 
diets containing 0 or 5 g/kg for 9 weeks (178) corresponding to approximately  
500 mg/kg bw/day (44). 
 
TIPP Tri-ortho-isopropylphenyl phosphate was given to hens. One oral dose of 
600 mg/kg bw or 1 000 mg/kg bw for 4 days did not produce OPIDN. The 600-
mg/kg bw dose produced a slight (12 %) decrease of NTE activity, whereas the 
1 000-mg/kg bw doses had no effect on the NTE activity. A single dose of ortho-
isopropylphenyl diphenyl phosphate at 1 200 mg/kg bw caused OPIDN and a 90 % 
decrease of NTE activity. Half the dose (600 mg/kg bw) caused an NTE activity 
decrease of 84 % with no OPIDN. Di-ortho-isopropylphenyl phenyl phosphate 
gave an ambiguous result regarding OPIDN at a single dose of 1 200 mg/kg bw 
and an 85 % decrease in NTE activity. The lower dose (600 mg/kg bw) caused no 
OPIDN and a 39 % decrease in NTE activity. Tri-meta-isopropylphenyl phosphate, 
tri-para-isopropylphenyl phosphate, di-para-isopropylphenyl phenyl phosphate 
and para-isopropylphenyl diphenyl phosphate given perorally to hens at 1 000 
mg/kg bw as a single dose did not produce OPIDN (109). 
Tri-ortho-isopropylphenyl phosphate and para-isopropylphenyl diphenyl phos-
phate were not neurotoxic when given to hens at a dose of 1 000 mg/kg bw and 
10 000 mg/kg bw, respectively, twice daily for six days. However, hens receiving 
1 000 mg/kg bw/day of ortho-isopropylphenyl diphenyl phosphate twice daily for 
six days exhibited signs of OPIDN (Table 12) (106).  
Male Long Evans rats were given single oral doses of 2 000 mg/kg bw of 4 
different triisopropylphenyl phosphate products from commercial suppliers or 
physiological saline for negative control. After 24 hours, the inhibition of serum 
cholinesterase activity was 81-90 % and that of brain NTE was 35-60 %. The 
corresponding inhibition for TOCP was 98 % and 93 %, respectively (141).  
In a review, Weiner and Jortner summarised the research on organophosphate-
induced delayed neurotoxicity of triarylphosphates. In general, commercial iso-
propylated triphenyl phosphates (Kronitex® 50, 100, 200, 300; see Chapter 2) 
were negative when tested at doses of 2 000-3 000 mg/kg bw in acute OPIDN hen 
studies. The most highly substituted product, Kronitex 300, did not produce signs 
of neurotoxicity in hens at doses of 2 000, 4 000 and 8 000 mg/kg bw and was 
thus not considered neurotoxic. At a higher dose (16 000 mg/kg bw), 3/10 ex-
hibited minimal and transient ataxia with general signs of toxicity. Kronitex® 200 
gave equivocal results when given as a single dose of 20 000 mg/kg bw (1/10 hens 
exhibited ataxia). Based on two acute hen OPIDN studies, it was concluded that 
the results on Kronitex® 100 did not reveal neurotoxicity when doses were at or 
below 2 000 mg/kg bw. The results at higher doses were considered difficult to 
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interpret because of e.g. inconsistent dose-response and excessive doses often 
producing general toxicity. Kronitex® 50 was administered orally in hens at doses 
of 2 000-8 000 mg/kg bw. The product showed weak neurotoxicity at 2000 mg/kg 
bw. Nervous system lesions were noted in hens dosed at 4 000, 6 000 and 8 000 
mg/kg without a clear dose-response relationship. This product was chosen for a 
90-day subchronic OPIDN study. Groups of 20 hens were administered doses of  
0, 10, 20, 90 or 270 mg/kg bw of Kronitex® 50 in corn oil by gavage 5 days/week 
for 13 weeks. The NOAEL was 20 mg/kg bw/day. At 90 mg/kg bw, an increased 
incidence of ataxia (4/20) and lesions in the nervous system (5/10) were observed. 
At 270 mg/kg bw, the incidences of ataxia and lesions were higher (9/20 and 9/10, 
respectively) (251). 
Reofos 65® is a mixture containing 23 % TPP, 33 % isopropylated triphenyl 
phosphate (24 % ortho-isopropylphenyl diphenyl phosphate, 8 % di-ortho-iso-
propylphenyl phenyl phosphate and 1 % tri-ortho-isopropylphenyl phosphate). 
Reofos 65® caused no clinical neurotoxic effect in hens after single oral doses of 
5 000, 10 000 and 15 000 mg/kg bw. Redosing at day 22 did not result in clinical 
delayed neurotoxicity, but minor histopathological changes were found in the 
spinal cord at 10 000 and 15 000 mg/kg bw and in the peripheral nerves at all 
doses given (161). 
Hens treated twice 3 weeks apart with doses of 12, 370 or 11 700 mg/kg bw  
of isopropylated triphenyl phosphate (described in Table 3) showed no clinical 
signs of delayed neurotoxicity and only mild signs of general toxicity. Further-
more, there were no neurohistological changes suggestive of delayed neuro-
toxicity. However, the mixture produced dose-dependent inhibitions of plasma 
cholinesterase and brain NTE activities (doses as above, and in addition 180 
mg/kg bw) starting at 180 and 370 mg/kg bw, respectively (208). 
To conclude, studies on mixed isopropylated triphenyl phosphates indicate that 
some induce OPIDN in hens but are less potent than TOCP.  
 
TMCPP In a 90-day dietary study, male and female rats were given diets con-
taining 0.8-20 g/kg (corresponding to approximately 40-1 000 mg/kg bw/day (44)) 
of Fyrol PCF containing ca 70 % tris(1-chloro-2-propyl) phosphate and ca 22 % 
tris(2-chloropropyl) phosphate. Brain, plasma or erythrocyte cholinesterase 
activities were unaffected by treatment (Stauffer 1981a, cited in (238)).  
Groups of rats fed ad libitum for 14 days at levels of 4.2, 6.6, 10.6 and 16.6 g 
Fyrol PCF/kg diet (same composition as in the study above) presented no treat-
ment-related changes in cholinesterases activity (Stauffer 1980a, cited in (102, 
238)). The dietary levels correspond to 420, 660, 1 060, 1 660 mg/kg bw (44).  
The study is also described in Section 10.3.  
The neurotoxic potential of Fyrol PCF or tri(2-chloropropyl) phosphate, i.e. 
presumably tris(1-chloro-2-propyl) phosphate, was evaluated in White Leghorn 
hens. A group of 18 hens received an initial oral dose of 13 200 mg/kg bw 
followed by the same treatment 3 weeks later. The animals were sacrificed 3 
weeks after the second dose. No behavioural or histological evidence for delayed 
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neurotoxicity was seen. In a separate group of hens, there was no significant in-
hibition of brain NTE and plasma cholinesterase activities as determined 24 hours 
after the first dose of Fyrol PCF (209).  
Adverse clinical signs including depression and intermittent muscle spasms were 
observed among rats after single oral dosing of 464 mg Fyrol PCF/kg bw. Higher 
dose levels (1 260 mg/kg bw in females and 2 000 mg/kg bw in males) induced 
spasms, salivation, ataxia and spasmodic jumping (Stauffer 1970, cited in (238)).  
 
TPP White Leghorn cockerels given 500 mg/kg bw subcutaneously or 1 000 mg/kg 
bw orally did not exhibit paralysis. After oral dosing, a 35 % decrease of plasma 
cholinesterase activity 24 hours after administration was observed. Brain and spinal 
cord acetylcholinesterase activity decreased with 2 and 24 %, respectively (84). 
Inhalation exposure of mice (n = 5-7) to 363 and 757 mg/m3 for 2-6 hours re-
sulted in slightly decreased whole blood cholinesterase activities, significant only 
after exposure to the highest level for 2 hours. The animals were prevented from 
preening and therefore ingestion of TPP. In addition, mice were administered 
single oral or intraperitoneal doses of TPP (0, 10, 50, 100, 200 and 500 mg/kg bw). 
After 4 hours, the cholinesterase (not specified) activity in whole blood decreased 
in all exposed groups. After oral dosing, the cholinesterase activities were 87, 89, 
61, 54 and 30 %, respectively. The decrease in cholinesterase activity was more 
pronounced when corresponding doses (on weight basis) of TOCP were given. In 
1-2 cats given a single intraperitoneal dose of TPP (100, 200, 300 and 400 mg/kg 
bw), neuromuscular signs were observed from 200 mg/kg bw (218).  
In a limited study, cats (n = 1-2) were given subcutaneous doses of 400, 700  
or 1 000 mg/kg bw of TPP (99.99 % purity). At the lowest dose, animals did not 
become ataxic. Histological examination did not reveal any evidence of axon 
degeneration or demyelination in the spinal cord at any dose level. Thus, there  
was no evidence of OPIDN. Plasma and erythrocyte cholinesterase activities 
(investigated in the 700-mg/kg group only) were not different from controls (256).  
A group of 9 hens were exposed orally to 5 000 mg TPP/kg bw in corn oil (the 
maximum feasible dosage) twice a day for 6 days. Birds were observed daily for 
possible neurotoxic reactions throughout the total 42-day test period. Hens were 
sacrificed on test day 42 and subjected to gross pathologic and microscopic ex-
aminations of the brain, sciatic nerve and spinal cord. No signs of neurotoxicity  
or OPIDN were observed regarding behaviour or histology (Table 12) (106). 
Table 12. Delayed polyneuropathy of some phosphate esters in hens (106). 
Neurotoxic response 
(no. of positive/no. of birds) 
Compound  Cumulative dose 
(g/kg bw) 
Behaviour Histology 
TOCP 1.5 4/4 - 
TCP 60 6/6 6/6 
TBP 3.7 0/9 0/9 
Tri-ortho-isopropyl phenyl phosphate 12   0/10   0/10 
Ortho-isopropylphenyl diphenyl phosphate 12 4/9 5/9 
TPP 60 0/9 0/9 
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Young male Sprague Dawley rats were fed diets containing TPP at levels of 0, 
0.25, 0.50, 0.75 or 1.0 % for 4 months. The calculated average doses were 161, 
345, 517 and 711 mg/kg bw/day. Treatment-related decrements in growth, in the 
absence of changes in food consumption, were found at all dietary levels from 
0.5 % and above. At approximately monthly intervals, a battery of behavioural 
tests was used to assess different facets of neuromotor function including motility, 
balance, coordination and muscular strength. None of the behavioural measures 
used were affected by the treatment (203). 
Wistar rats were administered a single intraperitoneal injection of a commercial 
cresyl diphenyl phosphate preparation (75, 150 or 300 mg/kg bw) containing 
approximately 35 % of TPP, 45 % of cresyl diphenyl phosphates, 18 % of dicresyl 
phenyl phosphates and 2 % of TCP. The product was almost free of the o-cresyl 
isomers as revealed by the analysis of its alkaline hydrolysis products. The plasma 
cholinesterase activity was significantly inhibited 4 and 24 hours (38 % and 26 %, 
respectively) after the injection of 300 mg/kg bw, but the effect levelled off. In-
jection of 150 mg/kg also caused a significant decrease, whereas 75 mg/kg did  
not. No effects on the activities of cerebral and muscle acetylcholinesterase were 
observed. The treatment (300 mg/kg) inhibited a brain diesterase (2',3'-cyclic 
nucleotide 3'-phosphohydrolase) throughout the 2-week observation period and 
was associated with demyelination in peripheral nerves (244). Other components 
than TPP may have contributed to the effects of this mixture. The study is also 
described in Section 10.2.  
Effects of Reofos® 65, a mixture containing 23 % TPP and 33 % isopropylated 
triphenyl phosphate is described under the sub-heading TIPP.  
Thus, pure TPP is not neurotoxic but commercial products may contain de-
rivates generating OPIDN. 
10.5 Mutagenicity and genotoxicity  
In summary, TDCPP was genotoxic in bacterial tests, showed equivocal results  
in in vitro mammalian tests and negative results in standard in vivo tests. In vitro 
tests of mutagenicity regarding TCEP were inconsistent and an in vivo bone marrow 
micronucleus test gave equivocal results. TMCPP was not genotoxic in bacterial 
tests, showed negative results in in vivo tests, but some in vitro mammalian tests 
showed equivocal results. TCP, TBEP, TBP, TEHP, TEP, TIPP and TPP were 
negative in bacterial tests when the doses were below the bacteriotoxic effect.  
 
TCP (100 to 10 000 µg/plate) was tested in two laboratories for induction of gene 
mutations in Salmonella typhimurium strains TA98, TA100, TA1535 and TA1537. 
No induction of gene mutations was observed in either laboratory in any of the 
strains (174).  
In cytogenetic tests with cultured Chinese hamster ovary (CHO) cells, TCP did 
not induce sister chromatid exchanges (SCEs) with (16-5 000 µg TCP/ml) or with-
out (0.05-16 µg TCP/ml) Aroclor 1254-induced male Sprague Dawley rat liver S9. 
TCP did not induce chromosomal aberrations with (160-5 000 µg TCP/ml) or 
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without (50-5 000 µg TCP/ml) S9. No TCP-induced cell cycle delay was observed 
in either of these two assays (174).  
Male F344 rats were treated orally for 10 days with TOCP (50 mg/kg bw) and 
DNA was isolated from liver, kidney, lung, heart, brain and testes 1, 4, 7 and 28 
days after giving the last dose. Analysis by 32P-postlabelling revealed that two 
adducts were present in the DNA isolated from liver, kidney, lung and heart 1 day 
after giving the last dose. DNA adducts were not detected in the brain and testes. 
The adduct pattern after in vivo treatment with TOCP was identical with that found 
in bacteria and hepatoma cells treated with the TOCP metabolite 2-phenoxy-4H-
1,3,2-benzo-dioxaphosphorin 2-oxide (demethylated saligenin phosphate), the 
major adduct being a cytidine adduct and the minor an uridine adduct. Both DNA 
adducts persisted in the lungs for the entire observation period, whereas in the 
kidney only the cytidine adduct could be detected 28 days after the last dose of 
TOCP. In liver and heart, the adducts were detectable only on the first day after 
completion of the treatment. The results indicate that TOCP may pose a genotoxic 
potential (151).  
 
TBEP was not mutagenic in a test performed with Salmonella typhimurium strains 
TA98, TA100, TA1535, TA1537 and TA1538 (concentrations not given) with and 
without metabolic activation (MacKeller 1978, cited in (103)).  
TBEP (0, 50, 100, 500, 1 000, 5 000 and 10 000 µg/plate) was tested for muta-
genic activity with Salmonella typhimurium strains TA98, TA100, TA1535 and 
TA1537 in the presence and absence of rat liver S9 metabolic system, in com-
parison with positive controls. TBEP did not cause any mutagenic response either 
with or without metabolic activation (Monsanto 1984c, cited in (103)). 
TBEP was not mutagenic in a CHO/HPRT (hypoxanthine-guanine phospho-
ribosyl transferase) mammalian cell forward gene mutation assay at 50, 100, 150, 
225 and 300 µg/ml with S9 or at 5, 50, 75, 100 and 130 µg/ml without S9 
(Monsanto 1985a, cited in (103)).   
 
TBP was tested for mutagenicity at concentrations up to 100 µl/plate (diluted with 
dimethyl sulfoxide) with Salmonella typhimurium strains TA98, TA100, TA1535 
and TA1538 in the presence and absence of metabolic activation by Aroclor in-
duced rat liver S9 fraction. TBP did not produce a positive response in any strain 
with metabolic activation. Strains TA1535, TA1537 and TA1538 without meta-
bolic activation produced twice the number of revertants per plate compared to  
the solvent control for at least three of the five test concentrations, but no dose-
response relationship was observed (US EPA 1978, cited in (101)). 
TBP was tested for mutagenic effects in a Salmonella/microsome test both with 
and without S9 mix at doses of up to 12.5 mg/plate using four Salmonella typhi-
murium strains TA98, TA100, TA1535 and TA1537. Doses up to 120 µg/plate 
produced no bacteriotoxic effects. At high concentrations, there was marked 
strain-specific bacterial toxicity so that only the range up to 500 µg/plate could be 
evaluated. There were no indications that TBP had any mutagenic effect (Bayer 
1985, cited in (101)).   
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In a Russian study, TBP was reported to be mutagenic in the Ames test with 
Salmonella typhimurium strains TA1535 and TA1538 at concentrations of 500 
and 1 000 µg/plate both with an without metabolic activation. No mutagenicity 
was noted at concentrations below 100 µg/plate (Gafieva and Chudin 1986, cited 
in (101)). 
Testing TBP at doses of 97 to 97 000 µg/plate both with and without a meta-
bolising system (S9 mix) on the Salmonella typhimurium strains TA98, TA100, 
TA1537 and TA1538 confirmed the lack of mutagenic activity (FMC 1985b, cited 
in (101)). 
TBP was also tested for mutagenicity in four bacterial strains, Salmonella 
typhimurium TA102 and TA2638 and Escherichia coli WP2/pKM101 and WP2 
uvrA/pKM101 at doses of 31-5 000 µg/plate. TBP was not mutagenic in this assay 
but was toxic at the highest doses (249).  
Tests with TBP on Escherichia coli strains WP2, WP2uvrA, CM561, CM571, 
CM611, WP67 and WP12 showed no mutagenic effect after 48 or 72 hours of 
incubation at 37 oC (77).  
TBP was not mutagenic when tested in the HPRT mutation assay in CHO cells, 
both with and without metabolic activation. Cell cultures were exposed for 5 hours 
at 0.05-0.11 µl/ml without activation and at 0.06-0.15 µl/ml with S9 activation. 
No increases of chromosome aberrations compared to negative controls were ob-
served in metaphases evaluated 12 hours after treatment initiation in CHO cells 
exposed to TBP at 0.013-0.15 µl/ml for 10 hours without activation or at 0.01-
0.15 µl/ml for 2 hours with S9 activation (presented as an abstract) (16). 
TBP was not mutagenic in recessive lethal mutation tests in Drosophila mela-
nogaster (77). 
In an in vivo cytogenetics study, male and female rats were dosed orally with up 
to 1 200 mg/kg of TBP in corn oil. Bone marrow was collected and evaluated after 
12, 24 and 36 hours. No increases in chromosome aberrations due to TBP were 
observed. TBP was not genotoxic in vivo under these conditions (presented as an 
abstract) (16).  
 
TCEP was not mutagenic in Salmonella typhimurium strains TA1535, TA1537, 
TA1538, TA98 and TA100 at dose levels up to 5 000 µg/plate both with and 
without metabolic activation with Aroclor 1254 induced rat liver S9 (Simmon et 
al 1977, cited in (102)).  
Negative results were obtained when TCEP was tested at doses of 3.3, 10, 33 
and 333 µg/plate in liquid pre-incubation assays employing Salmonella typhi-
murium TA1535, TA1537, TA98 and TA100 both with and without a metabolic 
system from Aroclor 1254 induced rat liver or Syrian hamster liver S9 (Haworth  
et al 1983, cited in (102)). 
In V79 cells, TCEP (1 µM-1 mM) did not induce DNA strand breaks in the 
alkaline version of the Comet assay neither without an external enzymatic meta-
bolising system nor in the presence of rat liver S9 mix. No mutagenic potential 
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could be detected for TCEP in eight Salmonella strains using concentrations up  
to 1 mM in the presence or absence of S9 (71).  
In contrast, TCEP at dose levels of 285, 755, 2 850 and 8 550 µg/plate produced 
a dose-related increase in mutations (with a maximum 7.6-fold increase of re-
vertants over the control at 2 850 µg/plate) in Salmonella typhimurium TA1535  
in the presence but not in the absence of metabolic system from Kanechlor 500-
induced Wistar rat liver S9. The same doses produced a dose-related increase in 
mutations in TA100 with a maximum 1.8-fold increase in revertants at 2 850 µg/ 
plate (Nakamura et al 1979, cited in (102)). 
TCEP was tested for chromosomal aberrations and SCE in CHO cells both with 
and without an exogenous metabolism system from Aroclor 1254 induced Sprague 
Dawley rat liver. The test doses for the cells varied from 5 to 1 600 µg/ml. TCEP 
did not induce chromosomal aberrations. The results of the SCE test were re-
garded as equivocal because a positive response was seen only in one trial with S9 
fraction at 500 and 1 600 µg/ml but was not observed in a repeated trial under the 
same conditions (Galloway et al 1987, cited in (102)).  
TCEP (0, 500, 1 000 and 2 000 µg/ml) did not significantly increase the number 
of 6-thioguanine-resistant mutants in V79 hamster cells without S9 (190). 
TCEP was tested for SCEs in V79 hamster cells in two separate experiments. 
The first experiment was performed at concentrations of 343, 490, 700 and 1 000 
µg/ml. A statistical increase in the number of SCEs was noted at 700 and 1 000 
µg/ml with S9 (3-methylcholantrene-induced rat liver) and at 700 µg/ml without 
S9 (1 000 µg/ml was not tested without S9). In the second experiment, TCEP  
was tested without S9 at 2 000 and 3 000 µg/ml and was positive at both con-
centrations. However, 3 000 µg/ml caused cytotoxicity (190). 
In the presence of S9 from methylcholantrene-induced Wistar rat livers, TCEP 
at 900 and 1 500 µg/ml gave a negative result in a transformation assay using 
C3H10T1/2 cells (102). 
A high level of transformation of Syrian hamster embryo cells was observed 
with TCEP at 400 and 500 µg/ml. The two highest concentrations (600 and 800 
µg/ml) were cytotoxic and no transformation was seen at these concentrations 
(190). 
TCEP caused a dose-related (343-1 000 µg/ml) increase in the incidence of 
SCEs in the Chinese hamster V79 cell line, but doses from 500 to 2 000 µg/ml  
did not induce mutations at the HPRT locus in the same cell line (190). 
TCEP was administered intraperitoneally at dose levels of 62.5, 125 and 250 
mg/kg bw to groups of male and female Chinese hamsters. No clear dose-
dependent increase in the number of micronuclei isolated from bone-marrow cells 
was seen. However, in some of the dose groups an approximate doubling in the 
number of micronuclei was noted (in females at 62.5 and 125 mg/kg bw and in 
males at 250 mg/kg bw) (190). 
TCEP gave a negative response in the w/w+ bioassay for somatic cell damage  
in Drosophila melanogaster when tested at doses of 2.5-40 mM (258). 
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TDCPP has been investigated several times in bacterial gene mutation studies 
using the Salmonella/microsome mutation test. The compound was tested (10-
10 000 µg/plate) in 3 different laboratories using strains of TA100, TA1535, 
TA98, TA97 (2 laboratories) and TA1537 (2 laboratories) in the presence and 
absence of metabolic activation by S9. There was no evidence of mutagenicity  
in the absence of S9, but all 3 laboratories obtained some positive results in the 
presence of S9. Positives were reported in at least some of the laboratories for 
strains TA97, TA100 and TA1535 with both hamster and rat S9. All 3 laboratories 
reported positive findings in TA100 (160). Two other studies also found a muta-
genic response in TA100 in the presence of metabolic activation at dose levels  
of 50-250 µg/plate (73) and 50-1 000 µg/plate (222), respectively. Brusick et al 
found no mutagenicity at doses of 50-200 µg/plate in strains TA1535 or G46 in 
the presence or absence of S9 but obtained different results in TA100 depending 
on the source of the S9 used in the assay. Mutagenic activity was seen with S9 
from rat liver activated with Aroclor 1254 or phenobarbital but not with S9 from 
human or mouse liver activated in the same way (23).  
Gold and coworkers proposed an oxidative dealkylation of TDCPP to 1,3-
dichloro-2-propanone analogous with the known metabolism of other related 
phosphate triesters. This compound was shown to be a powerful direct-acting 
mutagen (73). The metabolite 1,3-dichloro-2-propanol was mutagenic without 
activation with S9 in Salmonella typhimurium strain TA100. The number of 
revertant colonies/plate increased linearly with dose when tested at dose levels  
of 100-1 000 µg/plate (139).  
No mutagenic activity was noted in strains TA98, TA100, TA1535 and TA1537 
incubated with untreated or β-glucuronidase-treated urine from TDCPP-treated 
mice (0.05, 0.17 or 0.5 ml/kg bw or 76, 260 or 760 mg/kg bw by gavage) (23, 102).  
TDCPP did not induce gene mutations in the mouse lymphoma assay either in 
the absence or presence of various exogenous metabolic systems (S9 from rat or 
mouse liver induced with either Aroclor 1254 or phenobarbital) when tested up to 
a concentration causing a 50 % reduction in cell growth (23, 102).  
V79 Chinese hamster lung cells were used in a mammalian point mutational 
assay. These cells were fortified with a microsomal activation system from pheno-
barbital-pretreated rats. No increase in the number of 6-thioguanine-resistant 
clones was observed using 0.02 mM TDCPP. Hepatocyte monolayer cultures 
derived from either untreated or phenobarbital-pretreated rats were used to study 
unscheduled DNA synthesis. TDCPP at 0.05 mM did not cause a significant 
genotoxic effect, whereas at 0.1 mM TDCPP, a moderate increase in response was 
observed with hepatocytes from untreated rats (222).  
TDCPP was also tested for in vitro chromosome effects, i.e. chromosomal 
aberrations and SCEs, using mouse lymphoma (L5178Y) cells at concentrations 
up to those causing a 50 % reduction in growth rate. Tests were performed in the 
absence or presence of exogenous metabolic systems. The results for SCEs were 
equivocal, whereas those for chromosomal aberrations showed increased numbers 
(excluding gaps) with both metabolic activation systems (23, 102).  
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TDCPP did not induce primary DNA damage as measured indirectly as un-
scheduled DNA synthesis in a primary culture of rat hepatocytes (102, 255).  
TDCPP did not induce morphological cell transformations in BALB/3T3 cells 
(0.02-0.31 µl/ml) in two independent tests in the absence of metabolic activation 
(23, 102).  
TDCPP did not induce chromosomal aberrations in bone marrow cells of CD-1 
mice following either a single oral gavage dose of 0.05, 0.17 or 0.5 ml TDCPP/kg 
bw (76, 260 or 760 mg/kg bw) or 5 consecutive daily oral exposures at the same 
dose levels with a harvest time of 6 hours after the last dose (23).  
TDCPP did not induce sex-linked recessive lethal mutations in Drosophila 
melanogaster (23).  
TDCPP did not induce micronuclei in polychromatic erythrocytes in the bone 
marrow of either sex of mice that had been given a single dose of 2 000 mg/kg bw 
of TDCPP by a not specified route of administration. The ratio of normochromatic 
erythrocytes to polychromatic erythrocytes was not elevated at any of the sampling 
times (24, 48 and 72 hours post-dosing). As systemic toxicity was observed in the 
treated mice, TDCPP must have entered the blood circulation and thus the bone 
marrow cells must have been exposed to TDCPP or its metabolites (Thomas and 
Collier 1985, cited in (102)).  
Male CD-1 mice received TDCPP as a single intravenous dose (94 µmol/kg 
bw). The results indicated that TDCPP could bind covalently to macromolecules, 
including DNA of liver and kidney (157).  
 
TEHP was not mutagenic in a Salmonella/microsome assay using strains TA1535, 
TA1537, TA98 and TA100 in the presence and absence of S9 derived from livers 
of Aroclor 1254 treated Sprague Dawley rats (263). 
Concentrations of TEHP of up to and exceeding the apparent solubility limit of 
62.5 µl/l did not produce any increase of mutations in a mouse lymphoma assay. 
The assay was carried out with and without S9 from livers of Aroclor 1254-treated 
male F344 rats (162).  
In vitro cytogenetic assays (SCEs and chromosome abberations) in CHO cells 
were carried out using concentrations of TEHP up to 251 µg/ml in the presence 
and absence of S9 derived from livers of Aroclor 1254-treated Sprague Dawley 
rats. There was no evidence of induction of chromosome damage. However, at 
16.7 µg/ml and above there was severe cell cycle delay, which limited the number 
of cells available for analysis (105).  
A mouse bone marrow micronucleus assay was carried out in male B6C3F1 
mice. The mice were given intraperitoneal TEHP injections of 500, 1 000 or 2 000 
mg/kg bw on 3 consecutive days. Bone marrow was harvested at 24 hours after the 
last dose and was examined for micronucleus containing polychromatic erythro-
cytes (MN-PCEs). A significant dose-related increase in the number of MN-PCEs 
was observed in the bone marrow of treated mice. The assay was repeated in two 
further experiments using doses of 1 500 and 2 000 mg/kg bw in one and 2 000 
and 3 000 mg/kg bw in the other. No increase in the number of MN-PCEs was de-
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tected in either of these experiments. The authors concluded that the initial result 
was an artefact and that TEHP was not mutagenic in this assay (198).  
An in vivo cytogenetic assay was carried out in male B6C3F1 mice. The mice 
were given a single intraperitoneal injection of TEHP (dose not given). Bone 
marrow was harvested at 17 and 36 hours after the given injections. The number 
of chromosomal aberrations was not elevated in TEHP treated mice (199).  
In an in vivo liver hepatocyte replicative DNA synthesis assay, male B6C3F1 
mice were given TEHP doses of 1 000 or 2 000 mg/kg bw by gavage. The mice 
were killed at 24, 39 and 48 hours after given doses. There was no evidence of 
increased replicative DNA synthesis in hepatocytes from treated mice (155). 
 
TEP (313-5 000 µg/plate) was not mutagenic in four bacterial strains, Salmonella 
typhimurium TA102 and TA2638 and Escherichia coli WP2/pKM101 and WP2 
uvrA/pKM101 (249).  
Negative results were also reported in Ames tests conducted with Salmonella 
typhimurium strains (TA98, TA100, TA1535 and TA1537) in the absence or 
presence of rat and hamster liver S9 (262).  
TEP did, however, induce gene mutations without metabolic activation in some 
bacteria, viruses and a yeast strain. For clarification of the endpoint gene mutation, 
a HPRT test in V79 cell cultures was done, which revealed a negative result with 
and without metabolic activation (237).  
In an in vitro unscheduled DNA synthesis test on rat hepatocytes, TEP showed 
no DNA damaging effect. The results for Drosophila melanogaster in the limited 
documented recessive-lethal tests were contradictory, while in vivo studies on the 
mouse (cytogenetics in bone marrow, dominant lethal test) were negative (237). 
TEP gave a positive dose-response in the w/w+ bioassay for somatic cell damage 
in Drosophila melanogaster when tested at doses of 2.5-10 mM (258). 
 
TIPP was tested for mutagenicity in five strains of Salmonella typhimurium in 
presence and absence of a metabolic activating system. Five dose levels were used 
but were not described. TIPP was not mutagenic in this test. However, the re-
liability of these tests was not assignable according to Great Lakes Chemical 
Corporation (74). 
 
TMCPP There was no clear evidence that commercial TMCPP products were 
genotoxic from a battery of assays for mutagenic and related effects. TMCPP 
produced no gene mutations in strains TA1535, TA1537, TA1538, TA97, TA98 
and TA100 in Salmonella/microsome plate assays and one Escherichia coli nor  
in a yeast gene mutation assay in either the presence or absence of metabolic 
activation (Anonymous 1980, Kouri and Parmar 1977, Mehlman et al 1980, 
Nakamura et al 1979, Parmar 1977, Stauffer 1978b, Zeiger et al 1992, cited in 
(102)).   
In V79 cells, tris(1-chloro-2-propyl) phosphate (1 µM-1 mM) did not induce 
DNA strand breaks in the alkaline version of the Comet assay neither without an 
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external enzymatic metabolising system nor in the presence of S9 mix. No muta-
genic potential could be detected in eight Salmonella strains using concentrations 
up to 1 mM in the presence or absence of S9 (71). 
One mouse lymphoma assay gave equivocal results with TMCPP (Anonymous 
1981, cited in (102)) but a second mouse lymphoma assay was negative in the 
presence and absence of metabolic activation (Stauffer 1978c, cited in (102)). In 
vitro assays for unscheduled DNA synthesis in a primary culture of rat hepatocytes 
gave negative results (Bayer 1991b, cited in (102)), (255), whereas the results of 
the same test in an in vitro assay in WI-38 cells (Stauffer 1978a, cited in (102)) 
were equivocal in the presence and absence of metabolic activation.  
Two out of three cell transformation assays in BALB/3T3 cells gave negative 
results with Fyrol PCF in the absence of metabolic activation (Stauffer 1978a, 
1980b, cited in (102)), whereas the third was equivocal (Stauffer 1978d, cited in 
(102)).  
TMCPP caused no chromosomal damage in bone marrow in three in vivo cyto-
genetic assays using oral or subcutaneous administration to rats and intraperitoneal 
administration to mice (Bayer 1991a, Stauffer 1978e, cited in (102)). 
 
TPP did not demonstrate mutagenic activity in microbial assays using strains of 
Salmonella typhimurium (TA1535, TA1537, TA1538, TA98 and TA100) and 
Saccharomyces cerevisiae as indicator organisms (doses not given). All studies 
were carried out both with and without metabolic activation (Monsanto 1979, 
cited in (100)).  
Negative results were also reported in Ames tests conducted with Salmonella 
typhimurium strains (TA98, TA100, TA1535 and TA1537) in the absence or 
presence of rat and hamster liver S9 (262).  
TPP was also tested for its ability to induce mutations at the thymidine kinase 
locus in cultured L5178 mouse lymphoma cells (doses not given). When tested 
with or without metabolic activation, TPP did not induce a significantly increased 
frequency of mutations (Monsanto 1979, cited in (100)).  
10.6 Effects of long-term exposure and carcinogenicity  
Several of the phosphate triesters covered in this document have neoplastic 
potential in animal experiments (TBP, TCEP, TDCPP and TEHP) (Table 13). 
However, TCP does not seem to have such an effect. Some of the esters have not 
been properly tested.  
 
TCP The NTP has performed 13-week and 2-year-studies in rats and mice ad-
ministered TCP by gavage or in the diet. The TCP product contained 18 % di-
cresyl phosphate esters and 79 % TCPs (consisting of 21 % TMCP, 4 % TPCP, 
less than 0.1 % TOCP, and other unidentified TCPs) (174). The studies are de-
scribed below and also in Sections 10.4 and 10.7. 
Groups of 10 male and 10 female F344/N rats and B6C3F1 mice received TCP 
in corn oil by gavage at doses of 0, 50, 100, 200, 400 or 800 mg/kg bw for 13  
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Table 13. Tumours and hyperplasia in animals exposed to phosphate triesters.  
Species, sex  Tumours Hyperplasia Reference 
TCP    
Rat, female No neoplasms Ovarian interstitial cells (174) 
Mouse, both sexes No neoplasms Gall bladder mucosal 
epithelium 
(174) 
TBP    
Rat, both sexes 
Rat, males 
 Urinary bladder epithelium 
Renal pelvis epithelium  
(101, 121, 234) 
Rat, both sexes  
 
Transitional urinary cell 
carcinomas, urinary bladder 
papillomas  
Urinary bladder epithelium (13) 
Mouse, males Hepatocellular adenomas  (12) 
TCEP    
Rat, both sexes Renal tubule adenomas  Renal tubule  (173) 
Mouse, both sexes Renal tubule neoplasmas, 
Harderian gland adenomas 
Renal tubule  
 
(173) 
Mouse, both sexes Renal and hepatocellular 
adenomas/carcinomas, 
forestomach papillomas/ 
carcinomas and leukaemias 
Renal tubule  
 
(225) 
TDCPP    
Rat, both sexes 
 
 
Rat, female 
 
Rat, male  
Benign neoplastic liver nodules, 
liver carcinoma, renal cortical 
tumours  
Thyroid adenomas, adrenal 
cortical adenomas  
Benign testicular interstitial 
tumours, brain tumours 
Renal tubule, bone marrow 
erythroid/myeloid  
(102, 217) 
TEHP    
Rat, males 
 
Mouse, both sexes 
Mouse, female 
Phaeochromocytomas of the 
adrenal gland  
 
Hepatocellular carcinoma  
 
 
Thyroid follicular cell  
(172) 
TMCPP    
Rat, both sexes  Thyroid follicular cell  
(very mild) 
(238) 
 
weeks. All rats and mice survived. In the rats, final mean body weights of males 
receiving 200, 400 and 800 mg/kg bw were significantly lower than those of the 
controls. The principal lesions in rats occurred in the testis, ovary and adrenal 
glands (Section 10.7). Cytoplasmic vacuolisation of the adrenal cortex occurred  
in all exposed groups (50-800 mg/kg bw) and the severity increased with dose. 
The only neurobehavioural measure affected by the exposure was a slight but 
significant reduction of hindlimb grip strength in female rats receiving 400 and 
800 mg/kg. Females given 200 mg/kg bw of TCP and higher and males given 400  
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mg/kg bw and higher had significantly lower haemoglobin concentrations in blood. 
In the mice, final mean body weights and mean body weight gains were significant-
ly lower than those of the controls in males receiving 200, 400 and 800 mg/kg, and 
in females receiving 400 and 800 mg/kg. There were significant dose-related de-
creases in serum cholinesterases in all dosed groups. The principal lesions in mice 
occurred in the ovary, adrenal gland, spinal cord and sciatic nerve. The lesions in 
the ovary and adrenal gland were similar to those in rats. Female mice given 200 
mg/kg bw TCP and higher had significantly lower haemoglobin concentrations  
in blood. Male mice given 400 mg/kg TCP and higher had a significantly lower 
mean cell haemoglobin levels but not lower haemoglobin concentrations. The 
male mice had also an increased number of reticulocytes at 400 and 800 mg/kg  
bw (174) as an expression of bone marrow stimulation.  
In the diet study, groups of 10 male and 10 female F344/N rats were fed diets 
containing 0, 0.9, 1.7, 3.3, 6.6 or 13 g/kg of TCP for 13 weeks. The estimated 
delivered daily doses were 55, 120, 220, 430 and 750 mg/kg bw for males and  
65, 120, 230, 430 and 770 mg/kg for females. All rats survived. Cytoplasmic 
vacuolisation of the adrenal cortex was observed in all exposed groups. Ovarian 
interstitial cell hypertrophy occurred in all exposed groups of females. Renal 
papillary oedema and renal papillary necrosis occurred in 13-g/kg diet males and 
in 6.6- and 13-g/kg diet females. Basophilic hypertrophy of the pituitary gland 
pars distalis and atrophy of the seminiferous tubules were observed in males 
receiving 3.3, 6.6 and 13 g/kg diet. Both males and females given 1.7 g/kg (120 
mg/kg bw) TCP in the diet had an increased number of platelets in the blood. 
Female rats given 3.3 g/kg diet (230 mg/kg bw) and higher had significantly lower 
haemoglobin concentrations in blood. The effect was also seen in males at the 
highest dose level (174). B6C3F1 mice were fed diets containing 0, 0.25, 0.5, 1.0, 
2.1 or 4.2 g/kg of TCP for 13 weeks. The estimated delivered daily doses were 45, 
110, 180, 380 or 900 mg/kg bw for males and 65, 130, 230, 530 and 1 050 mg/kg 
bw for females. Final body weights were reduced at the two highest dose levels. 
Lesions associated with chemical exposure occurred in the spinal cord, sciatic 
nerve, adrenal gland, gall bladder, ovary and kidney. Cytoplasmic vacuolisation of 
the adrenal cortex occurred in all exposed groups of females and in males exposed 
to 0.5-4.2 g/kg diet. Hyperplasia of the mucosal epithelium of the gall bladder was 
observed in males exposed to 0.5 g/kg or more and in females exposed to 1 mg/kg 
diet or more (174). 
In the 2-year study, groups of 95 male and 95 female F344/N rats were fed diets 
containing 0, 0.075, 0.15 or 0.3 g/kg TCP. Approximately 50 animals/sex and 
dose group were exposed throughout the whole study period. The given dietary 
levels were estimated to deliver average daily doses of 3, 6 or 13 mg/kg bw in 
males and 4, 7 or 15 mg/kg bw in females. An additional group of animals were 
given 0.6 g/kg in their diet for 22 weeks and then received only control feed. 
Cytoplasmic vacuolisation of the adrenal cortex occurred in 0.6-g/kg males and 
0.15-, 0.3- and 0.6-g/kg females at the 3-month evaluation. At 9 and 15 months, 
cytoplasmic vacuolisation occurred only in females, primarily in the 0.3 g/kg 
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group. Cytoplasmic vacuolisation of the adrenal cortex and ovarian interstitial cell 
hyperplasia occurred in 0.3-g/kg females exposed throughout the 2-year study and 
the incidence and severity were significantly increased at the end of the study. 
There were no chemical-related increases in the incidence of neoplasms among 
these groups of rats.  
In the corresponding 2-year mouse study, groups of 95 male and 95 female 
B6C3F1 mice were fed diets containing 0, 0.06, 0.125 or 0.25 g/kg of TCP. Ap-
proximately 50 animals/sex and dose group were exposed throughout the whole 
study period. The given dietary levels were estimated to deliver average daily 
doses of 7, 13 or 27 mg/kg bw in males and 8, 18 or 37 mg/kg bw in females. 
Ceroid pigmentation of the adrenal cortex occurred in all groups of mice including 
controls. The severity was markedly increased in females receiving 0.25 g/kg. 
Incidences of clear cell foci, fatty change, and ceroid pigmentation of the liver 
were significantly increased in males receiving 0.125 and 0.25 g/kg. There were 
no chemical-related increases in the incidence of neoplasms. 
The NTP Task Group concluded that there was no evidence of carcinogenic 
activity of TCP in male and female F344/N rats or in male or female B6C3F1 mice 
(174).  
Male mice gavaged with 0, 5, 50 or 500 mg/kg bw of TOCP or 50 mg/kg bw  
of TMCP once a week for 13 weeks exhibited no effect on immunoglobulin levels 
and there was a non-dose-related suppression of lymphocyte proliferation (20). 
 
TBEP Wistar rats were given a diet containing 0, 0.3, 3 or 30 g TBEP/kg for 14 
weeks. There were 15 rats in each group. Suppression of body weight gain was 
observed in both sexes at 30 g/kg diet. Serum cholinesterase acitity decreased 
significantly in both sexes at 3 and 30 g/kg diet. Serum γ-glutamyl transferase 
activity was increased at 30 g/kg. After 5 weeks, serum amylase was significantly 
increased at 3 and 30 g/kg diet among males and at 30 g/kg among females. 
Absolute and relative liver weights in both sexes were significantly increased in 
the 30-g/kg groups after 5 and 14 weeks of exposure. Examination of the liver 
revealed moderate periportal hepatocyte swelling in males at 30 g/kg after 14 
weeks of exposure, but this change was not found in males given 3 g/kg or less. 
The NOAEL for TBEP in the diet was 0.3 g/kg diet, corresponding to 20 and 22 
mg/kg bw/day for males and females, respectively (189, 233). 
In a gavage study, groups of 12 male and 12 female Sprague Dawley rats were 
given 0, 0.25 or 0.5 ml/kg bw (250 or 500 mg/kg) undiluted TBEP, 5 days/ week 
for 18 weeks. During the first week, 2 high-dose females showed muscular weak-
ness and ataxia, which disappeared by the end of the 4th week. After about 7 
weeks, nearly all animals exhibited some signs of toxicity. All treated animals 
appeared less active and one female rat died during week 13. Breathing difficulties 
and ataxia were present in several males and females in both treatment groups, 
though the low-dose group was less affected. Tremors, piloerection, lacrimation 
and increased urination were observed in the high-dose group. After the last dose, 
the clinical signs decreased in intensity. High-dose females had significantly 
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elevated serum γ-glutamyl transferase levels. Haematological parameters were not 
different from controls and there were no differences between low- and high-dose 
groups of either sex. Animals were necropsied one week after the last dose. Liver 
weight was significantly increased in both treated groups. Kidney weight was in-
creased by about 20 % in both dose-groups and significantly so in the high-dose 
group. Histopathological changes were confined to the heart of males in both dose 
groups. In the high-dose group (3/6) and in the low-dose group (2/6), animals had 
multiple foci of mononuclear cell infiltration, haemorrhages and/or myocardial 
fibre degeneration. These lesions were more severe in the high-dose group than in 
the low-dose group and were absent among controls. Two of six (2/6) high-dose, 
3/6 low-dose rats and 1/6 control rat demonstrated multifocal interstitial fibrosis. 
The authors concluded that TBEP may have accelerated the development of focal 
myocarditis, which is a normal feature in older male Sprague Dawley rats (122, 
124). The studies are also described in Section 10.4.  
In an 18-week study, four groups of 20 male and 20 female Sprague Dawley rats 
were fed diets containing 0, 0.3, 3 or 10 g TBEP/kg. Body weight, food intake and 
clinical observations were similar in treated and control rats. In the groups exposed 
to 3 and 10 g/kg, there was an increase of serum γ-glutamyl transpeptidase and  
a decrease of plasma cholinesterase activity. Other haematological and clinical 
chemistry parameters were normal except for increased platelet counts in the 
highest dose group. Liver weight was increased in the highest dose group. Micro-
scopic examination showed mild periportal hepatocellular hypertrophy and peri-
portal vacuolisation in males receiving 3 and 10 g/kg in the diet. The NOAEL  
was 0.3 g/kg diet equivalent to 15 mg/kg bw/day and the LOAEL 3 g/kg diet 
equivalent to 150 mg/kg bw (Monsanto 1987a, cited in (103)).  
 
TBP Male and female adult Sprague Dawley rats received TBP (32.5, 100 and 325 
mg/kg bw) in corn oil by gavage for 13 weeks. Postdosing salivation was observed 
rarely at 32.5 mg/kg, frequently at 100 mg/kg and on almost all occasions in the 
high-dose animals. High-dose males and females had significantly decreased body 
weights. Some mortality was also observed at the two highest dose level (80). The 
study is also described in Section 10.4.  
TBP was administered in the diet at concentrations of 0, 0.2, 0.7 or 3 g/kg to 
groups of 50 male and 50 female Sprague Dawley rats for 2 years. The mean daily 
intake was 9, 32 and 143 mg/kg bw for males and 12, 42 and 182 mg/kg bw for 
females. At the highest dose, body weight was decreased in both sexes. A dose-
related increase in the incidence and severity of urinary bladder hyperplasia and 
the incidence of urinary bladder papillomas were evident in males and females 
receiving the 0.7 and 3 mg/kg diets. Transitional cell carcinomas were present in 
6/49 males and 2/50 females and squamous cell carcinoma was present in 1/49 
males in the group that received 3 g/kg (13).  
TBP was administered in the diet at concentrations of 0, 0.15, 1 or 3.5 g/kg to 
groups of 50 male and 50 female CD-1 mice for 18 months. The mean daily in- 
take was 29, 169 and 585 mg/kg bw for males and 24, 206 and 711 mg/kg bw for 
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females. A significant dose-related increase in absolute and relative liver weights 
was seen in both sexes receiving the two highest dietary concentrations (1 and 3.5 
g/kg). The incidence of hepatocellular adenomas was significantly increased in 
males treated with 3.5 g/kg TBP in diet. No other tumours were associated with 
TBP administration in this study. No urinary bladder alterations occurred attributed 
to TBP administration. The NOAEL for chronic toxicity was 24-29 mg/kg bw for 
mice (12).  
Groups of randomised female and male Sprague Dawley rats were divided into 
two dose groups and control groups with 12 rats per sex in each group. TBP was 
administered by gavage daily for 5 days/week over an 18-week period. Low-dose 
animals received 200 mg/kg bw throughout the experiment. High-dose animals 
received 300 mg/kg bw for the first 6 weeks followed by 350 mg/kg bw for the 
remaining 12 weeks. Histopathological examination of tissues revealed that all 
rats examined developed diffuse hyperplasia of the urinary bladder epithelium. 
Similar changes were not found in the control animals (121). 
In a 2-generation reproduction study in rats, the LOAEL for parental toxicity 
was approximately 10-21 mg/kg bw/day, based on microscopic evidence of a very 
low incidence of urinary bladder epithelium hyperplasia and transient reductions 
in body weight (234). The study is described in detail in Section 10.7. 
Sprague Dawley rats were fed diets containing 0, 0.008, 0.04, 0.2, 1 or 5 g/kg  
of TBP for 90 days (corresponding to approximately 0.4-250 mg/kg bw/day (44)). 
Clinical chemistry changes included increased serum γ-glutamyl transpeptidase 
levels in both sexes given 5 g/kg. Absolute and relative liver weights were in-
creased in both sexes at this dose. Histopathological studies indicated TBP in-
duced transitional cell hyperplasia in the urinary bladder of males given 1 or 5 
g/kg and females given 5 g/kg diet (presented as an abstract) (Cascieri et al 1985, 
cited in (101)).  
Skydrol 500B-4 is a fire resistant hydraulic fluid composed of 80-90 % phosphate 
esters including dibutyl phenyl phosphate and TBP. Rats inhaled an aerosol of 0, 
5, 100 and 300 mg/m3, 6 hours/day, 5 days/week for 6 or 13 weeks. Nasal dis-
charge was noted among 47/50 mid-exposure rats and 50/50 high-exposure rats 
during the first week of exposure. The incidence of the nasal discharge decreased 
over the course of the study. In high-dose animals, increased absolute and relative 
liver weights and decreased haematocrit were observed. High-dose females also 
exhibited decreased body weights, plasma cholinesterase levels, erythrocyte counts 
and haemoglobin levels, and centrilobular hepatocellular hypertrophy (10/15) (81).  
 
TCEP The NTP has performed 16- or 18-week and 2-year studies in rats and mice 
administered TCEP by gavage (173).  
Groups of 10 F344/N rats of each sex were administered 0, 22, 44, 88, 175 or 
350 mg/kg bw of TCEP in corn oil by gavage 5 days/week for 16 weeks (female) 
and for 18 weeks (male). There were deaths in the two highest dose groups (1 
male receiving 175 mg/kg, 5 high-dose males and 3 high-dose females). Final 
mean body weights were generally similar among dosed and control male rats, 
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although the final mean body weight of surviving high-dose females was about 
20 % greater than the control value. The final absolute and relative (organ-weight-
to-body-weight and organ-weight-to-brain-weight ratios) weights of liver and 
kidney were significantly increased in high-dose males (p = 0.01) and in females 
receiving 44-350 mg/kg (p = 0.01). These differences were considered related to 
the administration of TCEP. Necropsy examination showed no gross lesions 
attributable to chemical exposure (173). 
Groups of 10 mice of each sex were administered 0, 44, 88, 175, 350 or 700 
mg/kg bw TCEP in corn oil by gavage 5 days/week for 16 weeks. There were no 
chemical-related deaths. Weight gain and group mean body weights at the end of 
the study were similar among dosed and control mice. The mean absolute and 
relative liver weights were significantly increased in females receiving 175-700 
mg/kg bw and in males receiving 700 mg/kg bw. These increases were considered 
to be chemical-related. The absolute and relative testis weights of high-dose males 
were decreased relative to those of controls (p = 0.01). Male mice receiving 175-
700 mg/kg bw had significantly reduced relative kidney weights (p = 0.01), but 
absolute kidney weights were significantly reduced in high-dose males only. Al-
though necropsy examination showed no gross lesions attributable to chemical 
administration, epithelial cells with enlarged nuclei (cytomegaly and karyomegaly) 
were observed in the renal tubules in all males and females receiving 700 mg/kg 
bw of TCEP. These lesions were observed primarily in the proximal convoluted 
tubules of the inner cortex and outer stripe of the outer medulla and, to a lesser 
extent, in the straight portion of the loops of Henle in the outer medulla (173). 
Groups of 60 male and 60 female F344 rats received 0, 44 or 88 mg/kg bw/day 
of TCEP, 5 days/week by gavage for 103 weeks. At 103 weeks, there were no ad-
verse effects on the body weight gain and no clinical signs of toxicity. Reduced 
survival was noted in males and females at 88 mg/kg bw (males 51 % survival 
compared to 78 % in controls, females 37 % compared to 66 % in controls). In 
each group, 50 animals were examined microscopically. Non-neoplastic findings 
in the kidneys were hyperplasia (0/50, 2/50 and 24/50) in males and (0/50, 3/50, 
16/50) in females. Neoplastic lesions were observed in the kidney; the frequency 
of adenomas was 1/50, 5/50 and 24/50 in males and 0/50, 2/50, 5/50 in females. In 
the brain, benign granular cell tumours were observed in 3/50 males at 88 mg/kg 
only. A slight increase in the incidence of thyroid adenomas was noted in males 
(1/50, 2/48, 3/50), and of carcinomas in males (0/50, 0/48, 2/50) and in females 
(0/50, 2/50, 3/50). Marginal increases in mononuclear cell leukaemia were also 
observed in dosed males and females. Leukaemia occurred with a significant 
positive trend in both sexes and the incidences in the high-dose groups were 
significantly greater than those in controls. However, the incidences in the dosed 
groups were within the range of NTP historical control groups and the marginal 
increases in leukaemia in both sexes were not considered to be clearly chemical-
related (173) (also published in (150)).  
Groups of 60 male and 60 female B6C3F1 mice received 0, 175 or 350 mg/kg 
bw, 5 days/week by gavage for 103 weeks. The body weights of mice receiving 
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TCEP were not different from those of controls and there were no clinical signs of 
toxicity. Renal tubular neoplasms in male B6C3F1 mice are rare (historical vehicle 
controls 8/2 183, 0.4 %). Due to this, the kidneys were further sectioned for a more 
profound microscopic examination. Thus, the incidences of renal tubule neoplasms 
in original and further sections combined were 1/50, 1/50 and 4/50. Focal hyper-
plasia in the kidneys was observed in one control, one 175 mg/kg bw female, two 
350 mg/kg bw males and two 350 mg/kg bw females. Karyomegaly (nuclear en-
largement) was observed in approximately 80 % of mice receiving 350 mg/kg bw 
and less frequently at 175 mg/kg bw. The incidence of neoplasms (adenoma or 
carcinoma) of the Harderian gland was not significantly greater in female mice 
than in controls (3/50, 8/50 and 7/50). However, if the animals in a 66-week study 
were added to the 103-week study, a significant trend was observed and the in-
cidence in the high-dose group was significantly greater than that in controls 
(adenomas and carcinomas in 3/59, 8/60 and 10/60). This gland is located in the 
orbit behind the eye (173) (also published in (150)).  
The NTP Task Group concluded that there was clear evidence of carcinogenic 
activity for male and female F344/N rats receiving TCEP as shown by increased 
incidences of renal tubule adenomas. There was equivocal evidence of carcino-
genic activity for male and female B6C3F1 mice shown by marginally increased 
incidence of renal tubule cell neoplasms and Harderian gland adenomas, re-
spectively (173).  
Groups of 50 male and 50 female Slc:ddy mice received approximately 0, 12, 
60, 300 or 1 500 mg TCEP/kg bw by dietary administration (assuming 30 g body 
weight and 3 g/day food consumption) for 18 months. Histologically, hyperplasia, 
hypertrophy and karyomegaly were observed in the kidney of all treated animals. 
In addition, cysts of the kidneys, necrosis and interstitial fibrosis were reported in 
animals given 1 500 mg/kg bw per day. The number of tumour-bearing animals 
was increased at 300 among females and at 1 500 mg/kg bw in both sexes. An 
increased incidence of renal adenomas was noted in males (0/50, 0/49, 0/49, 2/49, 
9/50) and females (0/49, 0/49, 0/50, 0/49, 2/50). In addition, there was an increased 
incidence of renal carcinomas in males (2/50, 0/49, 2/49, 3/47, 32/50) and females 
(1/50 at 1 500 mg/kg per day and zero in all other groups). In the liver, there was 
an increased incidence of adenomas in males (3/50, 4/49, 3/49, 10/47, 16/50) and 
in females (2/50 at 1 500 mg/kg bw with zero in all other groups). The incidences 
of leukaemia and forestomach tumours were also increased (102, 225). 
 
TDCPP Slc:ddY mice (12 of each sex/group) were fed diets containing 0, 0.1, 0.4, 
1.3, 4.2 or 13.3 g/kg diet for 3 months. The daily intake of TDCPP was reported  
to be 0, 13, 47, 171, 576 or 1 792 mg/kg bw for males and 0, 15, 62, 214, 598 or 
1 973 mg/kg bw for females. The animals in the highest exposure group showed 
emaciation, rough hair and tremor, and all animals died within one month. Haemo-
globin concentration was decreased in males and females by 13 % and 11 %, 
respectively, in the group fed the 4.2 g/kg diet. There was an increase in relative 
liver weight in males (significant at 1.3 and 4.2 g/kg diet with increases of 32 % 
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and 51 %, respectively) and females (significant at 0.4, 1.3 and 4.2 g/kg with 
increases of 16 %, 29 % and 51 %, respectively). There was also an increase in 
relative kidney weight in males (significant at 4.2 g/kg with an increase of 39 %) 
and females (significant at 1.3 and 4.2 g/kg with increases of 34 % and 40 %, 
respectively). Thus, the NOAELs for the increase in relative liver weight were 47 
and 15 mg/kg bw for males and females, respectively. The LOAELs were 171 
mg/kg bw in males and 62 mg/kg bw in females (102, 114).  
Groups of 50 male and 50 female Sprague Dawley rats received approximately 
0, 5, 20 and 80 mg TDCPP/kg bw/day by dietary administration for 2 years 
(Aulette and Hogan 1981, cited in (102)). At the highest dose level, body weight 
was reduced and kidney, liver and thyroid weights were increased. In males, also 
mortality increased. Neoplastic changes were observed in the liver, kidneys, testes, 
brain, thyroid and adrenals. In the liver, the occurrence of benign neoplastic nodules 
was 2/45, 7/48, 1/48, 13/46 in males and 1/49, 1/47, 4/46, 8/50 in females. The 
incidences of liver carcinoma were 1/45, 2/48, 3/48, 7/46 in males and 0/49, 2/47, 
2/46, 4/50 in females. In the kidneys, the incidence of renal cortical tumours 
(benign and/or malignant) was 1/45, 3/49, 9/48, 32/46 in males and 0/49, 1/48, 
8/48, 49/50 in females. An increased occurrence of hyperplasia in the renal con-
voluted tubules was observed in all groups of treated males (2/45, 10/49, 28/48 
and 24/46) and females (0/49, 1/48, 3/48 and 22/50). At 80 mg/kg bw, also the 
incidence of chronic nephropathy was increased. The incidences of benign testi-
cular interstitial tumours were 7/43, 8/48, 23/47 and 36/45. At 80 mg/kg bw, a 
slight increase in the incidence of brain astrocytomas was observed in males (4/46 
versus 0/44 in controls) and a single oligodendroglioma was observed amongst 
males and females. At the same dose level, the occurrences in females of thyroid 
adenomas (5/49 versus 1/42 in controls) and of adrenal cortical adenomas (19/49 
versus 8/48 in controls) were increased. In addition, a slight increase in the 
occurrence of parafollicular cell adenomas was noted in males (3/41 versus 0/40) 
and in females (4/49 versus 2/42) at 80 mg/kg bw. Erythrocyte values were re-
duced in males and females at 80 mg/kg bw. An increased incidence of bone 
marrow erythroid/myeloid hyperplasia was recorded at the same dose in males  
and females. No samples were taken from other treated groups.  
It was concluded that TDCPP is carcinogenic at all exposure levels that were 
tested in both sexes of rats based on the increased occurrence of liver carcinomas. 
Kidney, testicular and brain tumours were also found. In addition, there were non-
neoplastic adverse effects in bone marrow, spleen, testis, liver and kidney. Effects 
in the kidney and testis occurred at all exposure levels. Only the animals in the 
highest dose and control groups were evaluated for effects in the bone marrow and 
spleen. It was therefore impossible to determine the dose-response relationship for 
these effects (Aulette and Hogan 1981, cited in (102)). The data are apparently the 
same as those presented by Stauffer 1981b, cited in (217), and by Freudenthal and 
Henrich 2000 (69), although group sizes differ.  
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TEHP In a 3-month inhalation study, three exposed groups, each consisting of 2 
dogs and 2 rhesus monkeys (equal numbers of each sex), were exposed to TEHP 
for 6 hours/day, 5 days/week for a total of 60 exposures. The mean concentrations 
(± standard deviations) of the exposure over the 12-week period were 10.8 (± 6), 
26 (± 17) and 85 (± 33) mg/m3. The median particle size was 4.4 µm. No mortality 
and normal increases in body weights were observed in dogs and monkeys. There 
were no treatment-related alterations in biochemical or haematological parameters 
or in organ function tests as compared to controls. The lungs of the monkeys were 
normal but the lungs of the dogs showed mild, chronic parenchymal inflammatory 
changes (140).  
In another 3-month inhalation study, groups of 20 male guinea pigs were ex-
posed to TEHP 6 hours/day, 5 days/week for 12 weeks. The mean concentrations 
(± standard deviations) of the two exposed groups were 1.6 (± 0.8) and 9.6 (± 1.5) 
mg/m3. The median particle size was 3.8 µm. The high-dose guinea pigs showed 
significantly increased body weights in comparison to controls. Both exposed 
groups exhibited a lower kidney-to-body weight ratio than the controls. Gross 
pathological examination of the 2 guinea pigs which died during the 9th week of 
exposure showed extensive consolidation of lung tissue. However, when the sur-
viving animals were sacrificed at the end of exposure, mildly congested lungs were 
noted in a quarter of the animals in the control group, whereas no abnormalities 
were observed in the treated groups. Histopathological alterations in the lung, liver 
and kidneys were not related to treatment. Sections of the spinal cord and sciatic 
nerve showed no pathologic changes. Activities of plasma and erythrocyte cholin-
esterase were unaffected in terminal blood samples (140).  
The NTP has performed 13-week and 2-year gavage (in corn oil) studies in rats 
and mice (172). In the 13-week studies, groups of 10 F344 rats of each sex re-
ceived 0, 250, 500, 1 000, 2 000 or 4 000 mg TEHP/kg bw for 5 days/week and 
groups of 10 mice of each sex received 0, 500, 1 000, 2 000, 4 000 or 8 000 mg 
TEHP/kg bw. In rats, mean body weights were depressed 5 % for males that re-
ceived 4 000 mg/kg, and 10 % and 5 % for females at 2 000 mg/kg and 4 000 mg/ 
kg, respectively. In male and female mice, body weight gain was suppressed by 7 
and 5 %, respectively, at the highest dose level. No deaths were attributable to 
TEHP administration. Dose-related inflammatory lesions were observed in the 
gastric mucosa in all groups of mice but no other compound-related effects were 
observed in either species at necropsy (172) (briefly reported also in (117)).  
In the chronic study, TEHP was administered 5 days/week for 103 weeks to 
groups of 50 male and 50 female F344/N rats and B6C3F1 mice. Male rats re-
ceived 2 000 or 4 000 mg/kg bw, female rats received 1 000 or 2 000 mg/kg bw. 
Male and female mice received 500 or 1 000 mg/kg bw. No compound-related 
clinical toxicity was observed in either sex or species. Decrease in body weight, 
compared to controls, was limited to male rats at the low dose (11.5 %) and the 
high dose (15.8 %). The decreased body weight did not affect survival.  
In male rats, the incidence of phaeochromocytomas of the adrenal gland in-
creased with dose: control 2/50 (4 %), low-dose 9/50 (18 %) and high-dose 12/50 
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(24 %). Two phaeochromocytomas of the high-dose group were malignant. In two 
previous gavage studies in the same laboratory, the incidences of phaeochromo-
cytomas among control males were 24 and 26 %. The overall historical incidence 
in this laboratory was 18 %. The incidence of phaeochromocytomas in dosed 
female rats was not significantly higher than in controls. There was a significantly 
positive trend for increased incidence of thyroid follicular cell tumours in male 
rats. However, the incidence in the dosed groups was not significantly higher than 
that in vehicle controls. Thus, this was not considered a positive effect.  
In B6C3F1 mice, TEHP caused a dose-related increase in the incidence of 
thyroid follicular cell hyperplasia in both males (0/49, 12/48, 24/47) and females. 
(1/44, 13/47, 12/46). In female mice, there was a dose-related increase in the in-
cidence of hepatocellular carcinomas (0/48, 4/50, 7/50), which was statistically 
significant at the highest dose level. In male mice, the incidence of hepatocellular 
carcinomas was 9/50, 12/50, 12/49 (172) (also published in (117)).  
The results of these 2-year gavage studies in rats and mice were interpreted by 
NTP as showing some evidence of carcinogenicity in female mice based on the 
increase in hepatocellular carcinomas and equivocal evidence of carcinogenicity in 
male rats based on the incidence of phaeochromocytomas. There was no evidence 
of carcinogenicity in female rats or in male mice receiving TEHP. TEHP caused a 
dose-related increase in the incidence of thyroid follicular cell hyperplasia in male 
and female B6C3F1 mice (172) (also published in (117)).  
 
TEP and TIPP No data were located. 
 
TMCPP In a 90-day dietary study, male and female rats (20/sex/group) were  
given diets containing 0.8-20 g/kg TMCPP (corresponding to approximately  
40-1 000 mg/kg bw/day (44)). The substance given was Fyrol PCF containing  
ca 70 % tris(1-chloro-2-propyl) phosphate and ca 22 % tris(2-chloropropyl) 
phosphate. No mortalities and no treatment-related clinical signs were noted. 
Males and females given 20 g/kg diet showed significantly reduced body weights. 
Significantly increased absolute and relative liver weights were found in males of 
all groups and in females fed 7.5 or 20 g/kg. The mean kidney weights of males 
given 7.5 g/kg or greater were significantly increased relative to controls, while 
female rats were unaffected. Histopathologic and treatment-related change was 
seen in the livers of rats fed 20 g/kg, which was characterised by a very mild 
swelling of cells located in the periportal region of the hepatic lobule. Very mild 
cortical tubular degenerative changes were observed in the kidneys of males fed 
7.5 and 20 g/kg and of females administered 20 g/kg. The sternal bone marrow of 
3 rats administered 20 g/kg was observed to be very mildly hypoplastic. Very mild 
thyroid follicular hyperplasia was found in all males and in females given 20 g/kg. 
There were no treatment-related effects observed in haematology, clinical chemist-
ry or in brain, plasma and erythrocyte cholinesterase activity. All histopathologic 
changes were considered reversible. According to the authors, the NOAEL for 
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male rats was 0.8 g/kg and for female rats 7.5 g/kg in the diet (increased liver 
weight was regarded as a non-adverse effect) (Stauffer 1981a, cited in (238)).  
 
TPP Young male Sprague Dawley rats were fed diets containing TPP (98 % 
purity) at levels of 0, 2.5, 5, 7.5 or 10 g/kg for 4 months. The calculated average 
doses were 161, 345, 517 and 711 mg/kg bw/day. Treatment-related decrements  
in growth in the absence of changes in food consumption were found at all dietary 
levels from 5 g/kg and above. There were no effects in behavioural tests (203) (see 
Section 10.4). 
Spartan Sprague Dawley rats were fed 0, 2.5, 5, 7.5 and 10 g TPP/kg diet for 
120 days (corresponding to approximately 125, 250, 375 and 500 mg/kg bw (44)). 
The immunotoxicity evaluation included total protein, electrophoretic analysis of 
serum proteins, lymphoid organ weights in relation to growth, and histopathology, 
together with expanded immunohistochemical evaluation of B- and T-lymphocyte 
regions in the spleen, thymus and lymph nodes using immunoperoxidase staining. 
Assessment was made of the humoral response to a T-lymphocyte-dependent 
antigen, sheep red blood cells, and was begun at midterm of the feeding period for 
the primary response followed by secondary and tertiary booster immunisations at 
3-week intervals. The kinetics of the response was measured by haemolysin assay 
of relative antibody titres at days 3, 4, 5 and 6 post-injection. No significant effects 
on the response were noted for either sex at any of the dose levels tested. The only 
effects observed were a decreased rate of growth in males at high levels of TPP 
and increased levels of α- and β-globulins (85).  
There was no increased incidence of lung adenomas after 24 weeks in male 
mice given 1-18 intraperitoneal injections of 20, 40 or 80 mg/kg bw/dose of TPP 
(purity 95-99.9 %) (229). 
10.7 Reproductive and developmental toxicity  
Reproductive and developmental toxicity studies are summarised in Table 14. 
Several of the phosphate triesters have shown effects on reproduction or develop-
ment in animal studies (TCP, TOCP, TCEP, TDCPP and TMCPP). TOCP affects 
testicular function in rats at low doses (10 mg/kg bw) and this compound may be 
responsible for the effects seen after exposure to TCP containing less than 9 % of 
TOCP. TDCPP exposure to rats caused atrophy of the seminal vesicle and de-
creased secretory product at all dose levels starting at 5 mg/kg bw. However, these 
effects were not confirmed in rabbits. In one study, there was equivocal evidence 
of an affect on development from TPP exposure. The data on TEP is regarded 
insufficient. No information has been found regarding TEHP and TIPP.  
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TCP Male rats gavaged with 100-1 600 mg/kg bw/day for 14 days of TOCP ex-
hibited decreased epididymal sperm density and disruption of the seminiferous 
epithelium in all treated animals (205).  
A subchronic 63-day study (reflecting the 49-day length of the rat seminiferous 
epithelium cycle plus the 14-day transit time of spermatids through the epididymis) 
was initiated. Dose-dependent (10-100 mg TOCP/kg bw/day) decreases in cauda 
epididymal sperm motility and density, testicular enzyme activities and alterations 
in sperm morphology were observed. The 10-mg/kg dose caused a significant 
decrease of non-specific esterase activity in testis. There was a normal testicular 
morphology and a slight increase of abnormal sperms, 0.25 % versus 0.17-0.19 % 
in controls. At 25 mg/kg bw, a significant decrease of non-specific esterase activity 
in testis was observed. The normal array of germ cells appeared disorganised. There 
was an increase of abnormal sperms (1.20 % versus 0.17-0.19 %) and amorphous 
sperms (16 % versus 0 % in controls). The 50-mg/kg dose caused a significant 
decrease of non-specific esterase activity in testis and a pathologic histology. 
There was an increase of abnormal (34 % versus 0.17-0.19 %) and amorphous 
sperms (39 % versus 0 %) and a significant decrease of motile sperms. At the 
doses 50, 75 and 100 mg/kg bw, there were no observable motile sperms. Con-
current pair-fed controls (matched to the highest dose group, 100 mg/kg/day) 
indicated that weight loss from TOCP administration had contributed minimally  
to the testicular toxicity. Plasma α-tocopherol acetate (vitamin E) and testosterone 
concentrations were unaffected. TPCP, the non-neurotoxic structural analogue of 
TOCP, produced a slight decrease of testosterone levels but no effect on sperm 
quality at 100 mg/kg bw. According to the authors, a minimum effective dose for 
observable testicular toxicity was determined to be 10-25 mg TOCP/kg bw. The 
data suggest that TOCP interferes with spermatogenic processes and sperm 
motility (205). 
Eight male F344 rats were given 150 mg/kg bw of TOCP in corn oil for 21 
successive days. The animals were allowed to recover for 98 days (two cycles  
of the seminiferous epithelium) with no further treatment. Complete absence of 
germinal cells in the testis was observed in all treated animals. Thus, this treat-
ment caused an irreversible testicular lesion (206). 
Pregnant Long Evans rats were gavaged with 87.5, 175 or 350 mg/kg bw/day 
TOCP throughout organogenesis, i.e. from gestation days 6 through 18 (Day of 
sperm = Day 0). The highest dose tested (350 mg/kg bw) was lethal in 28 % of  
the dams, whereas no maternal deaths or toxicity were observed in the 87.5- or 
175-mg/kg dose groups. There were no significant differences noted among the 
experimental and control groups for preimplantation loss or resorption. Foetal 
weights for both sexes in the TOCP groups were significantly greater than in the 
control group, however, no difference among the TOCP groups was observed. 
There was no difference regarding number of implants/litter, preimplantation loss 
and resorption between treated and controls. Malformation rates were too low to 
warrant statistical analysis. Numerous soft tissue and skeletal variations were 
observed in both control and TOCP-treated groups and there were no significant 
  
 92 
differences in the frequency of variations between the dose groups. The results  
of this study indicate that TOCP is not teratogenic in the Long Evans rat (231). 
In studies by NTP (detailed below), F344/N rats and B6C3F1 mice were gavaged 
or fed diets with a complex mixture of 18 % dicresyl phosphate esters and 79 % 
TCPs. Two of the TCPs were indentified as TMCP (21 %) and TPCP (4 %) with 
no detectable TOCP (< 0.1 %). 
In a sub-chronic toxicity study (described also in Section 10.6), groups of 10 
male and 10 female F344/N rats and B6C3F1 mice received TCP in corn oil by 
gavage at doses of 0, 50, 100, 200, 400 or 800 mg/kg bw for 13 weeks. All animals 
survived. In rats, ovarian interstitial cell hypertrophy occurred in all dosed female 
groups. Atrophy of the seminiferous tubules occurred in males receiving 400 and 
800 mg/kg. In mice, ovarian interstitial cell hypertrophy and adrenal cortex cyto-
plasmic vacuolisation occurred in all dosed female groups (174).  
In a similar study, groups of 10 male and 10 female F344/N rats were fed diets 
containing 0, 0.9, 1.7, 3.3, 6.6 or 13 g/kg of TCP for 13 weeks. The estimated 
delivered daily doses were 55, 120, 220, 430 and 750 mg/kg bw for males and 65, 
120, 230, 430 and 770 mg/kg bw for females. Ovarian interstitial cell hypertrophy 
and interstitial inflammation occurred in all exposed groups of females. Basophilic 
hypertrophy of the pituitary gland pars distalis and atrophy of the seminiferous 
tubules occurred in male rats receiving 6.6 and 13 g/kg diet (174). 
B6C3F1 mice were fed diets containing 0, 0.25, 0.5, 1.0, 2.1 or 4.2 g/kg of TCP 
for 13 weeks. The estimated delivered daily doses were 45, 110, 180, 380 or 900 
mg/kg bw for males and 65, 130, 230, 530 and 1 050 mg/kg bw for females. At the 
two highest doses, bilateral cytoplasmic vacuolisation of the interstitial ovarian 
cells was observed (174).  
In a chronic toxicology and carcinogenesis study (described also in Section 
10.6), groups of 95 male and 95 female F344/N rats were fed diets containing 0, 
0.075, 0.15 or 0.3 g/kg of TCP for 2 years. The estimated delivered daily doses 
were 3, 6 and 13 mg/kg bw for males and 4, 7 and 15 mg/kg bw for females. 
Ovarian interstitial cell hyperplasia was observed after 3 months (6/10 versus 
0/10) in the 7 mg/kg bw group of females but not later. These changes were ob-
served at all interim evaluations at the dose 15 mg/kg bw (174).  
In a corresponding 2-year study, B6C3F1 mice were fed diets containing 0, 0.06, 
0.125 or 0.25 g/kg TCP (corresponding to average daily doses of 7, 13 or 27 mg/kg 
bw in males and 8, 18 or 37 mg/kg bw in females). There were no significant 
lesions of the genital systems of males or females (174). 
Swiss CD-1 mice were exposed to TCP using the reproductive assessment by 
continuous breeding protocol (RACB). The TCP mixture contained 21 % TMCP, 
4 % TPCP and < 0.1 % TOCP. Overall, pure or mixed ortho-, meta-, para-tricresyl 
isomers composed 75 % of the total, with the remainder composed of dicresyl 
phenyl and di- and tricresylxylyl phosphates. TCP was mixed into the feed at 0, 
0.5, 1 or 2 g/kg. The estimated doses of TCP were 62.5, 124 and 250 mg/kg bw/ 
day. The fertility index was not changed in the animals consuming the high-
concentration feed. However, the number of litters per pair decreased in a dose-
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related fashion, and the proportion of liveborn pups and their weight were signi-
ficantly decreased in the high-dose group. A crossover mating trial demonstrated 
impaired fertility in both males and females exposed to 2 g TCP/kg diet, with a 
greater effect in females. Histopathology of the F0 pairs revealed dose-related 
seminiferous tubule atrophy and decreased testis and epididymal weights in the 
high-dose males, while the female reproductive tract showed no histopathological 
changes. There were dose-related changes in the adrenals of both sexes, and body 
weight was depressed in both sexes at the highest concentration. The last litter was 
reared by the dam until weaning, after which dosed feed was provided to the F1 
mice at the same concentrations as their parents had consumed. The last litter born 
in the 98-day breeding phase was reared to age 74 days and then mated within the 
control and two of the treatment groups (0, 0.5 and 1 g TCP/kg) (there were too 
few offspring in the 2 g/kg group). There was a decrease in the fertility index in 
the 1 g/kg group and a decreased proportion of liveborn and number of liveborn 
pups per litter. At necropsy, sperm concentration and morphology in the F1 males 
were normal at termination, although motility was decreased in both the 0.5 and 
the 1 g/kg diet groups compared to controls. These data show that TCP impaired 
fertility in both sexes of mice in the F0 generation and affected sperm motility at 
even the lowest dose in F1 males (62.5 mg/kg bw) (35, 128).  
In a later review of reproductive toxicants tested within the NTP, TCP was 
ranked as a highly toxic chemical with an effect observed at 62 mg/kg bw/day 
(156), a level based on the above mentioned study (35, 128).  
Long Evans rats were exposed to TCP containing less than 9 % TOCP, the 
remainder being a mixture of TPCP, TMCP and other tri-cresyl isomers. Male 
Long-Evans rats received 0, 100 or 200 mg/kg bw and females received 0, 200  
or 400 mg/kg bw of TCP in corn oil by gavage. The 100-mg/kg bw males were 
mated with 200-mg/kg females, and 200-mg/kg males were bred with 400-mg/kg 
females. Males were dosed for 56 days and females for 14 days prior to breeding 
and throughout the 10-day breeding period. Following breeding, the males were 
necropsied and evaluated for sperm parameters and reproductive tract histopatho-
logy. Females were dosed throughout gestation and lactation. Pups and adult fe-
males were necropsied on postnatal day 21. No clinical signs of toxicity or body 
weight depression were observed among male or female rats. Sperm concentration, 
motility and progressive movement were decreased for 200-mg/kg males. A dose-
dependent increase in abnormal sperm morphology was observed for males in 
both TCP dose groups. The percent of sperm-positive females per group was un-
changed but the number of females delivering live young was severely decreased 
by TCP exposure. Litter size and pup viability were decreased in the 400-mg/kg 
dose group. Pup body weight and developmental landmarks were unaffected by 
TCP exposure. Histopathologic changes were observed in the testes and epididy-
mides of male rats at 200 mg/kg. A dose-dependent diffuse vacuolar cytoplasmic 
alteration of ovarian interstitial cells was observed in female rats (31). 
 Male and female F344 rats received single daily oral doses of 400 mg/kg bw of 
TCP in sesame oil for 20, 40 and 60 days (the is study also described in Section 
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10.3). There was a significant increase of cytoplasmic lipidosis in ovarian inter-
stitial and adrenocortical cells in females. In males, there were decreased testicular 
weights and degeneration of the seminiferous tubules (131).  
In another study by the same research team, groups of breeding F344 rats re-
ceived single daily oral doses of 400 mg/kg bw of TCP in sesame oil for up to 135 
days beginning 7 days prior to pairing. A naive control group allowed to breed but 
not dosed or handled daily demonstrated that daily dosing and handling of the rats 
had no effect on reproduction. The fertility index, number of litters born and num-
ber of pups per litter were significantly decreased in rats exposed to TCP. A cross-
over mating experiment between exposed and vehicle controls demonstrated that 
TCP caused 100 % infertility in males, whereas no effects were observed in females. 
Both sexes in the crossover experiment exhibited significant decreases in terminal 
body weights and increases in adrenal gland and liver weights. TCP-dosed males 
had significantly decreased testicular and epididymal weights. TCP-dosed females 
had increased ovarian weights (132).  
 
TBEP was administered by gavage in corn oil to three groups of 25 mated Charles 
River CD female rats at dose levels of 0, 250, 500 or 1 500 mg/kg/day on gestation 
days 6-15. The treatment had no effect on foetal resorption, foetal viability, post-
implantation loss, total implantations or the incidence of foetal malformations. 
The NOAEL was the highest dose level tested, 1 500 mg/kg bw (Monsanto 1985d, 
cited in (103)). In an earlier range-finding study, maternal weight loss was ob-
served in animals receiving 2 000 but not 1 000 mg/kg bw/day (Monsanto 1985c, 
cited in (103)).  
 
TBP was administered by gavage to male and female Sprague Dawley rats at 
doses of 0.14 and 0.42 ml/kg bw (140 and 410 mg/kg) for 14 consecutive days. 
Effects were investigated at the end of the feeding period. Histopathological 
examination was only performed in the high-dose animals. Microscopic de-
generative changes were found in 50 % of the seminiferous tubules of the testis  
in one out of four rats (123). The study is described also in Section 10.3.  
Thirty CD Sprague Dawley rat weanlings of each sex (F0) were exposed to TBP 
in the diet ad libitum at 0, 0.2, 0.7 or 3 g/kg for 10 weeks and then randomly mated 
within groups for 3 weeks with continued exposure. The approximate ranges for 
daily TBP consumption for males during the prebreed period were 11-18 mg/kg 
bw for F0 (10-21 for F1) at 0.2 g/kg diet, 38-65 (36-72 for F1) mg/kg bw at 0.7 
g/kg diet, and 160-264 (166-328 for F1) mg/kg bw at 3 g/kg. For females, the 
approximate ranges were 12-17 mg/kg bw for F0 (13-21 for F1) at 0.2 g/kg diet, 
41-60 (44-70 for F1) mg/kg bw at 0.7 g/kg diet, and 178-266 (193-316 for F1) 
mg/kg bw at 3 g/kg diet. During gestation (gestation days 0-20), female daily TBP 
consumption was approximately 13 mg/kg bw for F0 and F1 at 0.2 g/kg diet, 47 
(45 for F1) mg/kg bw at 0.7 g/kg diet, and 214 (217 for F1) mg/kg bw at 3 g/kg 
diet. During lactation (postnatal days 0-21), the female daily TBP consumption 
was approximately 26 mg/kg bw for F0 (31 for F1) at 0.2 g/kg diet, 94 (107 for F1) 
  
 95 
mg/kg bw at 0.7 g/kg diet, and 404 (502 for F1) mg/kg bw at 3 g/kg diet. F0 
parents and 10 F1 weanlings/sex/dose were necropsied and adult reproductive 
organs, urinary bladders (both sexes), kidneys (males) and livers (females) were 
evaluated histologically. Thirty F1 weanlings/sex/dose continued exposure for 11 
weeks and were bred as described above. F1 parents and F2 weanlings, 10/sex/dose, 
were then necropsied as described above. Adult toxicity was observed in both 
sexes and generations at 0.7 and 3 g/kg diet. Observations included reduced body 
weights, weight gain and feed consumption, urinary bladder epithelial hyperplasia 
(both sexes), renal pelvis epithelial hyperplasia (only at 3 g/kg diet, males) and 
centrilobular liver hypertrophy (females). At 0.2 g/kg diet (10-21 mg/kg bw), tran-
sient reductions in body weight were observed in F0 and F1 females, and urinary 
bladder epithelial hyperplasia in F0 males and females and in F1 males. There was 
no evidence of reproductive toxicity, of reproductive organ pathology or of effects 
on gestation or lactation at any dose tested. Postnatal toxicity was evidenced by 
consistent reductions in F1 and F2 pup body weights at 3 g/kg diet and occasional 
weight reductions in F2 litters at 0.7 g/kg diet and was associated with maternal 
toxicity observed at these doses and during the postnatal period. The weight 
reductions were observed from postnatal day 1. According to the authors, the 
NOAEL for reproductive toxicity was at least 3 g/kg diet and the NOAEL for 
postnatal toxicity was approximately 0.2 g/kg diet (234).  
In a developmental toxicity study, pregnant New Zealand White rabbits were 
given TBP (100 % purity) in corn oil at doses of 0, 50, 150 or 400 mg/kg bw/day 
by gavage on gestational days 6-18. The animals were sacrificed on gestational 
day 30. Maternal - and embryotoxicity were suggested at 400 mg/kg bw, with  
no observations of foetotoxicity or teratogenicity in any dosage group. Groups of 
pregnant Wistar rats (24/group) received TBP (100 % purity) in corn oil at doses 
of 0, 188, 375 or 750 mg/kg bw/day by gavage on gestational days 6-15. On ge-
stational day 20, the animals were euthanised. Maternal toxicity was observed  
at all dosages. Only the dams administered 750 mg/kg bw displayed mortality. 
Significant foetotoxic effects, delayed ossification and reduced foetal body weights 
were observed in the 750-mg/kg dosage group only. TBP was not teratogenic or 
embryotoxic in the rat (presented as an abstract, no further details were given) 
(196). 
In a dose-finding study, pregnant Wistar rats were treated orally on gestation 
days 7-17 with TBP in olive oil at 0, 100, 200, 400 and 800 mg/kg bw/day. All 
pregnant rats died after five or six consecutive doses of 800 mg/kg bw. In the 
teratological study, the doses were 0, 62.5, 125, 250 and 500 mg/kg bw/day. The 
NOAEL for maternal toxicity was considered by the authors to be 62.5 mg/kg bw 
because of significant decreases in maternal body weight gain found at 200 mg/kg 
in the dose-finding study. There were no significant differences between the groups 
in the incidence of dead or resorbed foetuses, the number of living foetuses and 
the body weights of living foetuses of both sexes. The incidence of rudimentary 
lumbar rib increased significantly at 500 mg/kg bw. There were two cases of mal-
formations but the incidence was not significantly increased (168).  
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TBP was injected into the yolk sac of eggs from Leghorn hens and was reported 
to be slightly teratogenic at a high dose (5 mg/egg) in this test (187). The lack of 
details in the study precludes a sound conclusion on TBP teratogenicity.  
 
TCEP was given to mice by gavage at doses of 44, 175 and 700 mg/kg bw. The 
study was a regular 13-week study to which sperm morphology and vaginal cyto-
logy examinations were added. Decreased weights of epididymis and testis were 
recorded and an increase of abnormal sperms in one or more dose groups compared 
to a control group. Rats were given TCEP by gavage at 22, 88 and 175 mg/kg bw 
for 13 weeks and a decrease of sperm motility was noted in one or more dose 
groups compared to a control group (159). The study does not reveal at which 
dose the effect appears.  
TCEP was suspended in olive oil and administered by oral intubation to groups 
of 23-30 Wistar rats at dose levels of 50, 100 and 200 mg/kg bw during gestation 
days 7 through 15. No changes in maternal body weight gain, food consumption, 
and general appearance were observed at 50 and 100 mg/kg bw. A marked sup-
pression of food consumption and maternal body weight gain with toxic symptoms 
such as piloerection and general weakness was seen in the 200-mg/kg group and 7 
out of 30 dams died. There was no evidence of an increase in foetal death or of 
malformations attributable to the treatment with TCEP at any dose levels examined. 
In the postnatal examination, the development of the offsprings in all groups ex-
amined was well maintained, without any disorders attributable to the treatment in 
morphological examination and in some functional tests. The authors concluded 
that TCEP had no teratogenic effect in rats under the present experimental con-
ditions, although the compound elicited maternal toxicity at the highest dose (115). 
TCEP was tested for its effects on reproduction and fertility in Swiss CD-1 mice 
using a continuous breeding protocol (RACB). Data from a 2-week dose-range-
finding study were used to set exposure concentrations for the continuous co-
habitation phase (14 weeks) at 175, 350 and 700 mg/kg bw by gavage in corn oil. 
Body weights of treated animals were not different from those of controls. There 
were significant effects on reproduction. The number of litters per pair was 
significantly reduced in the mid- and high-dose groups by 8 and 63 %, respective-
ly. Only 2 of 18 pairs of high-dose mice delivered a third litter compared to 37 of 
38 controls. The number of live pups per litter was reduced by 20 and 32 % in the 
mid- and high-dose groups, respectively, although pup viability, sex ratio and 
body weight remained unchanged. Cumulative days to deliver each litter were 
increased in the high-dose group only, an effect which started at the second litter 
(40 days from the start of cohabitation for controls to deliver their second litter 
versus 66 days for high-dose mice).  
The last litter from all dose groups was reared by the dam and monitored for 
viability and growth. There were no pups at the high dose. Although dam weight 
was reduced by approximately 7 % in the middle dose group compared to control, 
there were approximately 50 % fewer pups per litter, so pup weight gain during 
nursing was greater in the middle dose group than in controls.  
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After the crossover mating, the control and high-dose F0 mice were killed and 
necropsied. In males, body weight was unchanged, absolute testis weight was 
reduced by approximately 30 %, and relative liver weight and kidney weight was 
increased by 15 % and decreased by 20 %, respectively. Epididymal sperm density 
was reduced by approximately 30 %, motility was reduced by more than 50 %  
and abnormal forms increased from a control value of 9 to 31 %. In high-dose F0 
females, body weight was unchanged and relative kidney weight was reduced by 
approximately 10 %. Oestrous cyclicity was unchanged.  
F1 adults were killed and necropsied. Mid-dose males weighed 6 % more than 
controls but there were no other changes seen at necropsy. Female body weights 
did not differ across groups nor were organ weights or oestrous cycle parameters 
different. Microscopically, there were more liver changes in middle dose males 
than in controls, an effect not seen in females. There were no other significant 
microscopic lesions.  
These data showed clear effects of TCEP on murine reproduction, manifest as 
fewer and smaller litters. At least at the high dose, the effect occurred primarily  
in the males. In both generations, doses that caused hepatic changes also reduced 
fertility. Whether the converse occurs (fertility changes at doses that do not affect 
the liver or kidneys) is unknown because of the lack of necropsy data for the F0 
middle dose group (36, 37). 
In a poorly reported inhalation study, male rats were continuously exposed to 
0.5 or 1.5 mg TCEP/m3 for 4 months. Testicular toxicity was seen at both ex-
posure levels, with more severe effects at the highest level. There were decreased 
sperm counts, decreased sperm motility and abnormal sperm morphology. Histo-
logy of the testes showed an increased number of spermatogonia but decreased 
numbers of sperm in the later stages of development. When the treated males were 
mated there was decreased fertility at 1.5 mg/m3 with increased pre- and post-
implantation loss and decreased litter sizes (200). 
 
TDCPP In a fertility study, male rabbits were given TDCPP orally at 2, 20 or 200 
mg/kg bw/day for 12 weeks. There were significant treatment-related increases in 
liver and kidney weights in the highest dose group. The treatment did not affect 
mating behaviour, fertility, sperm quality or quantity. No histopathological lesions 
were reported in testes or epididymides (presented as an abstract) (254). 
Male Sprague Dawley rats were fed 0, 5, 20 or 80 mg/kg bw/day in the diet for 
12 or 24 months. In the seminiferous tubules, there was a slight increase in occur-
rence of oligospermia (35/57, 31/60, 45/60, 51/56), eosinophilic material in the 
tubular lumen (2/57, 4/60, 12/60, 11/56), sperm stasis (5/57, 5/60, 11/60, 14/56) 
and periarteritis nodosa (5/57, 10/60, 19/60, 16/56). In the epididymides, males 
given 80 mg/kg bw had an increased incidence of oligospermia and degenerated 
seminal products. The lowest TDCPP dose of 5 mg/kg bw caused atrophy of the 
seminal vesicle and decreased secretory product. These effects were also observed 
at higher doses (Stauffer 1981b, cited in (217)). 
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Groups of 50 male rats received approximately 0, 5, 20 or 80 mg/kg bw of 
TDCPP by dietary administration for 2 years. In the seminiferous tubules, there 
was a slight increased occurrence of germinal epithelium atrophy and oligo-
spermia (30/43, 29/48, 42/47, 44/45), eosinophilic material in the tubular lumen 
(2/43, 4/48, 12/47, 11/45), sperm stasis (5/43, 5/45, 11/47, 14/45) and periarteritis 
nodosa (5/43, 10/48, 19/47, 14/45). There was also an increase of benign testicular 
interstitial tumours nodulus (7/43, 8/48, 23/47, 36/45). Seminal vesicle atrophy 
and decreased secretory products were reported in all treated groups. In the epidi-
dymides, males given 80 mg/kg bw had an increased incidence of oligospermia 
and degenerated seminal products (Aulette and Hogan 1981, cited in (102)). The 
data are apparently the same as those presented above by Stauffer 1981b, cited in 
(217), and by Freudenthal and Henrich 2000 (69), although group sizes differ. 
Female Wistar rats were given 25, 50, 100, 200 or 400 mg/kg bw by oral in-
tubation on gestation days 7-15. In the 400-mg/kg group, there was severe mater-
nal toxicity with markedly suppressed maternal body weight gain and food con-
sumption. Eleven out of 15 dams died. In the 200-mg/kg group, a significant 
increase in relative kidney weight by 15 % in the dams was observed. There was 
no evidence of an increased number of foetal deaths, of abnormal foetal develop-
ment or of malformations at an exposure of 200 mg/kg or less. The highest dose 
(400 mg/kg) was associated with a significantly higher incidence of foetal death. 
In this study, the NOAEL and LOAEL for maternal toxicity were 100 mg/kg bw 
and 200 mg/kg bw, respectively. The NOAEL and LOAEL for foetotoxicity were 
200 and 400 mg/kg bw, respectively. In postnatal examination performed at dose 
levels of 200 mg/kg and below, the development of offspring appeared well with-
out any appreciable change in functional tests. The authors concluded that TDCPP 
had no teratogenic effect in rats under the present experimental conditions, al-
though the compound elicited maternal and foetal toxicity at the highest dose, 400 
mg/kg bw (102, 227).  
Pregnant Sprague Dawley rats (20/group) received 0, 25, 100 or 400 mg/kg bw 
per day by gavage on gestation days 6-15. Maternal toxicity manifested as clinical 
signs, reduced food consumption and transient reductions in body weight was ob-
served at 100 and 400 mg/kg bw. TDCPP had no effect on implantation efficiency 
or mean number of corpora lutea. Treatment at 400 mg/kg significantly increased 
the number of resorptions and reduced foetal viability. Decreased skeleton de-
velopment in the highest dose group was related to growth retardation and de-
creased foetal size. The incidence of malformations were not treatment-related 
(Hazleton 1978, cited in (243)).  
 
TEHP No data were located. 
 
TEP In an early study using a small number of rats, the litter size was reduced 
after repeated feeding of both sexes at 670 mg/kg bw/day, although no symptoms 
of poisoning were described in the parent animals. The NOAEL for effects on the 
litter size was 335 mg/kg/bw/day. Neither testicular weights nor the histological 
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investigation of the testes revealed any remarkable findings (highest dose 6 700 
mg/kg bw) (237).  
In a 28-day study with doses up to 1 000 mg/kg bw, no effect on testicular 
weight was observed (237).  
A teratogenic study in rats showed no evidence of a teratogenic potential up to 
the highest dose of 625 mg/kg bw (NOAEL for developmental toxicity). At the 
highest dose, there was reduction of body weight gain, food intake and faeces 
excretion as signs of maternal toxicity (NOAEL 125 mg/kg bw/day) (237).  
In the UNEP review (237) from which the above data were taken, no further 
details were given and references were not adequately presented.  
 
TIPP No data were located. 
 
TMCPP Groups of 11-14 pregnant female Wistar rats were fed a diet containing 
0, 0.1, 1 or 10 g/kg TMCPP (not specified) during gestation days 0-20. The intake 
of TMCPP was estimated to 0, 6, 70 and 625 mg/kg bw/day. Some dams were 
sacrificed on gestation day 20, and the foetuses were examined for skeletal or 
visceral abnormalities. Litters born naturally from groups of five to seven dams 
were culled to eight neonates each and monitored for 4 weeks. TMCPP had no 
effect on food consumption or body weight gain in dams. TMCPP did not affect 
the number of implants, the number of resorptions or the number or weight of live 
foetuses. No foetuses died or had obvious external malformations. The incidence 
of skeletal or visceral malformations in foetuses from treated litters was not 
statistically different from controls. However, dose-related increases in the in-
cidence of missing 13th ribs and cervical ribs were observed in treated foetuses. 
Delayed ossification of sternebra was observed in all groups. Treatment in utero 
had no effect on growth or survival of weanlings up to postnatal day 28 (Kawasaki 
et al 1982, cited in (216)).  
A group of 18 adult White Leghorn hens received an initial oral dose of 13 200 
mg/kg bw of Fyrol PCF followed by the same treatment 3 weeks later. The animals 
were sacrificed 3 weeks after the second dose. Egg production ceased shortly after 
the first dose and there was severe loss of feathers (209).  
 
TPP Male and female Sprague Dawley rats were fed dietary levels of 0, 2.5, 5,  
7.5 or 10 g TPP/kg from 4 weeks post weaning for 91 days through mating and 
gestation. At these dietary levels, the daily intake of TPP during pregnancy was  
0, 166, 341, 516 and 690 mg/kg bw, respectively. No adverse effect on fertility 
was observed. All treated groups had significantly more foetuses with moderate 
hydroureter than the control group. However, the high baseline incidence ex-
hibited in the control group and lack of clear dose-related response make the 
biological significance of this finding unclear. The average number of foetuses 
having at least two soft-tissue variations was significantly higher in all dose 
groups except the highest. However, the proportion of litters with foetuses having 
at least two soft-tissue variations was 7 % (controls), 24 % (166 mg/kg), 41 % (341 
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mg/kg) 32 % (516 mg/kg) and 18 % (690 mg/kg). The authors concluded that TPP 
exposures had no toxic effects on mothers or offspring at these dosages. No sig-
nificant increases in the incidence of anomalies were seen in the treated groups as 
compared to the control values (252). NEG notes that the lack of dose-response 
may not be so such a spurious finding, since the spacing of doses is rather small.  
If the dose-response curve is shallow, one may not expect obvious variation with 
dose, taking general variation into account. The results of the study are classified 
as equivocal. 
10.8 Summary  
A condensed summary of main effects reported in animal or in vitro studies of 
flame retardant phosphate ester exposures is presented in Table 15. 
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11. Observations in man  
11.1 Irritation and sensitisation 
Respiratory and eye irritation data are lacking. Skin irritation data are presented 
below.  
 
TCP Mild irritation after initial contact with TCP formulations in patch tests on 
volunteers was reported by Broadhurst et al 1951, cited in (215).  
Totally 230 patients with occupational dermatitis in the metallurgic industry in 
Spain were studied with a standard patch test (10 % TCP in olive oil). The pro-
portion of tests positive to TCP was 2.6 % (9). In Finland, totally 839 patients 
were patch tested with a 5 % TCP solution and none reacted (228). 
In Germany, 199 metalworkers were patch tested with a 5 % TCP solution be-
cause of suspected metalworking fluid dermatitis. No positive reactions were seen 
(72).  
A patient with eczema gave a strong reaction to the surgical tape used in 
applying patch test, which was the result of sensitivity to TCP (tested with a 5 % 
solution). This patient also reacted to TPP (182).  
 
TBEP A repeat human insult patch test on a panel of 209 volunteers was under-
taken by Monsanto. In the 3-week induction period, 0.2 ml of TBEP was applied 
for 24 hours to occluded skin 4 times/week. During the 4th week, 4 similar ap-
plications were made to previously untreated skin. During induction, minimal 
irritation was observed in 9 of the individuals. The irritation was only observed 
once or twice during the 12 applications. There was no dermal reaction to the 
challenge applications. The results indicate minimal skin irritation and no sen-
sitising potential (Monsanto 1984a, cited in (103)). 
 
TBP In an occlusive skin irritation test, TBP was irritating when tested as a 75 % 
solution in lanoline for 3 hours. When applied as 50 % and 25 % solutions in 
lanoline for 24 hours, mild irritation and no irritation, respectively, were reported 
(German Chemical Society 1995, cited by (79)). TBP has been shown to have an 
irritant effect on the skin and mucous membranes in humans (101).  
Patches with a solution containing less than 25 % TBP were applied 15 times on 
alternate days on the skin of 53 volunteers. No reactions were observed 24 hours 
after the final patch. Thus, there was no evidence of sensitisation (Monsanto 1980, 
cited by (79)). 
One case of sensitisation to TBP was reported among 42 patients with furniture-
related dermatitis (129). 
 
TCEP and TDCPP No data were located. 
 
TEHP No irritant effects were seen after 24 hours of exposure to a TEHP-
saturated cotton swab placed on the skin of the forearm of 6 volunteers. A piece (2 
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cm2) of PVC plastic containing 40 % TEHP was placed on the arm of 8 volunteers 
for 72 hours. Slight redness but no irritation was observed (Kimmerle 1958, cited 
in (103)). 
 
TEP No data were located. 
 
TIPP Skin irritation was not reported among workers exposed to hydraulic fluids 
containing isopropylated triphenyl phosphate (27, 113).  
 
TMCPP No data were located. 
 
TPP Allergic contact dermatitis has been reported after exposure to TPP in 
cellulose acetate films (86), glues (25) and spectacle frames (26, 182). Between 
1950 and 1962, 15 out of 23 192 (0.065 %) patients in Denmark showed positive 
reactions when tested with discs of cellulose acetate film plasticised with 7-10 % 
TPP. Approximately 2 250 (out of the 23 192) were re-examined by routine patch 
tests after an interval of years. Two or possibly three patients with chronic eczema 
had been sensitised to the cellulose acetate film as a result of the patch test (86). In 
Finland, totally 343 patients were patch tested with a 5 % TPP solution and none 
reacted (228). 
Probable cross-reactivity between triphenyl phosphite and TPP has been ob-
served (87). 
11.2 Effects of single and short-term exposure  
TCP There are many reported cases of human poisoning, mostly from TCP con-
tamination of food-stuffs. Occupational poisoning, usually resulting from dermal 
exposure, has also been reported. Around 60 000 people have been poisoned 
worldwide. The ortho isomer of TCP is generally regarded as the responsible toxic 
agent (99). Mono-ortho and di-ortho isomers are even more neurotoxic than TOCP 
(257). Short-term symptoms after ingestion might involve vomiting, abdominal 
pain and diarrhoea. These clear up and a symptom-free interval follows lasting 
from 5 to 21 days. This interval is followed by soreness of the muscles below the 
knees and numbness of the toes and fingers lasting several days and followed by 
weakness of the toes and bilateral foot-drop. After another interval of about 10 
days, weakness of the fingers and wrist-drop follow. This paralysis is usually not 
as severe as that in the feet and legs. In the upper extremities, paralysis does not 
extend above the elbows. The thigh muscles may be involved in advanced cases 
(93). 
There is considerable variation in the sensitivity of individuals to TOCP. Severe 
symptoms were reported with a TOCP dose of 0.15 g in one individual, while 
others were unaffected by 1-2 g (259). There is also considerable variation in the 
rate of recovery from poisoning. Some patients recover completely, whereas others 
are still severely affected years later, after apparently similar exposure (99).  
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In 1960, 58 cases of TOCP-poisoning were reported in Bombay, India and 32 
patients were investigated in hospital. The patients had been using mustard oil for 
cooking and massaging the body for years. TOCP was detected in 49 out of 344 
samples of oil obtained from shops in the areas, and the concentrations varied 
from 0.7 to 32.5 mg per 100 g oil. As the contaminated oil did not differ from 
regular cooking oil in smell or taste, it was not possible to establish the interval 
between consumption of the toxic oil and the first symptoms. The clinical features 
were similar to those reported in previous outbreaks of TOCP poisoning. Cholin-
esterases in blood were measured in 9 patients. Erythrocyte acetylcholinesterase 
was reduced by about 50 % shortly after onset of clinical symptoms and reached 
normal values after 3 months. Plasma cholinesterase showed a transient increase 
reaching a maximum in about a month and then gradually decreased, reaching the 
normal range after a period of 3-6 months (260). No information was presented 
regarding duration of exposure. 
One of the latest outbreaks of toxic neuropathy was reported in July 1988 from 
India. About 600 victims were reported to Vidya Sagar Hospital, Calcutta, of 
which 343 were admitted. Some rapeseed oil samples were contaminated with 
TCP to the extent of 22-57 % (210). 
 
TBEP No data were located. 
 
TBP Workers exposed to 15 mg/m3 of TBP complained of nausea and headache 
(Mastromatteo, personal communication to ACGIH (3)). 
 
TCEP, TDCPP, TEHP, TEP, TIPP, TMCPP and TPP No data were located. 
11.3 Effects of long-term exposure  
TCP Three workers manufactured TCP with a high content of TOCP and also 
handled TPP. They performed similar working tasks and developed polyneuritis. 
All eventually returned to work (94). The first worker was 41 years of age and 
exposed for 2.5 years while manufacturing TOCP and TPP. Six months before 
admission, the process was speeded up and he worked every Sunday instead of 
one in four. For 2 days he suffered from abdominal pain and diarrhoea and 5 days 
later he could not walk properly. The disability progressed until he was unable to 
stand without support. One year after admission, he was completely recovered and 
returned to work. 
The second worker was 30 years old and exposed for 8 months prior to ad-
mission. He worked 63 hours/week. After 5 months, he complained of cramp-like 
pains in the thighs, calf muscles and toes. Later he experienced weakness of feet 
and only walked with difficulty. He made slow progress and after 3.5 years only 
slight residual signs of neuropathy were present.  
The third worker was 38 years old and exposed for 6 months prior to admission. 
During this time he complained of cramp-like pains in his hands, which started 
after he had been lifting heavy drums. He had diarrhoea and noticed some days 
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later that his toes dragged along the ground and that his feet slapped down as he 
walked. He suffered from severe pain in his calf muscles and in his hands. The 
weakness of his legs gradually became worse. He was discharged after ten months 
in hospital, able to walk with no evidence of foot drop (94). 
All the 3 men worked in a room 7.5 × 3.5 m with a height of 3.5 m that was 
totally enclosed during the hours of darkness due to black-out regulations, al-
though it was provided with a vent. During daylight, windows and doors were 
open. Crude TCP entered tanks at a temperature of about 60 oC. The TCP was 
immediately cooled with added cold water. Measurements of air concentrations 
were performed later but arranged in such a way as to represent the working 
conditions of interest. The measured air concentrations were 0.55-1.7 mg/m3 and 
the TOCP content of the finished product was about 60 % (94). Thus, the roughly 
calculated exposure to TOCP would be about 0.33-1.0 mg/m3. However, dermal 
exposure could have a great impact on body burden and consequently invalidate 
the apparent relation between air concentrations and response. 
The clinical picture of TOCP poisoning resulting in permanent disability was 
demonstrated by a 27-year old man who had manufactured meta and para isomers 
of TCP for use as plasticisers. The final product contained less than 1 % TOCP but 
6-10 % was present during manufacturing. The first symptoms appeared after 5 
months of exposure, being general malaise, anorexia, nausea, vomiting and aching 
of the lower limbs. His condition deteriorated and 3 months after the onset of 
symptoms, a coarse static tremor involving head, trunk and upper limbs had de-
veloped and he was unable to feed himself. Blurring of vision progressed slowly 
and there were flexor spasms of the lower limbs and progressive muscular wasting. 
Fifteen months after the first symptoms he was discharged from the hospital ward. 
He had spasticity and ataxia of the lower limbs and was unable to walk without 
assistance. Tremor of his hands was less severe and he was able to feed and shave 
himself. The clinical findings indicated that the lesions were present in the pyra-
midal and spinocerebellar tracts and in the cerebellum, and the patient was likely 
to remain permanently and almost totally disabled (17).  
Totally 34 out of approximately 40 men in a plant manufacturing a number of 
organic phosphates including TCP were investigated in a cross-sectional study. 
Twenty-eight men worked in the production and six belonged to the clerical and 
laboratory staff. Among the production workers, 5 of 28 had neuromuscular symp-
toms and signs (hypoesthesia, decreased vibratory sense and sluggish reflexes) 
(versus 0/6 in controls), 25/28 had respiratory symptoms (versus 3/6) and 14/28 
had gastrointestinal symptoms (nausea, heartburn and vomiting) (versus 1/6). 
Some of the symptoms may be associated with exposure to the irritant phosphorus 
chloride. There was no depression of erythrocyte acetylcholinesterase activity. 
Sixteen workers exhibited a depressed plasma cholinesterase activity (70 % of 
normal or lower), although no correlation was observed between degree or duration 
of exposure and cholinesterase activity. There was no correlation between gastro-
intestinal or neuromuscular symptoms and depressed cholinesterase activity. The 
men in production manufactured triaryl phosphates containing mixtures of TPP, 
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TCP and trixylyl phosphates and sometimes phosphates of higher alkyl substituted 
phenols. The air concentrations varied from 0.27 to 3.4 mg/m3 reported as TCP, 
although this chemical also contained other trialkyl phenyl phosphates varying 
after what was manufactured. The content of TOCP varied up to 20 %. Absorption 
through the skin may have occurred throughout the whole factory and the workers’ 
gloves and clothes were contaminated with TCP. There was no cafeteria or lunch-
room and consequently workers ate either in a smoke shed or on the job. The 
average length of exposure was 8.9 years and 16 men were exposed for 10 years  
or more (223, 224). Assuming a TOCP content of 20 %, the calculated air con-
centration of TOCP would be in the range 0.05-0.68 mg/m3. Intraindividual com-
parisons of plasma cholinesterase activities (activity prior to exposure compared  
to activity during exposure) were not reported and thus the presented plasma 
activities are of limited value (see Section 8.2).  
 
TBEP No data were located.  
 
TBP In a poorly described study, a group of 12 plant workers exposed to TBP  
for 7-30 hours during a workweek was studied. Exposure was not measured and 
occurrence of symptoms not presented. Blood samples were drawn at the end of 
the workweek. No significant difference in monocyte non-specific esterase staining 
was found between the exposed group and controls (142). The monocyte esterase 
activity is discussed in Section 8.2.  
 
TCEP A single human case report has been presented. A 5-year old girl developed 
neurological effects, which was later associated with repeated exposure to TCEP 
present in household timber (600 mg/kg wood). Clinical signs included weakness 
in arms and abdominal muscles and abnormalities in electromyogram and nerve 
conduction velocities. Following a further 9 months of exposure, the child was 
admitted to hospital with dystelectatic pneumonia where a diagnosis of spinal 
muscle dystrophy with tetraparesis was established. After cessation of exposure 
neurological impairment was still evident after several months, despite an im-
provement in her health status. However, no functional abnormalities were re-
ported 2 years post-exposure (personal communication to NICNAS (166)). The 
evidence in favour of a causal association between TCEP exposure and the neuro-
logical disorder in this case is meagre.   
 
TDCPP In a retrospective cohort study, mortality in 289 workers manufacturing 
TDCPP was examined. The cohort included all male workers employed for 3 
months or more in a manufacturing plant in the US during 1956-1977. The 
participants were followed until 1980. Overall mortality in the cohort was 75 %  
of the normally expected for the male population in the US. Air samples were not 
taken at the time of exposure but breathing zone samples were taken from other 
job classifications in 1981 and all contained less than 0.4 µg/m3 (7 ppb) of TDCPP. 
Three cases of lung cancer were found versus 0.8 expected. All three decedents 
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were moderate to heavy smokers. The increase of the number of workers with lung 
cancer was not significant and its association with TDCPP exposure remains un-
clear due to the small size of this study and to possible exposure to other chemicals 
(Stauffer 1983b, cited by (102)). 
During 1981, workers at a TDCPP manufacturing plant in the US had their 
health assessed in physical examinations. Potentially exposed workers (totally 93) 
were compared to 31 non-exposed workers who were matched for age, alcohol 
consumption and smoking habits. Exposed workers had a 2-fold increase in the 
prevalence of “abnormal” electrocardiograms, but fewer exposed workers had a 
history of heart disease. The prevalence of minor respiratory disease was slightly 
increased in exposed workers. The results of the study did not reveal any signi-
ficantly increased morbidity in workers exposed to TDCPP (Stauffer 1983a, cited 
by (102)). 
 
TEHP and TEP No data were located. 
 
TIPP A 48-year-old mechanic was daily and heavily exposed to hydraulic fluids 
containing isopropylated triphenyl phosphate, which exact composition was not 
known. For two years, he was testing hydraulic systems in ships. His underwear 
was often completely soaked with the fluid and his hands and forearms were 
always wet by the fluid. During the months preceding development of his symp-
toms he used hydraulic fluid containing about 0.5 % isopropylated triphenyl 
phosphates. According to the supplier’s analyses it contained less than 50 ppm 
TOCP. At vacation he noticed weakness in his hands and forearms, which de-
veloped 2 weeks after last exposure. He returned to work but the weakness in his 
hands made it impossible to work. Nerve conduction velocities in some nerves 
were decreased. Electromyography showed marked reduction of motor unit 
potentials. After 3 years, his symptoms had improved only slightly. A cross-
sectional examination of 8 other men exposed to hydraulic fluids and 8 controls 
showed differences in electromyography but not in nerve conduction velocities or 
other values measured in a clinical examination. The study indicated a possible 
association between heavy occupational exposure to hydraulic fluids and iso-
propylated triphenyl phosphate and polyneuropathy (113). 
In a Danish study, a 27-year old mechanic worked with pump oil for pressure 
testing. After some years, he developed paresis of both legs as well as thumb and 
index finger bilaterally. Chemical analysis showed that the oil contained 23 % 
TPP, 24 % mono (ortho-isopropylphenyl) diphenyl phosphate, 8 % bis(o-iso-
propylphenyl) phenyl phosphate and 1 % tris(o-isopropylphenyl) phosphate (27).  
Totally 38 resin-processing operators were exposed to a mixture of 30 % TPP, 
40 % monoisopropyl triphenyl phosphate, and 30 % of diisopropyl triphenyl 
phosphate, triisopropyl triphenyl phosphate and higher congeners. They were 
compared with 33 males between 20 and 50 years who were full-time employees 
or students. The erythrocyte acetylcholinesterase activity was significantly lower 
among the exposed than in the comparison group but the plasma cholinesterase 
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activity did not differ. There was a significant correlation between the erythrocyte 
acetylcholinesterase activity and the monocyte esterase activity (55). There was no 
quantitative information of exposure in the study.  
A case-control study was conducted at an automotive carburetor plant to in-
vestigate potential triaryl phosphate exposures associated with a cluster of 18 
cases exhibiting neurological symptoms resembling multiple sclerosis. Symptom 
onset was between 1970 and 1985. Four controls per case were selected randomly 
from the plant population. From work histories and telephone interviews, cumula-
tive exposures for 10 chemical or process categories were computed based on rank 
estimates of exposure levels. Two hydraulic fluid products containing high con-
centrations of triaryl phosphates were used at the plant during 1965-1982. Six 
stationary 4-hour samples for total particles contained aryl phosphates in the range 
0.04-0.15 mg/m3. There were significantly increased relative risks associated with 
die-casting and organophosphate exposures. However, if exposure to die-casting 
and organophosphates was defined as ever working in the main die-casting depart-
ment or ever having a job classification assigned to the high-exposure category, no 
cases qualified. According to the authors, the study is hampered by uncertainties 
of exposure assessment, by the small number of cases, and by the inability to pur-
sue further clinical neurological evaluation (50 % of the cases were seen only at 
initial diagnosis). The intriguing unanswered question is whether some of the 
diagnosed multiple sclerosis cases actually represent delayed neuropathy caused 
by organophosphate exposure (119). Out of 13 distinct aryl phosphates detected, 
TPP and isopropylphenyl diphenyl phosphate were identified at air levels of 0.057 
and 0.013 mg/m3 (100, 241). No further studies regarding the tentative association 
between organophosphate exposure and multiple sclerosis were located. 
 
TMCPP No data were located.  
 
TPP There was no evidence of adverse clinical effects in 32 men regularly engaged 
in the manufacture of TPP and exposed for 2-10 years (mean 7.4 years) to TPP 
mist and dust. A significant reduction (8.5 %) of erythrocyte cholinesterase 
activity was found in a sub-group of 11 men as compared to a non-exposed group 
of 9 persons. There was no difference regarding plasma cholinesterase levels. TPP 
measurements were performed over a period of 8 years and the estimated weighted 
average air concentration was 3.5 mg/m3 (218).  
12. Substance summaries with dose-effect and dose-response 
relationships 
In this chapter, a summary of the toxicological database for each substance is 
presented. A more extensive presentation of dose-effect and dose-response re-
lationships is found in Appendix 1 (Tables I-XI). Generally, most data originate 
from animal studies, whereas the human database is limited.  
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TCP and TOCP (Tables I-II) 
Commercial TCP is a complex mixture. The content of TOCP has decreased con-
siderably over time and TOCP occurs today only as contaminant (usually below 
0.1 %). 
TOCP is easily absorbed via the oral as well as the dermal route, which pre-
sumably applies also to TMCP and TPCP. The acute toxicity of TCP and TOCP in 
animals is low (measured as LD50). Occupational dermatitis with positive reactions 
to TCP is reported. TCP caused slight irritation in patch tests in volunteers. Eye 
irritation has not been studied. 
TOCP is highly neurotoxic, whereas TMCP and TPCP are not. Exposure to 
TOCP causes OPIDN with delayed central and peripheral neuropathy and inhibits 
cholinesterases and NTE activities. Numerous cases of human poisoning and poly-
neuritis involving accidental or occupational exposure of TCP have been reported. 
Severe symptoms were reported following ingestion of 0.15 g TOCP, while other 
individuals showed no toxic effect after ingesting 1-2 g. There is also considerable 
variation in the rate of recovery from poisoning after apparently similar exposure 
(259). These findings may be due to a variation in the individual sensitivity and/or 
differences in chemical composition of commercial TCP products. Both the pure 
TOCP and isomeric mixtures are considered major hazards to human. As pointed 
out by Winder and Balouet, mono-ortho and di-ortho isomers are even more 
neurotoxic than TOCP (257). 
 TCP air concentrations of 0.55-1.7 mg/m3 were associated with polyneuritis 
during the manufacture of TCP with a high content of TOCP and presence also  
of other compounds. The persons with polyneuritis were also manufacturing TPP 
(94). The calculated approximate exposure to TOCP was 0.33-1.0 mg/m3.  
In 28 production workers exposed to mixtures of TPP, TCP and trixylyl phos-
phates and sometimes phosphates of higher alkyl substituted phenols, neuromus-
cular symptoms and signs were more common than in clerical and laboratory staff 
(5/28 versus 0/6). There was no depression of erythrocyte acetylcholinesterase 
activity. Sixteen workers exhibited a depressed plasma cholinesterase activity 
(70 % of normal or lower), although no correlation was observed between degree 
or duration of exposure and the enzyme activity. The air concentrations varied 
from 0.27 to 3.4 mg/m3 reported as TCP, although this chemical also contained 
other trialkyl phenyl phosphates varying after what was manufactured. The content 
of TOCP varied up to 20 % (223, 224). Assuming a TOCP content of 20 %, the 
calculated air concentration of TOCP would be in the range 0.05-0.68 mg/m3.  
In these two industrial studies, dermal exposure may have had a great impact on 
body burden, which may have invalidated the relation between air concentrations 
and response. 
In animals, TCP/TOCP has been shown to have reproductive and develop-
mental effects. The available data do not indicate a carcinogenic potential of TCP. 
TOCP has not been tested for carcinogenicity or in standard in vitro and in vivo 
genotoxicity tests. However, the presence of DNA adducts in several organs of 
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rats given oral doses of TOCP (50 mg/kg bw/day) indicate that the compound may 
pose a genotoxic potential (151).  
Regarding commercial TCP, inhibition of brain and spinal cord NTE was 
reported in hens gavaged with 10 mg/kg bw of TCP for 10 weeks. Cytoplasmic 
vacuolisation of the adrenal cortex was observed in female rats after exposure to 
TCP at daily gavage doses of 15 mg/kg bw for 2 years (174). The overall LOAEL 
is 6-7 mg/kg bw/day. Reduced serum antibody titres as well as inhibition of leuko-
cyte and macrophage migration were reported in rats at 6 mg/kg bw after immuni-
sation with tetanus oxide (14). The study was considered preliminary by the authors 
and no other data confirming an immunotoxic effect of TCP were located. At 7 
mg/kg bw, decreased activity of serum cholinesterase (rats and mice) and minimal 
to mild ovarian interstitial cell hyperplasia were observed (rats). The effects could 
not be attributed to TOCP (< 0.1 %) and the causative agent is not known. Two of 
the TCPs were identified as TMCP (21 %) and TPCP (4 %) (174).  
The critical effects of TOCP are neurotoxicity (inhibition of brain and spinal 
cord NTE and plasma cholinesterase activities in hens) (70) and reproductive 
toxicity (decreased non-specific esterase activity in testis and increase of abnormal 
sperms in rats) (205) observed at 10 mg/kg bw/day (overall LOAEL), the lowest 
dose tested.  
 
TBEP (Table III)  
The acute animal toxicity of TBEP is slight. TBEP was non-irritating to the rabbit 
eye in four studies but doses were not given. The results indicate that skin irritation 
arise when exposure reach several days or weeks. Human data indicate minimal 
skin irritation and no sensitising potential of TBEP. 
TBEP was not mutagenic in bacterial or mammalian tests, but no tests for 
chromosomal damage were located. No carcinogenicity studies were found. No 
adverse effects on the foetuses were reported from one study of female rats 
(Monsanto 1985d, cited in (103)). Other aspects of reproductive toxicity have  
not been studied.  
TBEP does not cause OPIDN but has been associated with neurotoxicity in rats. 
Electrophysiological changes were observed in all animals dosed with 250 and 
500 mg/kg bw for 18 weeks and included a significantly reduced nerve conduction 
velocity. Most treated animals exhibited some degeneration of myelin sheaths 
accompanied by axonal swelling and an advanced stage of degeneration in the 
sciatic nerve. Unmyelinated nerve fibres of rats fed TBEP were more affected than 
those of animals treated with TOCP. In male rats, TBEP may have accelerated the 
development of focal myocarditis, which is a normal feature in older male Sprague 
Dawley rats (122, 124). At similar levels, reduced activities of serum cholinesterase 
(200 and 220 mg/kg bw/day, in males and females) (189, 233) and erythrocyte 
cholinesterase (250 mg/kg bw) were observed in rats (122). 
Subchronic animal studies have shown that TBEP affects the liver, and hepato-
toxicity is considered to be the critical effect. Based on an 18-week repeated dose 
study in rats, the NOAEL for liver effects is 15 mg/kg bw/day and the LOAEL 150 
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mg/kg bw/day (increased serum γ-glutamyl-transpeptidase and decreased plasma 
cholinesterase activity, and mild periportal hepatocellular hypertrophy and peri-
portal vacuolisation) (Monsanto 1987a, cited in (103)).  
Rats exposed to airborne TBEP (3 300 mg/m3) for 4 hours exhibited depressed 
and irregular respiration, increased salivation, sneezing, unsteadiness and tremor 
(Hoechst 1989, cited in (103)). 
 
TBP (Table IV)  
TBP is easily absorbed through the human skin in vitro. The acute toxicity in 
animals is slight. TBP is an irritant of the eyes, mucous membranes and skin  
of experimental animals and humans. There was no evidence of sensitisation in 
volunteers patch tested with TBP. 
TBP produced a reduction of conduction velocity of the caudal nerve and morpho-
logical changes of the sciatic nerve in one study (125), whereas other studies did 
not discover neurotoxic effects. TBP has not produced OPIDN. Plasma cholin-
esterase levels were affected in some studies but no consistent trend was observed.  
In a 2-generation reproduction study in rats, no treatment-related histopatho-
logic lesions in the reproductive organs were seen in males given up to 160 mg/kg 
bw/day or in females given up to 178 mg/kg bw/day for 13 weeks. Parental toxicity 
was observed at 10-21 mg/kg bw based on microscopic evidence of a very low 
incidence of urinary bladder epithelium hyperplasia and transient reductions in 
body weight (234). An overall animal LOAEL of approximately 15 mg/kg bw is 
obtained from this study. Non-significant increased incidences of urinary bladder 
hyperplasia were also observed in a 2-year dietary study in rats at 32 mg/kg bw/ 
day in males and 42 mg/kg bw/day in females. At 143 mg/kg bw/day, the hyper-
plastic changes increased and a significant increase in the frequency of bladder 
papillomas and transitional cell carcinomas was observed in males. In female rats, 
hyperplastic changes and a significant increase of bladder papillomas were ob-
served at 182 mg/kg bw/day. The NOAELs were 9 and 12 mg/kg/day for male and 
female rats, respectively (13). Another study showed a significant increase of 
hepatocellular adenoma in male mice at 585 mg/kg bw/day for 18 months (12). 
Overall, studies both in vitro and in vivo indicate that TBP is not genotoxic. Thus, 
TBP is presumably a non-genotoxic carcinogen in rats and mice. The oncogenicity 
may be related to a toxic metabolite (13).  
Nasal discharges were observed in rats exposed to 100 mg/m3 Skydrol 500B-4 
(mixture of dibutyl phenyl phosphate and TBP) (81). 
Workers exposed to 15 mg/m3 of TBP have complained of nausea and headache 
(3). However, the extent of dermal exposure is not known. This study indicates a 
LOAEL of approximately 15 mg/m3. This level seems to be significantly lower 
than those causing effects in animals. 
TCEP (Table V)  
TCEP seems to have a slight or moderate animal acute toxicity and be slightly 
irritating to eyes and skin.  
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TCEP is neurotoxic but does not cause OPIDN. Forty % of female rats given  
88 mg/kg/day for 103 weeks had a marked increase of degenerative lesions of the 
brainstem and cerebrum compared to 2 % in controls. Similar lesions occurred in  
a few male rats but these lesions were not clearly chemical-related (173).  
No firm conclusion can be drawn regarding the mutagenic effect of TCEP, 
although most studies were negative. TCEP has shown to be carcinogenic in rats 
(44 mg/kg bw, lowest dose tested, renal tubule adenomas) (150, 173), and there is 
evidence of carcinogenic activity in both male and female mice (300 mg/kg bw, 
leukaemia, hepatocellular adenomas/carcinomas) (102, 225). The mechanism of 
carcinogenicity is unknown.  
Repeated oral dosing of TCEP had an effect on liver and kidney. The NOAEL 
was 22 mg/kg bw/day and the LOAEL was 44 mg/kg bw/day for increased liver 
and kidney weights in female rats (149, 173). 
Studies in mice and rats have shown adverse affects on fertility (35, 159). In  
rats given TCEP by gavage (22, 88 and 175 mg/kg bw) for 70 days, a decrease of 
sperm motility was noted in one or more dose groups compared to a control group 
(159). Unfortunately, the study does not reveal in which dose group the effect was 
observed.  
Thus, the critical effects of TCEP are carcinogenicity and kidney and liver 
effects, which has appeared at 44 mg/kg bw (overall LOAEL). The level at which 
reproduction toxicity occurs is unknown. 
TDCPP (Table VI)  
The acute toxicity of TDCPP in animals is low. TDCPP was classified as irritant 
to rabbit skin in one study and slightly irritative to rabbit eye in another one (102).  
An increased liver weight in female mice was reported at 62 mg/kg bw/day for  
3 months (102, 114). In a 2-year study, mortality in male rats was increased at 80 
mg/kg bw and body weight gain was reduced in both sexes. A slight increase in 
plasma cholinesterase was also observed in females at the same level, whereas 
erythrocyte acetylcholinesterase was unaffected (Aulette and Hogan 1981, cited in 
(102)). 
Leg and wing weakness was reported in chickens exposed to 1 200 mg/kg bw or 
more for 5 days (235), whereas hens exposed 5 days to lower levels of 420 mg/kg 
bw exhibited no signs of neurotoxicity (Bullock and Kamienski, cited in (102)).  
The chemical was genotoxic in bacterial tests and showed equivocal or negative 
results in in vitro and in vivo mammalian tests. TDCPP was carcinogenic in both 
sexes of rats.  
No foetotoxicity and no teratogenicity was observed in rats at an oral dose of 
200 mg/kg bw. At 400 mg/kg bw/day, foetotoxicity was observed in the presence 
of maternal toxicity (11/15 dams died) (227), an observation also made in another 
study (Hazleton 1978, cited in (243)).  
The critical effects are cancer and male reproduction toxicity. The overall 
LOAEL is 5 mg/kg bw/day (lowest dose tested). At this level, a slight increase of 
liver carcinomas, renal cortical tumours and atrophy of the seminal vesicle and 
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decreased secretory product were observed in rats. At higher levels, also testicular 
and brain tumours were found (Aulette and Hogan 1981, cited in (102), Stauffer 
1981b, cited in (217), and (69)).  
The epidemiological studies of TDCPP exposed workers are inconclusive. 
TEHP (Table VII)  
The acute toxicity in rats is low. TEHP has been classified as a moderate irritant to 
rabbit skin (Guest, 1993a, cited in (103)). However, no irritation was observed in 
6 or 8 volunteers after 24 or 72 hours of exposure, respectively, to TEHP placed 
on the skin of the arm (Kimmerle 1958, cited in (103)). In a study performed 
according to OECD guidelines, TEHP was non-irritating to the rabbit eye (103). 
Studies on reproductive and developmental toxicity have not been located. 
TEHP was not mutagenic in bacterial or mammalian test systems. There was, 
however, some evidence of carcinogenicity in female mice based on the increase 
in hepatocellular carcinomas (dose levels were 500 and 1 000 mg/kg bw) and 
equivocal evidence of carcinogenicity in male rats based on the incidence of 
phaeochromocytomas of the adrenal gland (2 000 and 4 000 mg/kg bw). Male and 
female mice also exhibited a dose-related increase in the incidence of thyroid 
follicular cell hyperplasia (172).  
OPIDN has not been observed in hens or chickens (Kimmerle 1958, cited in 
(103)), (140). However, signs of neurotoxicity were observed in 2 dogs exposed 
for 6 hours/day, 5 days/week for 12 weeks to mean concentrations of 10.8, 26 and 
85 mg/m3. The performance of the dogs trained in conditioned avoidance de-
teriorated as the exposure concentration increased. The percent missed avoidance 
was 0 %, 10 % and 18 % in the exposure groups and 5.8 % in controls. Thus, the 
overall NOAEL for this compound is 10 mg/m3 and the overall LOAEL 26 mg/m3 
(140). 
TEP (Table VIII)  
Overall, the toxicological data base is poor. Oral or dermal acute toxicity data in 
animals are lacking as are data on irritation and sensitisation. Overall, the weight 
of evidence from genotoxicity studies is negative. Long-term animal studies were 
not available. 
TEP has a narcotic effect, but has not been tested in hens regarding OPIDN. The 
ED50 in rats for loss of righting reflex after intraperitoneal injection was 333 mg/kg 
bw for females and 412 mg/kg bw for males (21). 
The available reproductive and developmental toxicity data are insufficient and 
poorly reported. The litter size was reduced after repeated feeding of both sexes  
of rats at 670 mg/kg bw/day. There was no effect on the litter size at 335 mg/kg 
bw/day. A teratogenic study in rats showed no evidence of a teratogenic potential 
up to the highest dose of 625 mg/kg bw/day. At the highest dose, however, a 
reduction of body weight gain, food intake and faeces excretion as a sign of 
maternal toxicity were observed (no such effects at 125 mg/kg bw/day) (237).  
The critical effects are increases in absolute and relative liver and spleen 
weights as well as in absolute weight of kidneys and testes in rats after exposure 
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for 9 weeks to dietary concentrations corresponding to approximately 500 mg/kg 
bw/day (overall LOAEL) (178). 
TIPP (Table IX)  
Unspecified isopropylated triphenyl phosphate was not irritating to skin of rats and 
rabbits, and not or only slightly irritating to the rabbit eye. The fact that TIPP is not 
a well-defined chemical makes interpretation of the data in general difficult. How-
ever, some studies have been performed with pure and well-defined components. 
Tri-ortho-isopropylphenyl phosphate had a slight acute toxicity in animals. Tri-
ortho-isopropylphenyl phosphate and para-isopropylphenyl diphenyl phosphate 
were not neurotoxic when given to hens at doses of 1 000 mg/kg bw and 10 000 
mg/kg bw, respectively, twice daily for 6 days. However, hens receiving 1 000 mg/ 
kg bw of ortho-isopropylphenyl diphenyl phosphate twice daily for 6 days exhibited 
signs of OPIDN (106). In another study, a single dose of ortho-isopropylphenyl 
diphenyl phosphate at 1 200 mg/kg bw caused OPIDN, whereas half the dose (600 
mg/kg bw) did not. Di-ortho-isopropylphenyl phenyl phosphate gave an ambiguous 
result regarding OPIDN at a single dose of 1 200 mg/kg bw, whereas tri-ortho-
isopropylphenyl phosphate did not produce OPIDN at a single oral dose of 600 
mg/kg bw or 1 000 mg/kg bw for 4 days. Single oral doses of 600 mg/kg bw of 
mono-, di- and tri-ortho-isopropylphenyl phosphate reduced NTE activities by 84, 
39 and 12 %, respectively, as measured one day after dosing (109). 
In a review, different commercial isopropylated triphenyl phosphates did not 
produce OPIDN in hens when tested at single doses of 2 000-3 000 mg/kg bw. 
However, one product was evaluated in a 90-day subchronic OPIDN study at 
doses of 0, 10, 20, 90 and 270 mg/kg bw/day of Kronitex® 50. At 90 mg/kg bw,  
an increased incidence of ataxia and lesions in the nervous system were observed. 
The NOAEL was 20 mg/kg bw/day (251). One of the commercial products that 
did not produce OPIDN caused a dose dependent inhibition of plasma cholin-
esterase and brain NTE activities in hens starting at 180 and 370 mg/kg bw, 
respectively (208). 
Increased relative liver weight was observed in rats administered 100 mg/kg bw 
of Kronitex 100® via diet for 28 days (Foster 1976, cited in (74)).  
No long-term (chronic) animal studies were found.  
One Swedish and one Danish mechanic developed weakness in hands and legs 
after mainly dermal exposure to isopropylated triphenyl phosphates (27, 113). The 
Danish mechanic was exposed to an oil containing 23 % TPP, 24 % ortho-iso-
propylphenyl diphenyl phosphate, 8 % bis(ortho-isopropylphenyl) phenyl phosphate 
and 1 % tris(ortho-isopropylphenyl) phosphate (27). Exposure levels were not 
known.  
TMCPP (Table X)  
The acute toxicity of commercial TMCPP products was low in rats and rabbits. 
Tris(1-chloro-2-propyl) phosphate seems to cause only mild or no eye and skin 
irritation. Unspecified TMCPP produced no skin sensitisation in a study ex-
amining contact sensitisation potential. TMCPP was not mutagenic in bacterial 
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tests or in mammalian in vitro tests and caused no chromosomal damage in bone 
marrow after in vivo administration to rats and mice. No long-term animal studies 
were located.  
TMCPP has not been associated with OPIDN. However, adverse clinical signs 
including depression and intermittent muscle spasms were observed among rats 
given a single oral dose of 464 mg Fyrol PCF/kg bw (Stauffer 1970, cited in (102, 
238)). 
Increased absolute and relative liver weight in male rats were reported in a 90-
day study at 40 mg/kg bw of Fyrol PCF (Stauffer 1981a, cited in (238)). 
In female rats given 0, 8, 40, 200 and 1 000 mg/kg bw of unspecified TMCPP 
by gavage for 7 days, the only treatment-related effects were significant increases 
in the relative weights of the kidneys at or above 40 mg/kg bw and of the liver at 
1 000 mg/kg (Kawasaki et al 1982, cited in (216)). 
Pregnant Wistar rats were given 0, 6, 70, and 625 mg/kg bw/day of unspecified 
TMCPP during gestation days 0-20. The treatment did not affect the number of 
implants, the number of resorptions or the number or weight of live foetuses. No 
foetuses died or had obvious external malformations. The incidence of skeletal  
or visceral malformations in foetuses from treated litters was not statistically 
different from controls. However, a dose-related increase in the incidences of 
missing 13th ribs and cervical ribs were observed in the foetuses (Kawasaki et al 
1982, cited in (216)). An overall LOAEL of 6 mg/kg bw is obtained from this 
study. 
TPP (Table XI)  
Animal data indicate that TPP has a slight acute toxicity. TPP does not possess  
an irritation potential on the skin based on a study in mice. The eye irritation 
potential is low. No animal data regarding skin sensitisation were located. Contact 
dermatitis in humans due to TPP has been described but is uncommon. In more 
recent studies, TPP has not produced OPIDN or exhibited signs of causing neuro-
toxicity in animals. Long-term (chronic) studies are missing. Genotoxicity tests  
in vitro yielded negative results (Monsanto 1979, cited in (100)) but studies of 
chromosomal aberrations were not available. No adequate carcinogenicity studies 
were located. 
TPP may affect development. There was a significant increase of the number of 
foetuses having at least two soft-tissue variations in rats dosed 166 mg/kg bw/day 
compared to controls (252), a finding classified as equivocal.  
In a 35-day rat study, a dose of 500 mg/kg bw/day produced an increase of re-
lative liver weights and a slight depression of body weight gain (218). A reduced 
body weight gain was also seen in rats exposed for 4 months to 345 mg/kg bw/day. 
Body weight gain was not affected at 161 mg/kg bw/day (203).  
The critical effect of TPP is a reduction of erythrocyte acetylcholinesterase 
activity, which has been observed in both animals and humans. Mice exhibited a 
dose-dependent reduction (11-70 %) after single exposures to 10, 50, 100, 200  
and 500 mg/kg bw. In men, there was no evidence of adverse clinical effects after 
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exposure for 2-10 years to TPP mist and dust. However, a significant reduction 
(8.5 %) of erythrocyte acetylcholinesterase activity was found in a sub-group re-
gularly engaged in the manufacture of TPP at an estimated average air concentra-
tion of 3.5 mg/m3 (LOAEL) (218). This level seems to be significantly lower than 
those causing effects in animals.  
13. Previous evaluations by national and international bodies 
TCP  
International Programme on Chemical Safety (IPCS), 1990  
IPCS concluded that the neurotoxic symptoms involve initial inhibition of cholin-
esterases and subsequent delayed neuropathy characterised by severe paralysis. 
The committee stated that it was impossible to establish a safe level of exposure 
because of considerable variation among individuals in sensitivity to TOCP. It was 
also noted that severe symptoms had been reported from the ingestion of 0.15 g of 
TOCP, that animal studies showed considerable variation among species in the re-
sponse to TOCP, and that humans appear to be particularly sensitive. It was also 
noted that irritant and allergic dermatitis had been reported. 
Both the pure ortho isomer and isomeric mixtures containing TOCP were 
therefore considered major hazards to human health and exposure to the com-
pound trough dermal contact or inhalation should be minimised (99).  
 
American Conference of Governmental Industrial Hygienists (ACGIH), 2001  
ACGIH noted that TOCP may be absorbed through the skin and may exert frank 
toxicity upon ingestion. It was also stated that exposure to TOCP causes central 
and peripheral neuropathies with paralysis of the distal muscles of the upper and 
lower extremities and that air concentrations between 0.55 and 1.7 mg/m3 had 
been associated with polyneuritis. Reduced cholinesterase activity had been re-
lated to air concentrations from 0.27 to over 3 mg/m3. A TLV of 0.1 mg/m3 with  
a skin notation was recommended for occupational exposure to TOCP. ACGIH 
considered TOCP not classifiable as a human carcinogen (4). Erythrocyte acetyl-
cholinesterase activity has been recommended by ACGIH as a biological exposure 
index for TOCP (2).  
Subcommittee on Flame-Retardant Chemicals, Committee on Toxicology, Board 
on Environmental Studies and Toxicology, Commission on Life Sciences, US 
National Research Council, 2000  
The subcommittee concluded that the neurobehavioural effects and neuropatho-
logical findings in the NTP studies were consistent with TCP-induced delayed 
neuropathy and not cholinesterase inhibition. 
The subcommittee identified the adrenal gland and ovarian lesions in female 
rats and adrenal and liver lesions in female mice that occurred at 7 mg/kg/day to 
be the key critical effect for deriving an oral reference dose for TCP. Supporting 
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data were available from subchronic, reproductive and developmental toxicity 
studies, but studies of reproductive function did not identify a NOAEL for TCP.  
It was further concluded that extensive human experience with TCP including 
poisonings of tens of thousands of people over the past 100 years had produced  
no evidence that oral exposure to TCP can cause cancer in humans and that no 
evidence for the carcinogenicity of TCP was found in rats or mice chronically 
exposed to this compound for two years in their diet (174). Available genotoxicity 
studies including assays for mutagenicity, cytogenetic effects and DNA damage 
found no evidence that TCP produces genotoxic effects. Therefore, TCP was con-
sidered not likely to be carcinogenic (215). 
 
TBEP 
International Programme on Chemical Safety (IPCS), 2000 
IPCS concluded that the acute systematic mammalian toxicity and irritation 
potential are low and that several subchronic animal studies had shown that the 
liver is the target organ for TBEP toxicity. It was further stated that one study in 
male rats suggested that TBEP might cause focal myocarditis. Neurotoxic effects 
in rats after single exposures were considered inconsistent. In rats given repeated 
doses by gavage, decreased nerve conduction velocity was observed. TBEP did 
not cause delayed neurotoxicity in hens but did inhibit brain and plasma cholin-
esterases. Based on an 18-week repeated dose study in rats, the NOAEL for liver 
effects was reported to be 15 mg/kg bw/day, while the LOAEL was 150 mg/kg 
bw/day. It was noted that bacterial and mammalian cell tests for gene mutation 
gave negative results, but that no tests for chromosomal damage had been reported 
and, in addition, that the long-term toxicity and carcinogenicity of TBEP had not 
been studied. IPCS stated also that teratogenicity was not observed in one study of 
rats and that other aspects of reproductive toxicity had not been reported (103).  
 
TBP  
International Programme on Chemical Safety (IPCS), 1991 
It was stated that the available information did not permit an assessment of the 
risk presented by TBP as a potential carcinogen, neurotoxic agent or dermal 
sensitiser. Observations relating to hyperplasia of urinary bladder epithelium in 
rats, neurotoxicity signs in rats, and sensitisation of guinea pigs were considered 
inadequate to evaluate the hazardous potential of TBP for human health. IPCS 
noted that no tumour development had been observed in rats, that TBP did not 
produce delayed neurotoxic effects in hens and that no adequate data were 
available on the effects of TBP on reproduction.   
IPCS concluded that there were no reports that TBP has effects on occupational-
ly exposed humans other than headache, nausea, and symptoms of skin, eye and 
mucous membrane irritation, and further, that no cases of poisoning among the 
general population had been reported.  
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The committee stated that there was no indication from animal studies of a 
neurotoxic effect comparable to OPIDN and that systemic toxicity in humans 
following acute exposure was likely to be low.   
From in vitro test results, TBP was not considered to be mutagenic. 
IPCS stated further that TBP is absorbed through the skin and dermal exposure 
should be minimised. The likelihood of long-term effects in occupationally 
exposed humans was considered small (101).  
American Conference of Governmental Industrial Hygienists (ACGIH), 1992 
ACGIH summarised that TBP is an irritant of the eyes, mucous membranes and 
skin of experimental animals and humans and that repeated oral administration  
of TBP had caused pathological changes in the rat bladder epithelium.  
Given the scanty data, it was considered difficult to assign a TLV for TBP. 
ACGIH argued that the LD50 of TBP was about the same as that for TPP but, 
contrary to TPP, TBP irritates skin and is a narcotic. According to ACGIH, TBP  
is a weak cholinesterase inhibitor as compared with TPP. Given the absence of 
epidemiologic data on TBP, it was argued that the same TLV for both TBP and 
TPP seemed justified. Accordingly 0.2 ppm (2.2 mg/m3) was recommended as  
a TLV (3) and erythrocyte acetylcholinesterase activity was recommended as a 
biological exposure index for TBP (2). 
Deutsche Forschungsgemeinschaft (DFG), 2002  
The committee identified the bladder as the target organ of the toxic and carcino-
genic effects of TBP in the rat and noted that, in this organ, local cell damage with 
reversible hyperplastic, proliferative and necrotic changes had been observed. It 
was also noted that papillomas and, in particular in male animals, transitional cell 
carcinomas were found in long-term studies as a result of the damage to the bladder. 
In the liver, an increase in hepatocellular adenomas was observed, in particular in 
mice, but no carcinomas. Based on the results from the long-term studies and the 
negative results in the genotoxicity studies, the tumours were thought to be caused 
by direct cell damage and not by a genotoxic mechanism.  
The committee concluded that local irritation and systemic effects of TBP must 
be taken into consideration in derivation of a MAK value and that in particular  
the toxic effects on the bladder were of importance for the systemic effects. It  
was noted that slight hyperplasia of the bladder epithelium had been observed 
even after TBP concentrations as low as about 10-20 mg/kg bw/day and that the 
NOAELs found in a 13-week study and a 24-month study were 15 and 9 mg/kg 
bw/day, respectively. For man, a dose of 9 mg/kg bw/day would correspond to a 
concentration in air of 63 mg/m3, assuming a body weight of 70 kg and a volume 
of air inhaled in 8 hours of 10 m3. 
DFG stated further that TBP had been tested in studies of developmental 
toxicity with rats and rabbits and that embryotoxic and foetotoxic effects were 
observed only after doses that were toxic to the dams. The NOAEL for develop-
mental toxicity in the rat was identified as 250 mg/kg bw/day and in the rabbit as 
150 mg/kg bw/day (47).  
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In Germany, TBP has a skin notation indicating percutaneous absorption. TBP 
is classified as a substance with carcinogenic potential for which a non-genotoxic 
mode of action is of prime importance and genotoxic effects play no or most a 
minor part provided the MAK value (11 mg/m3) is observed. TBP belongs to 
pregnancy risk group C, indicating no reason to fear damage to the embryo or 
foetus when the MAK value is observed (48).  
United Nations Environmental Programme (UNEP) in its Screening Information 
Datasets (SIDS) for High Volume Chemicals, 2004  
UNEP regarded the toxicology database as large and well documented, and that 
there were adequate data with which to evaluate the potential hazard to human 
health of this compound. In inhalation studies on rats and rabbits, depressed 
cholinesterase levels were observed at the highest concentration 13.6 mg/m3, an 
effect that was reversible. Overall, the results of the rodent dietary/gavage studies 
consistently showed cellular and/or weight changes in the liver, kidney and bladder. 
In the rat, the NOAEL was 9 mg/kg bw/day in males and 12 mg/kg/day in females 
for cytotoxicity/hyperplasia in the urinary bladder. In an 18-month dietary study 
using CD-1 mice, the NOAEL was 28.9 mg/kg/day for females and 24.1 mg/kg 
per day for males, the lowest dose tested. TBP did not affect reproductive per-
formance in a two-generation feeding study in rats (NOAEL > 225 mg/kg bw per 
day). Developmental and teratogenic toxicity was observed only at levels at which 
maternal toxicity was observed. In three separate teratology experiments (two with 
rats and one with rabbits), teratogenic (delayed ossification and rudimentary ribs) 
and developmental (reduced foetal weights) were observed only at maternally 
toxic doses and only in rats. The increased incidence of rudimentary lumbar ribs at 
doses of 500 mg/kg bw/day was considered to be an effect of maternal toxicity and 
not a result of teratogenicity. The lowest NOAEL for developmental toxicity from 
these studies was 720 mg/kg bw/day based on an increased incidence of rudimen-
tary lumbar ribs. However, the lowest NOAEL for maternal toxicity was 62.5 mg 
kg bw/day.   
TBP was considered an animal carcinogen when administered in doses greater 
than 9 mg/kg bw/day in rats or 24 mg/kg bw/day in mice. Overall, the results of 
both in vitro and in vivo genotoxicity studies indicated that TBP is not genotoxic. 
A mechanistic study in rats found that the effects of TBP on the bladder were 
reversible upon withdrawal of treatment and thus likely due to the direct urothelial 
cytotoxicity of the chemical itself (or its metabolites) and not a result of urinary 
changes.  
It was noted that the neurotoxicity of TBP had been studied in several species 
including the rat, hen and rabbit. In these studies, TBP produced either no signs of 
neurotoxicity or only slight or transient effects on measured endpoints. TBP was 
judged irritating to the skin and eye of humans and laboratory animals but not to 
cause sensitisation in humans. The primary exposure to TBP was considered to be 
through dermal contact in the occupational setting. Based on this exposure route 
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and the NOAEL levels reported, UNEP concluded that the most likely effect of 
TBP exposure is irritation of the skin and eyes (239). 
Committee on Updating of Occupational Exposure Limits, a committee of the 
Health Council of the Netherlands, 2005  
The committee stated that human and animal data suggest a significant skin 
penetration ability. In humans, TBP was considered irritating to the skin, the eyes, 
the mucous membranes and the respiratory tract. In short-term toxicity studies in 
rats and mice, the urinary bladder, the liver and the kidneys were regarded as the 
target organs. In long-term studies (2 years), the bladder was identified as the 
target organ showing increased incidence of urinary bladder hyperplasia, papillo-
mas and transitional cell carcinomas. The carcinogenic effects showed a clear 
threshold at 33-42 mg/kg bw. The long-term NOAEL was 9 and 12 mg/kg bw/day 
for male and female rats, respectively. The NOAEL for neurotoxicity was > 325 
mg/kg bw/day in a 13-week study. 
The committee concluded that TBP is a non-genotoxic carcinogen in rats and 
mice and that tumours were only observed at dose levels associated with toxic, 
proliferative effects.  
Based on a 2-generation reproduction study in rats, the NOAEL for reproductive 
toxicity was identified as 225 mg/kg bw/day and that for postnatal toxicity as 53 
mg/kg bw/day. The LOAEL for parental toxicity was considered to be 15 mg/kg 
bw/day, based on microscopic evidence of a very low incidence of urinary bladder 
epithelium hyperplasia. In developmental toxicity studies, no developmental 
effects were observed at dose levels that did not cause maternal toxicity. The 
committee concluded that the NOAELs for maternal and developmental toxicity 
were 115 and 250 mg/kg bw/day in the rat and 150 and 400 mg/kg bw/day in the 
rabbit.  
Based on the above data, the committee took the 2-generation rat study demon-
strating a parental LOAEL of 15 mg/kg bw/day as starting point in establishing  
a health-based recommended occupational exposure limit. The committee re-
commended a health-based occupational exposure limit for TBP of 2 mg/m3 (0.18 
ppm) as an 8-hour TWA (79).  
Since the amount that may be absorbed through the skin is more than 10 % of 
the amount taken up by inhalation, the committee recommended a skin notation. 
Environment Canada, 2009 
Environment Canada concluded that a critical effect for the characterisation of  
risk to human health for TBP is carcinogenicity. It was argued that tumours in the 
urinary bladder were observed in male and female rats following dietary exposure 
at the highest dose tested and that tumours in liver were also observed in male 
mice. It was further noted that TBP did not show any genotoxicity from bioassays 
in bacteria, cultured mammalian cells or animals and that mechanistic study and 
evaluations by international and other national agencies suggest that TBP is a non-
genotoxic carcinogen and that tumors are associated with cytotoxicity and pro-
liferative effects (57). 
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European commission 
The European commission has classified TBP as a carcinogen (Category 3: limited 
evidence of a carcinogenic effect) (61, 62). 
TCEP  
International Agency for Research on Cancer (IARC), 1990 and 1999 
In 1990, IARC evaluated TCEP regarding its carcinogenicity and concluded that 
there was inadequate evidence for the carcinogenicity of TCEP in experimental 
animals. There were no data available from studies of humans and the overall 
evaluation of TCEP was group 3, i.e. TCEP was not classifiable as to its carcino-
genicity to humans (96). In 1999, IARC made a re-evaluation. There was now 
limited evidence for the carcinogenicity of TCEP in experimental animals. How-
ever, the overall evaluation was not changed (97).  
International Programme on Chemical Safety (IPCS), 1998 
The committee noted that the low volatility of TCEP precludes significant 
exposures from air. It was further assumed that exposure to TCEP from food, 
drinking water and air will not present an acute hazard to the general population. 
IPCS concluded that TCEP, in repeat dose studies, caused adverse effects on the 
brain (hippocampal lesions in rats), liver and kidneys. The NOAEL was 22 mg/kg 
bw/day and the LOAEL 44 mg/kg bw/day for increased weights of liver and 
kidneys in rats. TCEP was considered not teratogenic but to adversely affect  
the fertility of male rats and mice. The genetic toxicity data were considered 
ambiguous. TCEP was regarded to be carcinogenic in rats and mice. The com-
mittee concluded that a very high oral dose of TCEP caused some inhibition of 
plasma cholinesterase and brain NTE in hens but did not cause OPIDN and that  
a high dose of TCEP in rats caused convulsions, brain lesions and impaired per-
formance in a water maze. However, because of the low exposure, the risk of 
adverse health effects from TCEP to the general population was expected to be 
very low (102).  
Commentary by the authors of the present document regarding the 
carcinogenicity assessments made by IARC and IPCS  
IARC (96, 97) did not include the study in mice by Takada et al (225) in the 
evaluations and consequently tumours were observed in only one species (rat) 
(173). IPCS included both studies and thus concluded that TCEP has caused 
benign and malignant tumours at various organ sites in rats and mice (102). 
Environment Canada, 2009 
Based on weight of evidence and taking into consideration more recent data, the 
critical effects for the characterisation of risks to human health for TCEP were 
considered to be carcinogenicity and impaired fertility. Carcinogenic effects in-
cluded kidney tumours in rats and mice, thyroid tumours in rats, and liver, fore-
stomach and Harderian gland tumours and leukaemia in mice. Mixed results were 
obtained in the limited in vivo and in vitro genotoxicity assays in mammalian 
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cells. However, based on the range of tumours observed in multiple species of 
experimental animals for which the modes of induction have not been elucidated, 
it could not be precluded that TCEP induces tumours via a mode of action in-
volving direct interaction with genetic material.  
Non-neoplastic effects were also observed in the liver and kidneys of rats and 
mice in short-term repeated-dose and long-term studies. In was added that TCEP 
impaired fertility in mice and induced testicular toxicity in both mice and rats. 
Based on comparison of estimated exposures to TCEP in Canada with the critical 
effect level for non-cancer effects, a dose that was also associated with increased 
incidences of tumours in a long-term study in rats, and taking into account the 
uncertainties in the databases on exposure and effects, it was considered that the 
resulting margins of exposure may not be adequately protective of human health.  
On the basis of the carcinogenic potential of TCEP, for which there may be a 
probability of harm at any exposure level, as well as the potential inadequacy of 
the margins between estimated exposure and critical effect levels for non-cancer 
effects, it was concluded that TCEP is a substance that may be entering the en-
vironment in a quantity or concentration or under conditions that constitute or  
may constitute a danger in Canada to human life or health (56). 
European commission 
The European commission has classified TCEP as a carcinogen (Category 3: 
limited evidence of a carcinogenic effect) and as toxic to reproduction (Category 
2: substances which should be regarded as if they impair fertility in humans) (60-
62). 
TDCPP  
International Programme on Chemical Safety (IPCS), 1998 
IPCS concluded that the low volatility of TDCPP precludes significant exposures 
from air and that exposure to TDCPP from food, drinking water and air will not 
present an acute hazard to the general population. It was referred to a 3-month 
study in mice, in which an exposure of approximately 1800 mg/kg bw/day caused 
death within one month. The NOAEL for the study was 15.3 mg/kg bw/day and 
the LOAEL for increased liver weight was 62 mg/kg bw/day. The potential for 
TDCPP to affect human male reproductive ability was judged unclear, in view of 
testicular toxicity in rats but a lack of effect on male reproductive performance  
in rabbits. A teratology study on rats showed foetotoxicity at an oral dose of 400 
mg/kg bw/day. The NOAEL and LOAEL for maternal toxicity were 100 mg/kg 
and 200 mg/kg bw/day, respectively. No teratogenicity was seen.  
TDCPP was considered genotoxic in bacterial tests and in some in vitro mam-
malian tests. However, it was judged not sufficiently tested for mutagenicity in 
vivo. TDCPP was found to be carcinogenic in rats. The mechanism of carcino-
genicity had not been elucidated. The exposure level leading to the residues found 
in humans was said to be unknown. However, because of the low exposure, the 
risk was expected to be low (102).  
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Subcommittee on Flame-Retardant Chemicals, Committee on Toxicology, Board 
on Environmental Studies and Toxicology, Commission on Life Sciences, US 
National Research Council, 2000  
The subcommittee found statistically significant atrophy and decreased secretory 
product of the seminal vesicles in male rats fed diets containing 5 mg TDCPP/kg-
day (lowest dose tested) or greater. Using this as the critical effect and the LOAEL 
of 5 mg/kg/day, the oral reference dose was derived by applying a composite un-
certainty factor 1 000 (extrapolating from animals to humans) yielding an oral 
reference dose of 0.005 mg/kg/day. The subcommittee stated a moderate con-
fidence that the derived oral reference dose would protect against noncancer toxic 
effects in most persons. However, the subcommittee noted the presence of some 
uncertainty in the threshold dose associated with testicular and seminal vesicle 
effects after life-time exposure in rodents.  
It was further stated that in vitro data suggested that TDCPP is mutagen in the 
presence of liver S9 fraction, initiates DNA repair and is clastogenic and that  
these findings suggested that TDCPP (or one of its metabolites) is DNA-reactive. 
Therefore the subcommittee concluded that linear extrapolation is appropriate for 
estimating cancer risk in the low dose range.  
TDCPP is released from upholstery to ambient air and the average exposure con-
centration to TDCPP particles estimated by the subcommittee was used for cancer 
assessment. An inhalation cancer potency value was not available for TDCPP. 
Therefore a provisional inhalation cancer potency value was derived from oral 
cancer potency data. Multiplication of the TDCPP exposure estimate of 0.48 µg/m3 
for particles times the provisional cancer potency value of 1.71 × 10-5/µg/m3 pro-
duced an estimated lifetime cancer risks of 8.2 × 10-6, which suggested that the 
cancer risk associated with the inhalation of TDCPP particles was negligible at the 
given upholstery concentrations and the exposure parameters in the worst-case 
exposure scenario. However, the subcommittee noted that exposure to TDCPP by 
this route may need further evaluation (217).  
United States Environmental Protection Agency (EPA), 2005  
The US EPA noted that mild reversible irritation of the conjunctiva was observed 
when TDCPP was applied to the rabbit eye, that it was a non-irritant when applied 
for four hours and a mild irritant when applied for 24 hours to rabbit skin. It was 
considered not a skin sensitiser in guinea pigs. It was concluded that the results  
of genotoxicity tests in vivo (mutation in Drosophila, chromosomal aberration in 
mice) were negative, but that positive results were reported in several in vitro 
assays (mutagenicity in bacterial and mammalian cells, chromosomal aberration). 
An increased tumour incidence was observed in rats exposed to TDCPP in the 
diet. Several studies gave no evidence of acute cholinergic toxicity, inhibition of 
neurotoxic esterase (NTE) or delayed neurotoxicity. The available reproductive 
toxicity data were judged inadequate. However, chronic toxicity data indicated a 
LOAEL of 5 mg/kg/day for atrophy and decreased secretory product of the seminal 
vesicles (243). 
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TEHP 
International Programme on Chemical Safety (IPCS), 2000  
According to IPCS, occupational exposure to TEHP is likely to be by the dermal 
route during manufacture (accidental exposure) and from the use of some pro-
ducts. The committee stated that the compound is absorbed dermally in experi-
mental animals but that no information was available on its kinetics or metabolism 
via this route. Dermal exposure could not, therefore, be quantified but was ex-
pected to be low. In a study of human volunteers, no skin irritation was reported. 
Inhalation exposure in the office environment has been measured to be 10 ng/m3 
or less.  
Given the reported LOAEL for thyroid hyperplasia of 357 mg/kg bw/day in 
mice, the risk to the general population was considered very low. It was con-
sidered unlikely that TEHP poses a significant carcinogenic risk to humans. It was 
noted that neurotoxicity studies had been conducted in several species and that 
TEHP caused no alteration in activity of erythrocyte or plasma cholinesterases but 
that no studies of delayed neurotoxicity were reported. The risk to those exposed 
occupationally was also considered to be very low, although this could not be 
quantified (103). 
Note: The authors of the present document have not found the bases for the 
IPCS conclusion on dermal absorption in animals or for the reported LOAEL for 
thyroid hyperplasia.  
TEP  
United Nations Environmental Programme (UNEP) in its Screening Information 
Datasets (SIDS) for High Volume Chemicals, 1998 
For toxicological endpoints, UNEP identified NOAELs of 1 000 mg/kg bw for 
subacute toxicity, of 625 mg/kg bw/day for teratogenicity and of about 335 mg/kg 
bw for fertility effects. Due to missing data on carcinogenicity, a comprehensive 
description of the toxic effects of TEP was not considered possible. On the basis 
of all data on genotoxicity, a mutagenic effect of TEP was not assumed. The com-
mittee concluded that the substance is harmful with a narcotic effect and, at high 
doses, show certain neurotoxic properties (inhibition of cholinesterase) without 
indicating delayed neurotoxicity. The human dose estimated by UNEP from an  
8-hour inhalation exposure at 0.5 mg/m3 was < 0.071 mg/kg bw based on a res-
pirator volume of 10 m3 and a body weight of 70 kg. On the basis of the known 
facts and properties, a low concern for risk was to be expected to the human health 
or the environment (237). 
TIPP  
United States Environmental Protection Agency (EPA), 2005 
The US EPA noted that many of the available health effect studies were conducted 
with commercial mixtures that commonly contained TPP as well as Proprietary G 
(triaryl phosphate, isopropylated). Toxicity studies on acute inhalation, acute der-
mal and eye irritation, skin sensitisation, genotoxicity, reproduction, and develop-
ment were all judged inadequate to meet the endpoints. There was no available 
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data on cancer. In an acute study on a defined Proprietary G mixture, significant 
suppression of both brain neurotoxic esterase and plasma cholinesterase levels 
was reported. According to EPA, the majority of studies suggested that delayed 
neurotoxicity may result from exposure to oral doses in excess of 1 000 mg/kg 
(243).  
TMCPP  
 International Programme on Chemical Safety (IPCS), 1998  
Tris(1-chloro-2-propyl) phosphate CAS No. 13674-84-5. 
The committee concluded that the low volatility of TMCPP precludes significant 
exposures via air and that exposure to TMCPP from food, drinking water and air 
will not present an acute hazard to the general population. It was further stated that 
rabbit eye and skin irritancy studies indicated that TMCPP is either non-irritant or 
mildly irritant. A skin sensitisation study showed that TMCPP has no sensitising 
properties. It was noted that reproductive toxicity, immunotoxicity and carcino-
genic potential had not been investigated. The results of in vitro and in vivo muta-
genicity studies investigating an appropriate range of end-points indicated that 
TMCPP is not genotoxic. IPCS noted that there was no evidence of delayed 
neurotoxicity in hens when two oral doses (each 13 200 mg/kg bw) were given 3 
weeks apart. Although toxicological data from long-term studies were considered 
limited, because of low exposure to TMCPP the risk of adverse effects to the 
general population was considered negligible (102). 
Subcommittee on Flame-Retardant Chemicals, Committee on Toxicology, Board 
on Environmental Studies and Toxicology, Commission on Life Sciences, US 
National Research Council, 2000  
In the evaluation, TMCPP referred to commercial mixtures containing variable 
amounts of TMCPP isomers.  
The database on dermal toxicity was considered inadequate for developing a 
dermal reference dose. The duration of all available dermal studies was only 24 
hours. The committee noted that in vivo genotoxicity studies of TMCPP were 
lacking but that all of the in vitro tests of genotoxicity yielded negative results.  
The committee noted that no mortality or abnormalities were observed in 
groups of five female rats given 0, 8, 40, 200 and 1 000 mg/kg bw of TMCPP by 
gavage for 7 days, except for one rat that died in the 1 000 mg/kg group. The only 
treatment-related effects were significant increases in the relative weights of the 
liver (1000 mg/kg) and the kidneys (40 mg/kg). No chronic or subchronic studies 
in humans or animals had been located that could provide the basis for developing 
an inhalation reference concentration or oral reference dose for TMCPP, nor had 
long-term studies in humans or animals that could be used to assess the carcino-
genic potency of TMCPP by any route of exposure. Data on the effects of TMCPP 
exposure on reproduction were also not available (216). 
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United Nations Environmental Programme (UNEP) in its Screening Information 
Datasets (SIDS) for High Volume Chemicals, 2000  
As TMCPP (Tris(1-chloro-2-propyl) phosphate, CAS No. 13674-84-5) has low 
volatility at ambient temperature and pressure and is produced in a closed system, 
exposure to workers was expected to be minimal, as was exposure to the workers 
during the processing of the chemical as a flame retardant in rigid and flexible 
foam. 
It was further stated that TMCPP showed low acute toxicity following oral, 
dermal or inhalation exposures, was a slight skin and eye irritant and not ge-
netically active. Repeated dose studies showed no adverse effects. TMCPP was 
considered neither neurotoxic nor teratogenic. Pharmacokinetic data indicated  
a rapid elimination, 89 % within 72 hours. Therefore, adverse effects from any 
accidental exposure would not be expected (238).  
TPP  
Deutsche Forschungsgemeinschaft (DFG), 1990 
TPP was found to be associated with a low degree of toxicity in different species 
after oral, dermal, subcutaneous and inhalatory administration. The irritation 
potential of skin, eye and mucous membranes of the respiratory tract was con-
sidered low. A strong skin resorption was not expected. It was noted that studies 
of chronic effects were missing. It was further said that the neurotoxicity of TPP 
had been discussed and that more recent studies had not detected neurotoxic 
effects in vivo. However, a previous study observed an inhibition of neurite out-
growth by TPP, a result characteristic for neurotoxic phosphate esters.  
According to DFG, the single cases of sensitisation from TPP containing pro-
ducts were not convincing. 
To what extent the low immunotoxicity in rats can be extrapolated to humans 
was not possible to estimate. Other studies had shown a cytotoxic potential of TPP.  
In order to establish an OEL for humans, the animal studies were regarded as 
insufficient. The only human study was considered difficult to interpret due to 
insufficient data. Further studies, particularly regarding neurotoxicity in vivo, were 
considered necessary to perform (45). 
International Programme on Chemical Safety (IPCS), 1991  
It was stated that animal data indicated a low toxicity, that TPP produced no 
irritant effect on animal skin and that contact dermatitis due to TPP had been 
described. Despite an early report to the contrary, TPP was not considered neuro-
toxic in animals or man. The committee identified the NOAEL on mothers and 
offspring from a 90-day rat study of 690 mg/kg per day. It was noted that both 
exposure of the general population and occupational exposure to TPP were low. 
TPP was considered not mutagenic. It was concluded that the available data in-
dicated no hazard to humans (100). 
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The American Conference of Governmental Industrial Hygienists (ACGIH), 2001 
ACGIH stated that TPP has a low toxicity in experimental animals after oral, 
dermal or subcutaneous exposures, and is a limited cholinesterase inhibitor in 
animals and humans. It was noted that no evidence of neurological disease or 
other abnormalities were reported among workers exposed to TPP at a con-
centration of 3.5 mg/m3 for an average of 7.4 years. A TLV of 3 mg/m3 was 
recommended for occupational exposure. Sufficient data were not available to 
recommend a skin notation (5).  
United States Environmental Protection Agency (EPA), 2005  
It was noted that TPP caused mild reversible irritation primarily of the conjunctiva 
when administered to the rabbit eye but was not a skin irritant. It was also noted 
that a skin sensitisation study on guinea pigs was negative but that a few human 
cases of allergic dermatitis had been reported. A study of reproduction and de-
velopment in rats exposed for 91 days prior to mating and continuing through 
mating until day 20 of gestation was said to partially satisfy the reproductive 
screening component of the current guideline, but was considered not fully ade-
quate, primarily because it lacked histopathology of male and female reproductive 
organs. Findings relevant to reproduction were the absence of significant differen-
ces in number of corpora lutea, implants, implantation efficiency, viable foetuses, 
and number of early or late deaths at dietary levels as high as 1.0 % TPP (690 
mg/kg bw/day). Because both sexes were treated and there were no effects on litter 
size (as measured by number of viable foetuses), the study was said to provide 
some evidence that fertility is not affected by TPP in the rat. The body weights  
of the females fed the 1.0 % diets were slightly but significantly lower than those 
of controls on day 0 of gestation. Given a lack of dose response and uncertain 
biological significance of the slight foetal changes in this study, the highest dose 
level (1.0 % TPP in the diet, 690 mg/kg bw/day) was regarded as a possible 
NOAEL for foetotoxicity. TPP did not produce teratogenic effects in this study. 
According to the committee, this study suggested a minimal LOAEL for decreased 
body weight gain of 1.0 % TPP in the diet (690 mg/kg bw per day) for the dams.  
It was noted that three studies of gene mutation in vitro reported negative results, 
that these studies, two in bacteria and one in mammalian cells, predated the re-
levant guidelines but were conducted in a manner similar to them, and together, 
characterised the gene mutation in vitro endpoint. It was further stated that studies 
of chromosomal aberrations were not available, however, and were needed for 
adequate characterisation of the genotoxicity endpoint. The available carcino-
genicity data were judged inadequate. There was no evidence of acute cholinergic 
toxicity or of delayed neurotoxicity (243).  
United Nations Environmental Programme (UNEP) in its Screening Information 
Datasets (SIDS) for High Volume Chemicals, 2006  
Acute toxicity after oral and dermal administration was considered low: acute oral 
administration in rats, mice, rabbits and guinea pigs produced LD50 values in a 
range from 3 000 to above 20 000 mg/kg bw. One study in mice with limited 
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documentation gave a value of 1 320 mg/kg bw. After dermal application, an LD50 
of above 7 900 mg/kg bw was established in rabbits. The committee stated that no 
valid studies were available regarding the acute inhalation of TPP, that TPP did 
not possess an irritation potential on the skin and that the irritation potential of 
TPP on the mucous membrane of the eye is very low. It was noted that no animal 
data regarding skin sensitisation were available and that there were few human 
case reports showing evidence of skin sensitisation. The incidence of skin sen-
sitisation was considered very low. 
Based on the available data, the toxicity after repeated oral treatment of rats 
with TPP was considered low. A 35-day study using doses of up to 350 mg/kg 
bw/day produced a slight depression of body weight gain and an increase of liver 
weights at the highest dose. An estimated dose of ~ 70 mg/kg bw/day in the diet 
was without any effect. 
It was stated that three 4-month studies with doses of up to 1 % in the diet 
(~ 700 mg/kg bw/day) confirmed the effect on growth. Whereas body weight gain 
was depressed only at the highest dose of 1 % in two studies, a decrease was ob-
served even at 0.5 % in another study. The general well-being as well as neuro-
toxic or immunotoxic parameters were not affected in any of the dose groups. 
Therefore, the overall NOAEL for these studies was 161 mg/kg bw/day due to 
reduced body weight gain. The low toxicity was confirmed also after dermal ex-
posure of 100 and 1 000 mg/kg bw/day in rabbits for 15 days without any sign  
of toxicity besides a depression of acetylcholinesterase as the only dose-related 
effect. The committee considered the toxicological relevance of this effect hard 
to evaluate since quantitative data as well as the purity of the test material were 
not available. It was pointed out that neurotoxicity was a potential adverse effect 
of many organophosphates, but also noted that pure TPP did not induce immediate 
nor delayed neuropathy in available studies in hens and cats. Further, the com-
mittee noted that the findings of a decreased activity of cholinesterase and para-
lysis predominantly in cats in older studies indicating a neurotoxic potential were 
not reproduced in later studies and may be due to contamination of the tested 
samples by other organophosphorus esters. At the high doses of TPP used, even 
small concentrations of impurities might have sufficient activity. 
Tests for gene mutations in bacterial as well as yeast and mammalian cells were 
said not to reveal any sign of mutagenicity, and an unscheduled DNA synthesis 
test in Syrian hamster fibroblast cells showed no genotoxic effect. The committee 
stated that there were no data concerning chromosomal aberration and no findings 
indicating any adverse effects on fertility or the development of the foetus up to 
the highest tested dose level of 1 % in the diet (~700 mg/kg bw/day) in the rat 
treated for 4 months during gametogenesis prior to mating and throughout mating 
and gestation. The mouse lung adenoma assay gave no indication of a carcino-
genic potential (240). 
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14. Evaluation of human health risks  
14.1 Assessment of health risks 
This document comprises a number of phosphate triesters with flame retardant 
properties. The main groups are triaryl, trialkyl and tris(chloroalkyl) phosphate 
esters. The phosphate triesters differ widely in physical properties as well as in 
toxicological profiles and toxic potency. The major well-established clinical effect 
in humans is the delayed neurotoxicity caused by ingestion of tricresyl phosphate 
(TCP) contaminated food-stuff. In general, however, human data for these sub-
stances are scarce, particularly on occupational inhalation exposure.  
The vapour pressures for these compounds are generally low and a high human 
exposure to vapour is therefore not likely. However, aerosols may be generated 
under hot or pressurised conditions and phosphate triesters may also be adsorbed 
to other air pollutants. 
Two of the phosphate triesters (TOCP and TBP) have been shown to be easily 
absorbed through the human skin in vitro and many are absorbed through the skin 
of animals. A high absorption by inhalation is likely although this route has not 
been studied to a great extent. The combination of low vapour pressure at normal 
temperatures and a high skin uptake leads to the assumption that skin absorption 
may have a greater impact than absorption by inhalation. 
14.1.1 Irritation and sensitisation  
The phosphate triesters covered in this document are not strong irritants although 
several of the substances cause a slight to moderate eye and skin irritation. Re-
spiratory irritation data are generally lacking. 
Some of the phosphate triesters (TCP, TBEP, TBP and TPP) have been patch 
tested in patients with contact dermatitis or among volunteers. Positive responses 
were uncommon for TCP, TBEP and TPP even in groups exceeding 200 persons. 
14.1.2 Neurotoxicity 
Organophosphorus-induced delayed neuropathy (OPIDN) has been associated 
with exposure to some triaryl phosphates. There are three main types of triaryl 
phosphates in this document, triphenyl phosphate (TPP), tricresyl phosphate 
(TCP) and isopropylated triphenyl phosphates (TIPP). The most well-known and 
feared of these compounds is the tri-ortho-isomer of TCP (TOCP), which has been 
associated with around 60 000 cases of poisoning worldwide. TOCP is thus highly 
neurotoxic, whereas tri-meta- and tri-para-cresyl phosphate (TMCP and TPCP) 
are not. It has been shown in hens that engine oil containing 3 % commercial TCP 
(0.24 mg/kg bw/day of TOCP) was more neurotoxic than engine oil containing 
0.5 % TOCP (10 mg/kg bw/day TOCP), which indicates that commercial TCP 
may contain other neurotoxic compounds. It is known that triphenyl phosphate 
esters with one or two methyl group in the ortho positions, e.g. ortho-cresyl 
diphenyl phosphate, are more neurotoxic than TOCP. 
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The pure compounds TPP and the tri-ortho-, tri-meta- and tri-para-isopropyl-
phenyl phosphates are not neurotoxic. However, commercial products of these 
compounds may contain other isomers with a potency to cause OPIDN (shown for 
ortho-isopropylphenyl diphenyl phosphate).  
Other neurotoxic effects, not characterised as OPIDN, have been reported in 
animals for all other phosphate triesters except TPP.  
Some phosphate triesters act as cholinesterase inhibitors. Erythrocyte acetyl-
cholinesterase activity mirrors the activity of neuronal cholinesterase and is re-
commended by ACGIH as a biological exposure index for both TOCP and TBP. 
Pre-exposure baseline determination for the individual (on two occasions at least 
three days apart) is necessary because of the wide interindividual variation in 
acetylcholinesterase activity (2). Decreases of plasma cholinesterase levels were 
observed after varying doses to animals of TCP, TOCP, TBEP, TCEP, TIPP and 
TPP. Plasma cholinesterase is, however, not recommended as an index of ex-
posure due to the considerable range of normal activity and daily fluctuations in 
humans (2).  
14.1.3 Cancer  
Some phosphate triesters (TBP, TCEP, TDCPP and TEHP) have shown carcino-
genic effects in animal experiments. Genotoxicity data for TBP and TEHP are 
negative, whereas those for TCEP and TDCPP are inconclusive. Several of the 
esters have not been properly tested for cancer.  
There is only one epidemiological study addressing cancer. Among 289 workers 
manufacturing TDCPP, a statistically non-significant increase of lung cancer was 
observed. No firm conclusion can be drawn from this study. 
14.1.4 Reproduction  
Some of the phosphate triesters are toxic to the male reproductive system as shown 
in animal studies (TCP, TOCP, TCEP and TDCPP). In females, ovarian interstitial 
cell hyperplasia, hypertrophy and lipidosis, as well as decreased fertility have been 
observed after TCP exposure.  
Some of the compounds have also exhibited developmental toxicity (TCP and 
TMCPP). In addition, there is equivocal evidence from one study that TPP has an 
adverse effect on foetal development. TEHP and TIPP have not been studied. 
No human data have been located. 
14.1.5 Organ toxicity 
Several of the phosphate triesters have exhibited adverse effects on liver and 
kidney at relatively low levels. Liver or kidney toxicity (such as increased organ 
weights or hypertrophy) is considered the critical effect for TBEP, TCEP and TEP, 
in some cases in combination with other effects. In addition, increased relative 
liver weight is the critical effect for one commercial product of isopropylated tri-
phenyl phosphate. Cytoplasmic vacuolisation of the adrenal cortex was observed 
after exposure to TCP. 
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14.2 Groups at extra risk 
There are some indications that female animals may be more sensitive to the 
neurotoxic effects of TBEP and TCEP. There is a shortage of systematic studies 
regarding sex-differences of neurotoxic effects partially due to the regulatory 
protocols of using hens for studying OPIDN.  
It has been reported from several studies that erythrocyte acetylcholinesterase 
and plasma cholinesterase activities are significantly lower (approximately 10 %) 
in women than in men. A lower activity of these enzymes would increase the 
effects of cholinesterase inhibitors. Plasma cholinesterase activities may be de-
pressed in pregnant women and in individuals with liver disease, heart disease, 
allergic conditions and neoplasms (171).  
It has also been shown that a small sub-population possesses genetically de-
termined variants in their plasma cholinesterase resulting in very low activity 
levels and may thus be more sensitive to some of the phosphate triesters (171).  
14.3 Scientific basis for an occupational exposure limit 
There are insufficient human or animal data to establish dose-effect/dose-response 
relationships between airborne concentrations of the phosphate triesters and critical 
effects. The combination of low vapour pressure and a high dermal penetration 
rate implies that skin exposure may contribute significantly to the systemic dose 
and that dermal uptake may even be more important than inhalation. 
The major concerns from exposure to the phosphate triesters covered in this 
document are neurotoxicity, cancer, reproduction toxicity, and liver and kidney 
effects. Some of the neurotoxic esters are cholinesterase inhibitors. Commercial 
products of TCP, TIPP and TPP may contain other derivates of triaryl phosphates 
associated with neurotoxicity such as OPIDN. 
NOAELs and LOAELs for critical effects in animals after oral dosing of phos-
phate triesters covered in this document are presented in Table 16. For most of  
the phosphate triesters, no NOAELs could be identified. The NOAELs identified 
(TBEP, TBP and one commercial product of TIPP) are in the range 9-20 mg/kg 
bw. Identified LOAELs range from 5 to 600 mg/kg bw. The overall LOAEL for 
TEHP is 26 mg/m3 based on inhalation.  
Human inhalation data are few. A reduction of erythrocyte acetylcholinesterase 
activity was found in men manufacturing TPP at an estimated average air con-
centration of 3.5 mg/m3. Workers exposed to 15 mg/m3 of TBP complained of 
headache and nausea. These air levels correspond to 0.5 and 2.1 mg/kg bw, re-
spectively, assuming 100 % uptake by inhalation, no dermal uptake and 10 m3 
inhaled air during 8 hours. Thus, these human effect levels seem significantly 
lower than those causing effects in animals, however, the extent of dermal 
exposure is unknown.  
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15. Research needs 
There is a lack of data on human exposure and of the correlation between 
biomarkers of exposure and effects. Such information would be valuable to 
establish dose-response relations as absorption by skin may be more important 
than absorption by inhalation.  
There is also a need for studies on sensitive groups and sex differences. 
Long-term animal studies are lacking for several compounds such as TBEP, 
TEP, TIPP, TMCPP and TPP. 
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16. Summary  
Sjögren B, Iregren A, Järnberg J. The Nordic Expert Group for Criteria 
Documentation of Health Risks from Chemicals. 143. Phosphate triesters with 
flame retardant properties. Arbete och Hälsa 2010;44(6):1-220. 
This document comprises the following phosphate triesters: 
Tricresyl phosphate TCP Triethyl phosphate  TEP 
Tris(2-butoxyethyl) phosphate  TBEP TIPP 
Tri-n-butyl phosphate  TBP 
Triisopropylated phenyl phosphate/ 
isopropylated triphenyl phosphate
 
 
Tris(2-chloroethyl) phosphate  TCEP Tris(monochloropropyl) phosphate  TMCPP 
Tris(1,3-dichloro-2-propyl) phosphate  TDCPP Triphenyl phosphate TPP 
Tris(2-ethylhexyl) phosphate  TEHP   
 
The phosphate triesters are mainly used as flame retardants and plasticisers. They 
differ widely in physical properties as well as toxicological profiles and toxic 
potency. Most of these esters have low vapour pressures and are presumably ab-
sorbed to a substantial degree by the skin. The dermal exposure route may there-
fore be more important than inhalation. 
Human toxicological data on the phosphate triesters are scarce, particularly 
regarding occupational inhalation exposure. Based on animal data, the critical 
effects vary depending on substance and include cholinesterase inhibition, neuro-
toxicity, cancer, reproductive toxicity, and liver and kidney toxicity.  
Organophosphorus-induced delayed neuropathy (OPIDN) has been associated 
with exposure to some triaryl phosphates. The most well-known example is the 
TCP isomer tri-ortho-cresyl phosphate (TOCP), which has been associated with 
numerous cases of poisoning worldwide. The TOCP content is therefore kept at  
a very low level in commercial phosphate ester products of today. Commercial 
products of TCP, TIPP and TPP may, however, contain other triaryl phosphates 
associated with OPIDN. Several other phosphate triesters have shown other (non-
OPIDN) neurotoxic effects in animals.  
Some of the esters covered in this document exhibit carcinogenic effects in 
animals (TBP, TCEP, TDCPP and TEHP), whereas TCP shows no such potential. 
The other esters have not been properly tested.  
The lowest observed adverse effect levels (LOAELs) of the phosphate tri- 
esters range from 5 to 600 mg/kg bw/day. The no observed adverse effect levels 
(NOAELs), only identified for TBEP, TBP and one commercial product of TIPP, 
are in the range 9-20 mg/kg bw/day.  
 
 
 
Key words: cancer, flame retardant, neurotoxicity, occupational exposure limit, 
organophosphorus-induced delayed neuropathy (OPIDN), phosphate esters, 
reproductive toxicity, review, risk assessment, skin absorption  
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17. Summary in Swedish  
Sjögren B, Iregren A, Järnberg J. The Nordic Expert Group for Criteria 
Documentation of Health Risks from Chemicals. 143. Phosphate triesters with 
flame retardant properties. Arbete och Hälsa 2010;44(6):1-220. 
Detta dokument omfattar följande fosfattriestrar: 
Trikresylfosfat TCP Trietylfosfat TEP 
Tris(2-butoxietyl)fosfat  TBEP TIPP 
Tri-n-butylfosfat  TBP 
Triisopropylerad fenylfosfat/ 
isopropylerad trifenylfosfat  
Tris(2-kloretyl)fosfat TCEP Tris(monoklorpropyl)fosfat TMCPP 
Tris(1,3-diklor-2-propyl)fosfat  TDCPP Trifenylfosfat TPP 
Tris(2-etylhexyl)fosfat TEHP   
 
Fosfattriestrarna används huvudsakligen som flamskyddsmedel och mjukgörare.  
Dessa ämnen skiljer sig i såväl fysikaliska egenskaper som toxikologisk profil och 
potens. De flesta estrarna har lågt ångtryck och tas troligen väsentligen upp via 
huden, varför hudupptag kan vara viktigare än inandning.  
Överlag är data på människa knapphändiga, speciellt med avseende på yrkes-
mässig exponering via inandning. Djurförsök har visat att de kritiska effekterna, 
som varierar beroende på ämne, inkluderar kolinesteras-hämning, neurotoxicitet, 
cancer och effekter på reproduktion, lever och njure.  
En viss typ av neurotoxicitet, så kallad ”organophosphorus-induced delayed 
neuropathy” (OPIDN), har satts i samband med exponering för vissa triarylfos-
fater. Det mest kända och fruktade exemplet är TCP-isomeren tri-orto-kresylfosfat 
(TOCP) som associerats med ett stort antal förgiftningsfall i världen. TOCP-inne-
hållet är därför mycket lågt i dagens kommersiella fosfatesterprodukter. Kommer-
siella produkter med TCP, TIPP och TPP kan dock innehålla andra triarylfosfater 
som relaterats till OPIDN. Flera andra fosfattriestrar har i djurförsök orsakat neuro-
toxiska effekter som inte är OPIDN.  
Några av ämnena har orsakat cancer i djurförsök (TBP, TCEP, TDCPP, TEHP), 
dock inte TCP. De andra estrarna är inte testade.  
Identifierade lägsta effektnivåer (LOAEL) är 5-600 mg/kg kroppsvikt/dag. Icke-
effektnivåer (NOAEL), endast identifierade för TBEP, TBP och en kommersiell 
produkt med TIPP, är 9-20 mg/kg kroppsvikt/dag.  
 
 
 
 
 
 
Nyckelord: cancer, flamskyddsmedel, fosfatester, hudupptag, hygieniskt 
gränsvärde, neurotoxicitet, organophosphorus-induced delayed neuropathy 
(OPIDN), reproduktionstoxicitet, riskbedömning, översikt
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20. Data bases used in search of literature 
The major literature searches were performed in November 2004. The following 
databases were used: 
 
Arbline 
Cheminfo 
CISDOC 
HSELINE 
MHIDAS 
NIOSHTIC2 
PubMed 
RILOSH 
RTECS 
STN 
Toxline 
 
A final search in Toxline and PubMed was performed in November 2009. 
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Appendix 1. Dose-effect and dose-response relationships in 
animals 
Table I Tricresyl phosphate (TCP) 
Table II Tri-o-, tri-m-, and tri-p-cresyl phosphate (TOCP, TMCP, TPCP) 
Table III Tris(2-butoxyethyl) phosphate (TBEP) 
Table IV Tri-n-butyl phosphate (TBP) 
Table V Tris(2-chloroethyl) phosphate (TCEP) 
Table VI Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) 
Table VII Tris(2-ethylhexyl) phosphate (TEHP) 
Table VIII Triethyl phosphate (TEP) 
Table IX Triisopropylated phenyl phosphate/isopropylated triphenyl 
phosphate (TIPP) 
Table X Tris(monochloropropyl) phosphate (TMCPP)  
Table XI Triphenyl phosphate (TPP) 
  
15
8  
Ta
bl
e 
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
ic
re
sy
l p
ho
sp
ha
te
 
(T
CP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
Si
n
gl
e 
do
se
 
 
 
 
 
 
Kr
o
n
ite
x
 
TC
P 
 
 
 
 
 
75
 
O
ra
l 
H
en
 
4 
fe
m
al
es
 
-
 
A
ta
x
ia
 
in
 
0/
4,
 
21
 
da
ys
 
po
st
-
do
sin
g.
 
 
(25
1) 
15
0 
O
ra
l 
H
en
 
 
4 
fe
m
al
es
 
-
 
A
ta
x
ia
 
in
 
1/
4,
 
21
 
da
ys
 
po
st
-
do
sin
g.
 
Sa
m
e 
re
su
lt 
at
 
30
0 
m
g/
kg
 
bw
.
 
(25
1) 
40
0 
O
ra
l 
H
en
 
4 
fe
m
al
es
 
-
 
92
.
5 %
 
in
hi
bi
tio
n
 
o
f b
ra
in
 
N
TE
 
at
 
24
 
ho
u
rs
 
po
st
-
do
sin
g.
 
(25
1) 
D
ur
a
d 
12
5L
 
(<
 
0.
2 %
 
TO
CP
) 
 
 
 
 
 
2 
00
0 
O
ra
l 
H
en
 
 
11
 
fe
m
al
es
 
-
 
A
ta
x
ia
 
in
 
0/
10
.
 
N
er
v
o
u
s 
sy
st
em
 
le
sio
n
s 
in
 
4/
7.
 
Si
gn
ifi
ca
n
tly
 
re
du
ce
d 
ac
tiv
iti
es
 
o
f N
TE
 
in
 
br
ai
n
 
(45
 
%
) a
n
d 
in
 
sp
in
al
 
co
rd
 
(83
 
%
) a
t 4
8 
ho
u
rs
 
po
st
-
do
sin
g.
 
B
ra
in
 
ch
o
lin
es
te
ra
se
 
n
o
t i
n
hi
bi
te
d.
 
 
(25
1) 
TC
P 
m
ix
tu
re
 
(2.
2 %
 
TO
CP
) 
7 
90
0 
D
er
m
al
 
R
ab
bi
t, 
al
bi
n
o
 
 
-
 
LD
50
 
>
 
7 
90
0 
m
g/
kg
 
bw
.
 
(10
6) 
10
 
00
0 
G
av
ag
e 
H
en
 
Fe
m
al
es
 
-
 
LD
50
 
>
 
10
 
00
0 
m
g/
kg
 
bw
.
 
(10
6) 
15
 
80
0 
G
av
ag
e 
 
R
at
 
 
-
 
LD
50
 
>
 
15
 
80
0 
m
g/
kg
 
bw
.
 
(10
6) 
M
u
lti
pl
e 
do
se
s 
 
 
 
 
 
2.
4 
(90
 
%
 
o
,
 
m
, 
p) 
 
O
ra
l, 
in
 
di
et
 
R
at
,
 
 
al
bi
n
o
 
 
10
 
m
al
es
 
6 
w
ee
ks
 
R
at
s 
im
m
u
n
ise
d 
w
ith
 
te
ta
n
u
s 
to
x
o
id
 
af
te
r 
25
 
da
ys
 
o
f e
x
po
su
re
.
 
N
o 
ef
fe
ct
 
o
n
 
se
ru
m
 
an
tib
o
dy
 
tit
re
s.
 
N
o 
sig
n
s 
o
f c
ho
lin
er
gi
c 
o
r 
de
la
ye
d 
n
eu
ro
to
x
ic
 
ef
fe
ct
s.
 
(14
,
 
21
5) 
4 a
 
 
O
ra
l, 
in
 
di
et
 
R
at
 
53
 
fe
m
al
es
 
2 
ye
ar
s 
N
o 
cy
to
pl
as
m
ic
 
v
ac
u
o
lis
at
io
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
,
 
n
o
 
hy
pe
rp
la
sia
,
 
 
n
o
 
ch
em
ic
al
-
re
la
te
d 
in
cr
ea
se
s 
in
 
th
e 
in
ci
de
n
ce
 
o
f n
eo
pl
as
m
s.
 
 
(17
4) 
6 a
 
 
O
ra
l, 
in
 
di
et
 
R
at
 
50
 
m
al
es
 
2 
ye
ar
s 
N
o 
cy
to
pl
as
m
ic
 
v
ac
u
o
lis
at
io
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
,
 
n
o
 
hy
pe
rp
la
sia
,
 
 
n
o
 
ch
em
ic
al
-
re
la
te
d 
in
cr
ea
se
s 
in
 
th
e 
in
ci
de
n
ce
 
o
f n
eo
pl
as
m
s.
 
Sa
m
e 
re
su
lts
 
at
 
3 
m
g/
kg
 
bw
.
 
(17
4) 
6 
(90
 
%
 
o
,
 
m
, 
p) 
O
ra
l, 
in
 
di
et
 
R
at
,
 
 
al
bi
n
o
 
 
10
 
m
al
es
 
6 
w
ee
ks
 
R
at
s 
im
m
u
n
ise
d 
w
ith
 
te
ta
n
u
s 
to
x
o
id
 
af
te
r 
25
 
da
ys
 
o
f e
x
po
su
re
.
 
 
Si
gn
ifi
ca
n
tly
 
re
du
ce
d 
se
ru
m
 
an
tib
o
dy
 
tit
re
s.
 
In
hi
bi
tio
n
 
o
f l
eu
ko
cy
te
 
an
d 
m
ac
ro
ph
ag
e 
m
ig
ra
tio
n
.
 
N
o 
sig
n
s 
o
f c
ho
lin
er
gi
c 
o
r 
de
la
ye
d 
n
eu
ro
to
x
ic
 
ef
fe
ct
s.
 
(14
,
 
21
5) 
  
15
9  
Ta
bl
e 
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
ic
re
sy
l p
ho
sp
ha
te
 
(T
CP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
 
 
7 
a  
 
O
ra
l, 
in
 
di
et
 
R
at
 
50
 
fe
m
al
es
 
2 
ye
ar
s 
Se
ru
m
 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
 
sig
n
ifi
ca
n
tly
 
lo
w
er
 
co
m
pa
re
d 
to
 
co
n
tr
o
ls 
at
 
3,
 
9 
an
d 
15
 
m
o
n
th
s 
(al
so
 
se
en
 
at
 
15
 
m
g/
kg
 
bw
). C
yt
o
pl
as
m
ic
 
v
ac
u
o
-
lis
at
io
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
 
bu
t n
o
t s
ig
n
ifi
ca
n
tly
 
di
ffe
re
n
t f
ro
m
 
co
n
-
tr
o
ls.
 
M
in
im
al
 
to
 
m
ild
 
o
v
ar
ia
n
 
in
te
rs
tit
ia
l c
el
l h
yp
er
pl
as
ia
; s
ig
n
ifi
ca
n
t  
at
 
3 
m
o
n
th
s 
(6/
10
 
v
s.
 
0/
10
 
in
 
co
n
tr
o
ls)
.
 
(17
4) 
 
 
7 
a  
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
 
49
 
m
al
es
 
2 
ye
ar
s 
 
Se
ru
m
 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
 
sig
n
ifi
ca
n
tly
 
lo
w
er
 
co
m
pa
re
d 
to
 
co
n
tr
o
ls 
at
 
3,
 
9 
an
d 
15
 
m
o
n
th
s 
(al
so
 
se
en
 
at
 
13
 
an
d 
27
 
m
g/
kg
 
bw
). S
lig
ht
 
in
-
cr
ea
se
 
o
f c
er
o
id
 
pi
gm
en
ta
tio
n
 
o
f a
dr
en
al
 
co
rt
ex
 
at
 
3 
m
o
n
th
s 
(3/
10
 
v
s.
 
0/
8 
in
 
co
n
tr
o
ls)
; n
o
 
in
cr
ea
se
 
at
 
2 
ye
ar
s 
(47
/4
9 
v
s.
 
48
/5
2).
 
H
ar
de
ria
n
 
gl
an
d 
ad
en
o
m
as
 
in
 
1/
49
 
v
s.
 
0/
52
.
 
 
(17
4) 
 
 
8 a
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
 
50
 
fe
m
al
es
 
2 
ye
ar
s 
Se
ru
m
 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
 
sig
n
ifi
ca
n
tly
 
lo
w
er
 
co
m
pa
re
d 
to
 
co
n
tr
o
ls 
at
 
3,
 
9 
an
d 
15
 
m
o
n
th
s 
(al
so
 
se
en
 
at
 
18
 
an
d 
37
 
m
g/
kg
 
bw
). H
ar
de
ria
n
 
gl
an
d 
ad
en
o
m
as
 
in
 
3/
50
 
v
s.
 
5/
50
 
in
 
co
n
tr
o
ls.
 
(17
4) 
10
 
 
(0.
04
 
TO
CP
) 
G
av
ag
e,
 
en
gi
n
e 
o
il 
 
H
en
 
30
 
fe
m
al
es
 
10
 
w
ee
ks
 
M
o
rt
al
ity
 
in
 
1/
30
.
 
N
on
e 
ha
d 
at
ax
ia
.
 
In
hi
bi
tio
n
 
o
f p
la
sm
a 
ch
o
lin
es
te
ra
se
 
23
 
%
,
 
br
ai
n
 
N
TE
 
47
 
%
 
an
d 
sp
in
al
 
co
rd
 
N
TE
 
24
 
%
 
at
 
w
ee
k 
6 
(la
st
 
tw
o
 
sig
n
ifi
ca
n
t).
 
N
eu
ro
pa
th
o
lo
gi
ca
l l
es
io
n
s 
(>
 
gr
ad
e 
2) 
in
 
0/
11
.
 
 
(70
) 
12
 
 
(90
 
%
 
o
,
 
m
, 
p) 
O
ra
l, 
in
 
di
et
 
R
at
,
 
al
bi
n
o
 
 
10
 
m
al
es
 
6 
w
ee
ks
 
R
at
s 
im
m
u
n
ise
d 
w
ith
 
te
ta
n
u
s 
to
x
o
id
 
af
te
r 
25
 
da
ys
 
o
f e
x
po
su
re
.
 
 
Si
gn
ifi
ca
n
tly
 
re
du
ce
d 
se
ru
m
 
an
tib
o
dy
 
tit
re
s,
 
Ig
M
 
an
d 
Ig
G
. I
n
hi
bi
tio
n
 
 
o
f l
eu
ko
cy
te
 
an
d 
m
ac
ro
ph
ag
e 
m
ig
ra
tio
n
.
 
N
o 
sig
n
s 
o
f c
ho
lin
er
gi
c 
o
r 
de
la
ye
d 
n
eu
ro
to
x
ic
 
ef
fe
ct
s.
 
(14
,
 
21
5) 
13
 
a  
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
 
49
 
m
al
es
 
2 
ye
ar
s 
Sl
ig
ht
 
in
cr
ea
se
 
o
f c
er
o
id
 
pi
gm
en
ta
tio
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
 
at
 
3 
m
o
n
th
s 
(3/
10
 
v
s.
 
0/
8 
in
 
co
n
tr
o
ls)
; n
o
 
in
cr
ea
se
 
at
 
2 
ye
ar
s 
(49
/4
9 
v
s.
 
48
/5
2).
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f c
le
ar
 
ce
ll 
fo
ci
,
 
fa
tty
 
ch
an
ge
 
an
d 
ce
ro
id
 
pi
gm
en
ta
tio
n
 
in
 
liv
er
.
 
H
ar
de
ria
n
 
gl
an
d 
ad
en
o
m
as
 
in
 
2/
49
 
v
s.
 
0/
52
.
 
(17
4) 
13
 
a  
 
O
ra
l, 
in
 
di
et
 
R
at
 
 
50
 
m
al
es
 
2 
ye
ar
s 
 
Se
ru
m
 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
 
sig
n
ifi
ca
n
tly
 
lo
w
er
 
co
m
pa
re
d 
to
 
co
n
tr
o
ls 
at
 
3,
 
9 
an
d 
15
 
m
o
n
th
s.
 
H
in
dl
im
b 
gr
ip
 
st
re
n
gt
h 
sig
n
ifi
ca
n
tly
 
re
du
ce
d 
at
 
 
3 
m
o
n
th
s.
 
N
o 
in
cr
ea
se
 
in
 
th
e 
in
ci
de
n
ce
 
o
f n
eo
pl
as
m
s 
at
 
th
is 
o
r 
lo
w
er
 
 
(3 
o
r 
6 
m
g/
kg
 
bw
) l
ev
el
s.
 
(17
4) 
  
16
0  
Ta
bl
e 
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
ic
re
sy
l p
ho
sp
ha
te
 
(T
CP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
15
 
a  
 
O
ra
l, 
in
 
di
et
 
R
at
 
 
50
 
fe
m
al
es
 
2 
ye
ar
s 
Cy
to
pl
as
m
ic
 
v
ac
u
o
lis
at
io
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
 
sig
n
ifi
ca
n
tly
 
in
cr
ea
se
d 
(36
/5
0 
v
s.
 
15
/5
1 
in
 
co
n
tr
o
ls)
.
 
O
va
ria
n
 
in
te
rs
tit
ia
l c
el
l h
yp
er
pl
as
ia
 
sig
n
ifi
ca
n
tly
 
in
cr
ea
se
d 
(15
/5
0 
v
s.
 
0/
51
). L
es
io
n
 
ch
ar
ac
te
ris
ed
 
by
 
in
-
cr
ea
se
 
in
 
siz
e 
an
d 
po
ss
ib
ly
 
n
u
m
be
r 
o
f i
n
te
rs
tit
ia
l c
el
ls.
 
N
o 
in
cr
ea
se
 
in
 
th
e 
in
ci
de
n
ce
 
o
f n
eo
pl
as
m
s 
at
 
th
is 
o
r 
lo
w
er
 
(4 
o
r 
7 
m
g/
kg
 
bw
) l
ev
el
s.
 
(17
4) 
18
 
a  
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
 
48
 
fe
m
al
es
 
2 
ye
ar
s 
Ce
ro
id
 
pi
gm
en
ta
tio
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
 
in
 
m
o
st
 
ex
po
se
d 
an
d 
co
n
tr
o
l 
m
ic
e 
bu
t t
he
 
se
v
er
ity
 
w
as
 
in
cr
ea
se
d 
am
o
n
g 
ex
po
se
d 
in
 
a 
do
se
-
re
la
te
d 
m
an
n
er
.
 
N
o 
H
ar
de
ria
n
 
gl
an
d 
ad
en
o
m
as
 
(0/
48
 
v
s.
 
5/
50
 
in
 
co
n
tr
o
ls)
.
 
(17
4) 
20
 
(0.
08
 
TO
CP
) 
G
av
ag
e,
 
en
gi
n
e 
o
il 
 
H
en
 
 
30
 
fe
m
al
es
 
10
 
w
ee
ks
 
M
o
rt
al
ity
 
in
 
2/
30
.
 
N
on
e 
ha
d 
at
ax
ia
.
 
Si
gn
ifi
ca
n
t i
n
hi
bi
tio
n
 
o
f p
la
sm
a 
ch
o
lin
es
te
ra
se
 
(27
 
%
), b
ra
in
 
N
TE
 
(55
 
%
) a
n
d 
sp
in
al
 
co
rd
 
N
TE
 
(34
 
%
) 
ac
tiv
iti
es
 
at
 
w
ee
k 
6.
 
N
eu
ro
pa
th
o
lo
gi
ca
l l
es
io
n
s 
(>
 
gr
ad
e 
2) 
in
 
1/
9.
 
 
(70
) 
27
 
a  
 
O
ra
l, 
in
 
di
et
 
 
M
o
u
se
 
 
50
 
m
al
es
 
2 
ye
ar
s 
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f c
er
o
id
 
pi
gm
en
ta
tio
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
 
at
 
3 
m
o
n
th
s 
(6/
10
 
v
s.
 
0/
8 
in
 
co
n
tr
o
ls)
; n
o
 
in
cr
ea
se
 
at
 
2 
ye
ar
s.
 
Si
gn
ifi
ca
n
t i
n
-
cr
ea
se
 
o
f c
le
ar
 
ce
ll 
fo
ci
,
 
fa
tty
 
ch
an
ge
 
an
d 
ce
ro
id
 
pi
gm
en
ta
tio
n
 
in
 
liv
er
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f H
ar
de
ria
n
 
gl
an
d 
ad
en
o
m
as
 
(5/
50
 
v
s.
 
0/
52
). N
o 
in
cr
ea
se
d 
in
ci
de
n
ce
 
o
f n
eo
pl
as
m
s 
at
 
th
is 
o
r 
lo
w
er
 
(7 
o
r 
13
 
m
g/
kg
 
bw
) 
le
v
el
s.
 
(17
4) 
Ca
 
30
 
O
ra
l, 
in
 
di
et
 
R
at
 
10
 
m
al
es
,
 
 
9 
fe
m
al
es
 
22
 
w
ee
ks
 
Cy
to
pl
as
m
ic
 
v
ac
u
o
lis
at
io
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
 
in
 
bo
th
 
se
x
es
.
 
 
(17
4) 
37
 
a  
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
 
51
 
fe
m
al
es
 
2 
ye
ar
s 
Ce
ro
id
 
pi
gm
en
ta
tio
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
 
in
 
m
o
st
 
ex
po
se
d 
an
d 
co
n
tr
o
l 
m
ic
e 
bu
t t
he
 
se
v
er
ity
 
w
as
 
in
cr
ea
se
d 
am
o
n
g 
ex
po
se
d 
in
 
a 
do
se
-
re
la
te
d 
m
an
n
er
.
 
Si
gn
ifi
ca
n
t d
ec
re
as
e 
o
f H
ar
de
ria
n
 
gl
an
d 
ad
en
o
m
as
 
(0/
51
 
v
s.
 
5/
50
 
in
 
co
n
tr
o
ls)
.
 
N
o 
in
cr
ea
se
 
in
 
th
e 
in
ci
de
n
ce
 
o
f n
eo
pl
as
m
s 
at
 
th
is 
o
r 
lo
w
er
 
(8 
o
r 
18
 
m
g/
kg
 
bw
) l
ev
el
s.
 
R
ed
u
ce
d 
hi
n
dl
im
b 
gr
ip
 
st
re
n
gt
h 
at
 
3 
(bu
t n
o
t a
t 9
 
an
d 
15
) m
o
n
th
s.
 
(17
4) 
45
 
a  
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
 
10
 
m
al
es
 
13
 
w
ee
ks
 
N
o 
cl
in
ic
al
 
fin
di
n
gs
.
 
N
o 
cy
to
pl
as
m
ic
 
v
ac
u
o
lis
at
io
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
.
 
N
o 
n
eu
ro
to
x
ic
 
ef
fe
ct
s.
 
(17
4) 
  
16
1  
Ta
bl
e 
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
ic
re
sy
l p
ho
sp
ha
te
 
(T
CP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
 
 
50
 
a  
 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
10
/se
x
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f c
yt
o
pl
as
m
ic
 
v
ac
u
o
lis
at
io
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
 
in
 
bo
th
 
se
x
es
 
an
d 
o
v
ar
ia
n
 
in
te
rs
tit
ia
l c
el
l h
yp
er
tr
o
ph
y.
 
A
lso
 
se
en
 
at
 
10
0,
 
20
0,
 
40
0 
an
d 
80
0 
m
g/
kg
 
bw
 
(do
se
-
de
pe
n
de
n
t).
 
N
o 
n
eu
ro
to
x
ic
 
ef
fe
ct
s.
 
(17
4) 
 
 
50
 
a  
 
G
av
ag
e,
 
co
rn
 
o
il 
M
o
u
se
 
10
/se
x
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f c
yt
o
pl
as
m
ic
 
v
ac
u
o
lis
at
io
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
 
in
 
bo
th
 
se
x
es
 
an
d o
v
ar
ia
n
 
in
te
rs
tit
ia
l c
el
l h
yp
er
tr
o
ph
y.
 
D
ec
re
as
ed
 
se
ru
m
 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
.
 
Sa
m
e 
ef
fe
ct
s 
al
so
 
se
en
 
at
 
10
0,
 
20
0,
 
40
0 
an
d 
80
0 
m
g/
kg
 
bw
 
(do
se
-
de
pe
n
de
n
t).
 
N
o 
n
eu
ro
to
x
ic
 
ef
fe
ct
s.
 
(17
4) 
 
 
55
 
a  
 
O
ra
l, 
in
 
di
et
 
R
at
 
10
 
m
al
es
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f c
yt
o
pl
as
m
ic
 
v
ac
u
o
lis
at
io
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
.
 
A
lso
 
se
en
 
at
 
12
0,
 
22
0,
 
43
0 
an
d 
75
0 
m
g/
kg
 
bw
 
(do
se
-
de
pe
n
de
n
t).
 
N
o 
n
eu
ro
to
x
ic
 
ef
fe
ct
s.
 
(17
4) 
60
 (0.
24
 
TO
CP
) 
G
av
ag
e,
 
en
gi
n
e 
o
il 
 
H
en
 
30
 
fe
m
al
es
 
10
 
w
ee
ks
 
M
o
rt
al
ity
 
in
 
4/
30
.
 
22
/3
0 
ha
d 
at
ax
ia
.
 
Si
gn
ifi
ca
n
t i
n
hi
bi
tio
n
 
o
f p
la
sm
a 
ch
o
lin
es
te
ra
se
 
(49
 
%
), b
ra
in
 
N
TE
 
(77
 
%
) a
n
d 
sp
in
al
 
co
rd
 
N
TE
 
(62
 
%
) 
ac
tiv
iti
es
 
at
 
w
ee
k 
6.
 
N
eu
ro
pa
th
o
lo
gi
ca
l l
es
io
n
s 
(>
 
gr
ad
e 
2) 
in
 
10
/1
1.
 
(70
) 
62
.
5 
 
<
 
0.
1 %
 
TO
CP
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
20
/se
x
 
14
 
w
ee
ks
 
F 0
 
an
d 
F 1
 tr
ea
te
d 
w
ith
 
th
e 
sa
m
e 
do
se
.
 
Si
gn
ifi
ca
n
t d
ec
re
as
e 
o
f m
o
til
e 
sp
er
m
s 
(47
 
%
 
v
s.
 
72
 
%
 
in
 
co
n
tr
o
ls)
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f a
bn
o
rm
al
 
sp
er
m
s 
(4 
%
 
v
s.
 
3 %
). 
(35
) 
 
 
65
 
a  
 
O
ra
l, 
in
 
di
et
 
R
at
 
10
 
fe
m
al
es
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f c
yt
o
pl
as
m
ic
 
v
ac
u
o
lis
at
io
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
 
an
d 
o
v
ar
ia
n
 
in
te
rs
tit
ia
l c
el
l h
yp
er
tr
o
ph
y 
an
d 
in
fla
m
m
at
io
n
.
 
A
lso
 
se
en
 
at
 
12
0,
 
23
0,
 
43
0 
an
d 
77
0 
m
g/
kg
 
bw
 
(do
se
-
de
pe
n
de
n
t).
 
N
o 
n
eu
ro
to
x
ic
 
ef
fe
ct
s.
 
(17
4) 
 
 
65
 
a 
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
 
10
 
fe
m
al
es
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f c
yt
o
pl
as
m
ic
 
v
ac
u
o
lis
at
io
n
 
o
f t
he
 
ad
re
n
al
 
co
rt
ex
.
 
A
lso
 
se
en
 
at
 
13
0,
 
23
0,
 
53
0 
an
d 
1 0
50
 
m
g/
kg
 
bw
 
(do
se
-
de
pe
n
de
n
t).
 
N
o 
n
eu
ro
to
x
ic
 
ef
fe
ct
s.
 
(17
4) 
10
0 a
 
 
G
av
ag
e,
 
co
rn
 
o
il 
M
o
u
se
 
 
10
/se
x
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f m
u
lti
fo
ca
l a
x
o
n
al
 
de
ge
n
er
at
io
n
 
in
 
th
e 
sp
in
al
 
co
rd
 
in
 
fe
m
al
es
.
 
(17
4) 
  
16
2  
Ta
bl
e 
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
ic
re
sy
l p
ho
sp
ha
te
 
(T
CP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
10
0 
<
 
9 %
 
TO
CP
 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
12
 
m
al
es
 
66
 
da
ys
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f a
bn
o
rm
al
 
sp
er
m
s 
(19
 
%
 
v
s.
 
6 %
 
in
 
co
n
tr
o
ls)
.
 
(31
) 
11
0 a
 
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
 
10
 
m
al
es
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f c
yt
o
pl
as
m
ic
 
v
ac
u
o
lis
at
io
n
 
o
f a
dr
en
al
 
co
rt
ex
.
 
A
lso
 
se
en
 
at
 
18
0,
 
38
0 
an
d 
90
0 
m
g/
kg
 
bw
 
(do
se
-
de
pe
n
de
n
t).
 
N
o 
n
eu
ro
-
to
x
ic
 
ef
fe
ct
s.
 
(17
4) 
12
4 
 
<
 
0.
1 %
 
TO
CP
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
 
20
/se
x
 
14
 
w
ee
ks
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f d
ea
d 
pu
ps
.
 
 
(35
) 
18
0 a
 
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
 
10
 
m
al
es
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f h
yp
er
pl
as
ia
 
o
f g
al
lb
la
dd
er
 
m
u
co
sa
l e
pi
th
el
iu
m
.
 
N
o 
n
eu
ro
to
x
ic
 
ef
fe
ct
s.
 
(17
4) 
20
0 a
 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
10
/se
x
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t w
ei
gh
t r
ed
u
ct
io
n
 
in
 
m
al
es
.
 
Si
gn
ifi
ca
n
tly
 
lo
w
er
 
bl
o
o
d 
ha
em
o
gl
o
bi
n
 
co
n
ce
n
tr
at
io
n
s 
in
 
fe
m
al
es
.
 
N
o 
n
eu
ro
to
x
ic
 
ef
fe
ct
s.
 
(17
4) 
20
0 a
 
 
G
av
ag
e,
 
co
rn
 
o
il 
M
o
u
se
 
 
10
/se
x
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t w
ei
gh
t r
ed
u
ct
io
n
 
in
 
m
al
es
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f m
u
lti
fo
ca
l 
ax
o
n
al
 
de
ge
n
er
at
io
n
 
o
f s
pi
n
al
 
co
rd
 
an
d 
sc
ia
tic
 
n
er
v
e 
in
 
bo
th
 
se
x
es
.
 
R
ed
u
ce
d 
gr
ip
 
st
re
n
gt
h 
in
 
bo
th
 
se
x
es
 
(fo
re
-
 
an
d 
hi
n
dl
im
b 
in
 
fe
m
al
es
 
an
d 
hi
n
dl
im
b 
in
 
m
al
es
). 
(17
4) 
20
0 
 
<
 
9 %
 
TO
CP
 
G
av
ag
e,
 
co
rn
 
o
il 
 
R
at
 
12
 
m
al
es
 
66
 
da
ys
 
Si
gn
ifi
ca
n
tly
 
re
du
ce
d 
w
ei
gh
t o
f e
pi
di
dy
m
is.
 
R
ed
u
ct
io
n
 
o
f s
pe
rm
 
co
n
-
ce
n
tr
at
io
n
,
 
m
o
til
ity
 
an
d 
v
el
o
ci
ty
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f a
bn
o
rm
al
 
sp
er
m
s 
(66
 
%
 
v
s.
 
6 %
 
in
 
co
n
tr
o
ls)
.
 
H
ist
o
pa
th
o
lo
gi
ca
l c
ha
n
ge
s 
in
 
th
e 
te
st
es
 
an
d 
ep
id
id
ym
id
es
.
 
(31
) 
20
0 
 
<
 
9 %
 
TO
CP
 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
 
24
 
fe
m
al
es
 
14
 
da
ys
 
pr
io
r 
to
 
br
ee
di
n
g,
 
br
ee
di
n
g,
 
la
ct
at
io
n
 
an
d 
w
ea
n
in
g 
u
n
til
 
da
y 
21
 
M
al
es
 
o
n
 
do
se
 
10
0 
m
g/
kg
 
bw
 
w
er
e 
br
ed
 
w
ith
 
fe
m
al
es
 
in
 
th
is 
gr
o
u
p.
 
 
Fe
rt
ili
ty
 
ra
te
 
se
v
er
el
y 
af
fe
ct
ed
.
 
Th
e 
pe
rc
en
t o
f s
pe
rm
 
po
sit
iv
e 
fe
m
al
es
 
lit
te
rin
g 
w
as
 
45
 
%
 
v
s.
 
95
 
%
 
in
 
co
n
tr
o
ls.
 
O
ve
ra
ll 
br
ee
di
n
g 
su
cc
es
s 
38
 
%
 
v
s.
 
75
 
%
.
 
M
ea
n
 
lit
te
r 
siz
e 
9.
6 
v
s.
 
11
.
3.
 
D
iff
u
se
 
v
ac
u
o
la
r 
cy
to
pl
as
m
ic
 
al
te
ra
tio
n
 
o
f o
v
ar
ia
n
 
in
te
rs
tit
ia
l c
el
ls.
 
 
(31
) 
22
0 a
 
 
O
ra
l, 
in
 
di
et
 
R
at
 
10
 
m
al
es
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f b
as
o
ph
ili
c 
hy
pe
rt
ro
ph
y 
o
f p
itu
ita
ry
 
gl
an
d.
 
 
(17
4) 
23
0 a
 
 
O
ra
l, 
in
 
di
et
 
R
at
 
 
10
 
fe
m
al
es
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t w
ei
gh
t r
ed
u
ct
io
n
.
 
(17
4) 
  
16
3  
Ta
bl
e 
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
ic
re
sy
l p
ho
sp
ha
te
 
(T
CP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
23
0 a
 
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
 
10
 
fe
m
al
es
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t w
ei
gh
t r
ed
u
ct
io
n
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f h
yp
er
pl
as
ia
 
o
f 
ga
llb
la
dd
er
 
m
u
co
sa
l e
pi
th
el
iu
m
.
 
(17
4) 
25
0 
 
<
 
0.
1 %
 
TO
CP
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
20
/se
x
 
14
 
w
ee
ks
 
Se
m
in
ife
ro
u
s 
tu
bu
le
 
at
ro
ph
y 
an
d 
de
cr
ea
se
d 
te
st
is 
an
d 
ep
id
id
ym
al
 
w
ei
gh
ts
.
 
In
 
fe
m
al
es
,
 
n
o
 
hi
st
o
pa
th
o
lo
gi
ca
l c
ha
n
ge
s 
in
 
th
e 
re
pr
o
du
ct
iv
e 
tr
ac
t. 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f d
ea
d 
pu
ps
 
an
d 
a 
de
cr
ea
se
 
o
f n
u
m
be
r 
o
f 
liv
eb
o
rn
 
pu
ps
 
pe
r 
lit
te
r.
 
Cr
o
ss
o
v
er
 
m
at
in
g 
tr
ia
l r
ev
ea
le
d 
sig
n
ifi
ca
n
t 
im
pa
ire
d 
fe
rt
ili
ty
 
in
 
bo
th
 
se
x
es
,
 
w
ith
 
a 
gr
ea
te
r 
ef
fe
ct
 
in
 
fe
m
al
es
.
 
(35
) 
38
0 a
 
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
10
 
m
al
es
 
13
 
w
ee
ks
 
In
cr
ea
se
 
(no
n
-
sig
n
ifi
ca
n
t) 
o
f a
x
o
n
al
 
de
ge
n
er
at
io
n
 
o
f s
pi
n
al
 
co
rd
 
an
d 
sc
ia
tic
 
n
er
v
e.
 
R
ed
u
ce
d 
fo
re
lim
b 
gr
ip
 
st
re
n
gt
h.
 
 
(17
4) 
40
0 
(no
 
TO
CP
 
de
te
ct
ed
)  
G
av
ag
e,
 
se
sa
m
e 
o
il 
R
at
 
3/
se
x
/g
ro
u
p 
 
20
,
 
40
 
o
r 
60
 
da
ys
 
 
H
yp
er
tr
o
ph
y 
an
d 
lip
id
o
sis
 
pr
es
en
t i
n
 
o
v
ar
ia
n
 
in
te
rs
tit
ia
l c
el
ls 
an
d 
ad
-
re
n
o
co
rt
ic
al
 
ce
lls
 
by
 
20
 
da
ys
.
 
Th
e 
lip
id
 
de
po
sit
io
n
 
w
as
 
pr
o
gr
es
siv
e 
w
ith
 
du
ra
tio
n
 
o
f e
x
po
su
re
.
 
Si
gn
ifi
ca
n
tly
 
de
cr
ea
se
d 
w
ei
gh
t o
f t
es
tis
 
af
te
r 
60
 
da
ys
 
ex
po
su
re
.
 
D
eg
en
er
at
io
n
 
o
f t
he
 
se
m
in
ife
ro
u
s 
tu
bu
le
s 
by
 
40
-
60
 
da
ys
 
an
d 
de
cr
ea
se
 
in
 
sp
er
m
 
de
n
sit
y 
in
 
th
e 
ep
id
id
ym
is.
 
 
(13
1) 
40
0 
(no
 
TO
CP
 
de
te
ct
ed
)  
G
av
ag
e,
 
se
sa
m
e 
o
il 
R
at
 
12
 
fe
m
al
es
 
 
40
 
da
ys
 
 
A
dr
en
al
 
gl
an
ds
 
an
d 
o
v
ar
ie
s 
he
av
ie
r 
th
an
 
co
n
tr
o
ls.
 
Ch
o
le
st
er
yl
 
lip
id
o
sis
 
co
m
po
se
d 
o
f c
ho
le
st
er
yl
 
es
te
r 
in
 
th
e 
ad
re
n
al
 
gl
an
ds
 
an
d 
o
v
ar
ie
s.
 
N
eu
tr
al
 
ch
o
le
st
er
yl
 
es
te
r 
hy
dr
o
la
se
 
ac
tiv
ity
 
in
hi
bi
te
d 
by
 
97
 
%
 
co
m
pa
re
d 
to
 
th
at
 
o
f c
o
n
tr
o
ls.
 
A
cy
l c
o
en
zy
m
e 
A
: 
ch
o
le
st
er
o
l a
cy
l t
ra
n
sf
er
as
e 
ac
tiv
ity
 
de
pr
es
se
d 
by
 
27
 
%
 
co
m
pa
re
d 
to
 
th
at
 
o
f c
o
n
tr
o
l a
dr
en
al
 
gl
an
ds
,
 
re
su
lti
n
g 
in
 
el
ev
at
ed
 
in
tr
ac
el
lu
la
r 
ch
o
le
st
er
o
l l
ev
el
s 
in
 
ad
re
n
o
co
rt
ic
al
 
ce
lls
.
 
 
(13
0) 
40
0 
(no
 
TO
CP
 
de
te
ct
ed
)   
G
av
ag
e,
 
se
sa
m
e 
o
il 
R
at
 
20
 
pa
irs
 
U
p 
to
 
13
5 
da
ys
 
 
Fe
rt
ili
ty
 
in
de
x
 
an
d 
n
u
m
be
r 
o
f l
itt
er
s 
bo
rn
 
sig
n
ifi
ca
n
tly
 
de
cr
ea
se
d.
 
Si
gn
ifi
ca
n
tly
 
de
cr
ea
se
d 
te
st
ic
u
la
r 
an
d 
ep
id
id
ym
al
 
w
ei
gh
ts
.
 
In
cr
ea
se
d 
o
v
ar
ia
n
 
w
ei
gh
ts
.
 
Cr
o
ss
o
v
er
 
m
at
in
g 
w
ith
 
v
eh
ic
le
 
co
n
tr
o
ls 
re
su
lte
d 
in
 
10
0 %
 
in
fe
rt
ili
ty
 
in
 
tr
ea
te
d 
m
al
es
 
bu
t d
id
 
n
o
t a
ffe
ct
 
re
pr
o
du
ct
io
n
 
in
 
fe
m
al
es
.
 
D
ec
re
as
ed
 
bo
dy
 
w
ei
gh
t a
n
d 
in
cr
ea
se
d 
liv
er
 
an
d 
ad
re
n
al
 
w
ei
gh
ts
 
in
 
bo
th
 
se
x
es
.
 
(13
2) 
  
16
4  
Ta
bl
e 
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
ic
re
sy
l p
ho
sp
ha
te
 
(T
CP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
40
0 a
 
 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
 
10
/se
x
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t w
ei
gh
t r
ed
u
ct
io
n
 
in
 
m
al
es
 
an
d 
at
ro
ph
y 
o
f s
em
in
ife
ro
u
s 
tu
bu
le
s 
in
 
th
e 
te
st
is.
 
R
ed
u
ce
d 
hi
n
dl
im
b 
gr
ip
 
st
re
n
gt
h 
in
 
fe
m
al
es
.
 
Si
gn
i-
fic
an
tly
 
lo
w
er
 
ha
em
o
gl
o
bi
n
 
co
n
ce
n
tr
at
io
n
s 
in
 
bo
th
 
se
x
es
.
 
Sa
m
e 
ef
fe
ct
s 
al
so
 
se
en
 
at
 
80
0 
m
g/
kg
 
bw
 
(w
ith
 
sig
n
ifi
ca
n
t w
ei
gh
t i
n
cr
ea
se
 
in
 
fe
m
al
es
).  
(17
4) 
40
0 a
 
 
G
av
ag
e,
 
co
rn
 
o
il 
M
o
u
se
 
10
/se
x
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t w
ei
gh
t r
ed
u
ct
io
n
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f m
u
lti
fo
ca
l a
x
o
n
al
 
de
ge
n
er
at
io
n
 
o
f s
pi
n
al
 
co
rd
 
an
d 
sc
ia
tic
 
n
er
v
e.
 
In
cr
ea
se
d 
n
u
m
be
r 
o
f 
re
tic
u
lo
cy
te
s 
in
 
m
al
es
.
 
Sa
m
e 
ef
fe
ct
s 
al
so
 
se
en
 
at
 
80
0 
m
g/
kg
 
bw
.
 
 
(17
4) 
40
0 
 
<
 
9 %
 
TO
CP
 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
24
 
fe
m
al
es
 
14
 
da
ys
 
pr
io
r 
to
 
br
ee
di
n
g,
 
br
ee
di
n
g,
 
la
ct
a-
tio
n
 
+
 
w
ea
n
in
g 
u
n
til
 
da
y 
21
 
M
al
es
 
o
n
 
do
se
 
20
0 
m
g/
kg
 
bw
 
w
er
e 
br
ed
 
w
ith
 
fe
m
al
es
 
in
 
th
is 
gr
o
u
p.
 
 
Fe
rt
ili
ty
 
ra
te
 
se
v
er
el
y 
af
fe
ct
ed
.
 
Th
e 
pe
rc
en
t o
f s
pe
rm
 
po
sit
iv
e 
fe
m
al
es
 
lit
te
rin
g 
w
as
 
5 %
 
v
s.
 
95
 
%
 
in
 
co
n
tr
o
ls.
 
O
ve
ra
ll 
br
ee
di
n
g 
su
cc
es
s 
w
as
 
0 %
 
v
s.
 
75
 
%
.
 
M
ea
n
 
lit
te
r 
siz
e 
3.
0 
v
s.
 
11
.
3.
 
D
iff
u
se
 
v
ac
u
o
la
r 
cy
to
pl
as
m
ic
 
al
te
ra
tio
n
 
o
f o
v
ar
ia
n
 
in
te
rs
tit
ia
l c
el
ls.
 
(31
) 
43
0 a
 
 
O
ra
l, 
in
 
di
et
 
R
at
 
10
 
m
al
es
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t w
ei
gh
t r
ed
u
ct
io
n
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f b
as
o
ph
ili
c 
hy
pe
r-
tr
o
ph
y 
o
f p
itu
ita
ry
 
gl
an
d.
 
A
tr
o
ph
y 
o
f s
em
in
ife
ro
u
s 
tu
bu
le
s 
in
 
th
e 
te
st
is.
 
 
(17
4) 
43
0 a
 
 
O
ra
l, 
in
 
di
et
 
 
R
at
 
10
 
fe
m
al
es
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t w
ei
gh
t r
ed
u
ct
io
n
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f r
en
al
 
pa
pi
lla
ry
 
o
ed
em
a 
an
d 
n
ec
ro
sis
.
 
Sa
m
e 
ef
fe
ct
s 
al
so
 
se
en
 
at
 
77
0 
m
g/
kg
 
bw
.
 
 
(17
4) 
53
0 a
 
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
 
10
 
fe
m
al
es
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t w
ei
gh
t r
ed
u
ct
io
n
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f a
x
o
n
al
 
de
-
ge
n
er
at
io
n
 
o
f s
pi
n
al
 
co
rd
 
an
d 
sc
ia
tic
 
n
er
v
e 
an
d 
o
f o
v
ar
ia
n
 
in
te
rs
tit
ia
l 
ce
ll 
hy
pe
rt
ro
ph
y 
an
d 
in
fla
m
m
at
io
n
.
 
R
ed
u
ce
d 
fo
re
-
 
an
d 
hi
n
dl
im
b 
gr
ip
 
st
re
n
gt
h.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f h
yp
er
pl
as
ia
 
o
f g
al
lb
la
dd
er
 
m
u
co
sa
l 
ep
ith
el
iu
m
.
 
Sa
m
e 
ef
fe
ct
s 
al
so
 
se
en
 
at
 
1 0
50
 
m
g/
kg
 
bw
.
 
(17
4) 
75
0 a
 
 
O
ra
l, 
in
 
di
et
 
R
at
 
 
10
 
m
al
es
 
13
 
w
ee
ks
 
 
Si
gn
ifi
ca
n
t w
ei
gh
t r
ed
u
ct
io
n
,
 
in
cr
ea
se
 
o
f b
as
o
ph
ili
c 
hy
pe
rt
ro
ph
y 
o
f p
itu
i -
ta
ry
 
gl
an
d 
an
d 
in
cr
ea
se
 
o
f r
en
al
 
pa
pi
lla
ry
 
o
ed
em
a 
an
d 
n
ec
ro
sis
.
 
A
tr
o
ph
y 
o
f s
em
in
ife
ro
u
s 
tu
bu
le
s 
in
 
th
e 
te
st
is.
 
R
ed
u
ce
d 
hi
n
dl
im
b 
gr
ip
 
st
re
n
gt
h.
 
(17
4) 
90
0 a
 
 
O
ra
l, 
in
 
di
et
 
M
o
u
se
 
10
 
m
al
es
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
t w
ei
gh
t r
ed
u
ct
io
n
,
 
in
cr
ea
se
 
o
f a
x
o
n
al
 
de
ge
n
er
at
io
n
 
o
f s
pi
n
al
 
co
rd
 
an
d 
sc
ia
tic
 
n
er
v
e,
 
an
d 
re
ge
n
er
at
io
n
 
o
f r
en
al
 
tu
bu
le
s.
 
R
ed
u
ce
d 
fo
re
-
 
an
d 
hi
n
dl
im
b 
gr
ip
 
st
re
n
gt
h.
 
 
(17
4) 
  
16
5  
Ta
bl
e 
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
ic
re
sy
l p
ho
sp
ha
te
 
(T
CP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
 
 
1 
00
0 b
 
G
av
ag
e,
 
lu
br
ic
at
in
g 
o
il 
 
H
en
 
17
-
20
 
fe
m
al
es
 
13
 
w
ee
ks
 
Si
gn
ifi
ca
n
tly
 
in
hi
bi
te
d 
br
ai
n
 
N
TE
 
(32
-
34
 
%
) a
t t
he
 
en
d 
o
f e
x
po
su
re
.
 
W
al
ki
n
g 
ab
ili
ty
 
di
d 
n
o
t d
iff
er
 
co
m
pa
re
d 
to
 
co
n
tr
o
ls.
 
N
o 
sig
n
 
o
f O
PI
D
N
.  
(41
) 
10
 
00
0 
 
G
av
ag
e 
H
en
 
6 
fe
m
al
es
 
Tw
ic
e 
pe
r 
da
y,
 
3 
da
ys
 
H
en
s 
w
er
e 
sa
cr
ifi
ce
d 
o
n
 
da
y 
42
.
 
B
eh
av
io
u
ra
l n
eu
ro
to
x
ic
 
re
sp
o
n
se
 
 
in
 
6/
6.
 
H
ist
o
lo
gi
ca
l n
eu
ro
to
x
ic
 
re
sp
o
n
se
 
in
 
6/
6.
 
(10
6) 
M
u
lti
pl
e 
ex
po
su
re
s,
 
a
er
o
so
l, 
M
M
D
 2
 
µm
 
 
 
 
 
 
 
1.
8 
m
g/
m
3  
c  
In
ha
la
tio
n
 
 
H
en
 
 
4 
fe
m
al
es
 
14
1 
da
ys
 
d  
Si
gn
s 
o
f n
eu
ro
to
x
ic
ity
 
in
 
1/
4 
at
 
da
y 
10
1.
 
 
(20
1) 
 
 
4.
4 
m
g/
m
3  
c  
In
ha
la
tio
n
 
 
H
en
 
 
3 
fe
m
al
es
 
10
8 
da
ys
 
d  
N
o 
sig
n
s 
o
f n
eu
ro
to
x
ic
ity
 
at
 
th
is 
le
v
el
 
o
r 
at
 
2.
2 
an
d 
4.
3 
m
g/
m
3 .
 
(20
1) 
 
 
4.
4 
m
g/
m
3  
c  
In
ha
la
tio
n
 
M
o
n
ke
y 
6 
10
8 
da
ys
 
d  
N
o 
sig
n
s 
o
f n
eu
ro
to
x
ic
ity
 
at
 
th
is 
le
v
el
 
o
r 
at
 
4.
3 
m
g/
m
3 .
 
(20
1) 
 
 
23
 
m
g/
m
3  
c  
In
ha
la
tio
n
 
H
en
 
4 
fe
m
al
es
 
16
3 
da
ys
 
d  
Si
gn
s 
o
f n
eu
ro
to
x
ic
ity
 
in
 
1/
4.
 
(20
1) 
 
 
25
 
m
g/
m
3  
c  
In
ha
la
tio
n
 
H
en
 
6 
fe
m
al
es
 
6 
w
ee
ks
 
N
o 
sig
n
s 
o
f n
eu
ro
to
x
ic
ity
.
 
In
cr
ea
se
d 
bo
dy
 
w
ei
gh
t. 
(20
1) 
 
 
25
 
m
g/
m
3  
c  
In
ha
la
tio
n
 
D
og
 
ra
bb
it 
m
o
n
ke
y 
2 
 
3 
 
3 
6 
w
ee
ks
 
N
o 
sig
n
s 
o
f n
eu
ro
to
x
ic
ity
.
 
In
cr
ea
se
d 
bo
dy
 
w
ei
gh
t i
n
 
do
gs
 
an
d 
ra
bb
its
.
 
R
ed
u
ce
d 
bo
dy
 
w
ei
gh
t i
n
 
m
o
n
ke
ys
.
 
 
(20
1) 
 
 
50
 
m
g/
m
3  
c  
In
ha
la
tio
n
 
A
s 
ab
o
v
e  
A
s 
ab
o
v
e 
6 
w
ee
ks
 
N
o 
sig
n
s 
o
f n
eu
ro
to
x
ic
ity
.
 
R
ed
u
ce
d 
bo
dy
 
w
ei
gh
t i
n
 
al
l a
n
im
al
s.
 
(20
1) 
 
 
50
 
m
g/
m
3  
c  
In
ha
la
tio
n
 
H
en
 
6 
fe
m
al
es
 
6 
w
ee
ks
 
Si
gn
s 
o
f n
eu
ro
to
x
ic
ity
 
in
 
3/
6.
 
R
ed
u
ce
d 
bo
dy
 
w
ei
gh
t. 
(20
1) 
 
 
34
 
m
g/
m
3  
c  
In
ha
la
tio
n
 
H
en
 
3 
fe
m
al
es
 
15
6 
da
ys
 
d  
Si
gn
s 
o
f n
eu
ro
to
x
ic
ity
 
in
 
3/
3.
 
(20
1) 
 
 
34
 
m
g/
m
3  
c  
In
ha
la
tio
n
 
R
ab
bi
t  
3 
15
6 
da
ys
 
d  
N
o s
ig
n
s 
o
f n
eu
ro
to
x
ic
ity
 
(sa
m
e 
re
su
lt 
at
 
1.
8,
 
2.
2,
 
4.
3,
 
4.
4 
an
d 
23
 
m
g/
m
3 ).
(20
1) 
10
2-
10
3 
m
g/
m
3  
c  
In
ha
la
tio
n
 
R
ab
bi
t  
5 
41
 
o
r 
52
 
da
ys
 
d  
H
in
d 
le
g 
pa
ra
ly
sis
 
in
 
5/
5.
 
(20
1) 
10
2-
11
0 
m
g/
m
3  
c  
In
ha
la
tio
n
 
H
en
 
20
 
fe
m
al
es
 
36
-
99
 
da
ys
 
d  
Si
gn
s 
o
f n
eu
ro
to
x
ic
ity
 
in
 
19
/2
0 
o
n
 
da
ys
 
22
-
29
.
 
(20
1) 
 
11
0 
m
g/
m
3  
c  
In
ha
la
tio
n
 
R
at
 
50
 
36
 
da
ys
 
d  
N
o s
ig
n
s 
o
f n
eu
ro
to
x
ic
ity
 
at
 
th
is 
o
r 
lo
w
er
 
(1.
8,
 
23
,
 
34
,
 
10
2 
m
g/
m
3 ) l
ev
el
s.
 
(20
1) 
LD
50
: 
le
th
al
 
do
se
 
fo
r 
50
 
%
 
o
f t
he
 
ex
po
se
d 
an
im
al
s 
at
 
sin
gl
e 
ad
m
in
ist
ra
tio
n
,
 
M
M
D
: m
as
s 
m
ed
ia
n
 
di
am
et
er
,
 
N
TE
: 
n
eu
ro
to
x
ic
 
o
r 
n
eu
ro
pa
th
y 
ta
rg
et
 
es
te
ra
se
,
 
O
PI
D
N
: 
o
rg
an
o
ph
o
sp
ho
ru
s-
in
du
ce
d 
de
la
ye
d 
n
eu
ro
pa
th
y.
 
a 
 
Co
m
m
er
ci
al
 
TC
P 
co
n
sis
tin
g 
o
f 1
8 %
 
di
cr
es
yl
 
ph
o
sp
ha
te
 
an
d 
79
 
%
 
tr
ic
re
sy
l p
ho
sp
ha
te
 
es
te
rs
 
(in
cl
u
di
n
g 
21
 
%
 
TM
CP
,
 
4 %
 
TP
CP
 
an
d 
<
 
0.
1 %
 
TO
CP
). 
b  
80
 
%
 
TC
P 
w
ith
 
<
 
0.
5 %
 
TO
CP
 
o
r 
10
0 %
 
TC
P 
w
ith
 
<
 
1 %
 
TO
CP
.
 
c  
Tr
ia
ry
l p
ho
sp
ha
te
 
hy
dr
au
lic
 
o
il 
co
n
ta
in
in
g 
TC
Ps
 
(<
 
1.
5 
%
 
o
rt
ho
-
cr
es
yl
 
ph
o
sp
ha
te
s),
 
tr
ix
yl
en
yl
 
ph
o
sp
ha
te
s 
an
d 
o
th
er
 
tr
ia
lk
yl
ph
en
yl
 
ph
o
sp
ha
te
s.
 
d  
Co
n
tin
u
o
u
s 
ex
po
su
re
.
 
  
16
6  
Ta
bl
e 
II
.
 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
i-o
-,
 
tr
i-m
-
 
an
d 
tri
-
p-
cr
es
yl
 
ph
os
ph
at
e 
(T
O
CP
,
 
TM
CP
 
an
d 
TP
CP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
TO
CP
 
Si
n
gl
e 
do
se
 
 
 
 
 
10
 
In
tr
ap
er
ito
n
ea
l, 
 
co
rn
 
o
il 
R
at
 
5 
m
al
es
 
-
 
In
hi
bi
tio
n
 
o
f f
at
ty
 
ac
id
 
et
hy
l e
st
er
as
e 
sy
n
th
es
isi
n
g 
ac
tiv
ity
 
in
 
pl
as
m
a 
(do
se
-
de
pe
n
de
n
t) 
an
d 
liv
er
 
an
d 
o
f p
-
n
itr
o
ph
en
yl
 
ac
et
at
e 
hy
dr
o
ly
sin
g 
ac
tiv
ity
 
in
 
liv
er
.
 
A
lso
 
se
en
 
at
 
25
,
 
50
 
an
d 
10
0 
m
g/
kg
 
bw
.
 
 
(15
3) 
25
 
G
av
ag
e 
H
en
 
Fe
m
al
es
 
-
 
N
eu
ro
to
x
ic
 
re
sp
o
n
se
.
 
 
(10
9) 
25
 
G
av
ag
e 
Ch
ic
ke
n
 
4 
m
al
es
 
-
 
Pa
ra
ly
sis
 
in
 
1/
4.
 
Th
e 
sa
m
e 
ef
fe
ct
 
se
en
 
at
 
50
-
40
0 
m
g/
kg
 
bw
 
in
 
a 
 
do
se
-
re
la
te
d 
m
an
n
er
.
 
(84
) 
50
 
O
ra
l, 
co
rn
 
o
il 
H
en
 
 
8-
9 
fe
m
al
es
 
-
 
A
ta
x
ia
; s
co
re
 
2 
(sc
al
e 
0-
8) 
o
n
 
da
ys
 
9-
21
 
po
st
-
do
sin
g.
 
 
N
er
v
o
u
s 
sy
st
em
 
le
sio
n
s;
 
sc
o
re
 
<
 
1 
(sc
al
e 
0-
4) 
o
n
 
da
y 
21
.
 
70
 
%
 
in
hi
bi
tio
n
 
o
f b
ra
in
 
N
TE
 
48
 
ho
u
rs
 
po
st
-
do
sin
g.
 
 
(54
) 
90
 
O
ra
l, 
co
rn
 
o
il 
H
en
 
 
8-
9 
fe
m
al
es
 
-
 
A
ta
x
ia
; s
co
re
 
3 
(sc
al
e 
0-
8) 
o
n
 
da
ys
 
9-
21
 
po
st
-
do
sin
g.
 
 
N
er
v
o
u
s 
sy
st
em
 
le
sio
n
s;
 
sc
o
re
 
1 
(sc
al
e 
0-
4) 
o
n
 
da
y 
21
.
 
85
 
%
 
in
hi
bi
tio
n
 
o
f b
ra
in
 
N
TE
 
48
 
ho
u
rs
 
po
st
-
do
sin
g.
 
 
(54
) 
14
5 
G
av
ag
e 
R
at
 
5 
m
al
es
 
-
 
Tr
an
sie
n
t w
ei
gh
t l
o
ss
 
du
rin
g 
th
e 
fir
st
 
72
 
ho
u
rs
 
 
N
o 
ef
fe
ct
 
o
n
 
CN
S 
o
r 
PN
S 
14
 
da
ys
 
po
st
-
ex
po
su
re
.
 
 
N
on
-
sig
n
ifi
ca
n
t N
TE
 
in
hi
bi
tio
n
 
in
 
sp
in
al
 
co
rd
 
o
r 
br
ai
n
 
at
 
20
 
o
r 
 
44
 
ho
u
rs
; i
n
 
sp
in
al
 
co
rd
 
24
 
%
 
an
d 
in
 
br
ai
n
 
18
 
%
 
at
 
44
 
ho
u
rs
.
 
(18
1) 
25
0 
G
av
ag
e 
H
en
 
Fe
m
al
es
 
-
 
N
eu
ro
to
x
ic
 
re
sp
o
n
se
.
 
96
 
%
 
in
hi
bi
tio
n
 
o
f b
ra
in
 
N
TE
 
ac
tiv
ity
.
 
(10
9) 
25
0 
G
av
ag
e,
 
co
rn
 
o
il 
Fe
rr
et
 
(E
) 
5 
m
al
es
 
-
 
N
o 
de
fic
its
 
re
ga
rd
in
g 
O
PI
D
N
 w
ith
in
 
54
 
da
ys
.
 
23
 
%
 
in
hi
bi
tio
n
 
o
f b
ra
in
 
N
TE
 
48
 
ho
u
rs
 
po
st
-
ex
po
su
re
.
 
 
(21
4) 
25
0 
D
er
m
al
,
 
et
ha
n
o
l, 
 
6 ×
 
6 
cm
 
sh
av
ed
 
ar
ea
 
Fe
rr
et
 
(E
) 
5 
m
al
es
 
-
 
2/
5 
ha
d 
sli
gh
t l
eg
 
w
ea
kn
es
s 
w
ith
 
sli
gh
t c
ha
n
ge
 
in
 
n
o
rm
al
 
w
al
ki
n
g 
be
ha
v
io
u
r 
at
 
da
ys
 
51
 
an
d 
53
.
 
18
 
%
 
in
hi
bi
tio
n
 
o
f b
ra
in
 
N
TE
 
48
 
ho
u
rs
 
po
st
-
ex
po
su
re
.
 
(21
4) 
29
0 
G
av
ag
e 
R
at
 
5 
m
al
es
 
-
 
Tr
an
sie
n
t w
ei
gh
t l
o
ss
 
du
rin
g 
th
e 
fir
st
 
72
 
ho
u
rs
.
 
 
7.
5 %
 
ha
d 
sp
in
al
 
co
rd
 
da
m
ag
e 
14
 
da
ys
 
po
st
-
ex
po
su
re
.
 
 
N
on
-
sig
n
ifi
ca
n
t N
TE
 
in
hi
bi
tio
n
 
in
 
sp
in
al
 
co
rd
 
o
r 
br
ai
n
 
at
 
20
 
o
r 
 
44
 
ho
u
rs
; 4
0 %
 
in
 
sp
in
al
 
co
rd
 
an
d 
36
 
%
 
in
 
br
ai
n
 
at
 
44
 
ho
u
rs
.
 
 
(18
1) 
  
16
7  
Ta
bl
e 
II
.
 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
i-o
-,
 
tr
i-m
-
 
an
d 
tri
-
p-
cr
es
yl
 
ph
os
ph
at
e 
(T
O
CP
,
 
TM
CP
 
an
d 
TP
CP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
36
0 
O
ra
l, 
co
rn
 
o
il 
Ch
ic
ke
n
 
6/
se
x
 
 
-
 
D
el
ay
ed
 
n
eu
ro
pa
th
y 
th
at
 
ca
u
se
d 
at
ax
ia
 
in
 
al
l c
hi
ck
en
s 
(so
ci
al
ise
d 
 
an
d 
n
o
n
-
so
ci
al
ise
d,
 
st
re
ss
ed
 
an
d 
u
n
st
re
ss
ed
) w
ith
in
 
32
 
da
ys
.
 
A
ta
x
ia
 
sig
n
ifi
ca
n
tly
 
m
o
re
 
pr
o
n
o
u
n
ce
d 
ea
rli
er
 
in
 
m
al
es
.
 
N
o 
se
x
 
di
ffe
re
n
ce
 
 
18
 
da
ys
 
af
te
r 
do
sin
g.
 
 
(17
5) 
37
5 
G
av
ag
e,
 
co
rn
 
o
il 
H
en
 
6 
fe
m
al
es
 
-
 
D
ec
re
as
e 
o
f n
eu
ro
fil
am
en
t s
u
bu
n
its
 
in
 
sc
ia
tic
 
n
er
v
e 
af
te
r 
21
 
da
ys
.
 
 
A
lso
 
se
en
 
at
 
75
0 
m
g/
kg
 
bw
.
 
(26
5) 
50
0 
O
ra
l, 
co
rn
 
o
il 
 
H
en
 
8-
9 
fe
m
al
es
 
-
 
A
ta
x
ia
; s
co
re
 
8 
(sc
al
e 
0-
8) 
o
n
 
da
ys
 
9-
21
 
po
st
-
do
sin
g.
 
 
N
er
v
o
u
s 
sy
st
em
 
le
sio
n
s;
 
sc
o
re
 
4 
(sc
al
e 
0-
4) 
o
n
 
da
y 
21
.
 
 
90
 
%
 
in
hi
bi
tio
n
 
o
f b
ra
in
 
N
TE
 
48
 
ho
u
rs
 
po
st
-
do
sin
g.
 
(54
) 
50
0 
G
av
ag
e,
 
co
rn
 
o
il 
Fe
rr
et
 
(E
) 
5 
m
al
es
 
-
 
N
o 
de
fic
its
 
re
ga
rd
in
g 
O
PI
D
N
 w
ith
in
 
54
 
da
ys
.
 
37
 
%
 
in
hi
bi
tio
n
 
o
f b
ra
in
 
N
TE
 
48
 
ho
u
rs
 
po
st
-
ex
po
su
re
.
 
 
(21
4) 
50
0 
D
er
m
al
,
 
et
ha
n
o
l, 
 
6 ×
 
6 
cm
 
sh
av
ed
 
ar
ea
 
Fe
rr
et
 
(E
) 
5 
m
al
es
 
-
 
4/
5 
ha
d 
sli
gh
t l
eg
 
w
ea
kn
es
s 
w
ith
 
sli
gh
t c
ha
n
ge
 
in
 
n
o
rm
al
 
w
al
ki
n
g 
be
ha
v
io
u
r 
at
 
da
ys
 
23
-
27
.
 
3/
5 
ha
d 
le
g 
w
ea
kn
es
s 
w
ith
 
so
m
e 
re
lu
ct
an
ce
 
to
 
w
al
k 
at
 
da
ys
 
42
-
49
.
 
25
 
%
 
in
hi
bi
tio
n
 
o
f b
ra
in
 
N
TE
 
48
 
ho
u
rs
 
po
st
-
ex
po
su
re
.
 
(21
4) 
58
0 
G
av
ag
e 
R
at
 
5 
m
al
es
 
-
 
Tr
an
sie
n
t w
ei
gh
t l
o
ss
 
du
rin
g 
th
e 
fir
st
 
72
 
ho
u
rs
.
 
 
15
 
%
 
ha
d 
sp
in
al
 
co
rd
 
da
m
ag
e 
14
 
da
ys
 
po
st
-
ex
po
su
re
.
 
 
Si
gn
ifi
ca
n
t N
TE
 
in
hi
bi
tio
n
 
in
 
sp
in
al
 
co
rd
 
(65
 
%
) a
n
d 
br
ai
n
 
(57
 
%
)  
at
 
44
 
ho
u
rs
.
 
(18
1) 
60
0 
G
av
ag
e,
 
co
rn
 
o
il 
H
en
 
 
Fe
m
al
es
 
-
 
Co
m
pl
et
e 
m
o
to
r 
pa
ra
ly
sis
 
by
 
da
y 
15
 
(no
 
sy
m
pt
o
m
s 
be
fo
re
 
10
 
da
ys
 
af
te
r 
tr
ea
tm
en
t).
 
Se
v
er
al
 
n
ic
o
tin
ic
 
ac
id
 
de
riv
at
es
 
sig
n
ifi
ca
n
tly
 
al
le
v
ia
te
d 
th
e 
at
ax
ia
.
 
(34
) 
75
0 
G
av
ag
e 
H
en
 
5 
fe
m
al
es
 
-
 
D
ow
n
re
gu
la
tio
n
 
o
f n
eu
ro
fil
am
en
t m
R
N
A
 
in
 
th
e 
ce
re
br
al
 
co
rt
ex
 
af
te
r 
 
21
 
da
ys
.
 
 
(26
4) 
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Ta
bl
e 
II
.
 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
i-o
-,
 
tr
i-m
-
 
an
d 
tri
-
p-
cr
es
yl
 
ph
os
ph
at
e 
(T
O
CP
,
 
TM
CP
 
an
d 
TP
CP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
75
0 
O
ra
l, 
ge
la
tin
 
ca
ps
u
le
 
H
en
 
30
 
fe
m
al
es
 
-
 
A
x
o
n
al
 
le
sio
n
s 
ch
ar
ac
te
ris
tic
 
o
f W
al
le
ria
n
-
ty
pe
 
de
ge
n
er
at
io
n
 
in
 
pe
rip
he
ra
l n
er
v
es
 
an
d 
al
so
 
m
u
lti
fo
ca
l a
x
o
n
al
 
sw
el
lin
g,
 
fra
gm
en
ta
tio
n
 
an
d 
lo
ss
 
o
f m
ye
lin
 
st
ai
n
in
g 
in
 
al
l h
en
s 
21
 
da
ys
 
af
te
r 
tr
ea
tm
en
t. 
In
 
th
e 
sp
in
al
 
co
rd
,
 
m
u
lti
fo
ca
l a
x
o
n
al
 
sw
el
lin
g 
in
 
th
e 
la
te
ra
l a
n
d 
v
en
tr
al
 
co
lu
m
n
s.
 
A
x
o
n
al
 
sw
el
lin
gs
 
in
 
th
e 
la
te
ra
l w
hi
te
 
tr
ac
ts
 
o
f t
he
 
m
ed
u
lla
 
o
bl
o
n
ga
ta
 
in
 
8 
he
n
s.
 
B
ra
in
 
N
TE
 
w
as
 
8 %
,
 
br
ai
n
 
ac
et
yl
ch
o
lin
es
te
ra
se
 
88
 
%
 
an
d 
pl
as
m
a 
ch
o
lin
es
te
ra
se
 
28
 
%
 
o
f n
o
rm
al
 
v
al
u
e 
af
te
r 
24
 
ho
u
rs
.
 
(32
) 
80
0 
G
av
ag
e 
Ch
ic
ke
n
,
 
B
ab
co
ck
 
8 
-
 
D
ec
re
as
e 
o
f b
ra
in
 
N
TE
 
by
 
80
 
%
 
an
d 
pl
as
m
a 
ch
o
lin
es
te
ra
se
 
by
 
40
 
%
 
(re
co
v
er
y 
o
f l
ev
el
s 
af
te
r 
28
 
da
ys
). N
o c
ha
n
ge
 
o
f b
ra
in
 
ch
o
lin
es
te
ra
se
.
 
N
o 
cl
in
ic
al
 
sig
n
s 
o
f O
PI
D
N
 a
fte
r 
28
 
da
ys
.
 
(43
) 
83
5 
G
av
ag
e 
R
at
 
5 
m
al
es
 
-
 
Tr
an
sie
n
t w
ei
gh
t l
o
ss
 
du
rin
g 
th
e 
fir
st
 
72
 
ho
u
rs
.
 
 
90
 
%
 
ha
d 
sp
in
al
 
co
rd
 
da
m
ag
e 
14
 
da
ys
 
po
st
-
ex
po
su
re
.
 
 
Si
gn
ifi
ca
n
t N
TE
 
in
hi
bi
tio
n
 
in
 
sp
in
al
 
co
rd
 
(72
 
%
) a
n
d 
br
ai
n
 
(66
 
%
)  
at
 
44
 
ho
u
rs
.
 
(18
1) 
1 
00
0 
G
av
ag
e,
 
co
rn
 
o
il 
Fe
rr
et
 
(E
) 
5 
m
al
es
 
-
 
3/
5 
ha
d 
sli
gh
t l
eg
 
w
ea
kn
es
s 
w
ith
 
sli
gh
t c
ha
n
ge
 
in
 
n
o
rm
al
 
w
al
ki
n
g 
be
ha
v
io
u
r 
at
 
da
ys
 
21
-
27
.
 
2/
5 
ha
d 
le
g 
w
ea
kn
es
s 
w
ith
 
so
m
e 
re
lu
ct
an
ce
 
to
 
w
al
k 
at
 
da
y 
30
.
 
26
 
%
 
in
hi
bi
tio
n
 
o
f b
ra
in
 
N
TE
 
48
 
ho
u
rs
 
po
st
-
ex
po
su
re
.
 
(21
4) 
1 
00
0 
D
er
m
al
,
 
et
ha
n
o
l, 
 
6 ×
 
6 
cm
 
sh
av
ed
 
ar
ea
 
Fe
rr
et
 
(E
) 
5 
m
al
es
 
-
 
5/
5 
ha
d 
sli
gh
t l
eg
 
w
ea
kn
es
s 
w
ith
 
sli
gh
t c
ha
n
ge
 
in
 
n
o
rm
al
 
w
al
ki
n
g 
be
ha
v
io
u
r 
at
 
da
ys
 
11
-
21
.
 
4/
5 
ha
d 
le
g 
w
ea
kn
es
s 
w
ith
 
so
m
e 
re
lu
ct
an
ce
 
to
 
w
al
k 
at
 
da
ys
 
13
-
27
.
 
3/
5 
ha
d 
m
ild
 
at
ax
ia
 
w
ith
 
u
n
st
ea
di
n
es
s 
in
 
ga
it 
an
d 
m
o
v
em
en
t a
n
d 
 
m
in
o
r 
lo
ss
 
o
f c
o
o
rd
in
at
io
n
 
at
 
da
ys
 
16
-
25
.
 
5/
5 
ha
d 
se
v
er
e 
at
ax
ia
 
w
ith
 
u
n
st
ea
di
n
es
s 
an
d 
lo
ss
 
o
f c
o
o
rd
in
at
io
n
 
 
at
 
da
ys
 
18
-
39
.
 
3/
5 
ha
d 
sli
gh
t p
ar
es
is 
w
ith
 
in
ab
ili
ty
 
to
 
st
an
d 
at
 
da
ys
 
39
-
49
.
 
D
eg
en
er
at
in
g 
ax
o
n
s 
in
 
th
e 
sp
in
al
 
co
rd
.
 
46
 
%
 
in
hi
bi
tio
n
 
o
f b
ra
in
 
N
TE
 
48
 
ho
u
rs
 
po
st
-
ex
po
su
re
.
 
(21
4) 
  
16
9  
Ta
bl
e 
II
.
 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
i-o
-,
 
tr
i-m
-
 
an
d 
tri
-
p-
cr
es
yl
 
ph
os
ph
at
e 
(T
O
CP
,
 
TM
CP
 
an
d 
TP
CP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
1 0
00
 
G
av
ag
e 
Ch
ic
ke
n
 
5 
m
al
es
 
-
 
D
ec
re
as
e 
o
f p
la
sm
a 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
 
by
 
67
 
%
 
an
d 
br
ai
n
 
an
d 
sp
in
al
 
co
rd
 
ac
et
yl
ch
o
lin
es
te
ra
se
 
ac
tiv
iti
es
 
by
 
14
 
an
d 
32
 
%
,
 
re
sp
ec
tiv
el
y.
 
 
(84
) 
1 
16
0 
G
av
ag
e 
R
at
 
13
 
m
al
es
 
-
 
Tr
an
sie
n
t w
ei
gh
t l
o
ss
 
du
rin
g 
th
e 
fir
st
 
72
 
ho
u
rs
.
 
 
10
0 
%
 
ha
d 
sp
in
al
 
co
rd
 
da
m
ag
e 
14
 
da
ys
 
po
st
-
ex
po
su
re
.
 
 
Si
gn
ifi
ca
n
t N
TE
 
in
hi
bi
tio
n
 
in
 
sp
in
al
 
co
rd
 
an
d 
br
ai
n
 
at
 
20
 
an
d 
 
44
 
ho
u
rs
; i
n
 
sp
in
al
 
co
rd
 
75
 
%
 
an
d 
in
 
br
ai
n
 
85
 
%
 
at
 
44
 
ho
u
rs
.
 
(18
1) 
1 
60
0 
G
av
ag
e 
Ch
ic
ke
n
,
 
H
y-
lin
e 
w
36
 
 
8 
-
 
D
ec
re
as
e 
o
f b
ra
in
 
N
TE
 
by
 
72
 
%
 
an
d 
pl
as
m
a 
ch
o
lin
es
te
ra
se
 
by
 
58
 
%
 
af
te
r 
24
 
ho
u
rs
 
(re
co
v
er
y 
o
f l
ev
el
s 
af
te
r 
28
 
da
ys
). N
o 
ch
an
ge
 
o
f b
ra
in
 
ch
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). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
TP
CP
 
Si
n
gl
e 
do
se
 
 
 
 
 
1 2
00
 
G
av
ag
e 
H
en
 
Fe
m
al
es
 
-
 
N
o 
n
eu
ro
to
x
ic
 
re
sp
o
n
se
.
 
N
o 
in
hi
bi
tio
n
 
o
f b
ra
in
 
N
TE
 
ac
tiv
ity
.
 
(10
9) 
2 5
00
 
G
av
ag
e 
H
en
 
Fe
m
al
es
 
-
 
N
o 
n
eu
ro
to
x
ic
 
re
sp
o
n
se
.
 
(10
9) 
5 0
00
 
G
av
ag
e 
Ch
ic
ke
n
 
2 
m
al
es
 
-
 
N
o 
n
eu
ro
to
x
ic
 
re
sp
o
n
se
.
 
(84
) 
TP
CP
 
M
u
lti
pl
e 
do
se
s 
 
 
 
 
10
0 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
10
 
m
al
es
 
9 
w
ee
ks
 
Sl
ig
ht
 
de
cr
ea
se
 
(25
 
%
) o
f t
es
to
st
er
o
n
e 
le
v
el
s 
bu
t n
o
 
ef
fe
ct
 
o
n
 
sp
er
m
 
qu
al
ity
.
 
 
(20
5) 
26
0 
G
av
ag
e 
H
en
 
Fe
m
al
es
 
18
 
da
ys
 
N
o 
n
eu
ro
to
x
ic
 
re
sp
o
n
se
.
 
(10
9) 
50
0 
G
av
ag
e 
H
en
 
Fe
m
al
es
 
15
 
da
ys
 
N
o 
n
eu
ro
to
x
ic
 
re
sp
o
n
se
.
 
(10
9) 
50
0 
G
av
ag
e 
Ch
ic
ke
n
 
2 
m
al
es
 
50
 
da
ys
 
N
o 
n
eu
ro
to
x
ic
 
re
sp
o
n
se
.
 
(94
) 
1 0
00
 
G
av
ag
e 
Ch
ic
ke
n
 
2 
m
al
es
 
5 
da
ys
,
 
ev
er
y 
o
th
er
 
da
y 
N
o 
n
eu
ro
to
x
ic
 
re
sp
o
n
se
.
 
(84
) 
CN
S:
 
ce
n
tr
al
 
n
er
v
o
u
s 
sy
st
em
,
 
E:
 
Eu
ro
pe
an
,
 
LD
50
: 
le
th
al
 
do
se
 
fo
r 
50
 
%
 
o
f t
he
 
ex
po
se
d 
an
im
al
s 
at
 
sin
gl
e 
ad
m
in
ist
ra
tio
n
,
 
N
TE
: 
n
eu
ro
to
x
ic
 
o
r 
n
eu
ro
pa
th
y 
ta
rg
et
 
es
te
ra
se
,
 
O
PI
D
N
: o
rg
an
o
ph
o
sp
ho
ru
s-
in
du
ce
d 
de
la
ye
d 
n
eu
ro
pa
th
y,
 
PN
S:
 
pe
rip
he
ra
l n
er
v
o
u
s 
sy
st
em
.
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4  
Ta
bl
e 
II
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
is(
2-
bu
to
x
ye
th
yl
) p
ho
sp
ha
te
 
(T
B
EP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
Si
n
gl
e 
do
se
 
 
 
 
 
 
1 
00
0 
G
av
ag
e 
R
at
 
10
 
m
al
es
 
-
 
N
o 
sig
n
s 
o
f t
o
x
ic
ity
.
 
(12
7) 
1 
50
0 
G
av
ag
e 
R
at
 
10
 
fe
m
al
es
 
-
 
N
o 
sig
n
s 
o
f t
o
x
ic
ity
.
 
Sa
m
e 
re
su
lt 
at
 
1 
00
0 
m
g/
kg
 
bw
.
 
(12
7) 
1 
75
0 
G
av
ag
e 
R
at
 
3 
fe
m
al
es
 
-
 
Sl
ig
ht
 
tr
em
o
rs
 
an
d 
pi
lo
er
ec
tio
n
 
th
e 
fir
st
 
3 
da
ys
.
 
Si
gn
ifi
ca
n
tly
 
de
cr
ea
se
d 
n
er
v
e 
co
n
du
ct
io
n
 
v
el
o
ci
ty
.
 
 
(12
7) 
2 
00
0 
G
av
ag
e 
R
at
 
2 
fe
m
al
es
 
-
 
Sl
ig
ht
 
tr
em
o
rs
 
an
d 
pi
lo
er
ec
tio
n
 
th
e 
fir
st
 
3 
da
ys
.
 
Si
gn
ifi
ca
n
tly
 
de
-
cr
ea
se
d 
n
er
v
e 
co
n
du
ct
io
n
 
v
el
o
ci
ty
.
 
D
eg
en
er
at
iv
e 
ch
an
ge
s 
in
 
bo
th
 
m
ye
lin
at
ed
 
an
d 
u
n
m
ye
lin
at
ed
 
fib
re
s.
 
 
(12
7) 
3 
20
0 
G
av
ag
e 
R
at
 
1 
fe
m
al
e 
-
 
A
bn
o
rm
al
 
ga
it,
 
pi
lo
er
ec
tio
n
,
 
tr
em
o
rs
,
 
di
ar
rh
o
ea
 
an
d 
in
cr
ea
se
d 
u
rin
at
io
n
 
th
e 
fir
st
 
w
ee
k.
 
Si
gn
ifi
ca
n
tly
 
de
cr
ea
se
d 
n
er
v
e 
co
n
du
ct
io
n
 
v
el
o
ci
ty
.
 
A
dv
an
ce
d 
n
er
v
e 
fib
re
 
de
ge
n
er
at
io
n
.
 
(12
7) 
3 
20
0 
G
av
ag
e 
R
at
 
4 
m
al
es
 
-
 
Si
gn
ifi
ca
n
tly
 
de
cr
ea
se
d 
n
er
v
e 
co
n
du
ct
io
n
 
v
el
o
ci
ty
.
 
R
et
ra
ct
io
n
 
o
f t
he
 
Sc
hw
an
n
 
ce
ll 
pr
o
ce
ss
es
.
 
(12
7) 
4 
70
0 
O
ra
l 
R
at
 
 
-
 
LD
50
.
 
 
 
(10
3) 
a  
5 
00
0 
O
ra
l, 
ge
la
tin
 
ca
ps
u
le
 
H
en
 
5 
fe
m
al
es
 
-
 
Si
gn
ifi
ca
n
t d
ec
re
as
e 
o
f b
ra
in
 
ac
et
yl
ch
o
lin
es
te
ra
se
 
(55
 
%
 
o
f c
o
n
tr
o
ls)
 
an
d 
pl
as
m
a 
ch
o
lin
es
te
ra
se
 
(13
 
%
 
o
f c
o
n
tr
o
ls)
 
ac
tiv
iti
es
.
 
N
o 
ch
an
ge
 
o
f 
br
ai
n
 
N
TE
 
ac
tiv
ity
.
 
LD
50
 
>
 
5 
00
0 
m
g/
kg
 
bw
.
 
(32
,
 
33
) 
5 
00
0 
D
er
m
al
 
R
ab
bi
t 
 
-
 
LD
50
 
>
 
5 
00
0 
m
g/
kg
 
bw
.
 
 
 
 
(10
3) 
b  
6 
80
0 
G
av
ag
e 
R
at
 
4 
m
al
es
 
-
 
Sl
ig
ht
 
tr
em
o
rs
 
an
d 
pi
lo
er
ec
tio
n
 
th
e 
fir
st
 
3 
da
ys
.
 
Si
gn
ifi
ca
n
tly
 
de
-
cr
ea
se
d 
n
er
v
e 
co
n
du
ct
io
n
 
v
el
o
ci
ty
.
 
D
eg
en
er
at
iv
e 
ch
an
ge
s 
in
 
bo
th
 
m
ye
lin
at
ed
 
an
d 
u
n
m
ye
lin
at
ed
 
fib
re
s.
 
 
(12
7) 
8 
00
0 
G
av
ag
e 
R
at
 
4 
m
al
es
 
-
 
A
bn
o
rm
al
 
ga
it,
 
pi
lo
er
ec
tio
n
,
 
tr
em
o
rs
,
 
di
ar
rh
o
ea
,
 
an
d 
in
cr
ea
se
d 
u
rin
at
io
n
 
th
e 
fir
st
 
w
ee
k.
 
Si
gn
ifi
ca
n
tly
 
de
cr
ea
se
d 
n
er
v
e 
co
n
du
ct
io
n
 
v
el
o
ci
ty
.
 
A
dv
an
ce
d 
n
er
v
e 
fib
re
 
de
ge
n
er
at
io
n
.
 
Ef
fe
ct
s 
al
so
 
se
en
 
at
 
9 
00
0 
m
g/
kg
 
bw
.
 
(12
7) 
10
 
00
0 
D
er
m
al
 
R
ab
bi
t  
 
-
 
LD
50
 
>
 
10
 
00
0 
m
g/
kg
 
bw
.
 
 
 
(10
3) 
c  
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Ta
bl
e 
II
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
is(
2-
bu
to
x
ye
th
yl
) p
ho
sp
ha
te
 
(T
B
EP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
Si
n
gl
e 
ex
po
su
re
,
 
a
er
o
so
l 
 
 
 
 
 
3 
30
0 
m
g/
m
3  
In
ha
la
tio
n
 
R
at
 
 
5/
se
x
 
4 
ho
u
rs
 
 
N
o 
an
im
al
 
di
ed
 
bu
t a
ll 
ex
hi
bi
te
d 
de
pr
es
se
d 
an
d 
irr
eg
u
la
r 
re
sp
ira
tio
n
,
 
in
cr
ea
se
d 
sa
liv
at
io
n
,
 
sn
ee
zi
n
g,
 
u
n
st
ea
di
n
es
s 
an
d 
tr
em
o
r.
 
Th
es
e 
sy
m
pt
o
m
s 
cl
ea
re
d 
in
 
m
o
st
 
an
im
al
s 
9 
da
ys
 
la
te
r.
 
B
o
dy
 
w
ei
gh
ts
 
di
d 
 
n
o
t c
ha
n
ge
 
an
d 
gr
o
ss
 
n
ec
ro
ps
y 
re
v
ea
le
d 
n
o
 
ab
n
o
rm
al
iti
es
.
 
Sa
m
e 
o
bs
er
v
at
io
n
s 
at
 
3 
40
0 
an
d 
6 
40
0 
m
g/
m
3 ,
 
i.e
.
 
LC
50
 
>
 
6 
40
0 
m
g/
m
3 .
 
 
 
(10
3) 
d  
4 
43
0 
m
g/
m
3  
In
ha
la
tio
n
 
R
at
 
 
4 
ho
u
rs
 
LC
50
 
>
 
4 
43
0 
m
g/
m
3 .
 
 
 
(10
3) 
e  
M
u
lti
pl
e 
do
se
s 
 
 
 
 
 
 
 
10
 
D
er
m
al
 
R
ab
bi
t  
6/
se
x
 
3 
w
ee
ks
 
 
Th
e 
te
st
 
sit
es
 
w
er
e 
o
cc
lu
de
d 
fo
r 
6 
ho
u
rs
 
af
te
r 
ea
ch
 
ex
po
su
re
.
 
Lo
ca
l 
irr
ita
tio
n
,
 
o
ed
em
a,
 
at
o
n
ia
 
an
d 
de
sq
u
am
at
io
n
.
 
A
lso
 
se
en
 
at
 
10
0 
an
d 
1 0
00
 
m
g/
kg
 
bw
 
(do
se
-
re
la
te
d).
 
N
o 
ad
v
er
se
 
cl
in
ic
al
 
sig
n
s 
o
f s
ys
te
m
ic
 
ph
ar
m
ac
o
lo
gi
ca
l o
r 
to
x
ic
o
lo
gi
ca
l e
ffe
ct
s.
 
 
 
 
(10
3) 
f  
 
 
15
 
O
ra
l, 
in
 
di
et
 
R
at
 
20
/se
x
 
18
 
w
ee
ks
 
N
o 
ef
fe
ct
 
o
n
 
ha
em
at
o
lo
gi
ca
l o
r 
cl
in
ic
al
 
ch
em
ist
ry
 
pa
ra
m
et
er
s.
 
N
o
 
ef
fe
ct
s 
o
n
 
liv
er
.
 
 
 
(10
3) 
g  
 
 
20
 
(m
al
es
) 
 
 
22
 
(fe
m
al
es
) 
O
ra
l, 
in
 
di
et
 
R
at
 
7 
m
al
es
,
 
 
8 
fe
m
al
es
 
14
 
w
ee
ks
 
N
o 
ef
fe
ct
 
o
n
 
th
e 
liv
er
,
 
th
e 
in
di
ca
te
d 
cr
iti
ca
l o
rg
an
.
 
(18
9,
 
23
3) 
10
0 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
10
/se
x
 
2 
w
ee
ks
 
N
o 
bi
o
ch
em
ic
al
,
 
ha
em
at
o
lo
gi
ca
l o
r 
hi
st
o
pa
th
o
lo
gi
ca
l c
ha
n
ge
s.
 
Sa
m
e 
re
su
lt 
at
 
1 
an
d 
10
 
m
g/
kg
 
bw
.
 
(11
8) 
15
0 
O
ra
l, 
in
 
di
et
 
R
at
 
20
/se
x
 
18
 
w
ee
ks
 
In
cr
ea
se
d 
se
ru
m
 
γ-
gl
u
ta
m
yl
-
tr
an
sp
ep
tid
as
e 
an
d 
de
cr
ea
se
d 
pl
as
m
a 
ch
o
lin
es
te
ra
se
 
ac
tiv
iti
es
.
 
M
ild
 
pe
rip
o
rt
al
 
he
pa
to
ce
llu
la
r 
hy
pe
rt
ro
ph
y 
an
d 
pe
rip
o
rt
al
 
v
ac
u
o
lis
at
io
n
 
in
 
m
al
es
.
 
N
o 
cl
in
ic
al
 
sig
n
s 
o
f n
eu
ro
-
to
x
ic
ity
,
 
n
o
r 
at
 
15
 
m
g/
kg
 
bw
.
 
 
 
(10
3) 
g  
20
0 
O
ra
l, 
in
 
di
et
 
R
at
 
B
o
th
 
se
x
es
 
4 
w
ee
ks
 
N
o 
sig
n
s 
o
f t
o
x
ic
ity
 
(in
cl
u
di
n
g 
bo
dy
 
w
ei
gh
t o
r 
fo
o
d 
co
n
su
m
pt
io
n
). 
Sa
m
e 
re
su
lt 
at
 
50
 
m
g/
kg
 
bw
.
 
 
 
(10
3) 
h  
20
0 
(m
al
es
) 
22
0 (
fe
m
al
es
) 
O
ra
l, 
in
 
di
et
 
 
R
at
 
7 
m
al
es
 
 
8 
fe
m
al
es
 
14
 
w
ee
ks
 
Si
gn
ifi
ca
n
t d
ec
re
as
e 
o
f s
er
u
m
 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
 
in
 
bo
th
 
se
x
es
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f s
er
u
m
 
am
yl
as
e 
ac
tiv
ity
 
in
 
m
al
es
.
 
(18
9,
 
23
3) 
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Ta
bl
e 
II
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
is(
2-
bu
to
x
ye
th
yl
) p
ho
sp
ha
te
 
(T
B
EP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
25
0 
G
av
ag
e 
R
at
 
12
/se
x
 
18
 
w
ee
ks
 
A
lm
o
st
 
al
l a
n
im
al
s 
af
fe
ct
ed
 
at
 
th
e 
2n
d 
ha
lf 
o
f t
he
 
ex
pe
rim
en
t. 
D
iff
i-
cu
lty
 
in
 
br
ea
th
in
g 
an
d 
at
ax
ia
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f l
iv
er
 
w
ei
gh
t i
n
 
fe
m
al
es
.
 
Si
gn
ifi
ca
n
tly
 
lo
w
er
 
er
yt
hr
o
cy
te
 
ac
et
yl
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
 
(5 
%
) a
n
d 
u
ric
 
ac
id
 
co
n
ce
n
tr
at
io
n
 
(40
 
%
) c
o
m
pa
re
d 
to
 
co
n
tr
o
ls 
an
d 
m
yo
ca
rd
ia
l n
ec
ro
sis
 
w
ith
 
in
fla
m
m
at
o
ry
 
ce
ll 
in
fil
tr
at
io
n
 
an
d 
ha
em
o
rr
-
ha
ge
s 
in
 
m
al
es
.
 
N
o 
ha
em
at
o
lo
gi
ca
l e
ffe
ct
s.
 
(12
2) 
25
0 
G
av
ag
e 
R
at
 
12
/se
x
 
18
 
w
ee
ks
 
A
lm
o
st
 
al
l a
n
im
al
s 
af
fe
ct
ed
 
at
 
th
e 
2n
d 
ha
lf 
o
f t
he
 
ex
pe
rim
en
t. 
So
m
e 
di
ffi
cu
lty
 
in
 
br
ea
th
in
g 
an
d 
at
ax
ia
.
 
D
ec
re
as
ed
 
n
er
v
e 
co
n
du
ct
io
n
 
v
el
o
-
ci
ty
 
in
 
ca
u
da
l n
er
v
e 
af
te
r 
6 
w
ee
ks
.
 
Sc
ia
tic
 
n
er
v
e 
sh
o
w
ed
 
pr
es
en
ce
 
o
f 
de
ge
n
er
at
in
g 
m
ye
lin
 
sh
ea
th
s 
ac
co
m
pa
n
ie
d 
by
 
ax
o
n
al
 
sw
el
lin
g.
 
N
o 
m
o
rp
ho
lo
gi
ca
l s
ex
 
di
ffe
re
n
ce
s.
 
 
(12
4) 
50
0 
O
ra
l, 
in
 
di
et
 
R
at
 
20
/se
x
 
18
 
w
ee
ks
 
In
cr
ea
se
d 
se
ru
m
 
γ-
gl
u
ta
m
yl
-
tr
an
sp
ep
tid
as
e 
an
d 
de
cr
ea
se
d 
pl
as
m
a 
ch
o
lin
es
te
ra
se
 
ac
tiv
iti
es
.
 
M
ild
 
pe
rip
o
rt
al
 
he
pa
to
ce
llu
la
r 
hy
pe
rt
ro
ph
y 
an
d 
pe
rip
o
rt
al
 
v
ac
u
o
lis
at
io
n
 
in
 
m
al
es
.
 
In
cr
ea
se
d 
pl
at
el
et
 
co
u
n
ts
.
 
In
-
cr
ea
se
d 
liv
er
 
w
ei
gh
t. 
R
ed
u
ce
d 
ca
u
da
l n
er
v
e 
co
n
du
ct
io
n
 
v
el
o
ci
ty
 
in
 
fe
m
al
es
.
 
N
o 
tr
ea
tm
en
t r
el
at
ed
 
ch
an
ge
s 
in
 
pe
rip
he
ra
l n
er
v
e 
o
r 
sp
in
al
 
co
rd
 
hi
st
o
pa
th
o
lo
gy
.
 
 
 
(10
3) 
g  
50
0 
G
av
ag
e 
R
at
 
12
/se
x
 
18
 
w
ee
ks
 
D
ur
in
g 
th
e 
1s
t w
ee
k,
 
2 
fe
m
al
es
 
sh
o
w
ed
 
m
u
sc
u
la
r 
w
ea
kn
es
s 
an
d 
at
ax
ia
 
th
at
 
di
sa
pp
ea
re
d 
4 
w
ee
ks
 
la
te
r.
 
Tr
em
o
r,
 
pi
lo
er
ec
tio
n
,
 
la
cr
im
at
io
n
 
an
d 
in
cr
ea
se
d 
u
rin
at
io
n
.
 
Si
gn
ifi
ca
n
tly
 
lo
w
er
 
er
yt
hr
o
cy
te
 
ac
et
yl
ch
o
lin
e-
es
te
ra
se
 
ac
tiv
ity
 
(7 
%
) a
n
d 
u
ric
 
ac
id
 
co
n
ce
n
tr
at
io
n
 
(~
40
 
%
) c
o
m
pa
re
d 
to
 
co
n
tr
o
ls 
an
d 
m
yo
ca
rd
ia
l n
ec
ro
sis
 
w
ith
 
in
fla
m
m
at
o
ry
 
ce
ll 
in
fil
tr
at
io
n
 
an
d 
ha
em
o
rr
ha
ge
s 
in
 
m
al
es
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f r
el
at
iv
e 
liv
er
 
w
ei
gh
ts
 
in
 
bo
th
 
se
x
es
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f a
m
yl
as
e 
an
d 
γ-
gl
u
ta
m
yl
 
tr
an
sf
er
as
e 
ac
tiv
iti
es
 
in
 
fe
m
al
es
.
 
N
o 
ha
em
at
o
lo
gi
ca
l e
ffe
ct
s.
 
(12
2) 
  
17
7  
Ta
bl
e 
II
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
is(
2-
bu
to
x
ye
th
yl
) p
ho
sp
ha
te
 
(T
B
EP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
50
0 
G
av
ag
e 
R
at
 
12
/se
x
 
18
 
w
ee
ks
 
D
ur
in
g 
th
e 
1s
t w
ee
k 
2 
fe
m
al
es
 
sh
o
w
ed
 
m
u
sc
u
la
r 
w
ea
kn
es
s 
an
d 
at
ax
ia
,
 
th
at
 
di
sa
pp
ea
re
d 
4 
w
ee
ks
 
la
te
r.
 
A
lso
 
n
eu
ro
to
x
ic
 
ef
fe
ct
s 
as
 
at
 
25
0 
m
g/
kg
 
bw
 
bu
t m
o
re
 
ad
v
an
ce
d 
de
ge
n
er
at
io
n
 
as
 
in
di
ca
te
d b
y 
la
m
el
la
te
d e
le
ct
ro
n
 
de
n
se
 
in
cl
u
sio
n
s 
in
 
u
n
m
ye
lin
at
ed
 
n
er
v
e 
fib
re
s.
 
N
o 
m
o
rp
ho
lo
gi
ca
l s
ex
 
di
ffe
re
n
ce
s.
 
(12
4) 
75
0 
O
ra
l, 
in
 
di
et
 
R
at
 
B
o
th
 
se
x
es
 
4 
w
ee
ks
 
N
o 
sig
n
s 
o
f t
o
x
ic
ity
 
in
 
m
al
es
.
 
Sl
ig
ht
 
de
cr
ea
se
 
in
 
bo
dy
 
w
ei
gh
t a
n
d 
fo
o
d 
co
n
su
m
pt
io
n
 
in
 
fe
m
al
es
.
 
Sa
m
e 
re
su
lts
 
at
 
1 5
00
 
m
g/
kg
 
bw
.
 
N
o 
co
m
-
po
u
n
d 
re
la
te
d 
ch
an
ge
s 
o
bs
er
v
ed
 
at
 
n
ec
ro
ps
y.
 
 
 
(10
3) 
h  
80
0 
G
av
ag
e 
R
at
 
10
/se
x
 
2 
w
ee
ks
 
Sl
ig
ht
ly
 
(no
n
-
sig
n
ifi
ca
n
t) 
de
cr
ea
se
d 
n
er
v
e 
co
n
du
ct
io
n
 
v
el
o
ci
ty
 
in
 
ca
u
da
l n
er
v
e 
in
 
fe
m
al
es
.
 
Si
gn
ifi
ca
n
tly
 
in
cr
ea
se
d 
re
la
tiv
e 
re
fra
ct
o
ry
 
pe
rio
d 
in
 
m
al
es
.
 
N
o 
sig
n
 
o
f m
o
rp
ho
lo
gi
ca
l c
ha
n
ge
s 
in
 
sc
ia
tic
 
n
er
v
e.
 
(12
6) 
1 
00
0 
D
er
m
al
 
R
ab
bi
t 
6/
se
x
 
3 
w
ee
ks
 
 
Th
e 
te
st
 
sit
es
 
w
er
e 
o
cc
lu
de
d 
fo
r 
6 
ho
u
rs
 
af
te
r 
ea
ch
 
ex
po
su
re
.
 
Sq
u
am
o
u
s 
ce
ll 
hy
pe
rp
la
sia
,
 
hy
pe
rk
er
at
o
sis
,
 
er
o
sio
n
 
u
lc
er
s,
 
in
fla
m
m
at
io
n
,
 
co
n
ge
st
io
n
 
an
d 
ha
em
o
rr
ha
ge
s.
 
 
 
(10
3) 
f  
1 
00
0 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
Fe
m
al
es
 
 
N
o 
m
at
er
n
al
 
w
ei
gh
t l
o
ss
 
(do
se
-
ra
n
ge
-
fin
di
n
g 
st
u
dy
). 
 
 
(10
3) 
i  
1 
14
0 
G
av
ag
e 
R
at
 
10
 
fe
m
al
es
 
2 
w
ee
ks
 
Si
gn
ifi
ca
n
tly
 
de
cr
ea
se
d 
n
er
v
e 
co
n
du
ct
io
n
 
v
el
o
ci
ty
 
in
 
ca
u
da
l n
er
v
e.
 
 
N
o 
sig
n
 
o
f m
o
rp
ho
lo
gi
ca
l c
ha
n
ge
s 
in
 
sc
ia
tic
 
n
er
v
e.
 
(12
6) 
1 
50
0 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
25
 
fe
m
al
es
 
G
es
ta
tio
n
 
da
ys
 
6-
15
 
 
N
o 
ef
fe
ct
 
o
n
 
fo
et
al
 
re
so
rp
tio
n
,
 
fo
et
al
 
v
ia
bi
lit
y,
 
po
st
-
im
pl
an
ta
tio
n
 
lo
ss
,
 
to
ta
l i
m
pl
an
ta
tio
n
s 
o
r 
fo
et
al
 
m
al
fo
rm
at
io
n
s.
 
Sa
m
e 
re
su
lts
 
at
 
25
0 
an
d 
50
0 
m
g/
kg
 
bw
.
 
 
 
(10
3) 
j  
2 
00
0 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
Fe
m
al
es
 
 
M
at
er
n
al
 
w
ei
gh
t l
o
ss
 
(do
se
-
ra
n
ge
-
fin
di
n
g 
st
u
dy
). 
 
 
(10
3) 
i  
2 
00
0 
(m
al
es
) 
2 
20
0 
(fe
m
al
es
) 
O
ra
l, 
in
 
di
et
 
 
R
at
 
7 
m
al
es
 
 
8 
fe
m
al
es
 
14
 
w
ee
ks
 
Su
pp
re
ss
io
n
 
o
f b
o
dy
 
w
ei
gh
t g
ai
n
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f l
iv
er
 
w
ei
gh
ts
.
 
Si
gn
ifi
ca
n
t d
ec
re
as
e 
o
f s
er
u
m
 
ch
o
lin
es
te
ra
se
 
an
d 
sig
n
ifi
ca
n
t i
n
cr
ea
se
s 
o
f s
er
u
m
 
γ-
gl
u
ta
m
yl
 
tr
an
sf
er
as
e 
an
d 
am
yl
as
e 
ac
tiv
iti
es
.
 
M
o
de
ra
te
 
pe
ri-
po
rt
al
 
he
pa
to
cy
te
 
sw
el
lin
g 
in
 
m
al
es
.
 
(18
9,
 
23
3) 
2 
28
0 
G
av
ag
e 
R
at
 
10
 
m
al
es
 
2 
w
ee
ks
 
Si
gn
ifi
ca
n
tly
 
in
cr
ea
se
d 
re
la
tiv
e 
an
d 
ab
so
lu
te
 
re
fra
ct
o
ry
 
pe
rio
ds
.
 
N
o 
sig
n
 
o
f m
o
rp
ho
lo
gi
ca
l c
ha
n
ge
s 
in
 
sc
ia
tic
 
n
er
v
e.
 
(12
6) 
  
17
8  
Ta
bl
e 
II
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
is(
2-
bu
to
x
ye
th
yl
) p
ho
sp
ha
te
 
(T
B
EP
). 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
5 
00
0 
O
ra
l, 
ge
la
tin
 
ca
ps
u
le
 
H
en
 
 
20
 
Tw
ic
e,
 
21
 
da
ys
 
ap
ar
t 
A
ll 
su
rv
iv
ed
.
 
2 
he
n
s 
ha
d 
eq
u
iv
o
ca
l f
o
ca
l s
w
o
lle
n
 
ax
o
n
s 
bu
t t
he
 
ch
an
ge
s 
w
er
e 
n
o
t c
o
n
sid
er
ed
 
to
 
di
ffe
r 
fro
m
 
co
n
tr
o
ls.
 
N
o 
le
sio
n
s 
 
in
 
pe
rip
he
ra
l n
er
v
es
.
 
(32
,
 
33
) 
5 
00
0 
D
er
m
al
 
H
en
 
20
 
Tw
ic
e,
 
21
 
da
ys
 
ap
ar
t 
N
o 
le
sio
n
s 
in
 
th
e 
sp
in
al
 
co
rd
 
o
r 
in
 
pe
rip
he
ra
l n
er
v
es
.
 
(32
,
 
33
) 
LC
50
: 
le
th
al
 
co
n
ce
n
tr
at
io
n
 
fo
r 
50
 
%
 
o
f t
he
 
ex
po
se
d 
an
im
al
s 
at
 
sin
gl
e 
ad
m
in
ist
ra
tio
n
,
 
LD
50
: 
le
th
al
 
do
se
 
fo
r 
50
 
%
 
o
f t
he
 
ex
po
se
d 
an
im
al
s 
at
 
sin
gl
e 
ad
m
in
ist
ra
tio
n
.
 
A
ll 
st
u
di
es
 
be
lo
w
 
ci
te
d 
in
 
(10
3):
 
a 
M
o
n
sa
n
to
 
19
84
b.
 
b 
G
ab
rie
l 1
98
0a
.
 
c 
FM
C 
19
76
.
 
d 
H
oe
ch
st
 
19
89
.
 
e 
M
o
u
n
t 1
99
1.
 
f M
o
n
sa
n
to
 
19
85
e.
 
g 
M
o
n
sa
n
to
 
19
87
a,
 
b.
 
h 
M
o
n
sa
n
to
 
19
85
b.
 
i M
o
n
sa
n
to
 
19
85
c.
 
j M
o
n
sa
n
to
 
19
85
d.
 
  
  
17
9  
Ta
bl
e 
IV
.
 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
i-n
-
bu
ty
l p
ho
sp
ha
te
 
(T
B
P)
.
 
 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
Si
n
gl
e 
do
se
 
 
 
 
 
 
16
 
In
tr
ap
er
ito
n
ea
l, 
 
co
rn
 
o
il 
R
at
 
4 
-
 
In
cr
ea
se
 
o
f β
-
gl
u
cu
ro
n
id
as
e 
in
 
se
ru
m
 
(×
1.
6).
 
N
o 
ef
fe
ct
 
o
n
 
se
ru
m
 
ch
o
lin
es
te
ra
se
.
 
 
(22
1) 
17
 
In
tr
at
ra
ch
ea
l, 
do
de
ca
n
 
R
at
 
30
 
-
 
In
cr
ea
se
d 
to
ta
l c
el
l n
u
m
be
r 
an
d 
pr
o
te
in
 
in
 
br
o
n
ch
o
al
v
eo
la
r 
la
v
ag
e 
flu
id
 
da
y 
1 
po
st
-
ex
po
su
re
.
 
D
ec
re
as
ed
 
se
ru
m
 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
 
 
o
n
 
da
y 
1 
po
st
-
ex
po
su
re
.
 
(19
1) 
10
0 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
12
/se
x
 
-
 
N
o 
re
po
rt
ed
 
sig
n
s 
fro
m
 
th
e 
n
ar
es
,
 
n
o
 
ef
fe
ct
s 
o
n
 
m
o
to
r 
ac
tiv
ity
.
 
D
os
e-
re
la
te
d 
re
du
ct
io
n
 
o
f m
o
to
r 
ac
tiv
ity
 
(si
gn
ifi
ca
n
t a
t 1
 
00
0 
m
g/
kg
 
bw
). 
(80
) 
27
0 
In
tr
ap
er
ito
n
ea
l, 
 
co
rn
 
o
il 
R
at
 
4 
-
 
In
cr
ea
se
 
o
f β
-
gl
u
cu
ro
n
id
as
e 
in
 
se
ru
m
 
(×
50
). N
o 
ef
fe
ct
 
o
n
 
se
ru
m
 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
.
 
 
(22
1) 
32
5 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
12
/se
x
 
-
 
St
ai
n
in
g/
di
sc
ha
rg
e 
at
 
th
e 
m
u
zz
le
 
an
d 
n
ar
es
.
 
D
os
e-
re
la
te
d 
re
du
ct
io
n
 
 
o
f m
o
to
r 
ac
tiv
ity
 
(si
gn
ifi
ca
n
t a
t 1
 
00
0 
m
g/
kg
 
bw
). 
(80
) 
1 
00
0 
G
av
ag
e,
 
co
rn
 
o
il 
R
at
 
12
/se
x
 
-
 
R
ed
u
ce
d 
m
o
to
r 
ac
tiv
ity
.
 
Lo
w
er
 
ac
tiv
ity
 
ba
se
d 
o
n
 
Fu
n
ct
io
n
al
 
O
bs
er
-
v
at
io
n
 
B
at
te
ry
.
 
O
ne
 
fe
m
al
e 
di
ed
.
 
Lo
w
er
 
bo
dy
 
w
ei
gh
t i
n
cr
ea
se
 
am
o
n
g 
m
al
es
.
 
D
ec
re
as
ed
 
fo
re
lim
b 
gr
ip
 
st
re
n
gt
h.
 
In
cr
ea
se
d 
pa
lp
eb
ra
l c
lo
su
re
 
an
d 
gr
o
o
m
in
g 
in
 
fe
m
al
es
.
 
(80
) 
1 
40
0-
3 
20
0 
O
ra
l 
R
at
 
 
-
 
LD
50
.
 
(10
1,
 
10
6) 
1 
50
0 
O
ra
l 
H
en
 
5 
fe
m
al
es
 
-
 
LD
50
.
 
N
o 
ch
an
ge
 
o
f N
TE
 
o
r 
ac
et
yl
ch
o
lin
es
te
ra
se
 
ac
tiv
iti
es
 
in
 
br
ai
n
.
 
Si
gn
ifi
ca
n
t i
n
cr
ea
se
 
o
f p
la
sm
a 
ch
o
lin
es
te
ra
se
 
(26
9 %
 
o
f c
o
n
tr
o
ls)
.
 
 
(32
,
 
33
) 
3 
10
0 
D
er
m
al
 
R
ab
bi
t 
 
-
 
LD
50
 
>
 
3 
10
0 
m
g/
kg
 
bw
.
 
(10
6) 
M
u
lti
pl
e 
do
se
s 
 
 
 
 
 
9 
O
ra
l, 
in
 
di
et
 
R
at
 
50
 
m
al
es
 
2 
ye
ar
s 
U
rin
ar
y b
la
dd
er
 
hy
pe
rp
la
sia
 
in
 
3/
50
 
v
s.
 
3/
50
 
in
 
co
n
tr
o
ls.
 
N
o n
eo
pl
as
m
s.
 
(13
) 
10
 
O
ra
l, 
in
 
di
et
 
R
at
 
B
o
th
 
se
x
es
 
13
 
w
ee
ks
 
N
o 
hi
st
o
pa
th
o
lo
gi
ca
l c
ha
n
ge
s 
o
r 
cl
in
ic
al
 
ch
em
ist
ry
 
ch
an
ge
s 
(pr
es
en
te
d 
as
 
an
 
ab
st
ra
ct
). 
 
 
 
(10
1) 
a  
  
18
0  
Ta
bl
e 
IV
.
 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
i-n
-
bu
ty
l p
ho
sp
ha
te
 
(T
B
P)
.
 
 
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
12
 
O
ra
l, 
in
 
di
et
 
R
at
 
50
 
fe
m
al
es
 
2 
ye
ar
s 
U
rin
ar
y 
bl
ad
de
r 
hy
pe
rp
la
sia
 
in
 
1/
50
 
v
s.
 
1/
50
 
in
 
co
n
tr
o
ls.
 
N
o 
n
eo
pl
as
m
s.
 
(13
) 
10
-
21
 
O
ra
l, 
in
 
di
et
 
R
at
 
30
 
F 1
 
m
al
es
 
11
 
w
ee
ks
 
du
rin
g 
pr
e-
br
ee
d 
pe
rio
d 
+
 
m
at
in
g,
 
ge
st
at
io
n
,
 
la
ct
at
io
n
 
N
o 
m
o
rt
al
ity
.
 
N
o 
tr
ea
tm
en
t-
re
la
te
d 
cl
in
ic
al
 
o
bs
er
v
at
io
n
s 
(sa
m
e 
re
su
lts
 
o
bs
er
v
ed
 
at
 
36
-
72
 
an
d 
16
6-
32
8 
m
g/
kg
 
bw
). 
U
rin
ar
y 
bl
ad
de
r 
ep
ith
el
ia
l h
yp
er
pl
as
ia
 
in
 
2/
28
 
v
s.
 
0/
29
-
30
 
in
 
co
n
tr
o
ls.
 
 
N
o 
re
n
al
 
pe
lv
ic
 
ep
ith
el
ia
l h
yp
er
pl
as
ia
.
 
(23
4) 
11
-
18
 
O
ra
l, 
in
 
di
et
 
R
at
 
30
 
F 0
 
m
al
es
 
10
 
w
ee
ks
 
du
rin
g 
pr
e-
br
ee
d 
pe
rio
d 
+
 
m
at
in
g,
 
ge
st
at
io
n
,
 
la
ct
at
io
n
 
N
o 
m
o
rt
al
ity
.
 
N
o 
tr
ea
tm
en
t-
re
la
te
d 
cl
in
ic
al
 
o
bs
er
v
at
io
n
s 
(sa
m
e 
re
su
lts
 
o
bs
er
v
ed
 
at
 
38
-
65
 
an
d 
16
0-
26
4 
m
g/
kg
 
bw
). 
U
rin
ar
y 
bl
ad
de
r 
ep
ith
el
ia
l h
yp
er
pl
as
ia
 
in
 
1/
30
 
v
s.
 
0/
29
-
30
 
in
 
co
n
tr
o
ls.
 
 
N
o 
re
n
al
 
pe
lv
ic
 
ep
ith
el
ia
l h
yp
er
pl
as
ia
.
 
(23
4) 
12
-
17
 
O
ra
l, 
in
 
di
et
 
R
at
 
30
 
F 0
 
fe
m
al
es
 
10
 
w
ee
ks
 
du
rin
g 
pr
e-
br
ee
d 
pe
rio
d 
+
 
m
at
in
g,
 
ge
st
at
io
n
,
 
la
ct
at
io
n
 
N
o 
m
o
rt
al
ity
.
 
N
o 
tr
ea
tm
en
t-
re
la
te
d 
cl
in
ic
al
 
o
bs
er
v
at
io
n
s 
(sa
m
e 
re
su
lts
 
o
bs
er
v
ed
 
at
 
41
-
60
 
an
d 
17
8-
26
6 
m
g/
kg
 
bw
). T
ra
n
sie
n
t r
ed
u
ct
io
n
s 
in
 
bo
dy
 
w
ei
gh
t. 
U
rin
ar
y 
bl
ad
de
r 
ep
ith
el
ia
l h
yp
er
pl
as
ia
 
in
 
2/
30
 
v
s.
 
0/
29
-
30
 
in
 
co
n
tr
o
ls.
 
N
o 
he
pa
tic
 
ce
n
tr
ilo
bu
la
r 
hy
pe
rt
ro
ph
y.
 
(23
4) 
13
-
21
 
O
ra
l, 
in
 
di
et
 
R
at
 
30
 
F 1
 
fe
m
al
es
 
11
 
w
ee
ks
 
du
rin
g 
pr
e-
br
ee
d 
pe
rio
d 
+
 
m
at
in
g,
 
ge
st
at
io
n
,
 
la
ct
at
io
n
 
N
o 
m
o
rt
al
ity
.
 
N
o 
tr
ea
tm
en
t-
re
la
te
d 
cl
in
ic
al
 
o
bs
er
v
at
io
n
s 
(sa
m
e 
re
su
lts
 
o
bs
er
v
ed
 
at
 
44
-
70
 
an
d 
19
3-
31
6 
m
g/
kg
 
bw
). T
ra
n
sie
n
t r
ed
u
ct
io
n
s 
in
 
bo
dy
 
w
ei
gh
t. 
N
o 
u
rin
ar
y 
bl
ad
de
r 
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o
v
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N
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/5
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sin
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o
v
er
 
tim
e.
 
Sa
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at
io
n
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e 
fir
st
 
w
ee
k.
 
(81
) 
30
0 m
g/
m
3 
d  
In
ha
la
tio
n
 
M
M
A
D
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.
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R
at
 
25
/se
x
 
A
s 
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o
v
e 
N
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al
 
di
sc
ha
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cr
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sin
g 
o
v
er
 
tim
e.
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liv
at
io
n
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m
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%
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e 
fir
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w
ee
k.
 
In
cr
ea
se
d 
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so
lu
te
 
an
d 
re
la
tiv
e 
liv
er
 
w
ei
gh
ts
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d 
de
cr
ea
se
d 
ha
em
at
o
cr
it 
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al
l a
n
im
al
s.
 
D
ec
re
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ed
 
bo
dy
 
w
ei
gh
ts
 
an
d 
pl
as
m
a 
ch
o
lin
es
te
ra
se
 
le
v
el
s,
 
er
yt
hr
o
cy
te
 
co
u
n
ts
 
an
d 
ha
em
o
gl
o
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n
 
le
v
el
s 
an
d 
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n
tr
ilo
bu
la
r 
he
pa
to
ce
llu
la
r 
hy
pe
rt
ro
ph
y 
(10
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5) 
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m
al
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) 
D
FG
: D
eu
ts
ch
e 
Fo
rs
ch
u
n
gs
ge
m
ei
n
sc
ha
ft,
 
LD
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: 
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th
al
 
do
se
 
fo
r 
50
 
%
 
o
f t
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po
se
d 
an
im
al
s 
at
 
sin
gl
e 
ad
m
in
ist
ra
tio
n
,
 
M
M
A
D
: m
as
s 
m
ed
ia
n
 
ae
ro
dy
n
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ic
 
di
am
et
er
,
 
N
TE
: 
n
eu
ro
to
x
ic
 
o
r 
n
eu
ro
pa
th
y 
ta
rg
et
 
es
te
ra
se
.
 
a 
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sc
ie
ri 
et
 
a
l, 
19
85
,
 
ci
te
d 
in
 
(10
1).
 
b 
N
o 
in
fo
rm
at
io
n
 
o
f p
hy
sic
al
 
st
at
e 
o
f T
B
P.
 
c 
K
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in
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19
71
,
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te
d 
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(47
). 
d 
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ro
l 5
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B
-
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n
ta
in
in
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P 
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d 
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ty
l p
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n
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o
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tr
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n
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l 
M
o
u
se
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m
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-
 
N
o 
ef
fe
ct
 
o
n
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tiv
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u
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o
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v
at
io
n
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6) 
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n
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M
o
u
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m
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-
 
A
m
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to
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tiv
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n
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n
tly
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th
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fir
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m
in
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en
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m
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n
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o
l b
u
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u
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n
tr
o
l l
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y.
 
A
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.
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6) 
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G
av
ag
e 
R
at
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x
 
-
 
M
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o
cc
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io
n
al
 
se
iz
u
re
s.
 
(83
) 
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5 
G
av
ag
e 
R
at
 
Fe
m
al
es
 
-
 
Co
n
v
u
lsi
v
e 
ac
tiv
ity
 
w
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-
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m
in
u
te
s.
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te
n
siv
e 
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ss
 
o
f C
A
1 
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pp
o
ca
m
pa
l p
yr
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id
al
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lls
.
 
Im
pa
ire
d 
ac
qu
isi
tio
n
 
o
f a
 
re
fe
re
n
ce
 
m
em
o
ry
 
ta
sk
 
in
 
a 
w
at
er
 
m
az
e.
 
(23
0) 
35
0 
G
av
ag
e 
R
at
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se
x
 
-
 
M
o
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im
al
s 
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d 
se
iz
u
re
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w
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1 
ho
u
r 
(fe
m
al
es
 
m
o
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af
fe
ct
ed
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m
al
es
). 
(83
) 
43
0-
79
4 
 
O
ra
l 
R
at
 
 
Fe
m
al
es
 
-
 
LD
50
 (th
re
e 
di
ffe
re
n
t l
o
ts
). 
(23
5) 
50
1 
O
ra
l 
R
at
 
 
M
al
es
 
-
 
LD
50
.
 
Sp
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m
o
di
c 
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n
tr
ac
tio
n
s 
an
d 
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u
te
 
de
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sio
n
.
 
(23
5) 
70
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G
av
ag
e 
R
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se
x
 
-
 
A
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an
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al
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te
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u
re
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n
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g 
o
f r
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“
w
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do
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sh
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”
 
w
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u
r.
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G
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ag
e 
R
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x
 
-
 
N
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n
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o
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o
x
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o
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m
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o
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o
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n
o
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2) 
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G
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R
at
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x
 
-
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m
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o
n
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2.
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n
,
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liv
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n
,
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n
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u
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,
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n
o
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u
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sp
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n
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o
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,
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o
n
g 
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n
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al
s.
 
N
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ic
al
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n
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o
f t
o
x
ic
ity
 
o
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m
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-
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o
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o
lo
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n
o
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.
 
LD
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u
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d 
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1 1
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m
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kg
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.
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2) 
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O
ra
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R
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-
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.
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G
av
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x
 
-
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m
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m
al
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4.
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in
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al
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n
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as
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m
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.
 
N
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n
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o
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o
x
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o
n
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.
 
N
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m
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o
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o
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n
o
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is(
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D
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R
o
u
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o
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m
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ra
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n
 
Sp
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N
o.
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se
x
 
o
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n
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Ex
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gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
 
 
3 
60
0 
O
ra
l 
R
at
 
5/
se
x
 
-
 
LD
50
.
 
 
 
(10
2) 
b  
14
 
20
0 
O
ra
l 
H
en
 
 
Fe
m
al
es
 
-
 
Si
gn
ifi
ca
n
t d
ec
re
as
e 
o
f p
la
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a 
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o
lin
es
te
ra
se
 
(87
 
%
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n
d 
br
ai
n
 
N
TE
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%
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iv
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.
 
N
o 
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n
s 
o
f d
el
ay
ed
 
n
eu
ro
to
x
ic
ity
.
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9) 
M
u
lti
pl
e 
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O
ra
l 
M
o
u
se
 
50
/se
x
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m
o
n
th
s 
N
um
be
r 
o
f t
u
m
o
u
r-
be
ar
in
g 
an
im
al
s 
n
o
t s
ig
n
ifi
ca
n
tly
 
di
ffe
re
n
t f
ro
m
 
co
n
tr
o
ls,
 
38
/4
9 
v
s.
 
34
/5
0 
in
 
co
n
tr
o
ls 
(m
al
es
) a
n
d 
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/4
9 
v
s.
 
30
/4
9 
(fe
m
al
es
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2,
 
22
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G
av
ag
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co
rn
 
o
il 
R
at
 
 
10
/se
x
 
16
 
(fe
m
al
es
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r 
 
18
 
(m
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) w
ee
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N
o 
ef
fe
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n
 
o
rg
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w
ei
gh
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.
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10
 
m
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2/
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m
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R
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.
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.
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l l
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.
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.
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av
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o
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R
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/se
x
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(fe
m
al
es
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r 
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) w
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Si
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ca
n
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n
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se
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te
 
an
d 
re
la
tiv
e 
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er
 
an
d 
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ey
 
w
ei
gh
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m
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es
.
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se
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.
 
 
(14
9,
 
17
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n
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.
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n
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iv
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n
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o
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n
.
 
R
en
al
 
tu
bu
la
r 
hy
pe
rp
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sia
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m
al
es
 
(2/
50
 
v
s.
 
0/
50
 
in
 
co
n
tr
o
ls)
 
an
d 
fe
m
al
es
 
(3/
50
 
v
s.
 
0/
50
). R
en
al
 
tu
bu
la
r 
ad
en
o
m
as
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m
al
es
 
(5/
50
 
v
s.
 
1/
50
,
 
p =
 
0.
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3) 
an
d 
fe
m
al
es
 
(2/
50
 
v
s.
 
0/
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).  
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0,
 
17
3) 
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O
ra
l, 
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et
 
M
o
u
se
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/se
x
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m
o
n
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N
um
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r 
o
f t
u
m
o
u
r-
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ar
in
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n
o
t s
ig
n
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n
tly
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n
t f
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m
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n
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o
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9 
v
s.
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n
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o
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n
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v
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G
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x
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n
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n
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re
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n
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.
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l l
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o
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ra
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.
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D
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o
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m
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ra
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Sp
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G
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o
il 
M
o
u
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w
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N
o 
ef
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o
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er
 
o
r 
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ey
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.
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m
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lts
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.
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G
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R
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x
 
2 
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u
ce
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iv
al
.
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o
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w
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n
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n
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n
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o
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o
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cr
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se
d 
in
ci
de
n
ce
s 
o
f r
en
al
 
tu
bu
la
r 
hy
pe
rp
la
sia
 
in
 
m
al
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(24
/5
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v
s.
 
0/
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in
 
co
n
tr
o
ls)
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d 
fe
m
al
es
 
(16
/5
0 
v
s.
 
0/
50
), r
en
al
 
tu
bu
la
r 
ad
en
o
m
as
 
in
 
m
al
es
 
(24
/5
0 
v
s.
 
1/
50
,
 
p <
 
0.
00
1) 
an
d 
fe
m
al
es
 
(5/
50
 
v
s.
 
0/
50
,
 
p =
 
0.
00
3) 
an
d 
th
yr
o
id
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an
d 
fo
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cu
la
r 
ce
ll 
ad
en
o
m
as
 
o
r 
ca
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in
o
m
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m
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(5/
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v
s.
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p =
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m
al
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v
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n
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f d
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n
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.
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m
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sio
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o
t c
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.
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.
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.
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G
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m
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m
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n
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n
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m
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o
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ra
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n
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n
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o
f l
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n
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m
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m
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lo
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l p
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er
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u
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o
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u
n
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o
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o
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n
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n
ce
n
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at
io
n
,
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em
at
o
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m
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n
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la
r 
v
o
lu
m
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m
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m
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n
en
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l 
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o
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u
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n
itr
o
ge
n
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o
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st
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o
l, 
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di
u
m
,
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m
,
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o
th
ro
m
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n
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e,
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o
lin
-
pa
rt
ia
l t
hr
o
m
bo
pl
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tin
 
tim
e) 
o
r 
se
ru
m
 
en
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m
e 
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tiv
iti
es
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u
di
n
g 
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o
lin
es
te
ra
se
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tiv
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.
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ig
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m
o
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gi
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l c
ha
n
ge
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in
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e 
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er
.
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M
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n
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x
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i.e
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ct
io
n
 
o
f b
o
dy
 
w
ei
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t g
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n
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o
d 
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.
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o
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o
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n
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n
tia
l. 
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ra
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R
ed
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e.
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m
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f p
o
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n
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n
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n
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u
m
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ra
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N
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o
n
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u
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r 
w
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t. 
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O
ra
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N
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n
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u
la
r 
w
ei
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t o
r 
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u
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r 
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o
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gi
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n
ce
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al
l n
u
m
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r 
o
f a
n
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al
s).
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r 
50
 
%
 
o
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pu
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tio
n
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se
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le
th
al
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n
ce
n
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at
io
n
 
fo
r 
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%
 
o
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se
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al
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m
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ra
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n
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ra
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.
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.
 
(10
6) 
15
 
80
0 
O
ra
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a
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ra
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.
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.
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D
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o
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lp
he
n
yl
 
ph
en
yl
 
ph
o
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ha
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60
0 
O
ra
l 
H
en
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m
al
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-
 
N
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n
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x
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re
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o
n
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.
 
61
 
%
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n
 
N
TE
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.
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9) 
1 
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0 
O
ra
l 
H
en
 
 
Fe
m
al
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-
 
A
m
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o
u
s 
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lt 
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n
ce
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ai
n
 
n
eu
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to
x
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re
sp
o
n
se
.
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%
 
N
TE
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tiv
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.
 
(10
9) 
O
rth
o
-
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pr
o
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he
n
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ph
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o
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ha
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0 
O
ra
l 
H
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m
al
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-
 
N
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n
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x
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o
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n
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.
 
(10
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O
ra
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m
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-
 
N
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o
n
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D
N
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n
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.
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9) 
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00
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m
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.
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6) 
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0 
O
ra
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-
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.
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6) 
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o
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n
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o
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0 
O
ra
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H
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m
al
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-
 
N
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n
eu
ro
to
x
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re
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o
n
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.
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%
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n
 
N
TE
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tiv
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.
 
(10
9) 
>
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0 
O
ra
l 
H
en
 
Fe
m
al
es
 
-
 
LD
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.
 
(10
6) 
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o
pr
o
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te
d 
tr
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n
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o
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ha
te
 
(de
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in
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a
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O
ra
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rn
 
o
il 
H
en
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m
al
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-
 
N
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o
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m
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o
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ra
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.
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18
0 
O
ra
l, 
co
rn
 
o
il 
H
en
 
4 
fe
m
al
es
 
-
 
50
 
%
 
in
hi
bi
tio
n
 
o
f p
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a 
ch
o
lin
es
te
ra
se
.
 
N
o 
ef
fe
ct
 
o
n
 
br
ai
n
 
N
TE
.
 
(20
8) 
37
0 
O
ra
l, 
co
rn
 
o
il 
H
en
 
4 
fe
m
al
es
 
-
 
70
 
%
 
in
hi
bi
tio
n
 
o
f p
la
sm
a 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
 
an
d 
50
 
%
 
in
hi
bi
tio
n
 
 
o
f b
ra
in
 
N
TE
 
ac
tiv
ity
.
 
Tr
an
sie
n
t i
m
pa
ire
d 
w
al
ki
n
g 
be
ha
v
io
u
r.
 
(20
8) 
11
 
70
0 
O
ra
l, 
co
rn
 
o
il 
H
en
 
4 
fe
m
al
es
 
-
 
W
ei
gh
t l
o
ss
 
fro
m
 
da
y 
22
.
 
Tr
an
sie
n
t a
n
d 
do
se
-
de
pe
n
de
n
t i
m
pa
ire
d 
w
al
ki
n
g 
be
ha
v
io
u
r.
 
M
o
to
r 
in
co
o
rd
in
at
io
n
.
 
Th
e 
in
hi
bi
tio
n
 
o
f p
la
sm
a 
ch
o
lin
es
te
ra
se
 
an
d 
N
TE
 
w
as
 
80
-
90
 
%
.
 
(20
8) 
Is
o
pr
o
py
la
te
d 
tr
ip
he
n
yl
 
ph
o
sp
ha
te
 
(n
o
t s
pe
ci
fie
d) 
 
 
 
 
2 
00
0 
(4 
pr
o
du
ct
s) 
O
ra
l 
R
at
 
5 
m
al
es
/ 
pr
o
du
ct
 
-
 
81
-
90
 
%
 
in
hi
bi
tio
n
 
o
f s
er
u
m
 
ch
o
lin
es
te
ra
se
 
an
d 
35
-
60
 
%
 
in
hi
bi
tio
n
 
 
o
f N
TE
.
 
 
(14
1) 
2 
00
0 
De
rm
al
 
co
n
ta
ct
 
fo
r 
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ho
u
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R
at
 
3/
se
x
 
-
 
N
o 
m
o
rt
al
ity
 
an
d 
n
o
 
irr
ita
tio
n
.
 
N
o 
gr
o
ss
 
le
sio
n
s 
at
 
n
ec
ro
ps
y.
 
 
N
o 
ap
pa
re
n
t e
ffe
ct
 
o
n
 
bo
dy
 
w
ei
gh
ts
.
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20
 
00
0 
O
ra
l 
R
at
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se
x
 
-
 
N
o 
m
al
es
 
di
ed
 
bu
t 4
/5
 
fe
m
al
es
 
di
ed
.
 
N
o 
cl
in
ic
al
 
sig
n
s 
re
po
rt
ed
.
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Kr
o
n
ite
x
®
 
30
0 
 
 
 
 
 
 
8 
00
0 
G
av
ag
e 
H
en
 
4 
fe
m
al
es
 
-
 
A
ta
x
ia
 
in
 
0/
4 
(S
co
re
 
0-
8).
 
Sa
m
e 
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su
lt 
at
 
2 
00
0 
an
d 
4 
00
0 
m
g/
kg
 
bw
.
 
(25
1) 
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00
0 
G
av
ag
e 
H
en
 
10
 
fe
m
al
es
 
-
 
A
ta
x
ia
 
in
 
3/
10
 
(S
co
re
 
0-
8).
 
(25
1) 
Kr
o
n
ite
x
®
 
20
0 
 
 
 
 
 
 
20
 
00
0 
G
av
ag
e 
H
en
 
10
 
fe
m
al
es
 
-
 
A
ta
x
ia
 
in
 
1/
10
 
(S
co
re
 
0-
8).
 
(25
1) 
Kr
o
n
ite
x
®
 
10
0 
 
 
 
 
 
 
2 
00
0 
G
av
ag
e 
H
en
 
4 
fe
m
al
es
 
-
 
A
ta
x
ia
 
in
 
0/
4 
(S
co
re
 
0-
8).
 
Sa
m
e 
re
su
lt 
at
 
50
0 
an
d 
1 
00
0 
m
g/
kg
 
bw
.
 
(25
1) 
3 
00
0 
G
av
ag
e 
H
en
 
10
 
fe
m
al
es
 
-
 
A
ta
x
ia
 
in
 
0/
10
 
(S
co
re
 
0-
8).
 
N
er
v
o
u
s 
sy
st
em
 
le
sio
n
 
in
 
1/
10
.
 
(25
1) 
4 
00
0 
G
av
ag
e 
H
en
 
10
 
fe
m
al
es
 
-
 
A
ta
x
ia
 
in
 
2/
10
 
(S
co
re
 
0-
8).
 
80
 
%
 
in
hi
bi
tio
n
 
o
f b
ra
in
 
N
TE
 
ac
tiv
ity
.
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1) 
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00
0 
G
av
ag
e 
H
en
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fe
m
al
es
 
-
 
A
ta
x
ia
 
in
 
3/
10
 
(S
co
re
 
0-
8).
 
N
er
v
o
u
s 
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st
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le
sio
n
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0/
10
.
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1) 
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00
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G
av
ag
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H
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al
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-
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ta
x
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co
re
 
0-
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N
er
v
o
u
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st
em
 
le
sio
n
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.
 
(25
1) 
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00
0 
G
av
ag
e 
H
en
 
10
 
fe
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al
es
 
-
 
A
ta
x
ia
 
in
 
1/
10
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v
o
u
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10
.
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1) 
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00
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G
av
ag
e 
H
en
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fe
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al
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A
ta
x
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in
 
1/
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(S
co
re
 
0-
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N
er
v
o
u
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st
em
 
le
sio
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in
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10
.
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1) 
4 
00
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G
av
ag
e 
H
en
 
10
 
fe
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al
es
 
-
 
A
ta
x
ia
 
in
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10
 
(S
co
re
 
0-
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N
er
v
o
u
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em
 
le
sio
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.
 
(25
1) 
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00
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av
ag
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H
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10
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re
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N
er
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o
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(25
1) 
8 
00
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G
av
ag
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H
en
 
 
10
 
fe
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10
 
(S
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re
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1) 
M
u
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do
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rt
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pr
o
py
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n
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o
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ha
te
 
 
 
 
 
1 
00
0 
O
ra
l 
H
en
 
Fe
m
al
es
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N
o 
n
eu
ro
to
x
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re
sp
o
n
se
.
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9) 
1 
00
0 
G
av
ag
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H
en
 
10
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m
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fo
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an
d 
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n
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n
eu
ro
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ra
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) d
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O
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00
0 
G
av
ag
e 
H
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v
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ra
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 d
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ra
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R
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o
n
ite
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m
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.
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.
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re
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ra
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ra
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N
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n
eu
ro
to
x
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o
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n
eu
ro
pa
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ra
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O
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D
N
: o
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an
o
ph
o
sp
ho
ru
s-
in
du
ce
d 
de
la
ye
d 
n
eu
ro
pa
th
y.
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C 
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ci
te
d 
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(74
). 
b 
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o
d 
an
d 
D
ru
g 
R
es
ea
rc
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bo
ra
to
rie
s 
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te
d 
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te
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(25
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ra
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.
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ra
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at
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at
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.
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o
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.
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a  
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LD
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.
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O
ra
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io
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te
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en
t m
u
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m
s.
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O
ra
l 
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D
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.
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ab
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.
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m
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o
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n
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al
s).
 
 
M
ild
 
er
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n
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ca
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20
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O
ra
l 
H
en
 
 
Fe
m
al
es
 
-
 
N
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ig
n
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ca
n
t d
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e 
o
f p
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sm
a 
ch
o
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se
 
o
r 
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n
 
N
TE
 
ac
tiv
ity
.
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o
so
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g/
m
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(F
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o
l P
CF
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tio
n
 
R
at
 
 
4 
ho
u
rs
 
M
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le
th
ar
gy
 
an
d 
m
at
te
d 
fu
r.
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>
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0 
m
g/
m
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x
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m
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m
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.
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at
io
n
,
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ea
se
d 
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,
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o
se
d 
o
r 
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m
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o
se
d 
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es
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th
ar
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,
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cr
im
at
io
n
,
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dy
 
w
ei
gh
t d
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io
n
,
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o
w
n
ish
 
o
ra
l d
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n
v
u
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o
n
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n
o
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.
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fe
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iv
o
rs
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u
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0 m
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u
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.
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o
se
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,
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o
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n
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el
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at
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n
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ra
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ra
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Tr
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ch
lo
ro
pr
o
py
l) 
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o
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o
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m
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en
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ra
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n
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o 
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fe
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o
n
 
bo
dy
 
w
ei
gh
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n
o
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ic
al
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n
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n
o
 
ef
fe
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o
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.
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foe
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ef
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o
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ei
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ra
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.
 
N
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n
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n
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n
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o
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x
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,
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at
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in
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.
 
A
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n
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o
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m
e 
re
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.
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re
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.
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.
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el
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N
o 
ef
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o
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o
py
l) 
ph
o
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) p
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o
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n
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o
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.
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gy
 
o
r 
w
ei
gh
t o
f t
es
tis
 
(bu
t d
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d.
 
N
o 
ef
fe
ct
 
o
n
 
m
o
rt
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o
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.
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o
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o
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f t
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ra
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en
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.
 
D
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n
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v
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u
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l c
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n
ge
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in
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n
er
v
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n
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is(
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ra
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o
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o
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a
n
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o
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n
o
l p
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O
ra
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n
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cr
ea
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re
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n
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se
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re
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e 
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w
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gh
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w
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o
u
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o
n
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m
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n
t h
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o
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o
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l c
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n
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n
o
n
-
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v
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by
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o
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n
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re
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n
o
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v
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m
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kg
 
bw
). I
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m
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n
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n
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v
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m
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n
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n
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se
d 
ab
so
lu
te
 
an
d 
re
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f c
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o
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n
tly
 
in
cr
ea
se
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.
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m
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.
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ra
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at
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an
d 
er
yt
hr
o
cy
te
 
ch
o
lin
es
te
ra
se
 
ac
tiv
iti
es
 
at
 
th
is 
o
r 
lo
w
er
 
le
v
el
s.
 
 
 
(23
8) 
j  
1 
06
0 
O
ra
l, 
in
 
di
et
 
R
at
 
10
/se
x
 
2 
w
ee
ks
 
N
o 
ef
fe
ct
 
o
n
 
bo
dy
 
w
ei
gh
t, 
cl
in
ic
al
 
sig
n
s 
o
r 
fo
o
d 
co
n
su
m
pt
io
n
.
 
N
o 
ef
fe
ct
 
o
n
 
ch
o
lin
es
te
ra
se
 
ac
tiv
iti
es
.
 
Sa
m
e 
re
su
lts
 
at
 
lo
w
er
 
do
se
s 
(42
0 
an
d 
66
0 
m
g/
kg
 
bw
). 
 
 
(23
8) 
k  
1 
66
0 
O
ra
l, 
in
 
di
et
 
R
at
 
10
/se
x
 
2 
w
ee
ks
 
Si
gn
ifi
ca
n
t r
ed
u
ct
io
n
 
o
f b
o
dy
 
w
ei
gh
t g
ai
n
 
an
d 
re
du
ce
d 
fo
o
d 
co
n
su
m
pt
io
n
 
in
 
m
al
es
.
 
N
o 
ef
fe
ct
 
o
n
 
ch
o
lin
es
te
ra
se
 
ac
tiv
iti
es
.
 
In
cr
ea
se
d 
ab
so
lu
te
 
an
d 
re
la
tiv
e 
liv
er
 
w
ei
gh
ts
 
w
ith
o
u
t c
o
n
co
m
ita
n
t h
ist
o
pa
th
o
lo
gi
ca
l c
ha
n
ge
s 
(re
ga
rd
ed
 
as
 
a 
n
o
n
-
ad
v
er
se
 
ef
fe
ct
).  
 
 
(23
8) 
k  
LC
50
: 
le
th
al
 
co
n
ce
n
tr
at
io
n
 
fo
r 
50
 
%
 
o
f t
he
 
ex
po
se
d 
an
im
al
s 
at
 
sin
gl
e 
ad
m
in
ist
ra
tio
n
,
 
LD
50
: 
le
th
al
 
do
se
 
fo
r 
50
 
%
 
o
f t
he
 
ex
po
se
d 
an
im
al
s 
at
 
sin
gl
e 
ad
m
in
ist
ra
tio
n
,
 
N
TE
: 
n
eu
ro
to
x
ic
 
o
r 
n
eu
ro
pa
th
y 
ta
rg
et
 
es
te
ra
se
.
 
a 
G
or
do
n
 
19
80
,
 
Sm
ith
ey
 
19
81
c,
 
ci
te
d 
in
 
(10
2,
 
23
8),
 
b 
Cu
th
be
rt
 
19
89
a,
 
ci
te
d 
in
 
(10
2),
 
c 
St
au
ffe
r 
19
70
,
 
ci
te
d 
in
 
(10
2,
 
23
8),
 
d 
St
au
ffe
r 
19
72
,
 
ci
te
d 
in
 
(10
2,
 
23
8),
 
e 
St
au
ffe
r 
19
79
,
 
ci
te
d 
in
 
(23
8),
 
f M
eh
lm
an
 
an
d 
Si
n
ge
r 
19
81
,
 
ci
te
d 
in
 
(10
2,
 
23
8),
 
g 
A
n
de
rs
o
n
 
19
90
a,
 
ci
te
d 
in
 
(10
2),
 
h 
K
aw
as
ak
i e
t a
l 1
98
2,
 
ci
te
d 
in
 
(21
6),
 
i B
ay
er
 
19
93
,
 
ci
te
d 
in
 
(21
6),
 
 
j S
ta
u
ffe
r 
19
81
a,
 
ci
te
d 
in
 
(23
8),
 
k 
St
au
ffe
r 
19
80
a,
 
ci
te
d 
in
 
(23
8).
 
  
21
3  
 
Ta
bl
e 
X
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
ip
he
n
yl
 
ph
os
ph
at
e 
(T
PP
).  
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
Si
n
gl
e 
do
se
 
10
 
O
ra
l 
M
o
u
se
 
5 
m
al
es
 
-
 
13
 
%
 
de
cr
ea
se
 
o
f w
ho
le
 
bl
o
o
d 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
.
 
(21
8) 
50
 
O
ra
l o
r 
in
tr
ap
er
ito
n
ea
l 
M
o
u
se
 
5 
m
al
es
 
-
 
11
 
o
r 
14
 
%
 
de
cr
ea
se
 
o
f w
ho
le
 
bl
o
o
d 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
.
 
(21
8) 
 
 
 
 
 
75
 
a  
In
tr
ap
er
ito
n
ea
l 
R
at
 
5 
-
 
N
o 
sig
n
ifi
ca
n
t d
ec
re
as
e 
o
f p
la
sm
a 
ch
o
lin
es
te
ra
se
.
 
In
du
ct
io
n
 
o
f l
iv
er
 
m
ic
ro
so
m
al
 
CY
Ps
 
w
ith
 
a 
co
n
co
m
ita
n
t i
n
cr
ea
se
 
in
 
th
e 
ac
tiv
iti
es
 
o
f m
ix
ed
 
fu
n
ct
io
n
 
m
o
n
o
o
x
yg
en
as
es
 
(un
cl
ea
r 
if 
th
e 
ef
fe
ct
 
ap
pe
ar
s 
at
 
th
is 
le
v
el
,
 
se
e 
15
0 
an
d 
30
0 
m
g/
kg
 
bw
). 
(24
4) 
10
0 
O
ra
l o
r 
in
tr
ap
er
ito
n
ea
l 
M
o
u
se
 
5 
m
al
es
 
-
 
39
 
o
r 
50
 
%
 
de
cr
ea
se
 
o
f w
ho
le
 
bl
o
o
d 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
.
 
(21
8) 
10
0 
In
tr
ap
er
ito
n
ea
l 
Ca
t 
1 
fe
m
al
e 
-
 
N
o 
n
eu
ro
m
u
sc
u
la
r 
sig
n
s 
at
 
30
 
da
ys
.
 
(21
8) 
 
 
 
 
15
0 a
 
In
tr
ap
er
ito
n
ea
l 
R
at
 
5 
-
 
Si
gn
ifi
ca
n
t d
ec
re
as
e 
o
f p
la
sm
a 
ch
o
lin
es
te
ra
se
.
 
In
du
ct
io
n
 
o
f l
iv
er
 
m
ic
ro
-
so
m
al
 
CY
Ps
 
w
ith
 
a 
co
n
co
m
ita
n
t i
n
cr
ea
se
 
in
 
th
e 
ac
tiv
iti
es
 
o
f m
ix
ed
 
fu
n
ct
io
n
 
m
o
n
o
o
x
yg
en
as
es
.
 
(24
4) 
20
0 
O
ra
l 
M
o
u
se
 
5 
m
al
es
 
-
 
46
 
%
 
de
cr
ea
se
 
o
f w
ho
le
 
bl
o
o
d 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
.
 
(21
8) 
20
0 
In
tr
ap
er
ito
n
ea
l 
Ca
t 
2 
fe
m
al
es
 
-
 
O
ne
 
ca
t h
ad
 
fir
st
 
n
eu
ro
m
u
sc
u
la
r 
sig
n
s 
at
 
18
 
da
ys
 
an
d 
di
ed
 
at
 
50
 
da
ys
.
 
 
Th
e 
o
th
er
 
ca
t h
ad
 
n
o
 
n
eu
ro
m
u
sc
u
la
r 
sig
n
s 
at
 
28
 
da
ys
.
 
(21
8) 
30
0 
In
tr
ap
er
ito
n
ea
l 
Ca
t 
2 
fe
m
al
es
 
-
 
O
ne
 
ca
t h
ad
 
n
o
 
n
eu
ro
m
u
sc
u
la
r 
sig
n
s 
at
 
30
 
da
ys
.
 
Th
e 
o
th
er
 
ca
t d
ie
d 
af
te
r 
 
3 
da
ys
 
du
e 
to
 
a 
pe
rfo
ra
te
d 
u
lc
u
s 
o
f t
he
 
st
o
m
ac
h.
 
(21
8) 
 
 
 
 
30
0 a
 
In
tr
ap
er
ito
n
ea
l 
R
at
 
5 
-
 
Si
gn
ifi
ca
n
t d
ec
re
as
e 
o
f p
la
sm
a 
ch
o
lin
es
te
ra
se
 
by
 
38
 
%
 
an
d 
26
 
%
,
 
re
sp
ec
tiv
el
y.
 
Si
gn
ifi
ca
n
t i
n
du
ct
io
n
 
o
f C
Y
Ps
 
(as
 
at
 
15
0 
m
g/
kg
 
bw
). 
In
hi
bi
tio
n
 
o
f b
ra
in
 
2´
,
3´
-
cy
cl
ic
 
n
u
cl
eo
tid
e 
3´
-
ph
o
sp
ho
hy
dr
o
la
se
 
an
d 
de
m
ye
lin
at
io
n
 
in
 
pe
rip
he
ra
l n
er
v
es
.
 
 
(24
4) 
40
0 
In
tr
ap
er
ito
n
ea
l 
Ca
t 
1 
fe
m
al
e 
-
 
Fi
rs
t n
eu
ro
m
u
sc
u
la
r 
sig
n
s 
at
 
16
 
da
ys
.
 
(21
8) 
  
21
4  
Ta
bl
e 
X
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
ip
he
n
yl
 
ph
os
ph
at
e 
(T
PP
).  
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
40
0 
Su
bc
u
ta
n
eo
u
s 
Ca
t 
2 
-
 
O
ne
 
ca
t l
o
st
 
w
ei
gh
t (
ab
o
u
t 3
0 %
), r
eg
ai
n
ed
 
w
ei
gh
t w
ith
in
 
3 
m
o
n
th
s.
 
Th
e 
o
th
er
 
ca
t d
id
 
n
o
t l
o
se
 
w
ei
gh
t. 
N
o 
ev
id
en
ce
 
o
f d
el
ay
ed
 
n
eu
ro
to
x
ic
 
ef
fe
ct
s.
 
 
(25
6) 
50
0 
O
ra
l o
r 
in
tr
ap
er
ito
n
ea
l 
M
o
u
se
 
5 
m
al
es
 
-
 
70
 
o
r 
49
 
%
 
de
cr
ea
se
 
o
f w
ho
le
 
bl
o
o
d 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
.
 
(21
8) 
50
0 
Su
bc
u
ta
n
eo
u
s 
Le
gh
o
rn
 
co
ck
er
el
 
2 
-
 
N
o 
pa
ra
ly
sis
.
 
 
(84
) 
70
0 
Su
bc
u
ta
n
eo
u
s 
Ca
t 
2 
-
 
B
o
th
 
ca
ts
 
be
ca
m
e 
an
o
re
ct
ic
.
 
O
ne
 
ca
t b
ec
am
e 
pr
o
st
ra
te
d 
w
ith
in
 
3 
da
ys
 
 
(on
 
n
ec
ro
ps
y 
da
y 
5,
 
tw
o
 
bl
ee
di
n
g 
u
lc
er
s 
in
 
th
e 
st
o
m
ac
h) 
an
d 
th
e 
o
th
er
 
by
 
da
y 
7.
 
H
ist
o
lo
gi
ca
l e
x
am
in
at
io
n
 
o
f t
he
 
ca
ts
 
re
v
ea
le
d 
ge
n
er
al
ise
d 
v
as
cu
la
r 
da
m
ag
e 
w
ith
 
pe
riv
as
cu
la
r 
o
ed
em
a 
in
 
m
an
y 
tis
su
es
.
 
N
o 
sig
n
s 
o
f a
x
o
n
 
de
ge
n
er
at
io
n
,
 
de
m
ye
lin
at
io
n
 
o
r 
o
th
er
 
pa
th
o
lo
gi
c 
ch
an
ge
 
in
 
th
e 
n
er
v
o
u
s 
sy
st
em
.
 
N
o 
ef
fe
ct
 
o
n
 
pl
as
m
a 
an
d 
er
yt
hr
o
cy
te
 
ch
o
lin
es
te
ra
se
 
ac
tiv
iti
es
.
 
(25
6) 
1 
00
0 
O
ra
l 
Le
gh
o
rn
 
co
ck
er
el
 
2 
-
 
N
o 
pa
ra
ly
sis
.
 
D
ec
re
as
e 
o
f p
la
sm
a 
ch
o
lin
es
te
ra
se
 
(35
 
%
) a
n
d 
ac
et
yl
-
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
 
in
 
br
ai
n
 
(2 
%
) a
n
d 
sp
in
al
 
co
rd
 
(24
 
%
). 
(84
) 
1 
00
0 
Su
bc
u
ta
n
eo
u
s 
Ca
t 
1 
-
 
A
n
o
re
ct
ic
 
af
te
r 
1 
w
ee
k.
 
A
fte
r 
3 
w
ee
ks
,
 
u
n
ab
le
 
to
 
ris
e 
fro
m
 
th
e 
flo
o
r 
an
d 
so
m
e 
da
ys
 
la
te
r 
m
o
rib
u
n
d.
 
N
o 
sig
n
s 
o
f a
x
o
n
 
de
ge
n
er
at
io
n
 
o
r 
de
m
ye
lin
a-
tio
n
 
in
 
th
e 
br
ai
n
 
st
em
 
an
d 
sp
in
al
 
co
rd
.
 
 
(25
6) 
1 
32
0-
 
 
>
 
5 
00
0 
O
ra
l 
M
o
u
se
 
 
-
 
LD
50
.
 
 
 
(10
0) 
b  
3 
50
0-
 
 
>
 
5 
00
0 
O
ra
l 
R
at
 
 
-
 
LD
50
.
 
 
 
 
 
(10
0) 
b,
 
c  
3 
00
0 
O
ra
l o
r 
su
bc
u
ta
n
eo
u
s 
M
o
u
se
,
 
ra
t 
10
-
11
 
m
al
es
 
-
 
LD
50
 
>
 
3 
00
0 
m
g/
kg
 
bw
.
 
(21
8) 
4 
00
0 
O
ra
l 
G
ui
n
ea
 
pi
g 
5 
m
al
es
 
-
 
LD
50
 
>
 
4 
00
0 
m
g/
kg
 
bw
.
 
 
(21
8) 
5 
00
0 
O
ra
l 
H
en
 
 
-
 
LD
50
 
>
 
5 
00
0 
m
g/
kg
 
bw
.
 
(10
6) 
  
21
5  
Ta
bl
e 
X
I. 
D
o
se
-
ef
fe
ct
 
an
d 
do
se
-
re
sp
on
se
 
re
la
tio
n
sh
ip
s i
n
 a
n
im
al
s 
af
te
r 
ex
po
su
re
 
to
 tr
ip
he
n
yl
 
ph
os
ph
at
e 
(T
PP
).  
D
ai
ly
 
do
se
 
m
g/
kg
 
bw
 
R
o
u
te
 
o
f 
ad
m
in
ist
ra
tio
n
 
Sp
ec
ie
s 
N
o.
 
an
d 
se
x
 
o
f a
n
im
al
s 
Ex
po
su
re
 
re
gi
m
en
 
Ef
fe
ct
 
R
ef
er
en
ce
 
Si
n
gl
e 
ex
po
su
re
,
 
va
po
u
r 
 
 
 
 
36
3 
m
g/
m
3  
In
ha
la
tio
n
 
M
o
u
se
 
5 
m
al
es
 
6 
ho
u
rs
 
Sl
ig
ht
 
de
cr
ea
se
 
(17
 
%
) i
n
 
w
ho
le
 
bl
o
o
d 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
.
 
(21
8) 
75
7 
m
g/
m
3  
In
ha
la
tio
n
 
M
o
u
se
 
7 
m
al
es
 
2 
ho
u
rs
 
Si
gn
ifi
ca
n
t d
ec
re
as
e 
(24
 
%
) i
n
 
w
ho
le
 
bl
o
o
d 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
.
 
(21
8) 
75
7 
m
g/
m
3  
In
ha
la
tio
n
 
M
o
u
se
 
7 
m
al
es
 
4 
ho
u
rs
 
Sl
ig
ht
 
de
cr
ea
se
 
(16
 
%
) i
n
 
w
ho
le
 
bl
o
o
d 
ch
o
lin
es
te
ra
se
 
ac
tiv
ity
.
 
(21
8) 
M
u
lti
pl
e 
do
se
s 
 
 
 
 
 
10
0 
O
ra
l, 
in
 
di
et
 
R
at
 
5 
m
al
es
 
5 
w
ee
ks
 
N
o 
ef
fe
ct
 
o
n
 
bo
dy
 
w
ei
gh
t o
r 
re
la
tiv
e 
liv
er
 
an
d 
ki
dn
ey
 
w
ei
gh
ts
.
 
N
o 
ha
em
at
o
lo
gi
ca
l e
ffe
ct
s 
(ha
em
o
gl
o
bi
n
 
co
n
te
n
t, 
ce
ll 
v
o
lu
m
e,
 
er
yt
hr
o
cy
te
 
an
d 
le
u
ko
cy
te
 
co
u
n
t a
n
d 
di
ffe
re
n
tia
l).
 
(21
8) 
16
1 
O
ra
l, 
in
 
di
et
 
R
at
 
10
 
4 
m
o
n
th
s 
N
o 
ef
fe
ct
 
o
n
 
bo
dy
 
w
ei
gh
t g
ai
n
.
 
N
o 
ef
fe
ct
 
o
n
 
be
ha
v
io
u
ra
l t
es
t. 
 
(20
3) 
16
6 
O
ra
l, 
in
 
di
et
 
R
at
 
 
38
 
91
 
da
ys
 
th
ro
u
gh
 
m
at
in
g 
an
d 
ge
st
at
io
n
 
Si
gn
ifi
ca
n
tly
 
in
cr
ea
se
d 
av
er
ag
e 
n
u
m
be
r 
o
f f
o
et
u
se
s 
ha
v
in
g 
at
 
le
as
t t
w
o
 
so
ft-
tis
su
e 
v
ar
ia
tio
n
s 
an
d 
sig
n
ifi
ca
n
tly
 
m
o
re
 
fo
et
u
se
s 
w
ith
 
m
o
de
ra
te
 
hy
dr
o
u
re
te
r 
th
an
 
in
 
co
n
tr
o
ls.
 
N
o 
ef
fe
ct
 
o
n
 
fe
rt
ili
ty
.
 
Sa
m
e 
re
su
lts
 
at
 
34
1 
an
d 
51
6 
m
g/
kg
 
bw
.
 
U
nc
le
ar
 
do
se
-
re
sp
o
n
se
 
re
la
tio
n
sh
ip
s 
bu
t a
lso
 
sm
al
l 
sp
ac
in
g 
o
f d
o
se
s.
 
(25
2) 
34
5 
O
ra
l, 
in
 
di
et
 
R
at
 
10
 
4 
m
o
n
th
s 
R
ed
u
ce
d 
bo
dy
 
w
ei
gh
t g
ai
n
.
 
N
o 
ef
fe
ct
 
o
n
 
be
ha
v
io
u
ra
l t
es
t. 
Sa
m
e 
re
su
lts
 
 
at
 
51
7 
an
d 
71
1 
m
g/
kg
 
bw
.
 
 
(20
3) 
37
5 
O
ra
l, 
in
 
di
et
 
R
at
 
10
/se
x
 
 
4 
m
o
n
th
s 
R
ed
u
ct
io
n
 
in
 
th
e 
gr
o
w
th
 
ra
te
 
o
f m
al
es
.
 
N
o 
sig
n
ifi
ca
n
t p
at
ho
lo
gi
ca
l l
es
io
n
s 
in
 
in
v
es
tig
at
ed
 
ly
m
ph
o
id
 
tis
su
es
.
 
Sa
m
e 
re
su
lts
 
at
 
12
5 
an
d 
25
0 
m
g/
kg
 
bw
.
 
 
(85
) 
50
0 
O
ra
l, 
in
 
di
et
 
R
at
 
10
/se
x
 
4 
m
o
n
th
s 
R
ed
u
ct
io
n
 
in
 
th
e 
gr
o
w
th
 
ra
te
 
o
f m
al
es
.
 
Tr
en
d 
to
w
ar
ds
 
in
cr
ea
sin
g 
to
ta
l 
se
ru
m
 
pr
o
te
in
 
w
ith
 
in
cr
ea
sin
g 
TP
P 
co
n
ce
n
tr
at
io
n
s.
 
(85
) 
50
0 
O
ra
l, 
in
 
di
et
 
R
at
 
5 
m
al
es
 
5 
w
ee
ks
 
In
cr
ea
se
d 
re
la
tiv
e 
liv
er
 
w
ei
gh
t a
n
d 
sli
gh
tly
 
de
pr
es
se
d 
gr
o
w
th
 
ra
te
.
 
N
o 
ef
fe
ct
 
o
n
 
re
la
tiv
e 
ki
dn
ey
 
w
ei
gh
t. 
N
o 
ha
em
at
o
lo
gi
ca
l e
ffe
ct
s 
(ha
em
o
gl
o
bi
n
 
co
n
te
n
t, 
ce
ll 
v
o
lu
m
e,
 
er
yt
hr
o
cy
te
 
an
d 
le
u
ko
cy
te
 
co
u
n
t a
n
d 
di
ffe
re
n
tia
l).
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Appendix 2. Occupational exposure limit values 
Occupational exposure limit values for the phosphate triesters in different 
countries a as 8-hour TWAs (numbers in brackets are short-term exposure limits). 
Country TOCP TBP  TPP  Ref. 
 ppm mg/m3 ppm mg/m3 ppm mg/m3  
Denmark  - 0.1 (0.2) 0.2 (0.4) 2.5 (5) - 3 (6) (1) 
Finland  - 0.1 (0.3) 0.2 (0.4) 2.5 (5) - 3 (6) (2) 
Germany (MAK) -        - 1 11 (44) -     - (3) 
Norway  - 0.1 (0.3) 0.2 2.5 - 3 (6) (4) 
United Kingdom  - 0.1 (0.3) - 5 - 3 (5) 
US (ACGIH)  - 0.1 0.2 - - 3 (6) 
US (NIOSH)  - 0.1 0.2 2.5 (5) - 3 (7) 
a
 Sweden, the Netherlands and the European Union do not have occupational exposure limits for 
the phosphate triesters. 
TWA: time-weighted average. 
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Appendix 3. Previous NEG criteria documents 
NEG criteria documents published in the scientific serial Arbete och Hälsa (Work 
and Health): 
 
Substance/Agent Arbete och Hälsa issue 
Acetonitrile 1989:22, 1989:37* 
Acid aerosols, inorganic 1992:33, 1993:1* 
Acrylonitrile 1985:4 
Allyl alcohol 1986:8 
Aluminium 1992:45, 1993:1* 
Ammonia 1986:31, 2005:13* 
Antimony 1998:11* 
Arsenic, inorganic 1981:22, 1991:9, 1991:50* 
Arsine 1986:41 
Asbestos 1982:29 
Benomyl 1984:28 
Benzene 1981:11 
1,2,3-Benzotriazole 2000:24*D 
Boric acid, Borax 1980:13 
1,3-Butadiene 1994:36*, 1994:42 
1-Butanol 1980:20 
γ-Butyrolactone 2004:7*D 
Cadmium 1981:29, 1992:26, 1993:1* 
7/8 Carbon chain aliphatic monoketones 1990:2*D 
Carbon monoxide 1980:8 
Ceramic Fibres, Refractory 1996:30*, 1998:20 
Chlorine, Chlorine dioxide 1980:6 
Chloromequat chloride 1984:36 
4-Chloro-2-methylphenoxy acetic acid 1981:14 
Chlorophenols 1984:46 
Chlorotrimethylsilane 2002:2 
Chromium 1979:33 
Cobalt 1982:16, 1994:39*, 1994:42 
Copper 1980:21 
Creosote 1988:13, 1988:33* 
Cyanoacrylates 1995:25*, 1995:27 
Cyclic acid anhydrides 2004:15*D 
Cyclohexanone, Cyclopentanone 1985:42 
n-Decane 1987:25, 1987:40* 
Deodorized kerosene 1985:24 
Diacetone alcohol 1989:4, 1989:37* 
Dichlorobenzenes 1998:4*, 1998:20 
Diesel exhaust 1993:34, 1993:35* 
Diethylamine 1994:23*, 1994:42 
2-Diethylaminoethanol 1994:25*N 
Diethylenetriamine 1994:23*, 1994:42 
Diisocyanates 1979:34, 1985:19 
Dimethylamine 1994:23*, 1994:42 
Dimethyldithiocarbamates 1990:26, 1991:2* 
Dimethylethylamine 1991:26, 1991:50* 
Dimethylformamide 1983:28 
Dimethylsulfoxide 1991:37, 1991:50* 
Dioxane 1982:6 
Enzymes, industrial 1994:28*, 1994:42 
Epichlorohydrin 1981:10 
Ethyl acetate 1990:35* 
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Substance/Agent Arbete och Hälsa issue 
Ethylbenzene 1986:19 
Ethylenediamine 1994:23*, 1994:42 
Ethylenebisdithiocarbamates and Ethylenethiourea 1993:24, 1993:35* 
Ethylene glycol 1980:14 
Ethylene glycol monoalkyl ethers 1985:34 
Ethylene oxide 1982:7 
Ethyl ether 1992:30* N 
2-Ethylhexanoic acid 1994:31*, 1994:42 
Flour dust 1996:27*, 1998:20 
Formaldehyde 1978:21, 1982:27, 2003:11*D 
Fungal spores 2006:21* 
Furfuryl alcohol 1984:24 
Gasoline 1984:7 
Glutaraldehyde 1997:20*D, 1998:20 
Glyoxal 1995:2*, 1995:27 
Halothane 1984:17 
n-Hexane 1980:19, 1986:20 
Hydrazine, Hydrazine salts 1985:6 
Hydrogen fluoride 1983:7 
Hydrogen sulphide 1982:31, 2001:14*D 
Hydroquinone 1989:15, 1989:37* 
Industrial enzymes 1994:28* 
Isoflurane, sevoflurane and desflurane 2009;43(9)* 
Isophorone 1991:14, 1991:50* 
Isopropanol 1980:18 
Lead, inorganic 1979:24, 1992:43, 1993:1* 
Limonene 1993:14, 1993:35* 
Lithium and lithium compounds 2002:16* 
Manganese 1982:10 
Mercury, inorganic 1985:20 
Methacrylates 1983:21 
Methanol 1984:41 
Methyl bromide 1987:18, 1987:40* 
Methyl chloride 1992:27*D 
Methyl chloroform 1981:12 
Methylcyclopentadienyl manganese tricarbonyl 1982:10 
Methylene chloride 1979:15, 1987:29, 1987:40* 
Methyl ethyl ketone 1983:25 
Methyl formate 1989:29, 1989:37* 
Methyl isobutyl ketone 1988:20, 1988:33* 
Methyl methacrylate 1991:36*D 
N-Methyl-2-pyrrolidone  1994:40*, 1994:42 
Methyl-tert-butyl ether 1994:22*D 
Microbial volatile organic compounds (MVOCs) 2006:13* 
Microorganisms 1991:44, 1991:50* 
Mineral fibers 1981:26 
Nickel 1981:28, 1995:26*, 1995:27 
Nitrilotriacetic acid 1989:16, 1989:37* 
Nitroalkanes 1988:29, 1988:33* 
Nitrogen oxides 1983:28 
N-Nitroso compounds 1990:33, 1991:2* 
Nitrous oxide 1982:20 
Oil mist 1985:13 
Organic acid anhydrides 1990:48, 1991:2* 
Occupational exposure to chemicals and hearing 
impairment 
2010;44(4)* 
Ozone 1986:28 
Paper dust 1989:30, 1989:37* 
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Substance/Agent Arbete och Hälsa issue 
Penicillins 2004:6* 
Permethrin 1982:22 
Petrol 1984:7 
Phenol 1984:33 
Phthalate esters 1982:12 
Platinum 1997:14*D, 1998:20 
Polyethylene,  1998:12* 
Polypropylene, Thermal degradation products in the 
processing of plastics 
1998:12* 
Polystyrene, Thermal degradation products in the 
processing of plastics 
1998:12* 
Polyvinylchloride, Thermal degradation products in the 
processing of plastics 
1998:12* 
Polytetrafluoroethylene, Thermal degradation products 
in the processing of plastics 
1998:12* 
Propene 1995:7*, 1995:27 
Propylene glycol 1983:27 
Propylene glycol ethers and their acetates 1990:32*N  
Propylene oxide 1985:23 
Refined petroleum solvents 1982:21 
Refractory Ceramic Fibres 1996:30* 
Selenium 1992:35, 1993:1* 
Silica, crystalline 1993:2, 1993:35* 
Styrene 1979:14, 1990:49*, 1991:2 
Sulphur dioxide 1984:18 
Sulphuric, hydrochloric, nitric and phosphoric acids 2009;43(7)* 
Synthetic pyretroids 1982:22 
Tetrachloroethane 1996:28*D 
Tetrachloroethylene 1979:25, 2003:14*D 
Thermal degradation products of plastics 1998:12* 
Thiurams 1990:26, 1991:2* 
Tin and inorganic tin compounds 2002:10*D 
Toluene 1979:5, 1989:3, 1989:37*, 2000:19* 
1,1,1-Trichloroethane 1981:12 
Trichloroethylene 1979:13, 1991:43, 1991:50* 
Triglycidyl isocyanurate 2001:18* 
n-Undecane 1987:25, 1987:40* 
Vanadium 1982:18 
Vinyl acetate 1988:26, 1988:33* 
Vinyl chloride 1986:17 
Welding gases and fumes 1990:28, 1991:2* 
White spirit 1986:1 
Wood dust 1987:36 
Xylene 1979:35 
Zinc 1981:13 
* in English, remaining documents are in a Scandinavian language.  
D = collaboration with the Dutch Expert Committee on Occupational Safety (DECOS).  
N = collaboration with the US National Institute for Occupational Safety and Health (NIOSH).  
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